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Abstract  
 The emergence of vancomycin-resistant enterococci (VRE) since the 1980s has 
turned this Gram-positive bacterium into a serious and growing clinical challenge. 
Enterococci have acquired resistance to a number of different antibiotics and are 
intrinsically resistant to cephalosporin b-lactam drugs. As a result, they are now placed in 
the World Health Organisation list of priority pathogens for which new antibiotics are 
urgently needed. An important risk factor for the emergence of VRE is treatment with 
cephalosporins, suggesting a connection between the origins of resistance between these 
two different types of antibiotics, the mechanistic basis for which was unknown.  
 In this study I demonstrate that cephalosporin resistance is significantly enhanced 
in the well characterized E. faecalis OG1RF strain containing the Tn1549 transposon 
conferring the VanB type vancomycin resistance. Cephalosporin resistance is shown to 
be enhanced to the presence of the Tn1549 transposon and a single, chromosomally 
encoded Serine/Threonine (ST) kinase gene called ireK. Complementation experiments 
and fluorescence microscopy with a range of biophysical techniques to characterise the 
protein. Deletion of the gene results in cephalosporin sensitivity. Moreover, this 
phenotype can be chemically simulated by treatment of E. faecalis with inhibitors of 
cytoplasmic ST kinases such as staurosporine, demonstrating a requirement for ST kinase 
activity for cephalosporin resistance.  This also demonstrates a therapeutic potential for 
targeting ST kinases in Gram-positive pathogens with small molecule inhibitors to restore 
cephalosporin sensitivity which may have clear translational significance. IreK was 
identified as a key protein involved in enhanced cephalosporin resistance and led to 
examination of its extracellular and intracellular domains to understand its signal 
transduction mechanisms and its linkage to resistance. The extracellular domain of IreK 
was essential for cellular location. Further biophysical experiments identified ligands for 
the extracellular domains include sugar motifs such as the glycan backbone of 
peptidoglycans and sugar containing antibiotics.  This has led to a new functional model 
for ST kinases in enterococci.  
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Chapter 1. Introduction 
1.1. The Bacterial Cell Wall 
1.1.1. The role of Peptidoglycan 
Peptidoglycan (PG) is essential for bacterial survival and inhibition of its 
biosynthesis can result in cell lysis. PG is a macromolecular polymer that forms a semi-
rigid exoskeleton that surrounds the bacterial cytoplasmic membrane. Its role is to 
endure the cellular turgor pressure by stretching as the cytoplasm grows and is strong 
enough to prevent cellular rupture (Vollmer et al., 2008a; Bugg, 1999; Young, 2010). It 
can contribute to the cellular shape of bacteria through its close association with cell 
growth and division (Vollmer et al., 2008b). PG also provides a non-structural role as a 
scaffold to anchor extracellular structures such as lipoproteins in Gram-negative bacteria 
and teichoic acids in Gram-positive bacteria. The proteins that associate with PG on the 
bacterial cell surface in Gram-positives are involved in adhesion, invasion, and resistance 
to phagocytic killing and are therefore important in pathogenicity (Navaare and 
Schneevind, 1999). 
1.1.2. Peptidoglycan Structure 
1.1.2.1. The Gram-negative bacterial cell envelope  
The Gram-negative cell envelope is comprised of an outer membrane, a thin layer 
of PG, and an inner cytoplasmic membrane. The outer membrane outer leaflet is 
composed of glycolipid lipopolysaccharides, and the inner leaflet contains phospholipids. 
The outer-membrane acts as a semi-permeable surface and prevents molecules that 
result in lysis, including cell wall antibiotics and lysozyme from entering the cell (Silhavy 
et al., 2010) (Figure 1.1, Left). The PG layer in Gram-negatives is relatively thin in 
comparison to Gram-positives. Crosslinking in Gram-negatives also differs and is mostly 
achieved through direct cross-linking between adjacent peptide stems, compared to 
Gram-positives where more significant variation occurs in the third position of the 
peptide stem resulting in side-chain branching (Vollmer, 2008b). Due to the PG layer in 
Gram-negative being thin, advanced mechanisms have evolved to evade destruction by 
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the antibiotic that targets the cell wall by interfering with its polymerization such as ß-
lactamases that target ß-lactam antibiotics (Zeng and Lin, 2013). 
1.1.2.2. The Gram-positive bacterial cell wall  
The Gram-positive cell wall include the inner membrane and a thick PG layer 
(Figure 1.1, Right). An additional S-layer external to the PG layer is also present in some 
Gram-positive species. The cell walls are thick, with 20-50 interconnected layers of PG 
resulting in a sizeable macromolecular structure (Young, 2010). Although the PG is the 
primary component of the Gram-positive cell wall, this structure is supplemented by 
secondary cell wall glycopolymers that can alter the rigidity and biological characteristics 
of the wall. These include teichoic acid (a linear polymer of glycerol or ribitol connected 
by phosphate groups) and lipoteichoic acids (where fatty acid substitutions anchor 
teichoic acid to the plasma membrane). The role of these secondary components protects 
the cells from various chemicals and enzymes such as antimicrobial compounds and also 
decreases host immune defences to allow survival in hostile environments (Kohler et al., 
2009; Rajagopal et al.,2016). They may also play a role in recognition by internal and 
external proteins (Steen et al., 2003).  
 
Figure 1.1 - Bacterial cell wall architecture. Major features are highlighted in schematic form of both 
Gram-negatives (A) and Gram-positives (B). Both cell walls contain a PG layer which is thick in Gram-
positive bacteria (20-50 layers) and thin in Gram negatives (1-3 layers).  
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1.1.3. Peptidoglycan biosynthesis 
 PG biosynthesis is a complex polymerization process with the precursors of PG are 
synthesized in the cytoplasm and in the inner membrane of the cell, and the 
polymerization occurring at the extracellular region. PG synthesis begins in the 
cytoplasm, where multiple enzymatic steps are necessary to assemble a disaccharide-
peptide precursor attached to a lipid carrier molecule. This can be summarised in three 
main reactions including the formation of UDP-MurNAc from UDP-GlcNAc, the assembly 
of the peptide stem leading to UDP-MurNAc-pentapeptide and the membrane steps in 
the accumulation of lipid I and lipid II (Figure 1.2) (Barreteau et al., 2008).  
 
 
Figure 1.2 -  The cytoplasmic and membrane associated steps in PG biosynthesis. NAM = MurNAc, NAG 
= GlcNAc, P = periplasm, TM = Transmembrane and C = Cytoplasm. UDP-GlcNAc is converted to UDP-
MurNAc by MurA and MurB. MurC-MurF sequentially add L-Ala, D-Glu, L-Lys (or meso- DAP) and D-Ala-D-
Ala to UDP-MurNAc. MraY transfers UDP-MurNAc-pentapeptide to the undecaprenyl lipid carrier and 
MurG adds a final GlcNAc to form Lipid II. Lipid II is flipped to the extracellular space by a flippase. 
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 UDP-GlcNAc is the first precursor molecule in the PG biosynthesis pathway and is 
derived from fructose-6-phosphate. UDP-MurNAc is formed from UDP-GlcNAC and 
requires two enzymes. MurA catalyses the first step of this transformation by transferring 
the enolpyruvate moiety of the phosphoenolpyruvate (PEP) to the 3'hydroxyl of UDP-
GlcNAc with the release of the organic phosphate (Pi). The resulting product, UDP-
GlcNAc-enol-pyruvate, undergoes a reduction catalysed by MurB using NADPH and a 
solvent derived proton and results in UDP-MurNAc. In E. faecalis, there are two MurA 
proteins that have been identified, denoted MurAA and MurAB, with MurAA (and not 
MurAB) being associated with the intrinsic cephalosporin resistance of the organism 
(Vesic and Kristich, 2012).  
 The second step in PG biosynthesis is the stepwise assembly of the peptide stem, 
carried out sequentially by a group of enzymes known as the Mur ligases including MurC, 
MurD, MurE and MurF. The Mur ligases have the same reaction mechanisms and catalyse 
the formation of an amide or a peptide bond with simultaneous formation of ADP and Pi 
from ATP. A divalent cation, Mg2+ or Mn2+ is essential for the reaction. The ligase MurC 
incorporates the first amino acid into the peptide stem. In most bacterial species, this is 
L-Ala, but other amino acids including Gly or L-Ser have also been observed at this 
position (Schleifer & Kandler, 1972). The MurD ligase is responsible for the incorporation 
the second amino acid into the peptide stem. In all species, this amino acid is D-Glu, but 
chemical modifications can occur at a later step resulting in either D-Ile for most Gram-
negative bacteria or D-Ile for most Gram-positive bacteria in the second position. The 
ligase MurE catalyses addition of the third amino acid into the peptide stem. The amino 
acid substrate is a di-amino acid and is usually either meso-A2pm in most Gram-negative 
bacteria, Mycobacteria spp. and Bacilli spp., or L-Lys in most Gram-positive bacteria 
(Ruane et al., 2013). In certain species of bacteria, other di-amino acids and mono-amino 
acids are used as substrates. The specificity of the MurE ligase for its substrate is specific 
(Strancar et al., 2007). 
 The terminal amino acid residues in the peptide stem reside in the fourth and fifth 
positions and are incorporated as a dipeptide, usually as D-Ala-D-Ala. Ddl is the enzyme 
responsible for the synthesis of the D-Ala-D-Ala dipeptide, and MurF is the ligase 
responsible for the incorporation of the substrate into the peptide stem. The D-Ala 
residue in the fourth position is present all species to date, but variation can occur in the 
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5th position. D-Lac or D-Ser occurring in the terminating fifth position is often associated 
with bacteria that utilize intrinsic or acquired vancomycin resistance mechanisms. These 
changes in the fifth position can result in a reduced affinity of antibiotics like vancomycin 
from binding to PG precursors and allowing the continuation of PG maturation (Healy et 
al., 2000). 
 The membrane associated step begins with the transfer of the phosphor-MurNAc-
pentapeptide moiety from the cytoplasmic precursor to the membrane receptor 
undecaprenol phosphate (C55~P). This transfer is catalysed by the transferase enzyme 
MraY to yield Lipid I (undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide). MurG then 
catalyses the transfer of the GlcNAc moiety from UDP-GlcNAc to lipid I, yielding lipid II 
(undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide-GlcNAc). Once amassed, the lipid 
II is translocated through the cell membrane by a yet unidentified mechanism although 
candidates have been proposed and are of current debate (Al-Dabbagh et al., 2008). 
Recent evidence suggests that MurJ is the protein responsible for translocation of lipid II 
across the membrane although other candidates have included FtsW (Bolla et al., 2018; 
Leclercq et al.,2017; Mohammadi et al., 2011). On the periplasmic side of the cytoplasmic 
membrane, membrane-associated transglycosylases and transpeptidases attach the PG 
monomers to the nascent growing sacculus, forming rigid glycan chains and crosslinking 
adjacent stem peptides, respectively. 
 Variations in the PG peptide stem including amidation, hydroxylation, acetylation, 
attachment of amino acids or other groups, and attachment of proteins occur after the 
action of the Mur ligases, often at the level of lipid II. These modifications occur 
essentially at positions 2 and 3 although most of the enzymes for these modifications are 
still unknown. Most chemical and structural variation in PG is due to the different cross-
linking patterns that can occur. These variations are as a result not only the position in 
the peptide stem the cross-linking occurs but also the chemical composition of the cross-
link itself. 3-4 cross-linking between peptide stems is the primary form of cross-linking in 
most bacteria (except coryneform bacteria where 2-4 cross-linking occurs). The cross-
linkage extends from the amino group of the side-chain of the residue at position 3 of 
one peptide subunit (acyl acceptor) to the carboxyl group of D-Ala at position 4 of another 
(acyl donor).  A direct cross-link (most bacteria, Mycobacteria or Bacilli) or a branched 
bridge (most Gram-positive bacteria) is used to link peptide stems. Various amino acids 
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can be encountered during branching at varying lengths, with some examples listed in 
Table 1.1 along with the enzymes involved. Gly and L-amino acids are activated as 
aminoacyl-tRNAs and transferred to the precursors by a family of non-ribosomal peptide 
bond-forming enzymes called Fem transferases (Lavollay et al., 2008). By contrast, D-
Amino acids are activated as acyl phosphates by proteins belonging to the ATP-grasp 
family, which is composed of highly diverse enzymes that catalyse the ATP-dependent 
ligation of a carboxyl group to an amino or imino nitrogen, hydroxyl oxygen or thiol 
sulphur (Galperin and Koonin, 1997). 
 
Table 1.1 - Summary of PG branching in key Gram-positive bacteria (adapted from Vollmer et al., 2008). 
Species Branching Type Enzyme Family Reference 
E. faecalis L-Ala-L-Ala BppA1, BppA2 Fem Transferase Bouhss et al., 2002 
E. faecium D-Asx Aslfm ATP-grasp Bellais et al., 2006 
S. aureus (Gly)5 FmhB, FemA, FemB Fem Transferase Schneider et al., 2004 
S. pneumoniae L-Ala-L-Ala or  
L-Ala L-Ser 
MurM, MurN Fem Transferase Fiser et al., 2003; 
Lloyd et al., 2008 
 
 
D-Ala at position 4 is not the only possible acyl donor: the carboxyl group of the 
amino acid at position 3 can also play this role. This gives rise to the appearance of 3–3 
cross-links, which were initially discovered in Mycobacteria where their formation is 
catalysed by penicillin-insensitive L,D-transpeptidases (Mainardi et al., 2005). Such 
mechanisms have now been identified in bacteria including pathogens such as M. 
tuberculosis, E. coli and E. faecium. 
PG metabolism is a dynamic process which coordinates with the dynamic process 
of cellular growth and division. Old PG is actively hydrolysed and removed, and new cell 
wall material is incorporated into actively growing cells. Gram-negative bacteria have also 
evolved sophisticated PG recycling mechanisms which have not clearly demonstrated in 
Gram-positives (Reith and Mayer, 2011). PG hydrolases are a class of enzymes that 
associate with the removal of existing PG by digesting PG at a particular motif in the cell 
wall to help incorporate new precursors. New PG is incorporated into existing PG by a PG 
synthetase (also known as a Penicillin-binding protein; PBP). These enzymes can catalyse 
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the polymerization of glycol strands (transglycosylation) and the cross-links between 
peptide stems (transpeptidation) (Figure 1.3). PBPs are broadly classified into two 
classes; the high molecular weight Class A and Class B PBPs and the low molecular weight 
Class C PBPs. The functions of each PBP can vary from transglycosylation, 
transpeptidation, carboxypeptidation, and endopeptidation. Class A PBPs are multi-
modular and usually bifunctional enzymes with both a transglycoslase and D,D-
transpeptidase domain. Class B PBPs are monofunctional enzymes containing D,D-
transpeptidase domain (Figure 1.4). The activity of the Class C PBPs is often associated 
with cell operation, PG maturation, and recycling (Sauvage et al., 2008). Table 1.2 
highlights the key PBPs in various Gram-positive bacteria.  
 
 
Figure 1.3 - Summary of PG polymerisation and the cell wall antibiotics that can inhibit 
the process. Following the translocation of Lipid II to the side of the cytoplasmic 
membrane, the GlcNAc /MurNAc disaccharides of lipid II are polymerised into glycan 
chains by transglycosylases. Transpeptidases form cross-links between newly synthesised 
PG and existing PG via the pentapeptide stems to give structural rigidity. The lipid carrier 
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is translocated back across the cytoplasmic membrane either before or after 
dephosphorylation. 
Table 1.2 - Summary of Class A and Class B PBPs in key Gram-positive bacteria. MWs are in brackets in 
kDa adapted from Arbeloa et al., (2004). 
Species 
Class A Class B 
A3 A4 A5 B1 B4 B5 
E. faecalis 
ponA 
(85.4) 
pbpF 
 (79.5) 
pbpZ 
(88.5) 
pbp5 
(74.0) 
pbpB 
(81.7) 
pbpA 
(77.9) 
E. faecium 
ponA 
(86.6) 
pbpF 
(86.6) 
pbpZ 
(86.7) 
pbp5 
(73.7) 
pbpB 
(81.0) 
pbpA 
(78.9) 
S. aureus 
pbp2 
(79.3) 
- - 
pbp2a* 
(76.3) 
pbp1  
(82.7) 
pbp3 
(77.2) 
S. pneumoniae 
pbp1a 
(79.8) 
pbp2a 
 (80.8) 
pbp1b 
 (89.5) 
- 
pbp2x 
 (82.3) 
pbp2b 
 (73.9) 
*Note that Pbp2a is an acquired resistance mechanism that results in MSRA 
 
1.1.4. Polymerisation of Peptidoglycan 
The formation of 3-3 crosslinks is catalysed by the L,D-transpeptidases and is 
thought to be a bypass mechanism for the 4-3 cross-linking pathway that is a target by 
the ß-lactam antibiotics (Mainardi et al., 2008). L,D-transpeptidases cleave the remaining 
D-ala moiety of the peptide stem and transfers the bond energy to the side chain of 
another meso-diaminopimelic in an adjacent peptide chain. The first enzyme found to 
possess L,D transpeptidase activity was isolated from an E. faecium mutant strain that 
acquired high-level resistance to ampicillin by producing exclusively 3-3 cross-linked PG 
(Mainardi et al., 2000). Genes encoding L,D-transpeptidases have been identified in the 
genomes of Gram-positive and Gram-negative bacteria alike (Magnet et al., 2007). 
Although L,D-transpeptidases and PBPs perform similar reactions, they are structurally 
unrelated to one another. D,D-transpeptidases have a serine residue for their catalytic 
activity and use a pentapeptide stem as the acyl donor substrate (Goffin et al., 2002). L,D-
transpeptidases contain an active site cysteine and recognize tetrapeptide stems as the 
donor substrates (Figure 1.4) (Lecoq et al., 2012).  
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Figure 1.4 - Classification of the major types of proteins involved in PG transpeptidation in Enterococcus 
spp. Classifications identified on the left hand side and domain topology for each class is shown where 
TM: transmembrane, N: amino-terminus, C: carboxyl-terminus, Catalytic sequence motifs for each type 
identified (SXXK for D,D-transpeptidation and SXGC for L,D-transpeptidation).  
Other variations can occur in PG between different species. Classically, the glycan 
strands are composed of alternating MurNAc and GlcNAc residues linked by a β-1,4 
glycosidic bond. Many organisms display glycan modifications such as deacetylation of 
MurNAc/GlcNAc residues and N-glycosylation, O-acetylation or phosphorylation of 
MurNAc residues (Vollmer, 2008b). 
1.1.5. Peptidoglycan hydrolases 
As previously mentioned, PG hydrolyses are a class of enzymes responsible for 
cleaving PG at particular motif in the cell wall to help incorporate new precursors ensuing 
the maintenance of overall cell wall PG turnover. There are three main classes of bacterial 
PG hydrolases that include the glycosidase, which cleave the glycan backbone, the 
amidases, that cleave the side-chain peptides and the peptidases, which includes the 
endopeptidases and carboxypeptidases that can cleave within the peptide side chain. 
Figure 1.5 highlights the classes of hydrolases and the location of their hydrolase activity 
in the PG (Vollmer et al., 2008a; Ghuysen et al., 1966). Glycosidases are classified into 
two groups; the N-acetylglucosaminidases which hydrolyses GlcNAc residues and N-
acetylmuramidases which hydrolyse the ß-1-4 glycosidic bond between the MurNAc and 
GlcNAc residues from the glycan strands (Vollmer et al., 2008a).  
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Figure 1.5 - Summary of PG hydrolase classes and the cleavage sites for each hydrolase.  
 PG terminases have been described recently and have a similar function to that 
of hydrolases. MltG is a terminase first described in E. coli and has been associated with 
determining and regulating the length of the glycan strand in PG. The activity of the MltG 
terminase results in a terminating anhydro-MurNAc residue of oligomeric glycan chains. 
MltG-like proteins have been identified in 70% of sequenced bacteria including E. faecalis. 
Species that lack MltG includes coccal species or those that lack a cell wall (Yunck et al., 
2016). 
1.1.6. Antibiotics that target the wall 
Cell wall antibiotics are a class of antibacterial that interfere with the synthesis 
and maintenance of PG. They include mainly include the ß-lactam and glycopeptide 
classes alongside a few other independent antibiotics including Fosfomycin, Bacitracin, 
D-cycloserine, Colistin, Polymyxin B and Daptomycin (Bugg and Walsh, 1992).  
The function and role of each antibiotic including those associated with the cell 
wall are discussed further in relation to targeting Enterococcus spp. and associated 
resistance but a summary of clinically used antibiotics are summarised in Table 1.3 and 
highlights the most critical antibiotics as highlighted by the World Health Organization 
(WHO) list of essential medicines (WHO, 2017). The list highlights the most essential 
drugs in modern medicine and enables the assistance in the development of tools for 
antibiotic stewardship at local, national and global levels to reduce antimicrobial 
resistance in both adults and children. The number of antibiotics that fall under the WHO 
essential medicines and those prioritized for reservation highlights the importance of 
these antibiotics in modern medicine.
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Table 1.3 - List of both clinically used cell wall antibiotics and antibiotics in clinical trials. Antibiotics in the WHO essential medicines listed are included and include Group 
1 Access (Bold), Group 2 Watch (Underline) and Group 3 Reserve (Red Bold) (WHO, 2017).  
Class Sub-Class Generation Name 
B-lactam 
Penicillin’s 
β-lactamase sensitive Benzylpenicillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Phenoxymethylpenicillin 
β-lactamase resistant Cloxacillin,  Dicloxacillin , Oxacillin, methicillin 
Aminopenicillins Ampicillin, Amoxicillin, Pivampicillin, Bacampicillin, Flucloxacillin 
Carboxypenicillins Ticarcillin, Temocillin 
Ureidopenicillins Piperacillin, 
Penems  Faropenem 
Carbapenems  Ertapenem, Doripenem, Imipenem, Meropenem, 
Cephalosporin’s 
1st Generation Cefazolin, Cefalexin, Cefadroxil 
2nd Generation Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Cefuroxime axetil 
3rd Generation Cefixime, Ceftriaxone, Ceftazidime,  Cefdinir , Cefotaxime, Ceftibuten, Cefditoren 
4th Generation Cefepime 
5th Generation Ceftaroline, Ceftobiprole 
Monobactams - Aztreonam 
B-lactam inhibitors - Avibactam, Clavam 
Glycopeptides - - Vancomycin, Teicoplanin, Oritavancin ,  Ramoplanin , Telavancin 
Intracellular Targets - - Fosfomycin, D-Cycloserine, Bacitracin 
Other Targets - - Polymixin B, Colistin, Daptomycin 
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1.2. Background on Enterococci bacteria 
1.2.1. Characteristics and Physiology 
The genus Enterococcus belongs to the low GC branch of Gram-positive bacteria 
belonging to the phylum Firmicutes and members of the lactic acid bacteria group (Klare 
et al., 2001). Before 1984, Enterococcus spp. were classified with the Streptococcus spp. 
but were found later to be distinctly different to streptococci (Schleifer and Kilpper-Balz, 
1984). The Enterococcus genus is placed in the Enterococcaceae family along with genus 
Bavariicoccus, Catellicoccus, Melissococcus, Pilibacter, Tetragenococcus and Vagococcus 
(Ludwig et al., 2009). The genus contains 54 species and includes species that reside in 
the gastrointestinal (GI) tracts of humans and animals forming part of the healthy flora 
(Mundt, 1963a; Parte et al., 2013). Species can also be isolated from the guts of insects 
(Martin and Mundt, 1972), various environments including plants (Mundt, 1963b), 
sewage (Kenner et al., 1961) and water (Ator and Starzyk, 1976). 
Enterococcus spp. can in endure a broad pH and temperatures as well as 
hypotonic and hypertonic conditions which plays an important feature in their broad 
distrubution. They typically have an optimum growth temperature of 35°C and a growth 
range from 10 to 45°C (Sherman, 1937; Sherman, 1938; Byappanhalli et al., 2012). 
Enterococci colonise a small proportion of the gut consortium, (1 % of the adult 
microflora) (Finegold et al., 1983; Sghir et al., 2000). Little is known about the primary 
mechanisms used by enterococci to colonize GI tracts of either healthy individuals or 
hospitalized patients. The exposure of hospitalized patients to antibiotics results in 
significant modifications of the gut microbiota, which facilitate colonization of the GI tract 
by drug-resistant enterococci (Donskey et al., 2000; Ubeda et al., 2010). 
The main morphological characteristics of all enterococci include their spherical 
or ovoid shape and their arrangement in either pairs or chains with single cells having a 
diameter of around 1 µm (Domig et al., 2003). Physiologically, enterococci are non-spore 
forming facultative anaerobes and obligatory fermentative chemoorganotrophs 
(Facklam, 1973).  
As a reflection of their highly evolved role as members of a consortium in an 
extremely competitive environment, enterococci have reduced genomes that range from 
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2.3 Mb to 3.9 Mb across species sequenced thus far (Van Schaik et al., 2010; Dubin and 
Pamer, 2014). Gene mobility and exchange have allowed Enterococcus spp. to 
prominently rise as a nosocomial pathogen. The E. faecalis strain OG1X is a fully 
susceptible, well characterized and studied strain. It contained no mobile elements and 
no acquired DNA when its genome was sequenced (Bourgogne et al., 2008). This 
contrasts sharply with the genome of E. faecalis V583 which confers vancomycin 
resistance, in which approximately 25% of its genome consists of acquired DNA (Polidori 
et al., 2011; Kristich et al., 2014). The selective pressure in a clinical setting and the 
presence of antibiotics in the environment have resulted in clinical isolates that have 
gained an array of resistant mechanisms through the acquisition and exchange of DNA 
elements. 
1.2.2. Pathogenesis 
 Enterococcus spp. are a leading cause of infective endocarditis, bacteraemia, and 
urinary tract infections (UTIs) and have been emerging as leading causes of multidrug-
resistant hospital-acquired infections in the 1970s and 1980s (Huycke et al., 1998; Jett et 
al., 1994). They now rank among leading causes of hospital-acquired infections of the 
bloodstream, urinary tract, surgical wounds, and other sites (Hidron et al., 2008; 
Tacconelli et al., 2017). Both E. faecalis and E. faecium are identified as being the 
causative agents of over 90% of Enterococcus spp. related nosocomial infections and 
recently identified as high priority and placed at the top of the list of Gram-positive 
bacteria that are on the WHO priority list of antibiotic-resistant bacteria (Tacconelli et al., 
2017). Infections affect immunocompromised patients, children and the elderly. 
Infections by Enterococcus spp. are therefore associated with haemato-oncological, 
paediatric and intensive care units. The growing number of infections caused by 
Enterococcus spp. is also linked to a growing population, especially in industrialized 
countries. Some members of the microbiota, including commensal Enterococcus spp. can 
act as opportunistic pathogens and translocate across the mucosal barrier to cause 
systemic infection in immune-compromised hosts (Berg, 1996; Donskey et al., 2004). 
More commonly, however, infection results from the colonization, overgrowth, and 
translocation of hospital-adapted antibiotic-resistant strains with enhanced 
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pathogenicity. Enterococcus spp. can cause a variety of infections that are summarised 
below. 
1.2.2.1. Infective Endocarditis 
Infective endocarditis (IE) is causes inflammation of the endocardium in both 
native and prosthetic heart valves (Fitzsimmons et al., 2010). E. faecalis causes 97% of IE 
infection out of those from the Enterococcus spp. (Baddour et al., 2015). Colonization of 
the heart valves is thought to occur during transient bacteraemia where microorganisms 
adhere via cell surface receptors which are formed over areas of injured endothelial 
tissue. Endothelial cells respond to bacterial cell binding and internalization through 
tissue factor activity and cytokine production which attracts monocytes from the blood 
leading to enlargement of the endocardial vegetation which is poorly responsive to 
antimicrobial therapy. Disruption of these lesions through sheer force via blood flow or 
endothelial cells lysis can result in fragments of the lesions (septic emboli) travelling to 
remote areas of the body with sometimes fatal effects (Prendergast, 2006).  
Factors that coincide with IE include poor dental hygiene, long-term 
haemodialysis and diabetes mellitus with human immunodeficiency virus (HIV) also 
increasing the risk of IE (Mylonakis and Calderwood, 2001). Infections from Enterococcus 
spp. are associated with high mortality rates including IE. Mortality rates are as high as 
20-40 % in those patients with infections from Enterococcus spp. and has broadly 
remained unchanged in the past 30 years (Miro et al., 2013). 
Treatment of IE is often difficult as the organism must first be isolated and 
identified (Lang, 2008). In patients who have become acutely ill, empirical therapy will be 
given until the organism has been identified. Once antibiotic susceptibility tests have 
been carried out on the isolate, an appropriate antibiotic therapy regime can be initiated 
(Elliott et al., 2004). Different regimes have been developed with the use of 
aminoglycosides as a standard for IE infections caused by Enterococcus spp. but a rise in 
resistance has led to new therapies being explored. This includes double β-lactam 
therapies including ampicillin and ceftriaxone but comes a great risk as they both target 
the bacterial cell wall (Beganovic et al., 2018). 
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1.2.2.2. Bacteraemia 
 Bacteraemia is the presence of bacteria in the blood. 10% of all blood stream 
infections are caused by Enterococcus spp. The occurrence of bacteraemia by 
Enterococcus spp. is often the consequence of a primary infection. Common sources 
include the urinary tract from catheters, infections of the bile tract or an intra-abdominal 
infection (Murray, 1990; Soule and Climo,2016). Due to the ability for Enterococcus spp. 
to harbour different resistant mechanisms, mortality is often higher in patients with 
bacteraemia from these strains. The mortality associated with VRE bacteraemia is 20-46% 
(Salgado and Farr, 2003). Intensive care unit (ICU) patients are one of the most 
susceptible groups to be affected by infection from Enterococcus spp. due to the severity 
of illness and constant exposure to multiple antibiotic regimes (Zhu et al., 2009). A recent 
study demonstrated that recurrent bacteraemia from E. faecium was from different 
strains using genome-based analysis. This was likely due to cross transmission in a 
hospital environment (Raven et al, 2018).  
1.2.2.3. Urinary tract infections  
Urinary tract infections (UTIs) are one of the most common bacterial infections 
caused by both Gram-positive and Gram-negative bacteria effecting 150 million people 
worldwide every year. (Stamm and Norrby, 2001). E. coli is the most frequently reported 
pathogen causing 70-95 % of upper and lower UTIs (Foxman, 2010; Chakupurakal et al., 
2010). The urinary tract is usually a sterile environment, but this can be disturbed by a 
variety of factors. These include cystitis, having a prior UTI, sexual activity, pregnancy, 
vaginal infections, diabetes, obesity and genetic susceptibility (Foxman, 2010). UTIs 
account for the most common type of bacterial infection in women, with around half of 
them experiencing at least one infection in their lifetime (Nicolle, 2012). Factors that 
make Enterococcus spp. successful UTI pathogens include the presence of adherence 
factors Esp (adhesin), Ace (adhesin) and Ebp (Pili), which aid in biofilm formation (Flores-
Mireles et al., 2015).  
1.2.2.4. Meningitis 
Meningitis caused by Enterococcus spp. is rare and uncommon, but patients who 
suffer will have an underlying disease such as diabetes mellitus or renal failure (Laguna 
et al., 2009). Recently it was reported that Enterococcal meningitis was identified in a 70 
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year old male without any predisposing factors and highlights the significance of 
Enterococcal infections arising from a community setting (Dhanalakshmi et al., 2015).  
1.2.3. Antimicrobial Therapy and Resistance 
During antimicrobial chemotherapy, treatment aims to achieve a drug 
concentration above the minimum inhibitory concentration (MIC) for the organism 
concerned; the concentration of antimicrobial agent at which growth is sufficiently 
inhibited (Andrews, 2001; Baddour et al., 2005). Therapeutic treatment depends on the 
susceptibility profile of the microorganism to avoid the emergence of antimicrobial 
resistance. For antibiotic susceptible enterococci, glycopeptide antibiotics are 
bactericidal at clinically achievable concentrations, but the emergence of VRE strains has 
lead to the use of these antibiotics being limited to combination therapies when required 
(Landman and Quale, 1997; Elliott et al., 2004; Baddour et al., 2005). Combinations of 
glycopeptides and aminoglycosides or ampicillin and ceftriaxone are the main arsenal 
used to treat enterococcal infections. Hospital outbreaks of vancomycin-resistant 
enterococci (VRE) have been associated with haematology, renal surgery and intensive 
care units where patients are severely immunocompromised (Timmers et al., 2002; 
Kawalec et al., 2007; Beganovic et al., 2018).  
Difficulties in treating Enterococcal spp. infections has resulted in proposals for 
new therapies including the use of Niclosamide, a drug commonly used for tape work 
infections as it has been shown to have potent antibacterial properties against VRE strains 
(Mohammad et al., 2018). The evolution of antibiotics used to treat E. faecalis 
bloodstream infections and infective endocarditis has recently been evaluated and 
highlights how rapid in antibiotic regimes change to treat Enterococcal spp. infections 
(Beganovic et al., 2018). 
1.2.4. Antibiotics and antibiotic resistance in Enterococcus spp. 
The discovery of penicillin by Alexander Fleming (1929) led to the global 
introduction of antimicrobials to treat bacterial infections and has been considered one 
of the most significant developments in medicine. A large number of new classes of 
antibiotics emerged between 1940-1960 and kept bacterial infections at a low level 
(Walsh and Wright, 2005). Due to the success of these antimicrobials, the pharmaceutical 
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industry has been investing less in such therapeutics leading to a period of nearly 40 years 
in which no new antimicrobials have been introduced (von Nussbaum et al., 2006). Due 
to the lack of new antibiotic classes and the overuse of existing drugs, there is an 
increasing prevalence of antimicrobial resistance globally.  
Antimicrobial resistance is a significant threat to modern society, and a current 
concern leading to the commission of the O'Neill report (2015). This report estimates that 
by 2050, 10 million people will die annually, overtaking cancer death rates and a 
worldwide economic burden of $100 trillion. Besides the ability to adapt to a wide range 
of environmental and physiological stresses, Enterococcus spp. possess a broad spectrum 
of natural antibiotic resistance mechanisms (Murray., 1990; Klare et al., 2003; Arias and 
Murray 2008). The treatment of infections from Enterococcus spp. has become an 
enormous challenge for clinicians due to the ability of these organisms to develop 
resistance to the standard drug choices, namely ampicillin, vancomycin and 
aminoglycosides (Arias and Murray, 2012). Enterococcus spp. are intrinsically resistant to 
a large number of penicillin's, all classes of cephalosporins (except for the 5th generation 
cephalosporin, ceftobiprole in E. faecalis) and monobactams to name a few (Arias et al., 
2010; Kristich et al., 2014). Antibiotics that target Enterococcus spp. and their associated 
resistance mechanisms is discussed below. 
1.2.4.1. Types of antimicrobial resistance 
 Isolated or multiple genes can be involved in antimicrobial resistance. These 
genes can involve several different targets and have access to a variety of different 
protection pathways via different mechanisms (Martinez and Baquero, 2000). The 
mechanism for antimicrobial resistance can occur through inherent or intrinsic 
mechanisms within the organism, horizontal acquisition of resistance genes either carried 
by plasmids of transposons that results in the recombination of foreign DNA into the 
organism’s chromosome or by mutations that can occur in different chromosomal loci 
(Davies and Wright, 1997). 
Intrinsic resistance is the innate ability of a bacterial species to resist activity to a 
particular antimicrobial molecule through its inherent structural and functional 
mechanisms. This results in a particular tolerance of a specific antimicrobial or class. An 
example of this which will form a predominant focus of this thesis is intrinsic resistance 
 37 
to cephalosporin in Enterococcus spp. Although extensive research has been performed, 
the overall mechanism is not fully understood in either E. faecalis or E. faecium (Djoric 
and Kristich, 2017). 
The selective pressure of the antibiotic can result in acquired resistance by 
spontaneous mutations, which may be point mutations, deletions or insertions within the 
bacterial genome (Normark and Normark, 2002). In the absence of an antimicrobial 
agent, chromosomal mutations for resistance to antibiotics often have an adverse effect 
on the fitness of the organism (Levin et al., 2000). The acquisition of genes associated 
with antibiotic resistance will produce a general metabolic burden, and it is thought that 
in the absence of selection, the resistant organisms would be outcompeted by the 
susceptible ones. If that were always true, discontinuation of antibiotic use would render 
the disappearance of resistant microorganisms. Several studies have shown that, once 
resistance emerges, the recovery of a fully susceptible population even in the absence of 
antibiotics is not easy (Hernando-Amado et al., 2017). Factors that can influence the rate 
of mutation in an organism in the presence of an antibiotic include the antibiotic 
concentration, physiological conditions and bacterial stress (Foster., 1993; Kohler et al., 
1997; Shapiro, 1997). An example of this type of resistance includes linezolid resistance 
in Enterococci. Linezolid inhibits protein synthesis by interacting with the 23S ribosomal 
RNA. The resistance mechanism involves a point mutation G2576U in the genes encoding 
the 23S ribosomal RNA and results in the interaction of Linezolid to interact with the 23S 
ribosomal RNA and continuation of protein synthesis (Zurenko et al., 1996; Prystowsky et 
al., 2001).  
Eukaryotic organisms have evolved principally through the modification of the 
genetic information that already exists. The genetic diversity in bacteria has been a result 
of the acquisition of genes from other distantly related organisms. This is achieved 
through horizontal gene transfer where DNA can be introduced or deleted from the 
chromosome and can result in a different bacterial genotype and phenotype (Ochman et 
al., 2000). Antimicrobial resistance caused by horizontal gene transfer can occur through 
genes in bacteriophages, plasmids, naked DNA and transposon elements (Levy and 
Marshall, 2004). This occurs through either transduction, conjugation or transformation 
(Alekshun and Levy, 2007). Conjugation is the direct transfer of DNA between two 
bacterial cells in a mating process. Transduction requires a DNA carrier (bacteriophage) 
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to transfer genetic material into another bacterium, and transformation involves the 
uptake of DNA from the environment. Transposons are known to carry resistance 
elements and include those that are involved in Glycopeptide resistance throughout the 
Enterococcus spp. including Tn1546, Tn1547 and Tn1549 (Alekshun and Levy, 2007). 
There are many types of antibiotic resistance in Enterococcus spp. to different 
classes of antibiotics including to the aminoglycosides, rifampicin, quinolones and 
linezolid (Llano-Sotelo et al., 2002; Vakulenko and Mobashery., 2003; Telenti et al., 1993; 
Oyamada et al., 2006; Werner et al., 2010; Prystowsky et al., 2001; Pai et al., 2002; 
Ruggero et al., 2003; Seedat et al., 2006). As the primary focus of this project is on the 
cell wall in Enterococcus spp. and associated antibiotic resistance, only those antibiotics 
that affect the cell wall will be discussed.  
1.2.4.2. Daptomycin and Resistance in Enterococcus spp.  
Daptomycin is a lipopeptide antibiotic derived from Streptomyces roseosporus 
used to treat Gram-positive infections (Carpenter and Chambers, 2004). It has a unique 
mechanism of action compared to other antibiotics by disrupting multiple aspects of 
bacterial membrane function. It is only active against Gram-positive bacteria as it is 
unable to penetrate the outer membrane of Gram-negative bacteria (Miller et al., 2016). 
Daptomycin inserts into the cell membrane in a phosphatidylglycerol-dependent fashion 
and aggregates. The effect of aggregation in the membrane alters the curvature of the 
membrane resulting in holes that allow ions to leak. This causes rapid depolarization of 
ions (especially potassium) with an associated ion dissipation of the ion concentration 
gradient. This results in a loss of membrane potential leading to inhibition of protein DNA 
and RNA synthesis, resulting in bacterial cell death. Large molecules are not released from 
the cytoplasm (Tally et al., 1999; Tally and DeBruin, 2000). 
Daptomycin has been used to treat severe VRE infections, especially when a lack 
of other treatment options are available. Daptomycin resistance has been reported in 
cases where VRE infections are being treated. Little is known about the mechanism of 
resistance, but an essential event for the activity of daptomycin is a calcium-mediated 
interaction with the cell membrane, a property that daptomycin shares with related 
cationic antimicrobial peptides. The charge in the bacterial surface also appears to play 
an essential role in the interaction of daptomycin with the cell membrane, and it has been 
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postulated that a more positively charged cell envelope “repels” the cationic daptomycin 
from the cell membrane, contributing to the development of resistance (Jones et al., 
2008). 
A significant factor in the cell-envelope charge is the phospholipid composition of 
the inner and outer cell-membrane leaflets, such as the negatively charged phospholipid 
cardiolipin and the positively charged amino derivatives of phosphatidylglycerol. In some 
S. aureus isolates, reduced susceptibility to daptomycin has been attributed to a decrease 
in the negative surface charge of the cell membrane as a result of modifications in 
phospholipid content. This is mainly through increased synthesis and translocation 
("flipping") of the positively charged lysyl-phosphatidylglycerol from the inner to the 
outer leaflet of the cell membrane (Zhang et al., 2014). It has also been shown that lysyl-
phosphatidylglycerol attenuates membrane perturbations caused by cationic 
antimicrobial peptides. It has been shown that resistance to daptomycin in VRE strains is 
associated with the cell envelope and biophysical properties of the cell membrane. The 
genes responsible for such changes include liaF and gdpD, and both are required for full 
expression of the resistant phenotype. LiaFSR is a three-component system which is 
known to adapt the cell envelope to antibiotics and antimicrobial peptides in some Gram-
positive bacteria. This system is well characterized in B. subtilis, S. mutans, and 
Pneumococcal spp. The system is activated in the presence of antibiotics that disrupt the 
cell wall membrane and PG synthesis through alterations of Lipid-II metabolism (PG 
precursor). In daptomycin resistant Enterococcus spp., activation of the LiaFSR system 
occurs through mutations in liaF or other components of the LiaFSR system (which might 
be selected through exposure to antibiotics that alter lipid-II metabolism). It is thought 
that activation of the system may influence cell-envelope homeostasis by affecting the 
transcription of several genes that can help mitigate the damage caused by the antibiotic. 
A subsequent alteration in the cell membrane occurs through changes in enzymes 
involved in phospholipid metabolism leading to critical and compensatory changes in the 
composition or distribution of phospholipids in the cell membrane. GdpD has been shown 
to be important in glycerol metabolism, hydrolysing several cell-membrane 
glycerophosphodiesters that affect phospholipid metabolism (Schwan et al., 2003). 
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1.2.4.3. Glycopeptides and Resistance in Enterococcus spp. 
 Glycopeptides are a class of antibiotics that consist of a peptide ring to which 
several sugars are covalently linked. They are produced by actinomycetes and have a 
large complex structure that prevents the penetration through the outer membrane of 
Gram-negative bacteria limiting their therapeutic use only to treat infections with Gram-
positive bacteria. However recently it has been demonstrated that cold stress makes 
Gram-negatives such as E. coli more susceptible to glycopeptide antibiotics and can alter 
the outer membrane integrity (Stokes et al., 2016).  
 Two naturally produced antibiotics have historically been used in antimicrobial 
treatment, vancomycin and teicoplanin. Four glycopeptide derivatives have also been 
developed including ramoplanin, dalbavancin, telavancin, oritavancin and are promising 
candidate drugs that are partially active against multi-resistant bacteria and VRE (Zhanel 
et al., 2010). The primary target of glycopeptides is the C-terminal D-Alanyl-D-Alanine 
terminus of the peptide side chain of lipid II (Figure 1.6, left). Due to steric hindrance, cell 
wall synthesis enzymes like transglycosylases, transpeptidases and, D,D-
carboxypeptidases cannot access their target and, cell wall synthesis stops (Batchelor et 
al., 2010). 
 The emergence of vancomycin resistance took the clinical community by surprise 
in the late 1980s. Enterococcus spp. have acquired vancomycin resistance mechanisms 
and corresponding strains have been isolated from clinical samples from patients in the 
USA and Europe including the E. faecium strain BM4147 from France conferring VanA 
resistance and the E. faecalis strain V583 from the USA conferring VanB resistance 
(Leclercq et al., 1988; Leclercq et al., 1989; Sahm et al., 1989; Evers et al., 1996). The 
structure, localization and functional interplay of the resistance determinants arranged 
in specific transposable elements in Enterococcus spp. have been identified in multiple 
strains with nine types of vancomycin resistance throughout the Enterococcus spp. These 
share a related mechanism of resistance and a similar resistance gene cluster 
composition but show significant genotypic and phenotypic differences (Figure 1.7 and 
Table 1.4). VanA is the most prevalent type of vancomycin resistance followed by VanB 
resistance. The primary clinically relevant reservoir of vanA and vanB elements is in E. 
faecium but has been observed in other enterococcal species (Zirakzadeh and Patel, 
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2005; Werner et al., 2008). Phylogenetic analysis of the genes associated with 
vancomycin resistance has shown that the sequence clusters appeared in ancient strains 
of Actinobacteria. These also appear to have similarities to that of modern strains and 
functional studies have suggested that ancient strains also exhibited genuine antibiotic 
resistance mechanisms to vancomycin (D'Costa et al., 2011). Vancomycin-resistant 
Enterococcus spp. are also resistant to other antibiotics and host defences and have 
evolved to colonize the GI tract. Some strains have also been shown to colonize the 
bloodstream and have evolved antibiotic tolerance in an immunocompromised host 
achieving this by activating the stringent response as a result of a mutation in relA (Van 
Tyne and Gilmore, 2017). 
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Figure 1.6 – Mode of action of vancomycin and the effect of antibiotic resistance. Schematic of (Left) vancomycin forming five hydrogen bonds between the N-acetyl-D-
Ala-D-Ala of lipid II and (Right) the loss of a critical hydrogen bond caused by the vancomycin resistance mechanisms leading to a N-acetyl-D-Ala-D-Lac lipid II. This causes a 
1000-fold reduction in the affinity of vancomycin to lipid II and inhibition of the transglycosylation and transpeptidation steps (adapted from Bugg et al., 1991). 
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Figure 1.7 - Structure, composition and architecture of the vancomycin resistance clusters vanA-N. Two-component systems encoding Sensor Kinase (VanS) and Response 
Regulator (VanR) are coloured in Red, dehydrogenase (VanH) in Blue, ligase (VanA-N) in green, D,D-dipeptidase (VanX) in Orange, D,D-carboxypeptidase (VanY) in purple, 
Serine Racemase (VanT) in grey, bifunctional D,D-dipeptidase/ D,D-carboxypeptidase (VanXY) in gradient purple and orange and those of unknown function highlighted in 
white (VanZ and VanW) (adapted from Werner, 2008). 
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Table 1.4 - Types and distribution of glycopeptide resistance in Enterococcus spp. Summary of the different Van phenotypes that are present across the Enterococcus spp. 
and different characteristics between each phenotype. These include the species associated with the phenotype, the level of glycopeptide resistance, its specificity to 
different glycopeptides, the location of the van genes, mode of transctription activation and the modifications in PG that can occur (adapted from Werner, 2008). 
Resistance 
phenotype 
Microorganisms Level of resistance Glycopeptide Sensitivity Location of Genes Transcription of Genes 
C-terminal 
modification 
Reference 
VanA 
E. faecalis 
E. faecium 
High 
Vancomycin Resistant 
Teicoplanin Resistant 
Plasmid 
Chromosome 
Inducible D-Ala-D-Lac 
Arthur and Quintiloani, 
2001; Healy et al., 2000  
VanB 
E. faecalis 
E. faecium 
Variable 
Vancomycin Resistant 
Teicoplanin Sensitive 
Plasmid 
Chromosome 
Inducible D-Ala-D-Lac 
Courvalin, 2006; Arthur et 
al., 1996; Arthur and 
Quintiloani, 2001 
VanC 
E. gallinarum 
E. casseliflavus 
E. flavescens 
Intrinsic, low level 
resistance 
Vancomycin Resistant 
Teicoplanin Sensitive 
Chromosome Constitutive D-Ala-D-Ser Depardieu et al., 2004;  
VanD 
E. faecalis 
E. faecium 
Moderate 
Vancomycin Resistant 
Teicoplanin Resistant 
Chromosome Constitutive D-Ala-D-Lac 
Perichon et al., 1997; 
Ostrowsky et al., 1999 
VanE E. faecalis Low 
Vancomycin Resistant 
Teicoplanin Sensitive 
Chromosome Inducible D-Ala-D-Ser 
Fines et al., 1999; Patino et 
al., 2002 
VanG 
E. faecalis 
E. faecium 
Low 
Vancomycin Resistant 
Teicoplanin Sensitive 
Chromosome Inducible D-Ala-D-Ser 
McKessar et al., 2000; 
Depardieu et al., 2003 
VanL E. faecalis Low 
Vancomycin Resistant 
Teicoplanin Sensitive 
Chromosome Inducible D-Ala-D-Ser Boyd et al., 2008 
VanM E. faecium Variable 
Vancomycin Resistant 
Teicoplanin Sensitive 
Plasmid 
Chromosome 
Inducible D-Ala-D-Lac Xu et al.,2010 
VanN E. faecium Low 
Vancomycin Resistant 
Teicoplanin Sensitive 
Plasmid Constitutive D-Ala-D-Ser 
Nomura et al., 2012; 
Lebreton et al., 2011 
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1.2.4.3.1 VanA type resistance in Enterococcus spp. 
 The vanA gene is an integrated part of Tn1546 transposon which is usually located 
on transferable plasmids (Werner et al., 2008). The vanA gene cluster contains nine genes 
which are arranged in a transposon structure (Arthur et al., 1993). It is flanked by two 
incomplete inverted repeats and possesses two coding sequences. The entire element is 
10,981 bp and designated Tn1546, belonging to transposons of the Tn3-family which also 
encode a ß-lactamase (bla), the Tn3 transposase (tnpA) and the Tn3 resolvase (tnpR) for 
successful transposon integration. 
 Expression of VanA type vancomycin resistance in enterococci is through an 
inducible transcription mechanism. The mechanism for detecting the presence of the 
effect of vancomycin is still unknown, but the sensor kinase (VanS) of the regulator two-
component system is activated by autophosphorylation when changes in the 
extracellular environment have been detected, and the corresponding phosphate moiety 
is transferred to a cytoplasmic response regulator (VanR). Phosphorylated VanR functions 
as a transcriptional activator binding at two promoters in the VanA resistance gene 
cluster leading to the expression of two transcripts of genes that are arranged in an 
operon structure (Arthur et al., 1997). This includes the vanRS genes and the gene cluster 
vanHAXYZ. The proteins VanH, VanA and VanX possess essential functions for the 
expression of glycopeptide resistance whereas VanY encodes a D,D-carboxypeptidase 
contributing to elevated resistance levels and a VanZ protein of unknown function but 
contributing by an unknown mechanism to low-level teicoplanin resistance (Arthur and 
Quintiliani, 2001). The resulting enzymes of the VanA gene cluster provide an alternative 
pathway for synthesizing cell wall precursors ending in D-Alanyl-D-Lactate (D-Ala-D-Lac). 
This results in a 1000-fold reduction in vancomycin binding (Figure 1.6, Right) (Bugg et 
al., 1991; Arthur and Quintiliani, 2001). 
 
1.2.4.3.2 VanB type resistance in Enterococcus spp. 
 The typical VanB phenotype is characterized by inducible and variable levels of 
vancomycin but is susceptible to teicoplanin. The vanB gene can be divided into three 
different allele types (van B1-3) with vanB-2 the most prevalent type worldwide. The 
vanB alleles are part of Tn1547, Tn1549 or Tn5382 transposons which are mainly 
chromosomally located and less frequently, on plasmids (Zheng et al., 2009; Hegstad et 
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al., 2010; Bjorkeng et al., 2011). They are derivatives of the Tn196 transposon family 
associated with tetracycline resistance and can be separated into three functional 
regions: (i) the right end, implicated in the excision-integration process; (ii) the central 
part, in which the vanB2 operon replaces the tet(M) gene; and (iii) the left extremity, in 
which eight of the 18 ORFs could be implicated in the conjugative transfer (Garnier et al., 
2000). The vanB gene cluster resembles the core structure of the vanA gene cluster, but 
in a different arrangement (Figure 1.7). Genes of related composition and function are 
arranged similarly, an equivalent to vanZ is lacking, but an additional gene vanW of 
unknown function occurs. The TCS genes (vanRB and VanSB) are distant to their vanA gene 
cluster Tn1546 counterparts and regulation of gene expression is different. This may be 
the reason why it is only resistant to vancomycin, but not teicoplanin (Figure 1.8). The 
entire transposon backbone of vanB gene clusters is different to the vanA gene cluster. 
The vanB gene clusters are either flanked by certain IS elements or an integral part of 
more extensive mobile and/or conjugative elements (Carias et al., 1998; Dahl and 
Sundsfjord, 2003; Launay et al., 2006; Lopez et al., 2009). The conjugative transposon 
Tn1549 is widely prevalent among VanB type Enterococcus spp. and Clostridium spp. 
(Launay et al., 2006; Tsvetkova et al., 2010). 
 Teicoplanin does not induce VanB type resistance, but constitutively resistant 
mutants can occur following antimicrobial therapy through a point mutation in the VanS 
kinase domain or extracellular loop (Baptista et al., 1999; Kawalec et al., 2001; San Millan 
et al., 2009). Accordingly, teicoplanin treatment is not recommended for eradicating 
VanB VRE infections despite a correspondingly suggestive diagnostic result. 
 A recent study evaluating the VRE isolates from hospitals in Poland concluded 
that, although the initially VanA represented the primary phenotype in Poland, after 
2006, there has been an increasing number of cases with VanB type isolates in 
Enterococcus spp. since the first VanB type isolate was reported in Poland in 1999 
(Sadowy et al., 2018). Although VanA also appears to be the predominant phenotype in 
Enterococcus spp. in the USA and the rest of Europe, the VanB phenotype constitutes 
80% of the VRE isolates in Australia, and there is an increasing number of VanB isolates 
in Germany (Bender et al., 2016; Deshpande et al., 2007). 
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Figure 1.8 – The role Tn1549 in vancomycin resistance. Schematic of the TCS signalling cascade of VanSB 
and VanRB and the gene targets they upregulate. These include genes that change the biosynthesis 
pathway of PG such that D-Ala is no longer the fifth position and terminating amino acid in the peptide 
stem of Lipid II, but instead D-Lac. The three genes that are essential for VanB-type vancomycin 
resistance include VanHB, VanB and VanX.  
1.2.4.3.3 VanC type resistance in Enterococcus spp. 
 E. gallinarum and E. casseliflavus possess intrinsic resistance to vancomycin at a 
low level. The corresponding vanC ligase gene possesses minor sequence diversity 
resulting in the subtypes vanC-1 and vanC-2 respectively (Panesso et al., 2005). VanC type 
resistance is mediated via a modified D-Ala-D-Ser moiety which is shared by the VanE, 
VanG, VanL, and VanN gene clusters that also has a low level of resistance (Arias et al., 
2000). All these resistance types require the activity of a serine racemase converting L-
Ser into D-Ser. The vanC gene cluster was first described in E. gallinarum (Arias et al., 
1999). It contains a ligase gene vanC-1, a combined bifunctional D-Ala-D-Ala 
dipeptidase/carboxypeptidase vanXY gene, a vanT racemase gene and two genes 
encoding a sensor HK and RR TCS (vanRC and VanSC) (Reynolds et al., 1999; Reynolds and 
Courvalin 2005). Due to the different VanC resistance mechanism, a vanH equivalent is 
not required and is missing. Initially, it was thought that VanC type resistance was always 
constitutively expressed as a species-specific property, but in E. casseliflavus, an inducible 
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resistance phenotype is detected several hours after induction (Dutta and Reynolds, 
2002). E. gallinarum isolates expressing an inducible and constitutive phenotype have 
been identified with mutational changes in the amino acid sequences of the 
corresponding sensor HKs VanS correlating to constitutive and inducible strains (Panesso 
et al., 2005). 
 
1.2.4.3.4. VanD type resistance in Enterococcus spp. 
 The primary organization of the vanD operons, which are located exclusively on 
the chromosome, is similar to that of the vanA and vanB clusters (Figure 1.7) (Casadewall 
and Courvalin 1999; Boyd et al., 2000; Depardieu et al., 2003; Depardieu et al., 2004; 
Boyd et al., 2004). Genes equivalent to vanZ or vanW are absent. VanD type strains have 
negligible VanX activity, an enzyme that usually shuts down synthesis of vancomycin-
susceptible, housekeeping cell wall precursors. This otherwise physiological drawback is 
compensated by an inactivated D-Ala-D-Ala ligase host enzyme, preventing synthesis of 
vancomycin-susceptible precursors ending in D-Ala-D-Ala. However, vanD expression and 
corresponding essential cell wall precursor synthesis would still request induction by 
glycopeptides. Consequently, all investigated VanD type E. faecalis, E. faecium and E. 
avium strains show a constitutive resistance phenotype resulting from different 
mutations in the VanS or VanR. Another unusual feature of VanD type strains is their only 
slightly diminished susceptibility to teicoplanin which cannot be explained by already 
known DNA sequence diversities. Due to different strategies in establishing those 
complex and highly regulated networks independently and via different routes five 
different vanD cluster types had arranged and had been characterized (Boyd et al., 2000; 
Depardieu et al., 2004). 
 Different VanD type enterococci present a number of different combinations of 
mutations with the most significant amount of mutations occurring in VanS suggesting an 
independent development and convergent evolution (Depardieu et al., 2009). These 
various modifications also led to a wide range of resistance phenotypes with low to high-
level vancomycin-resistant strains. Remarkably, a VanD strain E. faecium BM4656 had a 
wildtype Ddl enzyme being the only VanD strain with a functional D-Ala-D-Ala ligase. In 
this strain, also enzymes VanX and VanY were active mainly for shutting down synthesis 
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of glycopeptide-susceptible cell wall precursors in a background of an active host Ddl 
enzyme for mediating vancomycin resistance (Depardieu et al., 2009). 
1.2.4.3.5. VanE type resistance in Enterococcus spp. 
 Isolates representing a VanE resistance type were described in a few E. faecalis 
strains from Northern America and Australia (Fines et al., 1999; Patino et al., 2002; Boyd 
et al., 2002; Patino et al., 2004). The VanE resistance cluster resembles structures of the 
VanC-1 cluster naturally occurring in E. gallinarum and also shows highest similarities 
with the corresponding proteins. Therefore, resistance is mediated by producing D-Ala-
D-Ser-terminated cell wall precursors. VanE type vancomycin resistance requires a VanT 
racemase converting L-Ser into D-Ser (Fines et al., 1999; Patino et al., 2002). It remains 
teicoplanin- susceptible and show moderate to low levels of inducible vancomycin 
resistance. Despite this phenotype, sequence determination suggested a putative non-
functional VanS protein indicating cross-talk between the VanR response regulator and 
other functional membrane- located kinase activators. All five consecutive genes of the 
vanE gene cluster were co-transcribed from a single promoter (Patino et al., 2004). 
 
1.2.4.3.6. VanG type resistance in Enterococcus spp. 
 E. faecalis possessing a VanG cluster were low-level vancomycin-resistant and 
teicoplanin susceptible (McKessar et al., 2000; Depardieu et al., 2003; Boyd et al., 2006). 
Resistance is mediated via inducible synthesis of D-Ala-D-Ser-terminated cell wall 
precursors. Only a few isolates have been described, and vanG gene clusters identified 
allow differentiation into two subtypes. The chromosomal vanG cluster consists of seven 
genes which according to its order and gene composition appear to be reassembled from 
different Van operons. The vanY gene is present, but a frame-shift mutation resulting in 
premature termination of the encoded protein accounted for the lack of disaccharide-
tetrapeptide precursors in the cytoplasm (Depardieu et al., 2003). VanG type resistance 
was successfully transferred in vitro and acquisition of the VanG cluster was associated 
with a transfer of a 240 Kb chromosomal fragment flanked by imperfect inverted repeats 
(Depardieu et al., 2003). Crystallisation and X-ray analysis of the VanG D-Ala-D-Ser ligase 
in complex with ADP has been recently described (Weber et al., 2009). Recently, the first 
strain of E. faecium harbouring the VanG cluster resistance mechanisms was isolated and 
shares a similar profile to the E. faecalis strain (Sassi et al., 2018).  
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1.2.4.3.7. VanL type resistance in Enterococcus spp. 
 An E. faecalis isolate from Canada expressed low levels of vancomycin resistance 
and was denoted VanL (Boyd et al., 2008). The vanL gene mediates D-Ala-D-Ser ligation 
and, the cluster was similar in organization to the vanC operon, but the VanT serine 
racemase was encoded by two separate genes including vanTm (membrane binding) and 
vanTr (racemase). The two genes resemble the two functional domains of the otherwise 
combined vanT type racemase (Boyd et al., 2008).  
 
1.2.4.3.8. VanM type resistance in Enterococcus spp. 
 The vanM genotype was identified in seven Chinese VRE isolates showing 
resistance to both vancomycin and teicoplanin from a single hospital (Xu et al., 2010). 
The translated sequence of the ligase VanM showed high sequence similarity to the VanA 
but, the vanM gene cluster shows a gene arrangement similar to vanB and vanD with the 
D,D-carboxypeptidase gene vanY preceding the ligase gene. VanM type resistance is 
transferable by conjugation in vitro and plasmid located.  
 
1.2.4.3.9. VanN type resistance in Enterococcus spp. 
 The VanN genotype was first described in E. faecium UCN71 isolated from blood 
culture. It shows resistance to vancomycin but is sensitive to teicoplanin (Lebreton et al., 
2011). It follows the same cultural architecture to VanC and VanE and also resulting in D-
Ala-D-Ser terminating pentapeptides. The VanN ligase shares 65% identity with the VanL 
ligase. Five VanN type vancomycin-resistant E. faecium strains have been further 
identified and isolated from a sample of domestic chicken meat in Japan (Nomura et al., 
2012) and more recently found to be in a plasmid form isolated from E. faecium strain 
form a 51-year male in Canada (Boyd et al., 2015).  
 
1.2.4.3.10. Other Gram-positive species with van gene clusters  
 The occurrence of the Van operon had been reported in different non-
enterococcal, human intestinal colonizers including Clostridium spp., Ruminococcus spp. 
and others (Patel 2000; Stinear et al., 2001; Domingo et al., 2005; Ballard et al., 2005; 
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Domingo et al., 2007). One of these isolates was investigated as a new naturally occurring 
vancomycin resistant species, Ruminococcus gauvreauii and possessed a vanD gene 
cluster (Domingo et al., 2007). In strains of Clostridium symbiosum an entire vanB2 type 
Tn1549 cluster was identified which was transferable in vitro and in vivo in the digestive 
tract of mice highlighting the critical role that commensal, intestinal, non-enterococcal 
hosts may play by acting as a reservoir for resistance elements by acquiring, preserving 
and distributing the vancomycin resistance genes to nosocomial pathogens (Launay et 
al., 2006). The corresponding conjugative transposon Tn1549 encodes all necessary 
functions for a successful transfer of the element across species and genus barriers also 
demonstrating its potential to transfer VanB type vancomycin resistance from 
Enterococcus spp. to other critical nosocomial pathogens like Staphylococcus spp., C. 
difficile and others (Tsvetkova et al., 2010). Conjugative transposons like Tn5397/Tn916 
(and also Tn1549) are easily exchanged between members of different bacterial species 
and genera and are identified in a wide range of different, Gram-positive bacterial species 
capable of self-transfer and mobilisation of other, genetic elements (Roberts et al., 2001; 
Jasni et al., 2010; Roberts and Mullany, 2011). 
 Certain soil bacteria produce glycopeptide antibiotics including vancomycin 
(Amycolatopsis orientalis) and teicoplanin (Actinoplanes teichomyceticus) as secondary 
metabolites. They prevent themselves from sensitivity against their own products by 
intrinsic resistance mechanisms similar but not identical to acquired resistance types in 
Enterococcus spp. (Marshall et al., 1997; Marshall et al., 1998; Patel, 2000). It was 
speculated that resistance in Enterococcus spp. originated from corresponding 
glycopeptide producers (Marshall et al., 1998; Patel 2000); however, comparably weak 
amino acid and nucleotide similarities among key genes and proteins involved in the 
resistance mechanism and the comparably high % GC of the VanRS regulatory system in 
the glycopeptide producers Streptomyces toyocaensis and A. orientalis suggested that a 
possible exchange between glycopeptide producers and nosocomial pathogens having 
acquired resistance properties did not happen recently (Courvalin, 2005).  
 
1.2.4.3.11. Vancomycin resistance in S. aureus 
 Vancomycin was once the antibiotic of choice for treating MRSA infected patients. 
Insusceptibility to vancomycin associated with treatment failure is insofar a matter of 
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serious concern. Various microbiological changes could lead to reduced susceptibility 
against vancomycin including increased cell wall thickness, activated cell wall synthesis 
and reduced autolysis. The former changes are based on a modified host gene expression 
of determinants involved in cell wall synthesis leading to a so-called “trapping effect” 
where more unlinked cell wall precursors are present being able to bind (more) 
vancomycin (“to trap” the drug) (Cui et al., 2005; Werner et al., 2008; Nannini et al., 
2010). The vancomycin intermediate-resistant phenotype (VISA) could be expressed 
homogeneously and, VISA phenotypes are not associated with the van gene acquisition. 
 Early in vitro studies demonstrated the capability of a transfer of the enterococcal 
VanA type resistance into non-virulent and virulent methicillin-resistant S. aureus (MRSA) 
rendering descendants as vancomycin and oxacillin resistant (Noble et al., 1992). The first 
clinical vanA mediated high-level vancomycin-resistant MRSA (VRSA) was isolated from a 
dialysis patient in Michigan, USA (Weigel et al., 2003; Chang et al., 2003). Since then, 
multiple cases have been described (Sievert et al., 2008; Finks et al., 2007; Nannini et al., 
2010). The USA VRSA isolates showed high-level vancomycin resistance of >32 mg L-1. All 
US patients affected by VRSA infections had a history of several underlying conditions, 
and accordingly, all of them were treated extensively with antibiotics including 
vancomycin and most of them were co-colonized with VRE, respectively. Typing of 
corresponding strains, their resistance plasmids and corresponding Tn1546 like VanA 
clusters revealed that the isolates were unique and had evolved separately. 
 From the first case-patient an MRSA strain, a VanA type E. faecalis and a VanA 
type MRSA were isolated which allowed constructing a scenario where the MRSA 
received the vanA type resistance from the resistant co-colonising E. faecalis. This has 
been confirmed by molecular analysis of the corresponding VanA type plasmids from 
related VRSA and MRSA isolates (Weigel et al., 2003; Clark et al., 2005; Zhu et al., 2008). 
The VRSA isolate contained a 58 Kb conjugative plasmid pLW1043, the MRSA contained 
a 47 Kb pAM829 plasmid, and the VRE two plasmids of 45 and 95 Kb pLW1043 was fully 
sequenced and revealed a Tn1546-like VanA cluster integrated between the blaZ (ß-
lactamase) and the aacA-aphD (gentamicin resistance) regions. It showed a mosaic-like 
structure, but the backbone was similar to staphylococcal type pSK1 plasmids and 
different from typical enterococcal plasmids suggesting acquisition of the VanA cluster 
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by a resident staphylococcal-type plasmid indicating a critical concern for the 
dissemination of VRSA clinical isolates (Kwong et al., 2008). 
 
1.2.4.4. ß -lactam antibiotics and resistance in Enterococcus spp. 
Antibiotics in the ß-lactam family target PBPs preventing crosslinking of PG by 
transpeptidation which results in the termination of cell wall synthesis. Enterococcus spp. 
can exhibit intrinsic resistance to a number of ß-lactam antibiotics, but this varies among 
the different classes of ß-lactams and between enterococcal species. This spectrum of 
antibiotic resistance is reflected in the utility of these drugs for treatment.  (Kristich 
1.2.4.3.10.., 2014). 
The intrinsic resistance of Enterococcus spp. to ß-lactams involves the production 
of the low-affinity class B PBP, Pbp5, an orthologue of the acquired PBP2a (MecA) in 
MSRA strains (See Table 1.2) (Arbeloa et al., 2004). Pbp5 is capable of carrying out PG 
synthesis in the presence of ß-lactam antibiotics in comparison to the other PBPs that are 
still sensitive and inactivated (Arbeloa, et al., 2004; Rice et al., 2005). Pbp5 is therefore a 
required component for intrinsic ß-lactam resistance in Enterococcus spp. (Kristich et al., 
2014).   
 
1.2.4.4.1. Ampicillin Resistance 
 Modifications in transpeptidase domain of Pbp5 has resulted in increase of 
ampicillin resistance where 5% of the gene (pbp5) can be altered in E. faecium strains in 
a hospital environment (Garnier et al., 2000). The sequence difference is not the only 
factor contributing to ampicillin resistance in E. faecium strains including the 
overproduction of Pbp5 (Fontana et al., 1994). The region upstream of Pbp5 has also been 
associated with ampicillin resistance. An 87 bp upstream of pbp5 in the open reading 
frame was associated with increased pbp5 levels and increased ampicillin resistance 
(Liggozzi et al., 1993). E. faecium strains can be divided into two main clades including the 
clade A1 and A2 (hospital associated) and clade B (community associated) and that both 
these clades differ in ampicillin susceptibility. This has been attributed to two different 
allele forms of the pbp5 gene whose sequences differ. These major clade rearrangements 
of pbp5 have been attributed to insertions, deletions and single nucleotide 
 54 
polymorphisms that are associated with the varying ampicillin resistance levels due to 
pbp5 (Montealegre et al., 2017).  
 
1.2.4.4.2. Cephalosporin Resistance 
Enterococcus spp. are intrinsically resistant to most cephalosporin's. 
Chromosomal determinants encode this in the core genome of these organisms, but its 
molecular basis remains to be identified. In E. faecalis, PBP5, a TCS (CroRS), a eukaryotic 
like serine/threonine kinases (eSTK), IreK, and one of the first enzymes involved in the 
synthesis of PG precursors, MurAA have been associated with intrinsic resistance in E. 
faecalis. The role of these determinants has been best studied in E. faecalis, and it 
appears likely that similar mechanisms are present in E. faecium (Sacco et al., 2014). 
 Genetic studies have demonstrated that Pbp5 has an essential role in intrinsic 
cephalosporin resistance in E. faecalis and E. faecium strains isogenic strains (Arbeloa, et 
al., 2004; Rice et al., 2005). Strains that lack pbp5 results in cephalosporin and ampicillin 
sensitivity. The deletion mutants also exhibit a decrease in resistance to the non-
cephalosporin ß-lactam including ampicillin. As Pbp5 is a class B PBP, and contains a TP 
domain, but lacks a TG domain which is necessary for cell wall biosynthesis to continue. 
During cephalosporin therapy, Pbp5 is the only functional PBP, therefore there has been 
a lot of interest in identifying a possible mechanism of TG activity in Enterococcal strains 
under cephalosporin therapy as Pbp5 must work with an alternative TG. S. aureus 
contains a monofunctional TG (MGT) but no examples have yet been identified in 
Enterococcus spp. (Kristich, 2014; Rice et al., 2005). Recently it has been shown that FtsW 
has transglycosylase activity which is not inhibited by moenomycin and therefore may 
constitute this missing GTase activity in Enterococcus spp. however this has not been 
proven yet (Meeske et al., 2016).  
 Systematic inactivation of the 17 two-component systems in the E. faecalis strain 
V583 TCSs demonstrated that a CroRS deletion rendered E. faecalis susceptible to 
cephalosporin’s, but not to other antibiotics (Hancock and Perego, 2004; Kristich, 2014). 
This is consistent with studies in another strain of E. faecalis, where the deletion of the 
genes encoding the CroRS TCS resulted in a loss of resistance to ceftriaxone (Comenge et 
al., 2003) A similar phenotype was also observed in E. faecium with the deletion of the 
CroRS TCS resulting in susceptibility to cephalosporin’s (Kellogg et al., 2017). CroR been 
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has shown to act directly as a promoter for the gene salB (Muller et al., 2006) and likewise 
SalB has been shown to be essential for intrinsic cephalosporin resistance in the E. 
faecalis strain JH2-2 (Djoric and Kristich, 2017). 
 A second signal transduction protein (IreK) is required for cephalosporin 
resistance in E. faecalis (Kristich et al., 2007). IreK is a eukaryotic-like Serine/Threonine 
kinase that contains an extracellular domain containing five penicillin-binding protein and 
serine/threonine kinases associated (PASTA) repeats. In the same operon as IreK is its 
cognitive Eukaryotic like Serine/Threonine phosphatase (eSTP) (IreP) and is thought to 
regulate the phosphorylation of IreK and its targets substrates. Deletion strains of IreK in 
the strain OG1RF has resulted in cephalosporin sensitivity and, deletion of IreP has caused 
hyper-resistance to cephalosporin’s. This highlights the key responsibly of IreP in 
regulating IreK activity (Kristich et al., 2007; Kristich et al., 2014; Yeats et al., 2002). 
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1.3. Bacterial Signalling 
 Bacteria are required to sense, respond and adapt to a wide range of 
environments to survive. They have evolved a series of mechanisms to probe variations 
in the extracellular environment that may be beneficial or detrimental to the survival of 
the organism. Extracellular signals are commonly relayed into the cells through reversible 
protein phosphorylation via protein kinases and phosphatases to result in modulation of 
their target activities. In this context, the TCSs are the best described prokaryotic 
signalling cascades which use a histidine kinase (HK) to detect extracellular 
environmental signals and are commonly found in both Gram-positive and Gram-
negative bacteria (Hoch and Silhavy, 1995). TCSs were thought to be the only way in 
which bacteria could sense their extracellular environments, but recently eukaryotic-like 
serine/threonine kinases (eSTKs) and eukaryotic-like serine/threonine phosphatases 
(eSTPs) have been found to play an essential role in prokaryotic environmental 
adaptation. Unlike their TCS counterparts, eSTKs and eSTPs are present at far fewer 
numbers per bacterial genome (Pereira et al., 2011). The VanS/VanR TCS and the 
IreK/IreP eSTK system is important for both vancomycin resistance and cephalosporin 
resistance respectively in E. faecalis, the architecture, genotypic and phenotypic roles of 
both signalling cascades will be discussed. Studies highlighting the convergence of both 
signalling cascades will also be reviewed to emphasize the importance of these two 
signalling systems and how highly evolved they have become for prokaryotic survival.  
 
1.3.1. Two-component systems 
 TCSs are considered to be one of the key and most common mechanisms in signal 
transduction in bacteria. Although they are abundant in most bacteria, they also can 
occur in yeast, fungi, archaea and some plants to regulate physiological and molecular 
processes, by sensing and responding to a specific signal (Gao and Stock, 2009). A 
bacterium can have tens to hundreds of these systems which have been implicated in 
mediating the response to a wide range of signals and stimuli including nutrients, cellular 
redox state, changes in osmolality, quorum signals and antibiotics (Bhate et al., 2015). 
Their basic architecture is formed from a membrane-bound HK which detects changes in 
its extracellular environment resulting in autophosphorylation of a particular His residue 
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within the cytoplasmic portion of the protein. The HK can then trans-phosphorylate a RR 
on an aspartate residue which acts as a transcription factor to upregulate a cellular 
response. These phosphorylation events are often labile, and a phosphatase is not usually 
required, but HKs can also exhibit phosphatase activity (Goulian., 2010; Dworkin., 2015; 
Stock et al., 2000). Well characterized TCSs included those that are involved in bacterial 
chemotaxis (Falke et al., 1997), sporulation of Bacillus subtilis (Hoch, 1993) and 
multicellular development in Myxococcus xanthus (Kaplan and Plamann, 1996).  
1.3.1.1. TCS Sensor Histidine Kinases  
HKs are multi-domain proteins and, the architecture of HKs is often complex and 
diverse. Although these proteins are prevalent in most bacteria and are important to 
study and many high-resolution structures have been solved of induvial or grouped 
domains from these proteins, a full-length structure has yet to be solved (Bhate et al., 
2015). HKs are active in the form of a dimer, which is controlled by the interaction of the 
dimerization domains of each monomer HK subunit. Dimerization of the transmembrane 
protein is also essential for its autophosphorylation and phosphorelay signal transduction 
to its RR (Taylor et al., 1981; Nikaido, 2003).  
A canonical HK model consists of an extracellular sensory domain, TM domain, 
and an intracellular kinase domain. The extracellular sensor domains are the most diverse 
domain of HKs to recognize the different ligands to upregulate a cellular response 
(Cheung and Hendrickson, 2010; Mascher et al., 2006). Although most sensor domains 
bind directly to the ligand, the binding interface can vary, for example, some HK sensors 
detect the state of a secondary protein that binds the ligand such as the sensor domain 
of LuxQ which interacts with LuxP and binds directly to AI-2 an autoinducer involved in 
light production in Vibrio harveyi (Neiditch et al., 2006). Despite the differences and 
diversity in the extracellular sensory domain, all are involved in sensing a stimulus that 
results in a conformational change that can propagate through the receptor and TM 
domains (Bhate et al.,2015). 
The TM domain is represented by an antiparallel pair of TM helix domains 
separate the extracellular sensor domain. The TM domain in many HKs form a four-helical 
bundle in the membrane with two TM helices being represented from each monomer. 
There are no crystal structures of a HK TM domain, but structures exist, but only acquired 
and solved in the monomeric form (Maslennikov et al., 2010). The TM domain for PhoQ 
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has shown through site-directed mutagenesis, disulphide crosslinking and molecular 
dynamics that a polar residue forms a small water pocket in the TM helix and is critical 
for the signal transduction (Goldberg et al., 2010; Lemmin et al., 2013).  
A variety of different signal-transducing elements can connect the extracellular 
domain and TM domain to the intracellular kinase domain. The first intercellular domain 
that is involved in signal transduction from the TM helix can vary and are predominately 
represented by either HAMP or PAS domains that reside in the cytoplasm just below the 
TM domain. These domains often reside below the TM domain and are present in either 
combination or tandem repeats. These types of transducing domains are generic and can 
be found in other bacterial and eukaryotic protein systems (Bhate et al., 2015). HAMP 
domains are formed of four parallel helical bundles with two helixes deriving from a single 
monomer. A conserved Gly residue marks the end of the first HAMP helix, and a 
conserved glutamate marks the beginning of the second HAMP helix. The PAS domains 
contain a mixed α/ß structure containing a central anti-parallel five-stranded ß-sheet 
surrounded by several helices. The central ß-sheet is curved, and the two faces make 
contacts that are critical in signalling. The inner surface is responsible for binding 
cofactors or ligands while the outer surface forms contacts between dimers or with 
flanking output helices. The architecture of a PAS domain allows ligand binding to alter 
the packing and dynamics of flanking α-helices that transmit the signal. These domains 
can function as linkers and as periplasmic linkers and are the sensor transducing domains 
for multiple HKs in B. subtilis (Chang et al., 2010; Cheung and Hendrickson, 2010).  
 
The second intracellular domain is the dimerization and histidine phosphotransfer 
(DHp) domain. This is the site of the three catalytic reactions including (i) His 
phosphorylation, (ii) phosphotransfer to the RR, and (iii) phosphatase reaction for 
bifunctional HKs. The DHp forms a homodimeric anti-parallel four-helical bundle with two 
helices connected by a hairpin loop. The catalytic His is located a few turns down the 
bundle on the solvent-exposed side of helix 1 and is the start of a stretch of seven 
conserved amino acids known as the H box (Table 1.5). Residue 2 serves to act as a 
hydrogen bond acceptor via the side chains for Asp or Glu, and residue 4 is involved with 
interactions of the acidic phosphoryl groups of the Lys and Arg residues during 
phosphotransfer. Residues 5 and 6 form a locus involved in helix bending that allows the 
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N-terminal end of helix 1 to form multiple confirmations during catalysis. The bottom of 
the DHp bundle hosts the binding interface for the RR and is connected to the catalytic 
domain through a flexible loop which is variable in size and sequence, fitting its role in 
providing a sequence-specific interaction for recognising its cognate RR (Capra and Laub, 
2012; Podgornaia et al., 2013; Bhate et al., 2015). 
 
 Table 1.5 - Commonly conserved amino acids residues located in the H box within the DHp domain of a 
prokaryotic HKs. 
 
 
The third and final intracellular domain from the TM helix is the catalytic domain 
(CA) and is the ATP binding domain containing a highly conserved α/ß sandwich with 
three helices packed against five anti-parallel ß strands. These are distinct from any 
known Ser/Thr kinases (Dutta & Inouye, 2000). The CA domain stands as a monomer 
when all of the other domains have been removed (Dutta et al., 1999). The nucleotide 
binds between two helices and is held by a loop known as the ATP lid which can adopt 
different positions upon ATP binding giving it an open or closed state upon binding to 
ATP. In the absence of ATP, this loop is partially disordered in crystal structures. Even in 
the presence of ATP, the lid shows flexibility, allowing ATP to bind and interact with the 
DHp domain for phosphotransfer. The ATP-lid also enables the CA domain to adopt 
multiple positions relative to the DHp domain, to function as a kinase, 
phosphotransferase or phosphatase in response to external stimuli. Conserved 
nucleotide binding sequences exist and comprise of the N, G1, G2, and F boxes (Kim and 
Forst, 2001). The F and G2 box resides in a highly mobile central loop containing the Phe 
residue that is located near the ATP binding cleft and extends away from the rest of the 
molecule. The G2 box forms the ATP lid that closes over the bound nucleotide. N, G1 and 
G2 motifs in solved structures make specific contacts with Mg2+ ions, phosphate oxygens 
and adenine moiety of the bound nucleotide (West and Stock, 2001). 
 
Residue 1 2 3 4 5 6 7 
AA sequence H D/E L/I K/R T/N P L 
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1.3.1.2. TCS Response Regulators 
Response regulators (RR) are the second component of the TCS and are more 
straightforward in structure than HK. They are mobile, cytoplasmic proteins that are 
composed of two primary domains; a receiver domain (REC) and an effector domain. A 
prototypical RR has an N-terminal receiver domain that participates in catalysis of 
phosphoryl transfer by accepting a phosphoryl group from its cognate HK onto a 
conserved aspartate residue. Phosphorylation of the receiver domain changes its 
conformation and causes activation of its C-terminal effector domain in a 
phosphorylation-dependent manner (Wang, 2012). The effector domain is variable in 
sequence due to its variability in different DNA sequence targets and elicits the output of 
the signalling event, allowing for a diverse array of output functions. The majority of RRs 
are transcription regulators with their effector domains acting as DNA-binding regions 
(Gao and Stock, 2009).  
The REC domain acts as a phosphorylation-induced switch and is a binary logical 
element either appearing in a phosphorylated or unphosphorylated state, although this 
is not always the case as TCSs are not restricted to on/off outputs and can be influenced 
through crosstalk. Phosphorylation in the REC domain occurs at a conserved Asp residue, 
generating a high-energy acyl-phosphate. It is thought that the acyl phosphate provides 
the energy to drive a conformational change in the REC domain (Gao and Stock, 2009). 
The REC domain has enzymatic activity, catalysing phosphotransfer and 
dephosphorylation. Phosphotransfer from HK to RR involves a complex of the two, where 
both proteins contribute to the active site. The catalytic activity of the RR is exemplified 
by its ability to autophosphorylate at the Asp residue using small-molecule 
phosphodonors such as acetyl phosphate too. However, the rate of phosphotransfer is 
much slower than that of the cognate HK (Lukat et al., 1992). The REC domain has an α/β-
fold, alternating β-strands and α-helices in the primary structure fold into a central five-
stranded parallel β-sheet surrounded by two α-helices on one side and three on the 
other. Three runs of four consecutive hydrophobic residues correspond to the three 
central β-sheet in the core of the REC domain. Conserved active site residues are located 
at the C-terminal ends of these three β-strands (1, 3 and 5). α1 is involved in binding to 
the DHp domain of HK and is likely to play an essential role in the specificity of HK-RR pair 
(Casino et al., 2009). In addition to the Asp site of phosphorylation on the β3 strand, the 
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active site contains two Asp/Glu residues on the β1 strand, that coordinate a Mg2+ ion 
(Gao and Stock, 2009). 
The effector domains are diverse in sequence and structure, in order to provide a 
variety of output responses. They can be characterised by a small number of structural 
families, named after highly characterised members. These include the OmpR/PhoB 
‘winged-helix’ domain and the four-helix NarL/FixJ ‘helix-turn-helix’ domain. The C-
terminal DNA-binding domain of the NarL/FixJ subfamily is a compact bundle of 4 α-
helices (Maris et al., 2005). In the inactive form, the REC and effector domains interact, 
masking the DNA-recognition helix (Maris et al., 2002). In the active phosphorylated 
state, the RRs dimerise and the DNA recognition helix (α9) from both monomers inserts 
into the major groove of DNA, leading to transcription. 
 
1.3.1.3. Two Component Systems in Enterococcus spp. 
 Many TCS have been identified between E. faecalis strains and describe those that 
are both HK and RR pairs. These have been classified according to previous literature and 
also using P2CS TCS database (Barakat et al., 2009; Hancock and Perego, 2002; Hancock 
and Perego, 2004). In some strains, orphan RRs are apparent, but in the strain OG1RF 
there are 16 intrinsic TCS with known HK and RR pairs, and in the V538 strain there are 
16 intrinsic and 1 acquired TCS pairs. The TCS can be organised and group according to 
the conservation of amino acids surrounding the His in the H-Box (Fabret and Hoch, 1998) 
but a some TCS HKs in E. faecalis does not fit into this current classification. Table 1.6 
summarises the grouping of TCS according to V538 and OG1RF and Figure 1.9 highlights 
the canonical architecture of these classes of the HKs in E. faecalis. All HKs in E. faecalis 
TCS localize to the membrane and have a TM domain except HK17. The majority of these 
HKs have been expressed and purified in a HK extensive study in E. faecalis and their 
phosphorylation activities further characterized (Ma et al., 2008). The majority of TCS 
found in E. faecalis share strong sequence homology with other TCS from different 
species, but it has been suggested that a small subset is specific to Enterococcus spp. The 
Van cassettes are all orthologues of the VanS and VanR TCS that is transferred through 
horizontal gene transfer and is present in other species too. The majority of TCS in 
Enterococcus spp. are yet to be functionally characterized in the genus, but some 
orthologues do exist and are highlighted in Table 1.6 where the TCS name for that species 
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is used to describe that in Enterococcus spp. The TCS in Enterococcus spp. that have been 
characterized and will be discussed include CroS/R, VicS/VicR, FsrAS/R and VanS/VanR. 
 The CroSR TCS has been shown to be essential for cephalosporin resistance in a 
study where RRs were individually knocked out from the vancomycin-resistant strain 
V538. Without the presence of CroR, intrinsically resistant Enterococcus spp. had become 
sensitive to cephalosporin's (Hancock and Perego, 2004). It has recently been 
demonstrated that a CroR knockout can interfere with the expression of other gene 
products including salB (a potential PG hydrolase), lytM (PG hydrolase), metC (PG 
hydrolase), alr (alanine racemase) and pbp5 (ß-lactam resistant PBP) (Muller et al., 2018). 
Specific to cephalosporin resistance, CroR been has shown to act directly as a promoter 
for the gene salB (Muller et al., 2006) and likewise SalB has been shown to be essential 
for intrinsic cephalosporin resistance in the E. faecalis strain JH2-2 (Djoric and Kristich, 
2017). The gene pbp5 encodes a class B PBP in Enterococcus spp. and is known to be 
sensitive to resistant cephalosporin's (Kristich et al., 2011; Arbeloa et al., 2004). 
The VicS/R TCS has been partially functionally and structurally characterised in E. 
faecalis. A VicR has been shown to be essential as a knockout could not be created in a 
RR study in E. faecalis V538 (Hancock and Perego., 2004). The structure of VicR from E. 
faecalis has been solved and, the DNA target for the promoter has been predicted (Trinh 
et al., 2007). The orthologue of VicR in B. subtilis WalR from the WalK/R TCS has also been 
shown to be essential for the organism and has been associated with PG synthesis (Libby 
et al., 2015).  
The FsrAS/R TCS in E. faecalis is a virulence regulator and is involved in the 
mediation of biofilm formation (Del Papa and Perego, 2011). The VanS/R TCS associated 
with vancomycin resistance is the most characterized system in Enterococcus spp. even 
though it is an acquired mechanism. 
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Table 1.6 - Summary and evaluation of the TCS distributed and identified in two E. faecalis strains 
including V538 and OG1RF (Adapted from Hancock and Perego, 2002). 
HK 
# 
TCS HK Group V538 OG1RF  Comments 
1 YesM/N 
Group I 
Kinases 
Yes Yes • Not functional characterised in 
Enterococcus spp. 
• Orthologue in B. subtilis 
2 LytS/R Yes Yes • Not functional characterised in 
Enterococcus spp. 
• Orthologue in S. aureus 
3 VraS/R Group II 
Kinase 
Yes Yes • Not functional characterised in 
Enterococcus spp. 
• Orthologue in S. aureus 
4 PhoP/R 
Group III 
Kinase 
Yes Yes • Functionally characterised in 
Enterococcus spp. 
5 CroS/R Yes Yes • Functional characterised in E. faecalis  
6 YclK/J Yes Yes • Not functional characterised in 
Enterococcus spp. 
• Orthologues in B. subtilis 
7 VicS/R Yes Yes • Characterised in E. faecalis 
• Orthologue in B. subtilis  
8 VncS/R Yes 
 
Yes • Not functional characterised in 
Enterococcus spp. 
• Orthologue in S. pneumoniae  
9 Unknown Yes Yes • Not functional Characterised in 
Enterococcus spp. 
10 LicS/R Yes Yes • Characterised in Enterococcus spp. 
11 VanS/R Yes No • Well characterised in Enterococcus spp. 
12 KdpD/E Yes Yes • Not functional Characterised in 
Enterococcus spp. 
• Multiple Orthologues 
13 Unknown Yes Yes • Not functional characterised in 
Enterococcus spp. 
• No known orthologues 
14 Unknown Group IV 
Kinase 
Yes Yes • Not functional characterised in 
Enterococcus spp. 
•  No known orthologues 
15 FsrAS/R Group Arg 
Kinase 
Yes Yes • Characterised in Enterococcus spp. 
16 Unknown N/A Yes Yes • Not functional characterised in 
Enterococcus spp. 
• No known orthologues 
17 Unknown N/A Yes Yes • Not functional characterised in 
Enterococcus spp. 
• No known orthologues 
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Figure 1.9:  Schematic of the canonical architecture and different types of the 17 HKs found in the E. faecalis V538 genome. They are classified by the homology of the 
residue surrounding the conserved phosphorylated His in the catalytic domain according to the classification by Fabret and Hoch., (1998) and are grouped and coloured 
accordingly.  Green rectangles highlight the TM domains and white boxes highlight the possible HAMP/PAS/GAF domains. VanSB is catagorised as a Group IIIA TCS kinase. 
Adapted from Hancock and from Perego (2002).
 65 
1.3.1.4. TCS and vancomycin resistant in Enterococcus spp. 
The mechanism of vancomycin resistance is well described in the literature and 
the architecture and function of the HK VanS and RR VanR from VanA and VanB systems 
will be discussed respectively. The VanS/R TCS is a part of the vancomycin resistance gene 
cassette that can be seen in many different Enterococcal spp. that have either acquired 
the gene cassette or forms an intrinsic part of the genome. High-level vancomycin-
resistance is associated with acquired resistance through plasmid and transposon 
mechanism, as exemplified by the VanA and VanB type resistance. A remarkable effect of 
this system is that the genes are only expressed in the presence of the drug which 
includes either vancomycin and teicoplanin for VanA resistance or just vancomycin for 
VanB. In contrast to many other antibiotic mechanisms, in strains of E. faecalis and E. 
faecium containing the Tn1549 cassette conferring VanB type resistance, it has been 
shown that the acquisition of the vancomycin resistance cassette had no fitness cost to 
the host in the absence of induction, but upon induction of vancomycin, the host not only 
had reduced fitness but was also severely impaired its ability to colonize and disseminate 
in mice (Foucault et al., 2010). The effect that the HK and RR in the TCS of the VanS/R 
system have on cellular fitness is essential in the ability for the system to work efficiently 
via an inducible system. Therefore, it is necessary for the sensor HK to efficiently detect 
the presence of glycopeptides to upregulate an efficient cellular response and the genes 
to be down-regulated when there is no vancomycin present (Foucault et al., 2010). 
VanSB catalyses both autophosphorylation and rapid phosphotransfer to VanRB 
(Wright et al., 1993). VanSB causes a 6-fold increase in VanRB~P dephosphorylation and 
acts as a VanRB specific phosphatase (Depardieu et al., 2003). The cytoplasmic domain of 
VanS can also autophosphorylate and catalyse both the phosphorylation and 
dephosphorylation of VanR in vitro (Hutchings et al., 2006). Therefore, like other TCS, 
VanS is a bifunctional protein that can switch between kinase and phosphatase activity. 
In Enterococcal spp., VanRB is converted from a monomer to a dimer upon 
phosphorylation (Depardieu et al., 2005). In the deletion of vanS in enterococci, there is 
up-regulation of expression in the vancomycin resistance genes, suggesting VanS 
negatively regulates VanR function in the absence of vancomycin. Therefore, VanR~P is 
generated in a VanS~P independent manner and VanS acts as a VanR~P phosphatase in 
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the absence of a glycopeptide inducer in which it maintains a basal expression of the van 
resistance genes (Arthur et al., 1997).  
Strains that constitutively upregulate the vancomycin-resistant genes have been 
isolated from VanB type strains. It had been identified that a T237K amino acid 
substitution in a H Box of VanSB leads to constitutive activation and has been 
demonstrated to be required for phosphatase activity (Baptista et al., 1997; Willett and 
Kirby, 2012). An 18 bp nucleotide deletion removing six amino acids (402-407) in VanSB 
was identified in a mutant strain with constitutive vancomycin resistance. This deletion 
occurs in the G2 motif which is a part of the ATP binding domain and is important in 
modulating the phosphatase actively. This deletion has been observed previously and 
was observed in vitro as well as in vivo. Therefore, this time of mutation may occur 
relatively frequently under the increased selection pressure of the antibiotic (Depardieu 
et al., 2003).  
The mechanisms of how VanR/S senses glycopeptide antibiotics is still unclear, 
and there are many theories regarding whether the glycopeptide is a direct ligand for 
VanSB or if VanSB measures the presence of vancomycin indirectly through the 
interaction with cell wall intermediates that accumulate or degrade upon antibiotic 
treatment (Hong et al., 2008). A third mechanism has been proposed that input from 
another sensory system is responsible for detecting cell wall fragments (Boudreau et al., 
2012). A signalling system that responds to cell wall fragments in E. faecalis has been 
identified as an eSTK denoted IreK (Kristich et al., 2007). As previously mentioned, the 
VanB type cluster confers resistance to vancomycin but not to teicoplanin. Previous 
resistant mutants have been isolated conferring VanB type resistance due to amino acid 
substitutions in the sensor HK. Two amino acid substitutions include S-232Y and T-237M 
in the H Box in four strains and are thought to be an indirect effect of teicoplanin 
resistance and causes impairment of vanRB phosphorylation. Amino acid substitutions in 
the glycopeptide sensor domain of VanSB led to a gain in function when induced by 
teicoplanin. The two substitutions were A-30G and D-114Y and located in the 
extracellular loop (Figure 1.10). Other mutations that have been identified in the sensor 
domain of this protein include A-167S. This suggests that this is the region that the 
glycopeptides could interact with the VanSB protein (Reynolds et al., 1989 and Baptista 
et al., 1999). This supports the idea that VanSB detects the presence of vancomycin 
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directly as these strains were resistant to vancomycin and teicoplanin but not 
moenomycin which has a different mode of action. VanA type strains are resistant to 
moenomycin as well as vancomycin and teicoplanin (Figure 1.11) (Handwerger and 
Kolokathis, 1990). Glycopeptides and moenomycin inhibit transglycosylation but through 
different mechanisms and are structurally unrelated compounds. This indicates that 
VanSA is unlikely to involve direct interaction of the drugs and that VanSA and VanSB may 
detect the presence of glycopeptides through different mechanisms. This is supported by 
the fact that there is no sequence homology in the sensor domain VanSA and VanSB 
(Figure 1.10) (Baptista et al., 1996; Evers and Courvalin, 1996). Vancomycin has been 
shown to bind directly to the sensor domain of VanS from Streptomyces coelicolor using 
a vancomycin photoprobe. This organism does not produce any glycopeptide antibiotics 
but does show resistance to vancomycin but is still sensitive to teicoplanin and therefore 
associated with the VanB phenotype (Koteva et al., 2010).  
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Figure 1.10 - CLUSTALW sequence alignment of the protein sequences of VanSA and VanSB. Sensor domain in green.  Membrane spanning regions in red. G2 box shown in 
blue. N motif highlighted in yellow. G1 motif highlighted in light blue. F motif highlighted in pink. The key conserved phosphorylated His residue in green. The mutations 
causing teicoplanin resistance in the sensor domain are boxed in Blue. The phosphorylated Thr residue (T223) associated only with VanSB is boxed. "*" amino acids are 
identical in all sequences in the alignment, ":" show where conserved amino acids substitutions have been observed and "." show where semi-conserved amino acids 
substitutions have been observed. 
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Figure 1.11 - The chemical structures of vancomycin, teicoplanin and moenomycin. Vancomycin (Left), teicoplanin (Centre) and moenomycin (Right), that can trigger 
resistance mechanisms for glycopeptide resistances depending on the type of Van resistance. Vancomycin, teicoplanin and moenomycin are inducers of VanA type 
resistance and only vancomycin is an inducer for normal VanB type resistance, unless specific mutations are introduced on the extracellular loop of the VanSB protein 
where teicoplanin can become an inducer for VanB type resistance.  
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1.3.2. Eukaryotic like Ser/Thr Kinases/Phosphatases 
The main family of Ser/Thr/Tyr protein kinases was initially described and 
highlighted in eukaryotic organisms (Hanks et al., 1988) It was initially believed that these 
kinases do not exist in bacteria, but extensive genome sequencing revealed their 
existence in many bacteria, even though Ser/Thr/Tyr protein kinases were described in E. 
coli in 1969 (Kuo and Greengard, 1969). A Ser/Thr kinase was identified in the social 
bacteria Myxococcus xanthus, with significant sequence homology to that of Eukaryotic 
kinases and denoted eukaryotic-like Ser/Thr kinases (eSTKs) (Munoz –Dorado et al., 1991; 
Pereira et al., 2011). Since the age of whole-genome sequencing, many bacteria were 
identified to contain an eSTK (Kannan et al., 2007).  
The ability for bacteria to detect changes in their extracellular environment and 
adapt accordingly was once thought to be a predominant function of the TCSs. Recently 
whole genome sequencing has also revealed that many bacteria contain eSTKs with 
signalling domains (Bakal and Davies, 2000; Pereira et al., 2011). These eSTKs share strong 
homology to that of the Hanks type eSTK but are structurally and functionally different 
to other Ser/Thr kinases in bacteria (Hanks and Hunter, 1995; Stancik et al., 2018). These 
kinases are present in all Gram-positive bacteria and have a cognate eukaryotic-like 
Ser/Thr phosphatase (eSTP) that is present in the same operon and is transcriptionally 
coupled. Unlike their TCS counterparts, eSTKs and eSTPs are also present at far fewer 
numbers per bacterial genome with one cognate pair found only in Gram-positive 
species. eSTKs are also pleiotropic in nature and phosphorylate a number of substrates 
that a crucial for cellular functions, including TCS HKs that often have only one RR partner 
(Pereira et al., 2011). 
eSTKs and eSTPs in Gram-positive bacteria are associated with many cellular 
functions including cell division, dormancy, antibiotic resistance, virulence and the 
control of transcription and translation mechanisms. Whilst the deletion of these kinase 
genes is not generally associated with essentiality, the eSTK in M. tuberculosis, PknB 
appears to have an essential role (Fernandez et al., 2006, Kang et al., 2005, Sassetti et al., 
2003).  
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1.3.2.1. Eukaryotic like Ser/Thr Kinases  
The eSTK PknB from M. tuberculosis was the first eSTK structure that was solved 
via X-ray crystallography and shown to have strong structural and mechanical similarity 
to that of the mouse cyclic AMP-dependent protein kinase (PKA) (Akamine et al., 2002; 
Ortiz-Lombardia et al., 2003; Young et al., 2003). Both PKA and PknB share a high degree 
of conservation in the intracellular kinase domain, but receptor eSTK in bacteria have an 
additional extracellular domain linked through a TM helix (Krupa and Srinivasan, 2005). 
The extracellular domain associated with eSTK in Gram-positive bacteria is the variable 
PASTA (penicillin-binding protein and Ser/Thr kinase-associated) domain (Yeats et al., 
2002).  
 
 
Figure 1.12 – Schematic highlighting the eSTK in E. faecalis, IreK and the architecture and distribution of 
PASTA domains from other Gram-positive bacteria.   
 
PASTA domains were first described in Pbp2X from S. pneumonia and including a 
structure with the ß-lactam antibiotic cefuroxime interacting with one of the PASTA 
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repeats (Yeats et al., 2002; Gordon et al., 2000). Cefuroxime bound to the PASTA domain 
is structurally analogous to that of unlinked PG, so it was proposed that these PASTA 
repeats can also bind PG. The architecture of these types of eSTK receptor proteins in 
Gram-positive have been highlighted and determined using the SMART database and 
shows how each of the PASTA domains vary in number between different Gram-positive 
bacteria not only on a genus level but also on a species level (Figure 1.12) (Letunic et al., 
2014). Structural studies of the PASTA domains from the eSTK PknB from M. tuberculosis 
and PknB from S. aureus has revealed that the PASTA domains extend into the 
extracellular space in a linear arrangement. It has been proposed that the 
autophosphorylation activity of the intracellular kinase is increased upon dimerization of 
the kinase domain mediated via a ligand-induced dimerization of the PASTA domains that 
propagates into the intracellular kinase domain (Barthe et al., 2010). PknB crystallized as 
a dimer, indicating interactions between the opposite or “back” sides of the N- terminal 
lobes of two catalytic domains (Wehenkel et al., 2006). The dimerization interface is 
conserved amongst Gram-positive receptor eSTK homologues.  
It has been shown that a PASTA containing kinase (PrkC) in B. subtilus was 
responsible for detecting PG derived muropeptides (Shah et al., 2008). It has also been 
shown that there is a direct interaction of PG with PASTA repeats or PrkC using 
biophysical techniques (Squeglia et al., 2011). This includes the PASTA domain of PrkC 
interacting with muropeptides at the meso-A2pm moiety in the third position in the 
pentapeptide stem with the Arg500 residue within the terminal PASTA domain using 
NMR (Squegila et al., 2011). Other supporting data includes homologs of PrkC also 
demonstrates that these PASTA domains interact with PG with great specificity. It was 
also demonstrated that the PASTA domains in PrkC are essential in stationary phase 
growth and not in the exponential (Libby et al., 2015).  
Biochemical evidence has recently shown that the PASTA domains form PrkC in S. 
aureus interact with Lipid II (Hardt et al., 2017). M. tuberculosis has many different 
modifications in its cell wall and PG containing a 1,6-anhydro-MurNAc and longer glycan 
chains exhibit a higher binding potency to PASTA domains and that the fourth residue in 
the peptide stem of PG was crucial for protein recognition (Wang et al., 2017). Previous 
experiments also studying PG interactions on PknB from M. tuberculosis used Surface 
Plasmon Resonance (SPR) and demonstrated that the second and third positions of the 
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peptide stem were important for binding to PASTA and also the presence of the sugar 
moieties (Mir et al., 2011). As there is high diversity in the modular structures and 
sequences found among the C-terminal sensory PASTA domains of eSTKs, different 
homologues may bind to different ligands for species-specific signalling. This is further 
exemplified by the fact that if PG is the ligand of these domains, there is already so much 
variability that can occur in PG between species.  
Recently, the four PASTA domains in StkP, the eSTK from S. pneumoniae have 
been characterized. It concluded that the first three PASTA membrane proximal domains 
had interchangeable modules and were required for StkP kinase activity. They also have 
a role in controlling and maintain the thickness of the PG cell wall with the removal of 
each PASTA domain resulting in a thinner cell wall. The fourth membrane distal PASTA 
domain had an alternative function in contrast to the other three PASTA domains and 
was found to have a unique motif that was critical in the final stages of cellular division 
and thought to interact with the cell wall hydrolase LytB (Zucchini et al., 2018).  
Although the extracellular PASTA domains and the intracellular kinase domain 
from eSTK in Gram-positive bacteria are well studied, the linker TM domains are not. The 
effect of homodimerization of PrkC in B. subtilis has been studied and showing not only 
was the extracellular domain capable of promoting dimerization, but the TM domain was 
also important in promoting dimerization (Madec et al., 2002).  
 
1.3.2.2. Eukaryotic-like Ser/Thr Phosphatases in Gram-positive bacteria  
The ability for an organism to reverse the phosphorylation event of kinases occurs 
is essential in controlling signal cascades and maintaining cell fitness in both Eukaryotic 
and Prokaryotic organisms. Unlike TCS HKs where the phosphorylated His residue is 
labile, phosphorylation of Ser, Thr and Tyr residues are not and require a cognate 
phosphatase to quench the signalling cascade (Dworkin, 2015). As it has been mentioned 
previously, eSTKs are involved in many cellular functions such as cell division and cell wall 
synthesis. Deletions of eSTPs have been shown to alter normal cell division and growth 
in bacteria. Recently it was demonstrated that MapZ, a membrane protein required for 
cell division in S. pneumoniae by identifying the division sites and positioning the Z-ring 
at the mid-cell undergoes phosphorylation by StkP (Garcia et al., 2016). 
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1.3.2.3. IreK and IreP in Enterococcus spp. 
It has been known for many years that E. faecalis are naturally resistant to the 
class of ß-lactams, the cephalosporin's, but the molecular basis to the resistance is not 
well understood. The eSTK from E. faecalis, IreK has been shown to be an essential 
protein involved in intrinsic cephalosporin resistance. Like other eSTKs, IreK is a signal 
transduction protein and exhibits a bipartite domain architecture (Figure 1.12). This 
includes the eSTK signalling domain through a putative TM segment and an extracellular 
domain comprised of PASTA domains (Kristich et al., 2007). Initial identification of Ser/Thr 
kinase domains in E. faecalis was identified by analysing the E. faecalis V583 genome 
where a homolog of the B. subtilis PrkC was identified. Phenotypic studies of its function 
showing that this protein was critical in intrinsic cephalosporin resistance led to its name 
IreK (Intrinsic resistance in Enterococcus kinase). The role of PASTA domains in IreK is not 
well understood, but it has been proposed that like other Gram-positive bacteria, that 
they bind to PG which suggests IreK could serve as a transmembrane receptor kinase that 
senses damage or perturbation of PG and that it initiates a signalling circuit to restore cell 
wall integrity (Squeglia et al., 2011). IreK differs to most other Gram-positive sensor eSTKs 
by having the most number of PASTA domains in E. faecalis with five in total (Figure 1.12). 
Its B. subtilis homologue PrkC responds to fragments of PG by growing cells as a signal to 
exit dormancy (Shah et al., 2008).  
E. faecalis IreK and its homologs in other low-GC Gram-positive bacteria are 
encoded immediately adjacent to a gene that encodes a PP2C-type protein phosphatase 
(called IreP in E. faecalis). IreP can dephosphorylate both IreK and substrates of IreK in 
vitro, and analysis of deletion mutants lacking IreP indicate that this activity is important 
in vivo. IreP mutants exhibit substantial hyper-resistance to cephalosporin's, a finding 
which is consistent with hyper-activation of the IreK kinase (Kristich et al., 2007). 
Furthermore, mutants that lack IreP exhibit a significant reduction in fitness in the 
absence of cephalosporin's compared to wild-type. E. faecalis, which indicates that 
uncontrolled activation of cephalosporin resistance mechanisms imparts a significant 
fitness cost to the cell. The complex regulatory circuitry controlling intrinsic 
cephalosporin resistance in E. faecalis may, therefore, stem from the fitness cost that is 
associated with expression of this phenotype.  
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 One known substrate of IreK is a protein of unknown function IreB but is 
widespread across low GC Gram-positive bacteria. IreB has an adverse effect on 
cephalosporin resistance and is a substrate for both IreK and IreP. Mutations on the 
phosphorylated Thr residues by IreK on IreB led to impaired cephalosporin resistance 
(Hall et al., 2013). There is an NMR structure of IreB that has revealed that it forms a 
dimer in vitro. Mutations at the dimer interface impaired IreB function and showed that 
dimerization is functionally essential for IreB (Hall et al., 2017).  
 The E. faecalis IreK homologue in E. faecium StkP has also been linked to 
cephalosporin resistance and that the activity of Pbp5 which has a low affinity to 
cephalosporin's allowing PG polymerization resume is controlled by kinase activity of StkP 
and the IreP homologue in E. faecium StpA (Desbonnet et al., 2016). The structure of StkP 
differs to that of other Gram-positive eSTKs and has an associated C-terminal tail formed 
predominantly of Ser residues. Mutations of this type result in a truncation that have ca 
cause an increase in StkP activity and are thought to occur in constitutive activation of 
the intracellular kinase portion and an increase in cephalosporin resistance. StkP and StpA 
have also been linked to alterations in PG biosynthesis. The loss of StpA activity that 
regulates StkP phosphorylation events leads to the production of DdcY, a D,D-
carboxypeptidase under the control of a TCS including the sensor HK DdcS and RR DdcR. 
The upregulation of DdcY leads to the production of tetrapeptide PG and provide a 
substrate for L,D-transpeptidases to bypass the mostly ß-lactam sensitive PBPs (Sacco et 
al., 2014).  
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1.3.3. Convergence of Eukaryotic-like Ser/Thr kinases and two-component systems 
It has previously been determined that crosstalk can occur between different TCSs 
in different organisms raising the question of there once though specificity between the 
HK and the RR. Studies of the PhoR-PhoB and the VanS-VanR TCSs have been particularly 
useful in highlighting the mechanisms used by cells to prevent cross-talk. The PhoR-PhoB 
TCS is endogenous to E. coli and allows the organism to sense and respond to changes in 
phosphate availability. The VanS-VanR TCS regulates the expression of genes conferring 
vancomycin resistance in enterococci and other Gram-positive bacteria but can be 
expressed and studied in E. coli. Cross-talk from the kinase VanS to the response regulator 
PhoB can occur in E. coli, but only in the absence of PhoR. Similarly, the kinase PhoR can 
cross-talk to the response regulator VanR, but just in the absence of VanS. In each case, 
the cross-talk is likely a consequence of eliminating the phosphatase activity normally 
provided by the other histidine kinase, which is bifunctional (Fisher et al., 1995). HKs and 
RRs each derive from paralogue gene families that share significant sequence and 
structural similarities; therefore, it is possible that cross-talk to occur in the same 
organism. It is essential for cross-talk between pathways to be kept to a minimum to 
ensure the organism can elicit the specific cellular response in the presence of a stimulus. 
It has also been demonstrated that the phosphatase activity of the sensory HK is 
vital in controlling and preventing RR cross-talk. In a study looking at the WalKR TCS in S. 
pneumoniae, it had been shown that WalK had a similar amino acid sequence to that of 
five other HKs and that there was low-level crosstalk between three of the HKs and WalR 
(Wayne et al., 2012). 
There are many similar and highly related signalling proteins in individual bacteria; 
therefore, it has been suggested that cells may take advantage of these signalling proteins 
by integrating signals or diversifying responses to enhance their ability to process 
information (Laub and Goulain, 2007). It has recently come to light that TCSs and eSTKs 
do not function in isolation but rather can converge to upregulate the same process. An 
advantage of this mechanism is that phosphohistidine and phosphoapartyl modifications 
are more labile compared to phosphothreonine and phosphoserine modifications which 
are more stable. Therefore, the convergence of these two signalling pathways could lead 
to kinetic regulation of the same pathway (Pereira et al., 2011).  
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 eSTKs have been shown to directly phosphorylate the TCS HKs including the HK 
DegS in B. subtilis showing direct phosphorylation by the eSTK PrkC (Jers et al., 2011). The 
majority of observed phosphorylation events observed between eSTKs and TCSs is 
between eSTKs and RR. The TCS WalKR is essential in B. subtilis and is involved in both PG 
biosynthesis and degradation. The RR WalR has been identified as a phosphorylation 
target of PrkC at position Thr101 immediately adjacent to the dimerization interface of 
the RR and though to influence dimerization and the DNA binding (Libby et al., 2015). 
 
1.3.4. Convergence of the E. faecalis eSTK, IreK and the vancomycin resistance TCS, 
VanS 
 In a previous study, a number of eSTKs in a range of Gram-positive bacteria and 
demonstrated cross talk between these eSTKs and TCSs (Goss, 2013). The study included 
PrkC from B. subtilis and its interaction with WalKR TCS (Libby et al., 2015), PknB from S. 
aureus and its interactions with PhoPR TCS and IreK from E. faecalis and its interaction 
with the VanSRB. 
1.3.4.1. IreK phosphorylates VanSB in vitro 
 It has been initially demonstrated that T101 on WalR is phosphorylated by the 
eSTK PrkC in B. subtilis (Libby et al., 2015; Goss, 2013). When comparing the sequence 
homology of WalR from B. subtilis to that of other TCS from other species, there was a 
conserved T101 residing in the sequence of VanRB. It was therefore hypothesised that 
T101 may be the site of phosphorylation by IreK on VanRB and contribute to the signal 
transduction cascade involved in vancomycin resistance. Initial experiments used 
recombinant expressed and affinity purified, full-length response regulator VanR, and the 
corresponding KD VanS (VanSBKD) and kinase domain of IreK (IreKKD). The hypothesis was 
explored in a classical radioactive phosphoryl-transferase assay. IreKKD was incubated 
with g32P labelled ATP and analysed by SDS-PAGE confirming autophosphorylation of IreK 
(Figure 1.13.A). Using autophosphorylated IreKKD which had been desalted to remove 
excess g32P labelled ATP, the protein was then further incubated with VanR and VanSKD 
proteins in separate experiments. This analysis revealed no distinct  phosphoryl transfer 
reaction between IreKKD and VanR but between IreKKD and VanSKD (Figure 1.13.Band 
Figure 1.13.C respectively).  
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Figure 1.13: IreKKD autophosphorylates and phosphorylates the VanSKD and not VanR of the VanB type 
Tn1549 cassette. The in vitro kinase assay included (A) 4µM IreKKD, (B) 4µM IreKKD and 4µM VanR and (C) 
4µM IreKKD and 4µM VanSKD. Samples were boiled at 95°C to ensure I was not observing phosphohistidine 
autophosphorylation. Gels were visualized by autoradiography (Goss, 2013). 
 As there was robust transphosphorylation, the in vitro phosphorylated VanSKD was 
analysed by mass spectrometry to identify the residues on VanS that underwent 
transphosphorylation by IreKKD. This analysis revealed multiple phosphopeptides with 
phosphorylation of VanS at residue T223, S243 and T244.  A series of point mutants of 
VanSKD were produced by site directed mutagenesis of T233, S243 and T242 and 
reanalysed by phosphotransfer from autophosphorylated IreKKD. This showed that the 
single amino acid substitutions of S243 and T242 had no effect on phosphoryl transfer 
from IreK to VanS but the substitution of T233A abolished the effect.   This analysis was 
extended to the corresponding IreK from Enterococcus faecium and the same 
phosphorylation pattern was found (Figure 1.14.A and Figure 1.14.B respectively). From 
the biochemical dissection, it can be concluded that IreKKD specifically phosphorylates 
VanSKD at T233 in vitro. This is in a location that is distinct from that used by VanS in its 
autophosphorylation reaction (H164) in the widely described TCS signalling cascade 
associated with vancomycin resistance (Bhate et al., 2015; Fisher et al., 1995).  
  IreP, the cognate phosphatase of IreK is normally associated with the 
physiological balance of IreK autophosphorylation (Kristich et al., 2011). Given the 
observed transfer of phosphate from IreKKD to VanSKD as reported above, the interaction 
of IreP with autophosphorylated IreKKD and phosphorylated VanSKD on T223 (as a result 
of IreKKD phosphorylation) was investigated. IreK was incubated with g32P labelled ATP 
and VanSKD prior to addition of IreP. Following an hour incubation with IreK, we analysed 
the phosphorylation state of VanS and IreK by autoradiography. In this analysis the 
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majority of both VanS and IreK had been dephosphorylated by IreP (Figure 1.15.A and 
Figure 1.15.B respectively). Furthermore, there appears to be appeared to be a shift in 
migration of the IreK sample in the SDS-PAGE analysis following dephosphorylation 
consistent with previous observations of IreK behaviour (Kristich et al., 2011). This 
demonstrates that IreK and VanSB are substrates for IreP.  
 
Figure 1.14: IreKKD from both E. faecalis (A) and E. faecium (B) phosphorylates VanSKD from the Tn1549 
cassette at position T223. The in vitro kinase assay included 2 μM E. faecalis or E. faecium IreKKD with 2 
μM of various VanSKD mutant proteins to verify the site of phosphorylation. Samples were boiled at 95°C 
to ensure I was not observing phosphohistidine autophosphorylation. Gels were visualized by 
autoradiography (Goss, 2013). 
 
Figure 1.15: The cognate phosphatase of IreK, IreP dephosphorylates IreK and its substrate VanS. The in 
vitro kinase assay included (A) 1 μM IreKKD which autophosphorylates and phosphorylates 3 μM VanSKD. 
Experiments were performed for 30 minutes at 37°C. (B) 1 μM IreKKD is incubated with 3 μM VanSKD 
where transphosphorylation is observed. 2μM IreP was added and allowed to incubate for 1 hour at 37°C. 
(Goss, 2013). 
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1.3.4.2. Staurosporine inhibits the effect of IreK phosphorylation in vitro 
 Many eukaryotic STKs are inhibited by staurosporine and that this effect may be 
extended to bacterial eSTKs as well (Lawrie et al., 1997). Staurosporine is an 
indolocarbazole compound and is known to have a range of biological activities as a result 
of its ability to bind to the ATP site of protein kinases and has been tested in an anticancer 
drug context. To test the hypothesis that staurosporine might also elicit an effect on IreK, 
the effect of increasing staurosporine concentration on IreK kinase domain 
autophosphorylation was also assessed.  Purified IreKKD was incubated with a range of 
staurosporine concentrations in the presence of ATP, prior to analysis by SDS-PAGE and 
autoradiography. This showed that with increasing staurosporine concentration, IreKKD 
autophosphorylation was reduced (Figure 1.16). 
 
Figure 1.16: Staurosporine inhibits IreKKD in vitro. The in vitro kinase experiment included Increasing 
concentration of staurosporine inhibits autophosphorylation of IreKKD. The amount of staurosporine is 
indicated above the lanes. DMSO was used as a negative control. Staurosporine was added prior to 
addition of radioactive ATP and reactions were allowed to incubate for 30 minutes at 37°C (Goss, 2013). 
1.3.4.3. Initial genetic attempts to understand the effects IreK on VanB resistance 
 Initial attempts to create a ∆ireK mutant strain in JH2-2 and JH2-2 Tn1549 were 
unsuccessful and it was concluded that ireK might be essential in the genetic background 
of that strain. It has been demonstrated previously that ireK can be deleted in an OG1RF 
strain (Kristich et al., 2007). Since an OG1RF ∆ireK strain had been created, both OG1RF 
and OG1RF ∆ireK were kindly provided by Christopher Kristich and the Tn1549 cassette 
was conjugated into both strains by Dr. Courvalin and Dr. Depardieu (Institute Pasteur). 
Unfortunately, only a single transfer event was obtained into the OG1RF ∆ireK strain but 
none was obtained into OG1RF.  
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1.4. Project Aims and Outline 
 The development of multi-drug resistance by pathogenic bacteria is an urgent 
clinical issue. A key mechanism underlying the acquisition of multi-drug resistance is 
cross-protection by one resistance mechanism for another antibiotic. The pathogen 
Enterococcus faecalis becomes resistant to the glycopeptide vancomycin when the 
bacterium acquires the Tn1549 transposon which encodes proteins that remodel the 
peptidoglycan. Enterococcus spp. that are resistant to vancomycin and has recently 
placed on the WHO priority list of antibiotic-resistant Gram-positive bacteria (Tacconelli 
et al., 2017).  The so-called VRE strains are thought to emerge in clinical settings following 
treatment with vancomycin. However, extensive epidemiological evidence, obtained 
over the past two decades, indicates that an important risk factor in VRE emergence is 
treatment with the b-lactam cephalosporins, suggesting a connection between the 
resistance to these two different classes of compounds. However, a mechanistic basis for 
this connection has been unclear. This project is aimed at investigating this question with 
the ultimate goal of identifying strategies that prevent this cross-resistance. 
 IreK from E. faecalis and homologues in other Enterococcus spp. has already been 
shown to be essential for cephalosporin resistance (Kristich et al., 2007). Preliminary data 
from my collaborators suggests that there is an interaction between IreK and the VanSB 
kinase. This thesis aims to:  
 
 (1) In considering the role of the Tn1549 cassette in relation to cephalosporin 
 resistance, is cephalosporin resistance mediated by the Vancomycin resistance 
 genes?  If not, what other genes may be implicated in this mechanism?   
 (2) Can the kinase activity of IreK be inhibited by well-defined eukaryotic kinase 
 inhibitors to restore antibiotic susceptibility?    
 (3) How does IreK function, what are its ligands and what is its cellular 
 localisation?  What extracellular ligands are implicated in binding to the PASTA 
 domains of IreK?  What influence do the PASTA domains have on cellular location?   
 (4) Does the additional PASTA domain found in Enterococcus faecalis IreK have 
 significance for ligand binding and overall structure? 
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Chapter 2. Materials and Methods 
2.1. Materials 
2.1.1. Bacterial Strains 
Bacterial strains used in this study are listed in Table 2.1 E. coli Top10 and NEB5 
were used for cloning and BL21 (DE3) cells were used for the expression of recombinant 
proteins and E. faecalis JH2-2 and OG1RF strains were used for the preparation of PG, 
mutagenesis and fluorescent microscopy experiments. Antibiotic susceptibility testing 
was performed on multiple clinical and standard isolates listed in Table 2.1. All bacterial 
strains were stored in cryogenic tubes supplemented with 20% glycerol in a -80˚C freezer. 
2.1.2. Media 
The composition of E. coli and E. faecalis culture media are described in Table 2.2. 
Selective media was supplemented with either 100 µg mL-1 Ampicillin (Amp) and either 
30 µg mL-1 or 200 µg mL-1 Erythromycin (Erm). For media containing agar, antibiotics were 
added at 50˚C and poured into sterile Petri dishes. Selective agar plates were composed 
of the required broth, to which 15 g of bacto-agar was added in 1 L of media and 
autoclaved. 
2.1.3. Buffers and solutions 
All chemicals obtained were of analytical grade unless otherwise stated. 
Companies and vendors are referenced with specific chemicals. MilliQ pure water was 
used to make all buffers. A summary of protein buffers used for the purification, storage 
and assays of recombinant proteins are summarised in Table 2.3. Buffers were sterilised 
with a 0.2 µm filter and stored at 4˚C for up to 1 month. 
2.1.4. Vectors for Cloning, Complementation and Protein Expression 
Vectors used for cloning, mutagenesis, expression of recombinant protein and 
complementation are described in Table 2.5, Table 2.6 and Table 2.7.
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Table 2.1 - Experimental Strains used for E. coli and Enterococcus spp. experiments. Relevant charactersitics and sources of each strain are included. 
Strain Relevant Characteristics Reference 
Experimental E. coli 
Top10 Δ(ara-leu) 7697 araD139 fhuA ΔlacX74 galK16 galE15 e14-  ϕ80dlacZΔM15  recA1 relA1 
endA1 nupG  rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-mcrBC)  
Grant et al., (1990) 
NEB5 F’ proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) / fhuA2∆(argF-lacZ)U169 phoA glnV44 
Φ80Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
NEB 
BL21(DE3) F- ompT hsdSB(rB-, mB-) gal dcm(DE3)  Stratagene; Studier and Moffatt (1986) 
Experimental E. faecalis  
JH2-2 FusR, RifR, JH2 spontaneous mutant Jacob and Hobbs (1974) 
JH2-2 Tn1549 VanR, vanB (Tn1549) Launay et al., 2006 
OG1RF RifR, FusR, OG1 isolate from human oral cavity Dunny et al., (1978) 
OG1RF::∆ireK RifR, FusR, ireK,  Kristich et al., 2007 
OG1RF Tn1549 RifR, FusR, VanR, vanB (Tn1549) This Study 
OG1RF ∆ireK::Tn1549  RifR, FusR, VanR, vanB (Tn1549), ∆ireK Goss, 2013 
Clinical and Control Strains  
E. faecalis ATCC 51299 VanR, vanB2 (Tn1542) ant(6)-I aac(6') aph(2"") ATCC 
E. faecium ATCC 700221 VanR, vanA (Tn1549) ATCC 
E. faecium BM4525 VanR, vanB (Tn1549) Depardieu et al.,2003 
E. faecalis ATCC 29212 CSLI Control Strain ATCC 
E. coli ATCC 25922 CSLI Control Strain ATCC 
K. pneumoniae ATCC 700603 CSLI Control Strain ATCC 
  
 84 
Table 2.2: Media used for culturing bacteria in this study. 
Name Composition Reference 
Standard Media 
LB Broth 10 g Tryptone, 5 g Sodium Chloride, 5 g Yeast Extract, prepared to 1 L in water and autoclaved N/A 
SOC 20 g Tryptone, 0.5 g Sodium Chloride, 5 g Yeast Extract, 0.2 g Potassium Chloride, 3.6 g Glucose and 1 g 
Magnesium Chloride and made up to 1 L with double-distilled water and autoclaved 
Hanahan (1983) 
BHI Manufacturer’s Instructions (Oxoid CM1135) N/A 
Media for Expression of Isotopically labelled proteins 
5x M9 Salts 32 g Sodium Phosphate Dibasic, 6 g Potassium Phosphate Monobasic, 2.5 g Sodium chloride made up to 
500 mL with double distilled water and autoclave 
Adapted from (Cai et al., 1998) 
Minimal Media 200 mL 5x M9 Salts, 2 mL 1 M Magnesium Sulphate, 100 µL Calcium Chloride Adapted from (Cai et al., 1998) 
Media for antibiotic susceptibility 
Muller Hinton II Broth See Manufacturer’s Instructions (BD L007475) N/A 
Isosensitest Broth See Manufacturer’s Instructions (Oxoid CM0471) N/A 
Media for E. faecalis competent cells 
5x M17 broth 5.0 g Pancreatic Digest of Casein, 5.0 g Soy Peptone, 5.0 g Beef Extract, 2.5 g Yeast Extract, 0.5 g Ascorbic 
Acid, 0.25 g Magnesium Sulphate and 10.0 g Disodium-glycerophosphate and was prepared to 200 mL in 
water and autoclaved 
Terzaghi and Sandine (1975) 
M17Glu 1x M17 Broth and sterile 0.5% Glucose Shepard and Gilmore (1995) 
SGM17 1x M17 Broth, sterile 0.5 M Sucrose, sterile 2% Glycine and sterile 10% Glycerol pH 7.0 Shepard and Gilmore (1995) 
SM17MC 1x M17 Broth, sterile 0.5 M Sucrose, sterile 10 mM Magnesium Chloride and sterile 10 mM Calcium 
Chloride pH 7.0 
Shepard and Gilmore (1995) 
Suc-Gly Sucrose 0,5M, and 10% Glycerol, pH 7.0 Shepard and Gilmore (1995) 
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Table 2.3: Buffers used for protein purification, storage and assays. 
Name Composition 
Buffers used for competent cells 
TFB1 30 mM potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl and 15% glycerol 
TFB2 10 mM MOPS, pH 6.5, 75 mM CaCl2, 10 mM RbCl and 15% glycerol 
General Buffers 
TAE 40 mM Tris acetate, 1 mM EDTA 
Purification of recombinant IreK domain proteins 
Buffer A 20 mM Sodium Phosphate, 500 mM Sodium Chloride, 10 mM Imidazole and 10% Glycerol, pH 7.4 
Buffer B 20 mM Sodium Phosphate, 500 mM Sodium Chloride, 200 mM Imidazole and 10% Glycerol, pH 7.4 
Gel Filtration Buffer 20 mM Sodium Phosphate, pH 7.4 
Purification of Recombinant TEV protease 
Buffer A 100 mM Tris, 20 mM Imidazole, 500 mM Sodium Chloride, 10 mM Magnesium Chloride pH 8.0 
Buffer B 100 mM Tris, 500 mM Imidazole, 500 mM Sodium Chloride, 10 mM Magnesium Chloride pH 8.0 
Dialysis Buffer 10 mM Tris, pH 8.0, 300 mM NaCl, 1 mM TCEP, 10 % glycerol 
Purification of Recombinant Atl Amidase 
Buffer A 10 mM Tris pH 8.0, 20 mM Imidazole, 500 mM Sodium Chloride 
Buffer B 10 mM Tris pH 8.0, 500 mM Imidazole, 500 mM Sodium Chloride 
Gel Filtration Buffer 10 mM TrisHCl pH 7.0 and 1 mM Calcium Chloride 
Buffers used in Biophysical Experiments 
NMR Buffer 20 mM Sodium Acetate pH 4.5 
CD and AUC Buffer 10 mM Sodium Phosphate pH 7.4 
SEC-MALS and SEC SAXS Buffer 10 mM HEPES pH 7.4 and 150 mM Sodium Chloride 
SPR Running Buffer 10 mM HEPES pH 7.4, 150 mM Sodium Chloride 0.005% (v/v) Tween-20 
SPR Regeneration Buffer 6M Guanidine Hydrochloride 
MST Buffer Phosphate Buffered Saline, 0.05% Tween  
  
 86 
Table 2.4: Plasmids used for recombinant protein expression in E. coli. 
Plasmid Features Content Cloning (Type and Features) Source and Primers Reference Vector 
pAT816 T7-6x His-VanSB KD (AmpR) E. faecalis Tn1549 VanSB KD N/A N/A Depardieu et 
al., 2003 
pET28/16 
pLG226 T7-6x His-IreK KD (AmpR) E. faecalis IreK Soluble KD N/A N/A Goss, 2013 pET Duet 
pLG234 T7-6x His-IreK KD (AmpR) E. faecium IreK Soluble KD  N/A N/A Goss, 2013 pET Duet 
pLG370 T7-IreP-6x His (AmpR) E. faecalis IreP FL N/A N/A Goss, 2013 pET Duet 
pCWT001 T7-Strep-HRV3C-IreK FL-
Thrombin-10His (AmpR) 
E. faecalis IreK FL Synthetic, codon optimised for E. 
coli expression, NcoI and XhoI 
GenScript This Study pET52b 
pCWT002 trc-TEV-6x His-IreK PASTA 
1,2,3,4 and 5 ED (AmpR) 
E. faecalis IreK PASTA 1, 2, 3, 
4 and 5 ED 
Restriction Cloning, NcoI and 
HindIII 
pCWT001, 
CWT001/CWT002 
This Study pProEX 
HTa 
pCWT003 trc-TEV-6x His-IreK PASTA 
1,2,3 and 4 ED (AmpR) 
E. faecalis IreK PASTA 1, 2, 3 
and 4 ED 
Restriction Cloning, NcoI and 
HindIII 
pCWT001, 
CWT001/CWT003 
This Study pProEX 
HTa 
pCWT004 trc-TEV-6x His-IreK PASTA 
1,2 and 3 ED (AmpR) 
E. faecalis IreK PASTA 1, 2 and 
3 ED 
Restriction Cloning, NcoI and 
HindIII 
pCWT001, 
CWT001/CWT004 
This Study pProEX 
HTa 
pCWT005 trc-TEV-6x His-IreK PASTA 1 
and 2 ED (AmpR) 
E. faecalis IreK PASTA 1 and 2 
ED 
Restriction Cloning, NcoI and 
HindIII 
pCWT001, 
CWT001/CWT005 
This Study pProEX 
HTa 
pCWT006 trc-TEV-6x His- IreK PASTA 4 
and 5 ED (AmpR) 
E. faecalis IreK KD IreK PASTA 
4 and 5 ED 
Restriction Cloning, NcoI and 
HindIII 
pCWT001, 
CWT006/CWT002 
This Study pProEX 
HTa 
pCWT007 trc-TEV-HIS- IreK PASTA 4 
and 5 (C-terminal 
truncation) ED (AmpR) 
E. faecalis IreK PASTA 4 and 
5 (C-terminal truncation) ED 
Restriction Cloning, 
NcoI and HindIII 
pCWT001, 
CWT006/CWT007 
This Study pProEX 
HTa 
pSR002 T7-AtlA-6x His (AmpR) B. subtilis AtlA catalytic 
domain 
N/A N/A Hayhurst et al., 
2008 
pET21a 
pEF1473_21 T7-EnpA-6x His 
(AmpR) 
E. faecalis EnpA 
Endopeptidase 
N/A N/A De Roca 
et al., 2010 
pET2818 
pRK793 tac-MBP-6x His-Tev (AmpR) Tobacco etch virus protease N/A N/A Kapust et al., 
2001 
pMal-C2 
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Table 2.5: Plasmids used for mutagenesis in E. faecalis strains. 
Plasmid Features Content Cloning (Type and 
Features) 
Source and Primers Reference Vector 
pCWT020 ireK 
insertion FL 
construct 
(ErmR) 
500 bp upstream and downstream flanking and 
including ireK merged leaving first 13 codons 
and last 6 codons 
Gibson Assembly 
(NEBuilder) 
OG1RF (CWT020/CWT021), pGhost9 
(CWT022/CWT023) 
This Study pGhost9 
pCWT021 ireK 
deletion FL 
construct 
(ErmR) 
500 bp upstream and downstream flanking 
ireK merged leaving first 13 codons and last 6 
codons 
Overlap Extension PCR and 
Gibson Assembly 
(NEBuilder) 
gCWT012, pGhost9 (CWT022/CWT023) This Study pGhost9 
pCWT022 ireP 
Deletion FL 
construct 
(ErmR) 
500 bp upstream and downstream flanking 
ireP leaving first 10 codons and last 10 codons. 
Overlap Extension PCR and 
Gibson Assembly 
(NEBuilder) 
gCWT013, pGhost9 (CWT022/CWT023) This Study pGhost9 
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Table 2.6: Plasmids used for complementation in E. faecalis. 
Plasmid Features Content Cloning (Type and 
Features) 
Source and Primers Reference Vector 
pCWT050 TetP-IreK FL (ErmR) E. faecalis IreK FL WT Gibson Assembly 
(NEBuilder) 
OG1RF (CWT050/CWT051), 
TetH (CWT052/CWT053) 
This Study TetH (Unpublished) 
pCWT051 TetP-IreK with a 15 aa C 
terminal truncation (ErmR) 
E. faecalis IreK minus PASTA 5 Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT054/CWT055) 
This Study TetH (Unpublished) 
pCWT052 TetP-IreK minus PASTA 5 
(ErmR) 
E. faecalis IreK minus PASTA 5 Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT054/CWT056) 
This Study TetH (Unpublished) 
pCWT053 TetP-IreK minus PASTA 4 and 
5 (ErmR) 
E. faecalis IreK minus PASTA 4 
and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT054/CWT057) 
This Study TetH (Unpublished) 
pCWT054 TetP-IreK minus PASTA 3, 4 
and 5 (ErmR) 
E. faecalis IreK minus PASTA 3, 
4 and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT054/CWT058) 
This Study TetH (Unpublished) 
pCWT055 TetP-IreK minus PASTA 2, 3, 4 
and 5 (ErmR) 
E. faecalis IreK minus PASTA 2, 
3, 4 and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT054/CWT059) 
This Study TetH (Unpublished) 
pCWT056 TetP-IreK minus PASTA 1, 2, 
3, 4 and 5 (ErmR) 
E. faecalis IreK minus PASTA 1, 
2, 3, 4 and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT054/CWT060) 
This Study TetH (Unpublished) 
pCWT057 TetP-IreK minus PASTA 1, 2 
and 3 (ErmR) 
E. faecalis IreK minus PASTA 1, 
2, 3 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT060/CWT061) 
This Study TetH (Unpublished) 
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pCWT058 TetP-IreK minus PASTA 1, 2 
and 3 and C terminal 
truncation (ErmR) 
E. faecalis IreK minus PASTA 1, 
2 and 3 with a 15 aa C terminal 
truncation 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT051 
(CWT060/CWT061) 
This Study TetH (Unpublished) 
pCWT062 TetP-IreK ∆K41R  (ErmR) E. faecalis IreK with a 
substitution ∆K41R ) 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT071/CWT072) 
This Study TetH (Unpublished) 
pCWT063 TetP-IreK minus KD (ErmR) E. faecalis IreK minus KD Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT050 
(CWT073/CWT074) 
This Study TetH (Unpublished) 
pCWT064 TetP-IreK KD and TM with S. 
aureus PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
S. aureus PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT050 (CWT075/CWT076), 
gCWT001 (CWT077/CWT078) 
This Study TetH (Unpublished) 
pCWT065 TetP-IreK KD and TM with B. 
subtilis PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
B. subtilis PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT050 (CWT075/CWT076), 
gCWT002 (CWT079/CWT080) 
This Study TetH (Unpublished) 
pCWT066 TetP-IreK KD and TM with S. 
Pyrogenes PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
S. Pyrogenes PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT050 (CWT075/CWT076), 
gCWT003 (CWT081/CWT082) 
This Study TetH (Unpublished) 
pCWT067 TetP-IreK KD and TM with L. 
monocytes PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
L. monocytes PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT050 (CWT075/CWT076), 
gCWT004 (CWT083/CWT084) 
This Study TetH (Unpublished) 
pCWT068 TetP-IreK KD and TM with S. 
coielocor PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
S. coielocor PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT050 (CWT075/CWT076), 
gCWT005 (CWT085/CWT086) 
This Study TetH (Unpublished) 
pCWT069 TetP-IreK KD and TM with M. 
tuberculosis PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
M. tuberculosis PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT050 (CWT075/CWT076), 
gCWT006 (CWT087/CWT088) 
This Study TetH (Unpublished) 
pCWT070 TetP-IreK KD and TM with B. 
sphaericus PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
B. sphaericus PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT010 (CWT089/CWT090) 
This Study TetH (Unpublished) 
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Table 2.7: Plasmids used for complementation with N-terminal GFP fusions in E. faecalis. 
Plasmid Features Content Cloning (Type and 
Features) 
Source and Primers Reference Vector 
pCWT080 TetP-mEGFP-TEV linker- 
IreK FL (ErmR) 
E. faecalis IreK FL WT with 
N-terminal mEGFP 
Gibson Assembly 
(NEBuilder) 
pCWT050 
(CWT090/CWT091), 
gCWT001 
This Study TetH 
(Unpublished) 
pCWT081 TetP-mTFP-TEV linker- 
IreK FL (ErmR) 
E. faecalis IreK FL WT with 
N-terminal mTFP 
Gibson Assembly 
(NEBuilder) 
pCWT050 
(CWT090/CWT091), 
gCWT002 
This Study TetH 
(Unpublished) 
pCWT082 TetP-mCherryP-TEV linker- 
IreK FL (ErmR) 
E. faecalis IreK FL WT with 
N-terminal mCherry 
Gibson Assembly 
(NEBuilder) 
pCWT050 
(CWT090/CWT091), 
gCWT003 
This Study TetH 
(Unpublished) 
pCWT083 TetP-mEGFP-TEV linker- 
IreK FL (ErmR) 
E. faecalis IreK FL WT with 
N-terminal codon optimised 
mEGFP 
Gibson Assembly 
(NEBuilder) 
pCWT050 
(CWT090/CWT091), 
gCWT004 
This Study TetH 
(Unpublished) 
pCWT084 TetP-IreK with a 10 aa C 
terminal truncation (ErmR) 
E. faecalis IreK minus PASTA 5 Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT054/CWT055) 
This Study TetH 
(Unpublished) 
pCWT085 TetP-IreK minus PASTA 5 
(ErmR) 
E. faecalis IreK minus PASTA 5 Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT054/CWT056) 
This Study TetH 
(Unpublished) 
pCWT086 TetP-IreK minus PASTA 4 and 
5 (ErmR) 
E. faecalis IreK minus PASTA 4 
and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT054/CWT057) 
This Study TetH 
(Unpublished) 
pCWT087 TetP-IreK minus PASTA 3, 4 
and 5 (ErmR) 
E. faecalis IreK minus PASTA 3, 4 
and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT054/CWT058) 
This Study TetH 
(Unpublished) 
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pCWT088 
 
TetP-IreK minus PASTA 2, 3, 4 
and 5 (ErmR) 
E. faecalis IreK minus PASTA 2, 3, 
4 and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT054/CWT059) 
This Study TetH 
(Unpublished) 
pCWT089 TetP-IreK minus PASTA 1, 2, 
3, 4 and 5 (ErmR) 
E. faecalis IreK minus PASTA 1, 2, 
3, 4 and 5 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT054/CWT060) 
This Study TetH 
(Unpublished) 
pCWT090 TetP-IreK minus PASTA 1, 2 
and 3 (ErmR) 
E. faecalis IreK minus PASTA 1, 2, 
3 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT060/CWT061) 
This Study TetH 
(Unpublished) 
pCWT091 TetP-IreK minus PASTA 1, 2 
and 3 and C terminal 
truncation (ErmR) 
E. faecalis IreK minus PASTA 1, 2 
and 3 with a 10 aa C terminal 
truncation 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT060/CWT061) 
This Study TetH 
(Unpublished) 
pCWT092 TetP-mEGFP (ErmR) Codon optimised mEGFP Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT060/CWT061) 
This Study TetH 
(Unpublished) 
pCWT095 TetP-IreK _K41R (ErmR) E. faecalis IreK with a 
substitution (K41R) 
Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT071/CWT072) 
This Study TetH 
(Unpublished) 
pCWT096 TetP-IreK minus KD (ErmR) E. faecalis IreK minus KD Q5 Site-Directed 
Mutagenesis - 
Deletion 
Mutagenesis of pCWT083 
(CWT73/CWT091) 
This Study TetH 
(Unpublished) 
pCWT097 TetP-IreK KD and TM with S. 
aureus PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
S. aureus PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT005 (CWT077/CWT078) 
This Study TetH 
(Unpublished) 
  
 92 
pCWT098 TetP-IreK KD and TM with B. 
subtilis PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
B. subtilis PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT006 (CWT079/CWT080) 
This 
Study 
TetH 
(Unpublished) 
pCWT099 TetP-IreK KD and TM with S. 
Pyrogenes PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
S. Pyrogenes PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT007 (CWT081/CWT082) 
This 
Study 
TetH 
(Unpublished) 
pCWT100 TetP-IreK KD and TM with L. 
monocytes PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
L. monocytes PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT008 (CWT083/CWT084) 
This 
Study 
TetH 
(Unpublished) 
pCWT101 TetP-IreK KD and TM with S. 
coielocor PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
S. coielocor PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT009 (CWT085/CWT086) 
This 
Study 
TetH 
(Unpublished) 
pCWT102 TetP-IreK KD and TM with M. 
tuberculosis PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
M. tuberculosis PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT010 (CWT087/CWT088) 
This 
Study 
TetH 
(Unpublished) 
pCWT103 TetP-IreK KD and TM with B. 
sphaericus PASTA ED (ErmR) 
E. faecalis IreK KD and TM with 
B. sphaericus PASTA ED 
Gibson Assembly 
(NEBuilder) 
pCWT083 (CWT075/CWT076), 
gCWT010 (CWT089/CWT090) 
This 
Study 
TetH 
(Unpublished) 
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Table 2.8: Primers used for sequencing and analytical PCR. 
Primer Identifier 5’-3’ Sequence 
pGhost Up GTCACGACGTTGTAAAACGACGG 
pGhost Down CTAGCGGACTCTAGAGGATCCCA 
pProEx Up AGCGGATAACAATTTCACACAGGA 
pProEx Down CGCCAGGGTTTTCCCAGTCACGAC 
TetH Up CTGGACTTCATGAAAAACTAAAAAAAATAT 
TetH Down TAAAACTTATAGGATCTGGTGCGCC 
T7 Up TAATACGACTCACTATAGGGG 
T7 Down GCTAGTTATTGCTCAGCGG 
 
Table 2.9: Primers used in the design of plasmids used for expression of recombinant protein. 
Restriction sight are in italics and underlined.  
Primer Identifier 5’-3’ Sequence 
CWT001 GATCCCATGGGCGGTAAAGATGTGGAAGTTCCGGAC 
CWT002 CGTAAGCTTTTATTAGTTGCTGGTAGATGATTCGCTGGTGGTGCT 
CWT003 CCCAAGCTTTATTATTTCGAGACATGCAGGGTAATCGTGTC 
CWT004 CCCAAGCTTTATTATTTTGAGACGTACAGCGTAACTTGACC 
CWT005 CCCAAGCTTTATTATTCGCTCACGGTCAGCGTGACTTTATC 
CWT006 GATCCCATGGGCTCGGATAAAGTCACCCTGAGCGAC 
CWT007 CCCAAGCTTTTTGCTATCGTTCGCTTTGCTGTAGTAGA 
 
 
Table 2.10: Primers used for the design of plasmids used or mutagenesis in E. faecalis. 
Primer Identifier 5’-3’ Sequence 
CWT020 ACTCATGACAACCACACCTAGATCCACAT 
CWT021 GAAAAAATTTATGAACGCGGACAATCGAAA 
CWT022 TTGATATCGAATTCCTGCAG 
CWT023 GGTACCCAATTCGCCCTATAG 
CWT032 TGGTTAATTCAAGCAATTCAAAAGGAAAAT 
CWT033 CAAATTAAACGAAAAATTTGGCGAAACCAT 
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Table 2.11: Primers used fluorescence and complementation plasmids. 
Primer Identifier 5’-3’ Sequence 
CWT050 ACAGATCTGAGCTCAAGGAGGAGACTGACCATGATAGAAATCGGCAAGAAG 
CWT051 TCTTTAGTGATGATGGTGATGGTGATGGTGTTAATTACTCGTACTACTTTCACTAG 
CWT052 CACCATCACCATCACCATC 
CWT053 GGTCAGTCTCCTCCTTGAG 
CWT054 TAACACCATCACCATCACCATCACTA 
CWT055 GCCAGCGGATGGGCTAGTTC 
CWT056 TTTGCTGACATAAAGTAATC 
CWT057 TTTACTTACATATAACGTCAC 
CWT058 TTCACTGACCGTTAAAGAG 
CWT059 CAATGAAATATATAGTAAC 
CWT060 CGACATTGCAAAGGCTAAG 
CWT061 GGTAGCGACAAAGTGACAC 
CWT062 CTCGGCATGGACGAGCTGTACAAG 
CWT063 GATGGTGATGGTGATGGTGTTA 
CWT071 CGTTGCAGTAGCCGTCTTGCGCTTTG 
CWT072  TCTCGGTCTAAAATTAAATCG 
CWT073 GGTGGTAAAGACGTTGAAGT 
CWT074 ACTGGTCAGTGTGGTGGT 
CWT075  CCGACATTGCAAAGGCTAAG 
CWT076  TAACACCATCACCATCACC 
CWT077  GGTGGCTTAGCCTTTGCAATGTCGGGGTAATAAATACGAAGAGACACC 
CWT078  AGTGATGATGGTGATGGTGATGGTGTTATTATACATCATCATAGCTGACTTC 
CWT079  GGTGGCTTAGCCTTTGCAATGTCGGATGCCTAAGGATGTCAAAATAC 
CWT080  AGTGATGATGGTGATGGTGATGGTGGTAATAATCATCTTTCGGATACTCAATG 
CWT081  TGGTGATGGTGATGGTGTTAAGGAGTCTGAGCGGTGGTTTC 
CWT082 GCTTAGCCTTTGCAATGTCGAAGCCAACATCAGTCAAGGTTC 
CWT084 TGGTGATGGTGATGGTGTTAATTCGGATATGGCACCGTTC 
CWT083 GCTTAGCCTTTGCAATGTCGTCACCAGATGAGGTAGCTG 
CWT085 TGGTGATGGTGATGGTGTTAATCGCCGAAGCCCGGCAA 
CWT086 GCTTAGCCTTTGCAATGTCGGGAAATGACAAGGTCCCTGTCCC 
CWT087 TGGTGATGGTGATGGTGTTACTGCCCAAAGCGTAGGGTAATTATC 
CWT088 GCTTAGCCTTTGCAATGTCGATCACCCGAGATGTACAAGTC 
CWT089 TGGTGATGGTGATGGTGTTAGTTTACATCATCGTAACTGAAC 
CWT090 GCTTAGCCTTTGCAATGTCGAGTCCTAAAAAGATAGCTG 
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CWT091 CTTGTAAAGCTCGTCCATGCCAA 
 
Table 2.12: gBlock Identifiers and description. Sequences are displayed in Chapter 8: Appendix 8.1 
gBlock Identifier 5’-3’ Sequence 
gCWT001 mEGFP 
gCWT002 Codon Optimised for E. faecalis mCherry 
gCWT003 Codon Optimised for E. faecalis mTFP 
gCWT004 Codon Optimised for E. faecalis mEGFP 
gCWT005 S. aureus Extracellular PASTA domains  
gCWT006 B. subtilis Extracellular PASTA domains 
gCWT007 S. pyogenes Extracellular PASTA domains 
gCWT008 L. monocytes Extracellular PASTA domains 
gCWT009 S. coelicolor Extracellular PASTA domains 
gCWT010 M. tuberculosis Extracellular PASTA domains 
gCWT011 B. sphaericus Extracellular PASTA domains  
gCWT012 500 bp up and down stream of ireK flaking the first 13 codons and last 6 codons  
gCWT013 500 bp up and down stream of ireP flaking the first 6 codons and last 6 codons 
 
2.1.5. Oligonucleotides and Synthetic DNA 
Oligonucleotides were designed against the appropriate gene or plasmid targets 
with relevant restriction enzyme or mutation sites included and ordered from Integrated 
DNA Technologies (IDT) or Sigma Aldrich for primers larger that 50 bp. A list of primers is 
summarised in Table 2.8, Table 2.9, Table 2.10 and Table 2.11 and categorised to their 
applications. Synthetic DNA was ordered from IDT (gBlocks) and was codon optimised 
where appropriate and summerised in Table 2.12.  
2.2. Methods in Molecular Biology 
2.2.1. Preparation of Competent cells 
BL21 (DE3), TOP10 and NEB5 chemically competent cells were prepared according 
to an adapted version Hanahan (1985). A single colony from an LB plate was inoculated 
in 2.5 mL LB broth and incubated overnight at 37˚C and 180 RPM. The entire culture was 
used to inoculate 250 mL of LB medium containing 20 mM MgSO4. The cells were grown 
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in a 1 L flask until A600 reached between 0.4 and 0.6. The cells were pelleted by 
centrifugation at 4,500 x g for 5 minutes at 4˚C. The supernatant was discarded, and the 
cell pellet was gently re-suspended in 40 mL TFB1 buffer and incubated on ice for 5 
minutes. The cells were pelleted by centrifugation at 4,500 x g for 5 minutes at 4˚C. The 
cells were re-suspended in 4 mL TFB2 and incubated on ice for 60 minutes and aliquoted 
into 200 µL volumes in 1.5 mL microcentrifuge tubes and stored at -80˚C. 
2.2.2. Polymerase Chain Reaction 
The composition of a standard PCR mix was followed using manufacturers 
protocol. Either Q5 or Phusion polymerase (NEB) was used. Occasionally DMSO was 
added to disrupt secondary structure formation.  Manually designed primers were 
synthesised by IDT. PCRs were performed on an SureCycler 8800 Thermal cycler following 
recommendations using the online BaseChanger tool (NEB) or NEBuilder tool (NEB).  
2.2.3. Agarose Gel Electrophoresis 
0.8 % (w/v) agarose gels were prepared in TAE buffer Table 2.3 supplemented 
with ethidium bromide. DNA was mixed with 6x DNA loading dye (NEB) according to 
manufacturer’s instructions and loaded onto the gel. Separation was achieved following 
the application of 100 V for 1 hour. DNA was visualised using a UV transilluminator. 
2.2.4. Transformation of Electrocompetent cells 
2.2.4.1. Transformation in E. coli 
Transformation of chemically competent cells were performed on E. coli BL21 
(DE3), TOP10 and NEB5 cells. Cryo-preserved competent cells were thawed on ice, mixed 
with 5 - 50 ng of plasmid DNA and incubated on ice for 30 minutes. Cells were then heat-
shocked by incubation at 42˚C for 30 seconds. Following incubation on ice for 5 minutes, 
pre-warmed SOC was added to a final volume 10 times the original cell suspension 
volume. Prior to plating on selective LB agar, cells were incubated at 37˚C at 180 RPM for 
an hour. 
2.2.4.2. Transformation in E. faecalis  
Transformation of electrocompetent cells were performed on various strains of E. 
faecalis cells. Cryo-preserved competent cells, plasmid DNA and the electroporation 
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cuvettes were chilled on ice. Competent cells were gently mixed with 100 ng - 1 µg of 
plasmid DNA. The mixture was transferred to the 2 mm electroporation cuvette and 
performed at 25 V, 200 Ohms and 2.4 kV. 1 mL of cold SM17MC was immediately added 
to the cells which were stored on ice for 5 minutes. Prior to plating on selective BHI agar, 
cells were incubated at 28˚C without agitation for 3 hours. 
2.2.5. Preparation of Plasmid DNA 
A single colony of freshly transformed Top10 or NEB5 E. coli cells were grown 
overnight in LB medium at 28˚C for pGhost9 plasmids or 37˚C for other plasmids at 180 
RPM. Plasmid DNA was isolated using GeneJET plasmid MiniPrep kit (ThermoFisher) 
according to manufacturer’s instructions. DNA concentration was determined by 
measuring the absorbance on a nanodrop (ThermoFisher). The purity of DNA was 
estimated using A260/A280 and samples with a ratio between 1.6 and 2.0 were stored at 
-20˚C. 
2.2.6. Purification of amplified DNA 
Purification of DNA after PCR was conducted using Gel purification kit (QIAGEN). 
Briefly, 40 µL of DNA with 6x Loading buffer was loaded onto a 0.8% agarose gel. The 
band was visualised on a UV transilluminator and extracted using a scalpel. Purification 
of the DNA from the gel was conducted following manufactures protocol.  
2.2.7. Restriction Digestion 
Reaction digests of PCR products and plasmids were performed using NcoI and 
HindIII from New England Biolabs (NEB). Reactions were conducted according to 
manufactures protocol. Reaction mixtures were typically 1000 ng with 10 - 20 units of 
each restriction enzyme and reaction buffer in 50 µL reaction volume. Reactions were 
incubated at 37˚C between 4 hours to overnight. Digested plasmid DNA was incubated 
with recombinant shrimp alkaline phosphatase (rSAP) for a further 30 minutes at 37˚C to 
prevent self-ligation. Enzymes were inactivated at 65˚C for 10 minutes. Digested DNA was 
separated using a gel extraction kit (QIAGEN) and re-quantified using a nanodrop 
(ThermoFisher). DpnI was occasionally added to PCRs prior to ligation to ensure any 
template plasmid DNA was removed. Reactions were incubated at 37˚C for 60 minutes 
before inactivation at 80˚C for 20 minutes. 
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2.2.8. Restriction Cloning Ligation 
Ligation mixtures composed approximately 50 ng of linearized vector with 150 ng 
of digested insert DNA, 20 units of T4 DNA ligase (NEB) and the supplied reaction buffer 
to 20 µL. Ligation reactions were incubated at 16˚C overnight. 10 µL of each reaction was 
then used to transform 100 µL of competent TOP10 or NEB5 cells. 
2.2.9. Plasmid Mutagenesis 
Plasmid mutagenesis including insertion, deletions and substitutions were carried 
out using the Q5 mutagenesis kit (NEB) according to the manufacturer’s instructions. The 
kit is advantageous as it allows amplified material to be added directly to a unique Kinase, 
Ligase and DpnI enzyme mix for ligation at room temperature and the removal of 
template DNA. 
2.2.10. Gibson Cloning 
Multiple DNA fragments were cloned together with Gibson assembly (Gibson et 
al., 2009). The NEBuilder cloning kit (NEB) was used and experiments conducted following 
manufacturer’s instructions. Briefly, the aim of Gibson assembly is to fuse two or more 
different sequences of DNA together. To achieve this, both DNA fragments must be 
modified to contain complimentary overlapping ends. The primers were designed so that 
PCR of fragment A will result in an end product containing at the 3' end of the 20 bases 
of fragment B. The PCR of the two fragments thus creates a 20 bp region of overlap 
between the two genes. 
2.2.11. Construct Validation 
Plasmid DNA constructs or genetic mutants was verified by Sanger sequencing. 5 
µL of 80 - 100 ng DNA with 5 µL of 10 µM primer (GATC-Biotech). 
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2.3. Methods in Microbiology 
2.3.1. Genetically modifying E. faecalis chromosome 
Insertion and deletions of genes was carries out by allelic exchange using the 
pGhost9 system (Maguin et al., 1992). Briefly, for gene deletions, two chromosomal 
fragments flanking roughly 500 bp upstream and downstream of the gene of interest in 
the chromosomal DNA were designed in silico and fused together and a gBlock ordered 
(Table 2.12) for both IreK and IreP. This fragment was fused together with the pGhost9 
vector via Gibson assembly. For reinsertion of ireK back into mutant OG1RF strains, a 
fragment encompassing 500 bp upstream and downstream of ireK and ireK itself was 
amplified and also used with the pGhost9 vector via Gibson assembly. The resulting 
plasmids ligations were Transformed in E. coli NEB 5α cells and incubated at 28˚C and 
selected on Erm 200 plates. Colonies were selected inoculated in a 10 mL culture for mini-
prep at 28˚C. Potential positive constructs were identified and confirmed by sequencing. 
The plasmids were then electroporated into electrocompetent OG1RF cells and selected 
at the permissive temperature (28˚C) on BHI plates with erythromycin. Single colonies 
were selected and grown overnight in BHI broth at 28˚C without shaking before diluting 
(1:100) to the non-permissive temperature 42˚C in the presence of erythromycin to select 
for single-crossover integrant. Plasmid excitation by a second recombination event was 
stimulated by growing integrant at 28˚C without erythromycin. Overnight cultures were 
passaged at least 5 times and then plated on BHI plates with and without erythromycin 
at 42˚C to confirm successful transformation. Successful targeted mutations were 
confirmed via PCR and sequencing of the PCR product.  
2.3.2. MIC Determination 
Minimum inhibitory concentrations (MICs) are defined as the lowest 
concentration of antimicrobial that will inhibit the visible growth of a micro-organism 
after overnight incubation. The range of antibiotic concentrations used for determining 
MICs is universally accepted to be in doubling dilution steps. All testing was undertaken 
according to CSLI standards or adapted when stated. The MIC defined here is 95% 
inhibition.  
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 2.3.2.1. Preparation of inoculum 
 Direct colony suspension was used to prepare MIC determination tests. This 
method is suited to fastidious organisms such as E. faecalis. Colonies are taken directly 
from the plate into sterile distilled water. The suspension should match the density of the 
0.5 McFarland standard. Suspensions should contain between 107 and 108 cfu mL-1 
depending on genus. For the agar dilution method, further dilution of suspension in 
sterile distilled water before inoculation was required 1:10 for Enterococcus spp. and CSLI 
control strains. For broth microdilution methods, a final inoculum of 5 x 105 cfu mL-1 is 
required and therefore suspensions equivalent to a 0.5 McFarland standard should be 
diluted 1:100 in broth medium used for preparing the antibiotic dilutions. 
2.3.2.2. Agar M.I.C. Evaluator method 
Strains were isolated on Iso-Sensitest agar. The MICs of various antibiotics were 
determined by the method of M.I.C. Evaluation after 24 hours of incubation. High level 
antibiotic resistance is confirmed after 48 hours. The system (Oxoid) comprises a 
predefined and continuous concentration gradient with 30 graduations of antimicrobial 
agent over a range of 256 - 0.015 µg mL-1. When applied to inoculated agar plates and 
incubated at 37˚C in an aerobic atmosphere, creates an ellipse of microbial inhibition. 
The MIC is determined where the ellipse of inhibition intersects the strip and the MIC 
corresponds to the graduation at the intersection with the strip. 
2.3.2.3. Broth microdilution method 
Antibiotic ranges are prepared one step higher than the final dilution range 
required. For microdilution experiments, the equivalent broth media was used to that in 
the E-test method. A 96 well sterile microtiter tray with appropriate antibiotics was 
labelled with triplicates at each concentration. Stock solutions of antibiotic were 
prepared according to manufactures instructions. Further dilutions were prepared in the 
chosen media for the experiment. 100 µL of antibiotic was added to each well at twice 
the concentration for the MIC. This was further diluted to the correct concentration by 
adding 100 µL of test organism in media. Inoculated and uninoculated wells of antibiotic-
free broth were included to determine the adequacy of the broth to support the growth 
of the organism and check of sterility. 
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2.3.3. Real Time Quantitative PCR analysis of transcripts 
500 µL of an overnight culture of E. faecalis was used to inoculate 50 mL BHI broth. 
Cells were incubated at 37˚C with shaking until OD600 0.6 was reached. Cells were divided 
into 10 mL fractions and incubated with and without antibiotics for 30 minutes at 37˚C 
with agitation. Cells were centrifuged (10,000 RPM; 10 minutes) and the supernatant was 
decanted into waste. E. faecalis cultures were stabilized with 300 µL TRIzol reagent 
(amicon) stored at -80˚C for at least one night. Cells were lysed via mechanical disruption 
by adding 0.2 g of 0.1 mm silica beads (BioSpec) and agitated using the FastPrep 
homogeniser (MP Biomed) with 4 cycles of 40 seconds homogenization at 6.0 m/sec with 
300 seconds rest in-between.  
Lysates were centrifuged (10,000 RMP, 10 minutes) and the supernatant 
collected. RNA was extracted using the Direct-zol RNA MiniPrep according to 
manufacturer’s instructions (Zymo Research) with on column DNase treatment. RNA was 
quantified using the Nanodrop (ThermoFisher) and 500 ng of DNase treated RNA was 
used as a template in the High-capacity cDNA reverse transcription kit using random 
hexamer primers according to manufacturer’s instructions (Applied Biosystems). qPCR 
primers were designed using Primer3Plus online qPCR primer tool. All products are 
between 70-150 bp with an annealing temperature of 60˚C. 2 primer sets were ordered 
for each locus in order to identify primers with high efficiency and low presence of primer 
dimers. RT-qPCR was performed in 10 µL reaction volumes of 1X Perfecta SYBR-Green 
(Quanta) using 2.5 µL of a 1:200 dilution of cDNA as input. A final concentration of primers 
(0.1 M) was used for all experiments. RT-PCR was performed on a Bio-Rad CFX384 Touch 
Real-Time PCR detection system with cycle parameters of: 95˚C 3 min followed by 35 
cycles of 95˚C 10 seconds, 60˚C 30 seconds. Technical triplicates were used and averaged 
to generate Ct values. Minus reverse transcriptase controls were performed to ensure 
efficient DNase treatment. Melting curves were also generated to confirm specific PCR 
products. Water controls were also used to check for primer dimers. Data was analysed 
using ∆∆Ct normalizing to 16S rRNA. 
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Table 2.13: Primers used for qPCR experiments. 
 
2.3.4. Fluorescence Microscopy 
E. faecalis cells were prepared for microscopy by inoculating 1:100 overnight 
culture into 50 mL fresh BHI media containing 20 ng uL-1 anhydrotetracycline. Cells were 
incubated at 37°C with shaking until A600 0.6 was reached. For visualization of 
membranes, the membrane dye FM4-64 (100 mg mL-1 stock; Molecular Probes) was 
added to cells at a final concentration of 10 μg mL-1 prior to mounting the cells on 
agarose-coated slides (Gene frame – ThermoFisher). The pellet was resuspended in 10 μL 
phosphate-buffered saline and added to a poly-L-lysine-pre-treated coverslip. All 
microscopy was performed on a Nikon Eclipse 90i with a 100× objective using phase 
contrast and fluorescence images and captured by using a Hamamatsu Orca-ER camera 
using Nikon Elements BR software. 
Primer Identifier  5’-3’ Sequence Target Primer Direction  Size (bp) 
CWT150 AGCAACGCGAAGAACCTTAC 16s F 
92 
CWT151 ATGCACCACCTGTCACTTTG 16s R 
CWT152 GCTAAAGCGGAAGCAGAAAC VanY F 
135 
CWT153 GCTGTTTTCATCCCAGCCATC VanY R 
CWT154 GGCTGCGATATTCAAAGCTC VanB F 
119 
CWT155 TCCGGCTTGTCACCTTTATC VanB R 
CWT156 AAAATCCGCATCTTGAATGG VanR F 
147 
CWT157 TGGGCATGAACTTCTACGTG VanR R 
CWT158 CAGGGCTGTCATCATCAGAA VanR F 
87 
CWT159 ATTATGCTGCCCGGTATGAA VanR R 
CWT160 AGCAGAACGTCAGGGAGAAG DdcR F 
117 
CWT161 TCCCTTAAACGGCCAATATG DdcR R 
CWT162 TGGCCGTTTAAGGGAAAAAT DdcR F 
77 
CWT163 TATACCCCACTCCCCAAACA DdcR R 
CWT164 CCATGATTGATCGCCTTCTT DdcY F 
124 
CWT165 TATTGTGGGCATGGCTGTTA DdcY R 
CWT166 ATCGCTTACTTTGCGCATTT DdcY F 
112 
CWT167 GGATTCAGCGAACAAGAAGC DdcY R 
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2.4. Protein Expression and Purification 
2.4.1. Expression of unlabelled proteins 
Recombinant proteins were over expressed in BL21 (DE3) E. coli strains that were 
suitable for protein expression using Isopropyl-D-1-thiogalactopyranoside (IPTG) 
induction. A single colony expressing the recombinant gene of interest was picked for a 
small-scale pre-culture in 5 mL LB broth containing Amp and incubated overnight (37˚C 
at 180 RPM). 
For large scale expression, 10 mL of the overnight small-scale pre-culture was 
used to inoculate 1 L of LB broth containing and incubated (37˚C at 180 RPM) until an 
OD600nm of 0.7-1.0 was reached. IPTG was added to each 1 L culture to a final 
concentration of 1 mM and incubated (22˚C at 180 rpm for 3 hours). Cells were harvested 
by centrifugation (10,000 x g for 10 minutes) (Beckman Coulter - Avanti J-20 XPI). The 
supernatant was discarded, and the cell pellets were collected in a falcon tube and stored 
at -80˚C. 
2.4.2. Expression of labelled proteins 
PASTA 4 to 5 with (pCWT006) were over expressed in BL21 (DE3) E. coli strains 
using IPTG induction. A single colony expressing the recombinant gene of interest was 
picked for a small-scale pre-culture in 100 mL LB broth containing Amp and incubated 
overnight (37˚C at 180 RPM). For large scale expression, 10 mL of the overnight small-
scale pre-culture was used to inoculate 2 x 1 L of LB broth containing 1 mL Amp and 
incubated (37˚C at 180 RPM) until an OD600nm 0.6 was reached. The 2 L cultures were 
harvested by centrifugation (10,000 x g for 10 minutes, 4˚C) (Beckman Coulter - Avanti J-
20 XPI). To obtain high yield of the labelled protein, the cell condensation method was 
used (Sivashanmugam et al., 2009). The supernatant was discarded, and cells washed and 
resuspended in 200 mL M9 salts. Cells were centrifuged again (10,000 x g for 10 minutes, 
4˚C) (Beckman Coulter - Avanti J-20 XPI). The supernatant was discarded and 
resuspended in 500 mL M9 media wither supplemented with 1 g 15N Ammonium chloride 
and 0.5 g 13C Glucose. Both cultures were pooled together and continued to incubate at 
25°C and 180 RPM for 1 hour to equilibrate. After 1 hour, cells were induced with 1 mM 
IPTG and allowed to express overnight. Cells were harvested by centrifugation (10,000 x 
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g for 10 minutes) (Beckman Coulter - Avanti J-20 XPI). The supernatant was discarded, 
and the cell pellets were collected in a falcon tube and stored at -80˚C. 
2.4.3. Preparation of cell lysates 
 In preparation of cell lysates, frozen cell pellets were left to thaw. Buffer A was 
added to the to 30 mL in a falcon tube and a protease inhibitor tablet (ThermoFisher - 
88666F) was added. The cells were sonicated on ice (20 seconds at 70%, x 5) using an 
ultra-sonicator (Bandelin Sonoplus) and then centrifuged (45 minutes at 50,000 x g) 
(Beckman Coulter - Avanti J-20 XPI) to remove the cell debris and produce a clear lysate 
and then stored on ice for immobilised metal ion affinity chromatography (IMAC). 
2.4.4. Protein Purification 
 The basic methods describing the main purification techniques used in this study 
are summarised below.  
2.4.4.1. Affinity Chromatography 
Proteins with a poly-histidine (x6) affinity tag were purified by immobilised metal 
affinity chromatography (IMAC) using pre-packed HiTrap HP Nickel column (GE 
Healthcare) at room temperature unless stated otherwise. Columns are washed with 10 
column volumes (CV) sterile water and equilibrated with a further 10 CV with Buffer A 
(Binding and equilibration buffer; see Table 2.3). Protein supernatant are loaded directly 
onto the column using a peristaltic pump. Columns were washed further with 10 CV 
Buffer A to remove un-bound protein. Columns were attached to an AKTA and protein 
was eluted using a gradient with Buffer B. 5 mL fractions were collected and protein 
elution was monitored by absorbance at 280 nm and occasionally also at 230 nm. 
Columns were washed with 10 CV of buffer containing 1 M imidazole, 10 CV sterile water 
and 10 CV 20% ethanol and stored at 4˚C. Columns were stripped, cleaned and recharged 
between different protein preparations following manufacturer protocols. 
 2.4.4.2. Size exclusion Chromatography 
 For highly concentrated proteins and large volumes, preparative size exclusion 
chromatography was used. Proteins were separated by size using wither a Superdex 200 
(16/60), Superdex 200 (26/60) or Superdex 75 (16/60) on an AKTA Pure system at RT. 
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Columns were equilibrated with 1.5 CV of the required buffer and samples loaded on via 
a super-loop. Elution was with 1 CV buffer at 1 mL min-1 and 5 mL fractions were collected. 
Protein elusion was monitored at 280 nm and occasionally 230 nm. For analytical studies, 
size exclusion chromatography was performed using a Superdex 200 increase 10/300 GL 
column (GE Healthcare). Pre-equilibrated columns were initially subjected to calibration 
using a LMW and HMW calibration kit (GE Healthcare) in the chosen buffer to allow for 
molecular weight determination. 100 μL of protein was loaded onto the column using an 
injection loop and elution was at 0.5 mL min-1. 
 2.4.4.3. Buffer Exchange and concentration  
 Buffer exchange was either initially through size exclusion chromatography, or 
with a VivaSpin centrifugal concentrator (Sartorius) with a molecular weight cut off either 
5 or 10 kDa unless otherwise stated. Concentrators were centrifuged at 4˚C at 3,000 x g 
in a bench-top centrifuge (Eppendorf Centrifuge 5810R) and if buffer exchange was 
required, refilled with exchange buffer until a sufficient dilution factor was reached. 
Protein solutions were concentrated until the required volume was achieved and 
subsequently quantified.  
 2.4.4.4. Protein Purification of TEV protease 
 To remove the poly-histidine tag of recombinant proteins, TEV protease was 
prepared and used. Buffers used are listed in Table 2.3. Cell pellets of TEV were re-
suspended in Buffer A on ice and passed through the cell disruptor three times (10,000 
psi). The lysate was centrifuged at 14,000 RPM for 45 minutes. The supernatant was 
collected and loaded onto a 5 mL HiTrap HP Nickel column (GE Healthcare) pre-
equilibrated with Buffer A using a peristaltic pump at 5 mL min-1. The column was loaded 
onto an AKTA and a gradient was performed from Buffer A to Buffer B from 0 to 100% 
respectively over 30 minutes at 2 mL min-1. Fractions were analysed on a 12% SDS-PAGE 
gel and fractions were pooled for dialysis overnight in dialysis buffer overnight at 4˚C. The 
protein concentration was measured using nanodrop at 8 mg mL-1 and stored at -80˚C. 
2.4.5. SDS-PAGE analysis 
 Proteins were separated and visualised under denaturing conditions by SDS- Poly- 
acrylamide Electrophoresis (SDS-PAGE) with Tris-glycine buffer with either a 12 or 15 % 
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acrylamide gels. Gels were prepared and run on the Mini- PROTEAN tetra system 
(BIORAD). 4.2 mL of the separating gel (1.75 mL distilled water, 2.5 mL 1.5 M Tris-HCl pH 
8.8, 100 µL 10% SDS, 4.0 mL 30% acrylamide (Geneflow - 12-0066), 30 µL 10% ammonium 
persulfate (APS) (fresh), 30 µl tetram-ethylethylenediamine (TEMED) (Sigma Life Sciences 
- t9281) was added and overlaid with 100% ethanol whilst it set to remove the meniscus. 
The stacking gel (6.1 mL distilled water, 2.5 mL 0.5 M Tris-HCl pH 6.8, 100 µl 10% SDS, 1.3 
mL 30% Acrylamide (Geneflow - 12-0066), 40 µl 10% ammonium persulfate (fresh), 40 µl 
TEMED (Sigma-T9281) was then added to the gel once the ethanol was removed and the 
comb was added. Protein samples for analysis were prepared in sample buffer (12% 1 M 
Tris- HCl pH 6.8, 20% glycerol, 0.4% SDS, 1% bromophenol blue, 10% β-mercaptoethanol). 
The protein samples and 10 µl of low molecular weight calibration ladder (Phosphorylase 
b, Bovine Serum Albumin, Ovalbumin, Carbonic anhydrase, Trypsin Inhibitor, β -
Lactalbumin) (GE Healthcare - 17-0446-01) were heat denatured in a heat block (80˚C for 
10 minutes). The cast gel was loaded onto the electrophoresis unit Mini-PROTEAN tetra 
system (BIORAD) and 15 µl of each sample was loaded into the respective well and gels 
were run in electrode buffer (25 mM Tris, 0.192 M Glycine, 0.1 % SDS, pH 8.3) for 45 
minutes at 180 V. Development of SDS-PAGE gels were stained overnight with instant 
blue (Expedeon - ISB1L) then washed with water. Gels were imaged GelBox (Syngene) 
with a short-pass filter. Precast gels were occasionally used for analysis using either 
Criterion TGX Stain-Free gels, 4-20% gradient gels (BIORAD) or Mini-PROTEAN TGX Stain-
Free gels, 4-20% (BIORAD). 
2.4.6. Western Blots 
 E. faecalis cells were cultures in BHI broth containing 20 ng µL-1 
anhydrotetracycline at 37°C with agitation until OD600nm = 0.6. After centrifugation (5000 
x g, 10 min, 4°C) pellets were resuspended in SDS loading buffer and cells were then lysed 
by sonication. 20 µL of crude cell extract was analysed by SDS-PAGE and transferred to a 
polyvinylidene difluoride (PVDF) membrane using a BioRad Mini Transfer Blot. The 
Western membrane was blotted in 20% milk powder in PBS buffer for 1 hour. The blot 
was washed for 3 x 5 minutes in PBS. Detection of GFP fusions was performed with an 
anti-GFP-HRP goat polyclonal antibody (ThermoFisher – GF28R) (1/2000 in 10 mL PBS-
tween) and left to incubate overnight. The blot was washed for 3 x 5 minutes in PBS. After 
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a further 1hour wash, blots were imaged by HRP chemiluminescence. Briefly a 1:1 ratio 
of the ECL substrate (BioRad) was mixed to a final volume of 10 mL. The mixed ECL 
substrate was added to the membrane for 5 minutes. After, excess ECL substrate was 
removed from the membrane and the membrane was placed in between two sheets of 
acetate. The membrane was imaged on a digital imager (Image Quant, GE). 
2.4.7. Protein Quantification 
 To determine protein concentrations the Nanodrop ND-1000 Spectrophotometer 
(Nanodrop Technologies) was used. Each purified protein construct was determined 
measuring the protein absorbance at 280 nm and the specific molecular weight and molar 
extinction coefficients of each protein construct.  
2.5. Peptidoglycan Purification and Hydrolysis 
2.5.1. Growth of Bacteria 
A single colony of E. faecalis JH2-2 was added to one litre of BHI and left overnight 
at RT without shaking. The following day, the growth phase of bacteria was recorded to 
ensure it was in the exponential phase at OD600 of 0.7. Cultures were harvested by 
centrifugation (10,000 x g for 10 minutes, RT) (Beckman Coulter - Avanti J-20 XPI). Pellets 
were harvested and resuspended in 25 mL saline buffer and frozen in liquid nitrogen. 
2.5.2. Peptidoglycan Extraction 
 PG was extracted from E. faecalis cells using boiling SDS. Briefly, the cells pellet 
was boiled with 15 mL of 8% SDS at 100˚C for 30 minutes with a magnetic stirrer and 
allowed to cool overnight. The PG was washed five times by centrifugation (12,000 x g 
for 10 min at 20˚C) with 20 mL water. The PG was serially treated overnight first at 37˚C 
with Pronase (200 µg mL-1) in 1 mL Tris-HCL (10 mM, pH 7.4) and then with trypsin (200 
µg mL1) in 1 mL phosphate buffer (20 mM, pH 7.8). The volume was adjusted to 15 mL 
with MilliQ water and treated again with 8% SDS at 100˚C for 30 minutes and left to cool 
overnight. The PG was washed five times by centrifugation (12,000 x g for 10 min at 20˚C) 
with 20 mL water. The PG was lyophilised and resuspended in MilliQ water at 20 mg ml-
1. The PG was then treated with hydrofluoric acid (48%) at 5 mg mL-1 for 48 hours at 4˚C 
to remove PG bound secondary polymers. The pellet was then washed extensively as 
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described previously at least 5 times with centrifugation. The PG was lyophilised and 
resuspended in MilliQ water at 20 mg mL-1. 
2.5.3. Peptidoglycan Hydrolysis 
 PG sacculi were digested with well-characterised enzymes that display distinct PG 
cleavage specificity. S. aureus PG fragments were a kind gift from Dr. Stephane Mesnage 
(University of Sheffield) and were prepared and purified as described in Mesnage et al., 
(2014). For E. faecalis sacculi, the following enzymes were used for PG cleavage including 
Mutanolysin, a muramidase (Sigma – M9901); the amidase domain from S. aureus AtlA 
autolysin and EnpA, an endopeptidase recombinantly expressed and purified from E. 
faecalis. Both AtlA and EnpA was expressed and purified accordingly and is previously 
described (Hayhurst et al., 2008; De Roca et al., 2010). 1 mg of PG was digested in a final 
volume of 250 µL. Specific buffers and enzyme amounts were as follows: mutanolysin, 50 
unit’s phosphate buffer (pH 6.5) and AtlA amidase, 75 µg in phosphate buffer (pH 7.5) 
containing CaCl2. Double digestion with AtlA then Mutanolysin was also in 20 mM 
phosphate buffer (pH 7.5) containing CaCl2 with a heat denaturation step in between 
(100˚C 30 mins) and then the pH adjusted (pH 6.0) before the addition of mutanolysin, 
50 units. Double digestion of Mutanolysin was also in 20 mM phosphate buffer (pH 6.5) 
then EnpA with an adjusted pH (pH 7.5) was performed with a heat denaturation step in 
between (100˚C, 30 mins) and centrifugation (22,000 x g) to obtain the soluble fragments. 
Each hydrolysis step was for 16 hours overnight at 37˚C After centrifugation for 20 min at 
22,000 x g, two-fold serial dilutions of the digestion mixtures in PBS were used to test the 
interaction of PG fragments with the PASTA domains from E. faecalis.  
2.6. Biophysical Techniques 
2.6.1. Circular Dichroism 
Recombinant proteins were diluted into 10 mM Sodium Phosphate to a final 
concentration of 50 µM. 200 µL of protein was loaded into a quartz cuvette with a path-
length of 0.1 mm. Proteins were initially characterised at 25˚C from 300 - 180 nm using 2 
nm bandwidth, 1 sec response time, 0.2 nm data pitch and 100 nm min-1 scanning speed 
on a Jasco J810 CD spectrophotometer. The High Tension (HT) was monitored in parallel 
to the spectra to ensure the salt content in the samples did not interfere with CD analysis. 
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Temperature melts (TM) were performed on proteins from 20°C to 100°C. Data was 
processed using Dichroweb (Whitmore and Wallace, 2004) and Prism (GraphPad). The 
reported TM is the inflection point of the sigmoidal curve and is calculated using the 
Boltzmann sigmoid equation below: ! = #$% + #'( − #$%1 ∙ exp /01 − (23456 7 
The Boltzmann sigmoid equation is characterised by a plateau Max (Top) and Min 
(Bottom) with a TM where the X value is exactly between top and bottom of the plateau. 
The slope indicates the range in which the temperature transition occurs.  
2.6.2. Size Exclusion Chromatography-Multiple Angle Laser Light Scattering 
 SEC-MALS experiments were performed using either a Superdex 200 HR10/30 
increase or Superdex 75 10/30 increase column (GE Healthcare) on a AKTA HPLC system 
at the Research Complex Harwell, Didcot. 100 µL of 1 mg mL-1 protein samples were 
loaded onto the size exclusion column and eluted at 0.75 mL min-1 with 1 CV (24 ml) of 
an appropriate running buffer. Protein elution was monitored using a Wyatt Technologies 
Dawn HELEOS- II light-scattering detector and an Optilab REX refractive index monitor. 
Recorded data were analysed using Astra 5.0 software (Wyatt Technologies). 
2.6.3. Size Exclusion Chromatography-Small Angel X-Ray Scattering 
SAXS data were collected on beamline BM29 from the European Synchrotron 
Radiation Facility in Grenoble (France) using the in-line Shimadzu size exclusion 
chromatography system with a Superdex 200 increase (3.2/300) (GE Healthcare) to 
separate potential oligomers and contaminants at low concentration at 0.75 mL min-1. 
Protein samples were previously dialysed, and column were equilibrated in 50 mM 
HEPES, 150 NaCl pH 7.4. 900 frames of 2 sec each was recovered over the course of each 
run. For each sample, frames were normalised to the intensity of the transmitted beam 
before being merged. The buffer was subtracted from the scattering using SCATTER. The 
radius of gyration (Rg), forward scattering intensity (I90), maximum particle dimension 
(Dmax) and distance distribution function (P(R)) was evaluated using the same software. 
The sample was positioned at 2.86m from a Pilatus detector, at a wavelength of 0.99 nm. 
To determine ab initio models, 3D envelopes were determined using the ATSAS package 
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and DAMMIF programme to generate a compact bead model fitting the experimental 
data to minimize discrepancy (Svergun, 1999). Dummy atom models from repeated 
calculations were superimposed and compared using the program DAMAVER (Volkov and 
Svergun, 2003).  
2.6.4. Surface Plasmon Resonance (SPR) 
 PASTA proteins with the 6x His-Tag were immobilised on a CM5 sensor chip using 
amine coupling at a flow rate of 10 µL min-1. Briefly, the carboxymethylated dextran 
surface was activated by injecting 40 µL of a solution containing 0.2M 1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide hydrochloride (EDC; Sigma) and 0.05 M N-
hydroxysuccinimide (NHS; Sigma). Covalent immobilization of PASTA proteins was carried 
out using 70 µL of a protein solution diluted in 10 mM sodium acetate (pH 4.5). The 
reaction was quenched with 40 µL of 1 M ethanolamine-HCl (pH 8.5).  
SPR experiments were performed on a BIACORE T200 instrument with research 
grade CM5 sensor chips at a temperature of 25°C. The running buffer was HEPES-buffered 
saline (HBS-P; 10 mM HEPES (pH 7.4), 150mM NaCl, 0.005% (v/v) Tween-20). If not 
otherwise indicated, the flow rate was 10 µL min-1. The sample compartment 
temperature was kept at 5°C. The chip was regenerated using a 1-min pulse of 6 M 
guanidine hydrochloride followed by an injection of 30 µL of HBS-P buffer. Various 
immobilization densities and flow rates were tested to test optimal steady-state analysis 
conditions. 
2.6.5. Microscale thermophoresis 
 The dissociation constant between the PASTA domains and a short list of different 
ligands from the previous SPR experiments was determined by Monolith NT.115 
(NanoTemper Technologies, Germany). Protein was labelled with red (MO-L008 NT-647) 
using Monolith NT Protein Labelling Kit Red-NHS (Nano Temper Technologies, Germany) 
according to the manufacturers protocol. The label was covalently linked to the protein 
at the x6 His site. Unlabelled ligands were serially diluted by two-fold scheme in HBS-P 
supplemented with 0.05% Tween-20. A total of 5 µL labelled PASTA proteins (200 nM) 
and 5 µL ligand titrations were mixed and incubated at room temperature for 1 h before 
loaded into standard capillaries (NanoTemper Technologies, Germany). 
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2.6.7. Analytical Ultracentrifugation  
 AUC experiments were performed at the Research complex at Harwell, Didcot. 
For, characterisation of the protein samples, SV scans were recorded for a two-fold 
protein dilution series, starting from 1 mg mL-1, unless otherwise stated. All experiments 
were performed at 50,000 RPM, using a Beckman XL-I analytical ultracentrifuge with an 
An-50Ti rotor. Data were recorded using the absorbance (at 280 nm) and interference 
optical detection systems. The density and viscosity of the buffer was measured 
experimentally using a DMA 5000M densitometer equipped with a Lovis 200ME 
viscometer module. Data and interpretation was analysed with the help of Gemma 
Harris. The partial specific volume for the protein constructs were calculated using 
Sednterp from the amino acid sequences. Data were processed using SEDFIT, fitting to 
the c(s) model. 
2.6.8. Mass Spectrometry 
 Electrospray ionisation mass spectrometry (ESI-MS) was conducted with 
assistance from Dr. Adrian Lloyd. Protein samples were buffer exchanged into 10 mM 
ammonium acetate and concentrated to a final concentration of 5 µM. Protein samples 
were mixed with an equal volume of 99.8 % (v/v) acetonitrile and 0.2 % (v/v) formic acid. 
 Samples (0.2 mL) were dispensed into glass vials and were then loaded into the 
96 well sample rack of a Waters M-class sample manager interspersed with blank vials 
containing 50% (v/v) acetonitrile and 0.1% formic acid. The sample manager was held at 
10°C and was interfaced with a Waters M-class solvent manager and a Waters Synapt G2-
Si time of flight mass spectrometer equipped with an electrospray source. 
 The synapt G2-Si was set up to run in positive ion and resolution modes, with a 
capillary voltage of 2.5 kV, a sampling cone voltage of 30 V and a source temperature of 
80°C. Desolvation gas (N2) was applied at 300 L h-1.  Data was collected in continuum 
mode at a scan rate over the desired m/z range of one per second with a total cycle time 
of 1.014 seconds.  Calibration of the instrument was carried out using 32 sodium iodide 
clusters in the m/z range 300-5000 (smallest m/z cluster = 322.809 to largest m/z cluster, 
4967.415). All 32 clusters were matched with reference values and the RMS residual of 
the resulting calibration was. 0.3 ppm. 
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 Samples were delivered to the mass spectrometer by injection of 5 µl sample into 
a solvent stream delivered at a flow rate of 30 µL min-1 by the M-class solvent manager. 
The solvent stream was composed of a 1:1 mixture of 0.1 % (v/v) formic acid in water and 
0.1% (v/v) formic acid in acetonitrile. For sample analysis the Synapt G2-Si was set to scan 
between 300 and 2500 m/z in one second scans and data was accumulated over 9 
minutes. 
 The total ion chromatograms resulting from these analysis were combined to 
generate mass spectra, where typically only the first 2 minutes of the chromatogram 
contained the ionising species of interest. Data was then interrogated using the 
Maximum Entropy algorithm to resolve the protein mass spectra to the simplest 
interpretation of the data on a mass scale. This algorithm regenerates a mock mass 
spectrum based upon its interpretation of the raw mass spectrum. We confirmed the 
quality of the Maximum Entropy interpretation of our raw data by superimposition of 
mock and raw data. 
2.6.9. Nuclear Magnetic Resonance  
 All NMR experiments were carried out at 25°C unless otherwise stated on a 700 
MHz Bruker Avance spectrometer fitted with a cryoprobe running in triple resonance 
mode for 1H/15N/13C NMR experiments. All samples were analysed in 3 mm NMR tubes 
and spectra recorded on Bruker instruments were referenced to residual water on the 
DSS scales (Wishart et al., 1995). All samples contained 10% D2O so that the spectrometer 
field was locked on to the resonance position of deuterium during acquisition. The basic 
parameters of all NMR experiments used throughout this work are listed in Table 2.14. 
2.6.8.1. 1D Experiments  
 1D proton spectra were acquired using the zggpw5 pulse programme using 
WATERGATE methods for water suppression (Liu et al., 1998). Spectra were acquired 
using 32k complex data points and 32 co-added scans. The acquisition time was 1.67 secs 
and the spectral window was 20 ppm. The data was Fourier transformed using zero-filling 
to 32k and processed using a squared sine window function. 
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2.6.8.2. 2D Experiments  
 2D 1H-15N HSQC spectra were acquired over a wide range of conditions and 
parameters to ensure the best resolution in the shorted time which is important for later 
titration experiments (Kay et al., 1992). The data were Fourier transformed using a 
zerofilling on 4k in F2 and 2k in F1. Processing was done using Gaussian multiplication 
(GM) window function with a line broadening of -10 Hz in both dimensions. Additionally, 
a polynomial baselines correction was used in F2 and a linear prediction was used in F1.  
2.6.8.3. 3D Experiments  
 The triple resonance (1H-13C-15N) experiments included CBCA(CO)NH (Grzesiek 
and Bax, 1992), CBCANH (Wittekind and Mueller, 1993), HNCA (Kay et al., 1990), 
HN(CO)CA (Bax and Ikura, 1991), HNCO (Kay et al., 1990), 15N-TOCSY-HSQC (Marion et al., 
1989b) and 15N-NOSEY-HSQC (Marion et al., 1989a). Processing was done by Fourier 
transforming using Gaussian multiplication (GM) window function and using a line 
broadening of -10 Hz in all dimensions. Baseline correction was done in F1 and linear 
prediction was used in dimensions F2 and F3. 
 Table 2.14: Pulse Programmes and basic parameters used in NMR experiments. 
Experiment Pulse Programme Scans 
Number of Points Spectral Width (ppm) 
1H 15N 13C 1H 15N 13C 
HSQC hsqcf3gpph19 32 2048 128 - 14 50 - 
HNCA hncagpwg3d 16 2048 40 90 14 32 32 
HN(CO)CA hncocagpwg3d 16 2048 40 90 14 32 32 
HNCO hncogpwg3d 16 2048 40 80 14 32 22 
HN(CA)CO hncacogpwg3d 16 2048 40 65 14 32 22 
HNCACB hncacbgpwg3d 32 2048 40 110 14 32 75 
HN(CO)CACB cbcaconhgpwg3d 32 2048 40 100 14 32 75 
Experiment Pulse Programme Scans 
Number of Points Spectral Width (ppm) 
1H 15N 15N 1H 1H 1H 
15N-HSQC-TOCSY dipsihsqcf3gpsi3d 56 2048 40 90 14 40 14 
Experiment Pulse Programme Scans 
Number of Points Spectral Width (ppm) 
1H 15N 15N 1H 15N 1H 
15N-HSQC-NOSEY noesyhsqcfpf3gpsi3d 40 2048 40 90 14 40 14 
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2.6.8.4. NMR Titration Experiments 
 HSQC spectra were used to monitor interactions between vancomycin and ther 
terminal PASTA domains 4-5 from IreK. Eight aliquots of vancomycin were prepared with 
a total amount of ligand corresponding to 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 mM in 200 µL 
and the aliquots were lyophilised in 1.5 mL microcentrifuge tubes (Table 2.15).  
Table 2.15: Overview of lyophilized ligand aliquots for incremental titration experiments for chemical 
shift perturbation experiments with 15N-PASTA 4 to 5. 
 Ref. Exp. 1 Exp. 2 Exp. 3 Exp.4 Exp. 5 Exp. 6 Exp. 7 
Protein Conc. 1 mM 1 mM 1 mM 1 mM 1 mM 1 mM 1 mM 1 mM 
Ligand Increment - 0.125 mM 0.25 mM 0.5 mM 1 mM 2 mM 4 mM 8 mM 
Ligand Conc. 0 mM 0.25 mM 0.5 mM 1 mM 2 mM 4 mM 8 mM 16 mM 
 
 After HSQC acquisition of the reference sample containing only protein, the ligand 
concentration was increased stepwise by transferring the protein sample to the 
microcentrifuge tube with the denoted amount of vancomycin prior to acquisition of the 
next HSQC spectrum. The pH and temperature were maintained throughout 
experiments. Saturation was not achieved as protein samples began to aggregate at 16 
mM and impaired the HSQC resolution. A total of eight spectra were acquired by 
repeating this procedure totalling in one reference spectrum and seven titration 
experiments. The protein was equilibrated inside the NMR spectrometer for 15 minutes 
at 25°C before starting the NMR spectra acquisition. Once the HSQC spectrum was 
obtained, the sample was removed from the spectrometer and transferred to the first 
microcentrifuge containing the lyophilized ligand and vortexed and centrifuged (5000 x 
RCF, 1 min, RT) and transferred to the previously used NMR tube and re-equilibrated in 
the NMR spectrometer as described. This process was repeated for each ligand.   
2.6.8.5. Data Processing 
 Spectra were processed using Topspin 4.0.2 and analysed using CCPN Analysis 
Assign (Fogh et al., 2002; Vranken et al., 2005). 
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Chapter 3. Phenotypic characterisation of IreK in 
E. faecalis 
3.1. Introduction  
 Our collaborators in the Dworkin group at Columbia University (New York) 
demonstrated that there is an in vitro interaction between IreK and VanSB. The IreKKD 
domain phosphorylated VanSKD on position T223 and that the cognate phosphatase of 
IreK (IreP), dephosphorylates IreK and the associated substrate VanSB. Early experiments 
tried to obtain an E. faecalis isogenic series to compare the effect of both Irek and the 
Tn1549 cassette but were unsuccessful in obtaining the full strain series. The aim of this 
chapter is to build on the work that has already been conducted in the Dworkin group by 
complementing the in vitro biochemical experiments to gain a further understanding on 
the effects of IreK in antibiotic resistance.  
 An isogenic series of mutants to study the effect of IreK and Tn1549 in antibiotic 
resistance was constructed to study their effect in antibiotic resistance. Other 
experiments include methods to understand the role of staurosporine and other 
inhibitors on IreK in vivo and also the relationship between the intracellular KD and 
extracellular PASTA domains of IreK and its overall roles in the capacity of antibiotic 
resistance in E.  faecalis.   
3.2. E. faecalis isogenic series to study antibiotic resistance 
mechanisms 
 To understand the consequences for VanB resistance mechanisms of IreK, a set of 
isogenic strains were constructed to study the potential effects in vivo. An isogeneic 
series was generated in a suitable parental strain of E. faecalis. Analysis between OG1RF 
and V583 conferring VanB type resistance has demonstrated that OG1RF is clonally 
distinct from V583 (Nallapareddy et al., 2005). Although OG1RF does confer rifampicin 
and fusidic acid resistance, up to one quarter of the DNA from V583 has derived from 
mobile elements which confers multiple antibiotic resistance determinants, and 
therefore makes it a difficult strain to create mutants and study antibiotic resistance and 
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therefore is unsuitable to use in this study (Sahm et al., 1989). OG1 strains and derivatives 
have also been successfully used in animal models to characterise virulence of E. faecalis 
including peritonitis in a mouse model (Singh et al., 1998), endophthalmitis in a rabbit 
model (Mylonakis et al., 2002), endocarditis in a rat model (Singh et al., 2005) and UTIs 
in a mouse model (Singh et al., 2007). OG1RF has also been shown to be as virulent as 
V583 in the model Caenorhabditis elegans (Sifri et al., 2001). For this reason, OG1RF was 
chosen as a model strain for the construction of the isogenic series. Additional 
advantages of OG1RF as a strain to create an isogenic series are that is does not carry any 
plasmids, it is readily transformable by electroporation and it is not resistant to any other 
antibiotics other than rifampicin and fusidic acid and these resistances were selected in 
the OG1 derivative to provide strain markers (Oliver et al., 1977). The lack of resistance 
to common antibiotics facilitates the selection of plasmids, transposons and allelic 
replacement markers into the strain (Bourgogne et al., 2008). JH2-2 is another laboratory 
strain of E. faecalis that is well characterised and in a previous study has successfully had 
the Tn1549 transposon conferring VanB type resistance transfer into the strain and 
therefore enables another platform for an isogenic series to study the interaction 
between IreK and the Tn1549 cassette (Quintiliani and Courvalin, 1994).  
3.2.1. Construction of the OG1RF ∆ireK and Tn1549 isogenic series 
 The principle strains used in this study include OG1RF, a common lab strain of E. 
faecalis, OG1RF ∆ireK, a kind gift from Christopher Kristich and OG1RF::Tn1549 ∆ireK is a 
strain created for a previous study (Goss, 2013) where Tn1549 was conjugated into E. 
faecalis, OG1RF ∆ireK. Unfortunately, in that study Tn1549 could not be conjugated 
successfully into OG1RF WT strain after many attempts. To ensure we had the full 
isogenic strain library, we took an inverse approach. We reinserted ireK back into the 
OG1RF::Tn1549 ∆ireK strain. We used the pGhost9 system (Maguin et al., 1996) to make 
the genetic insertion of ireK back into the OG1RF::Tn1549 ∆ireK . 
 The pGhost9 system is an efficient insertional mutagenesis method by associating 
the insertion sequence ISS1 (transposable bacterial sequences) with the thermosensitive 
replicon pGhost. This mutagenic tool, named pGhost9::ISS1, can be used even in poorly 
transformable strains, and has been reported to be transformed in a number of 
Enterococcus, Lactobacillus, Lactococcus, and Streptococcus species. High frequency 
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transposition using pGhost9::ISS1 allows efficient gene inactivation and direct cloning of 
DNA surrounding the insertion. Excision of the plasmid replicon by a temperature shift, 
gives rise to a stable mutant strain, which doesn’t contain any antibiotic resistant 
markers. This is achieved when pGhost9::ISS1 is transformed at a permissive 
temperature, and transposition is selected for at a higher non-permissive temperature. 
This temperature increase causes the replicative transposition of the ISS1 sequences to 
insert into the chromosome and leads to the integration of the plasmid vector. 
Transposition is therefore revealed by selection for antibiotic-resistant clones able to 
grow at a temperature restrictive for plasmid replication.  
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Figure 3.1: Schematic of inserting the ireK gene back into an OG1RF::Tn1549 strain using the pGhost9 
plasmid. This strategy resulted in scarless insertion of ireK gene from the OG1RF::Tn1549 ∆ireK strain via 
homologous recombination. The erythromycin cassette allowed for selection of single cross over events 
(SCO). Passaging positive SCO without erythromycin allowed for selection of double cross over events 
(DSO). Positive constructs were PCR amplified and sequence to confirm insertion.  
 The schematic for the insertion is depicted in Figure 3.1. Using OG1RF WT as a 
template, ireK and sequences immediately 500 bp upstream and downstream of ireK 
were amplified and inserted into the temperature-sensitive pGhost9 plasmid through 
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Gibson assembly. After transformation into E. faecalis the plasmid is propagated at the 
permissive temperature (28˚C) with antibiotic selection. It is shifted to the non-
permissive temperature (42˚C) in the presence of antibiotic selection to stimulate single 
crossover events to occur. After selecting for single crossover events, the cultures are 
further shifted back to the permissive temperature in absence of selection and screened 
for double crossover events by passaging into BHI (at least 5 times) and screened on both 
BHI only and BHI Erm30 plates. Double cross over events were confirmed when no 
colonies are present on the BHI Erm plates but are present on the BHI only plates. The 
strain was screened via PCR using primers that flank the gene of interest to confirm the 
successful insertion of ireK to form an OG1RF::Tn1549 ∆ireK strain. A summary of strains 
is in Table 3.1.  
3.2.2. Construction of the JH2-2 ∆ireK isogenic series 
 Although other groups had tried to create a ∆ireK deletion strain in both JH2-2 
and JH2-2::Tn1549, it was attempted again in this study to try and obtain another isogenic 
series to compare the effects ireK and Tn1549 on the OG1RF isogenic series. The pGhost9 
system was used again and a plasmid construct containing 500 bp upstream and 
downstream flanking ireK and inserted into the temperature sensitive pGhost9 plasmid 
(pCWT021). Unfortunately, neither single or double crossover events were observed.  
3.2.3. Construction of ∆ireP strains in OG1RF 
 Deletion of ireP in OG1RF and OG1RF::Tn1549 was attempted to understand the 
effects of the cognate phosphatase in a Tn1549 background. The pGhost9 system was 
used and a plasmid construct containing 500 bp upstream and downstream flanking ireP 
was inserted into the temperature sensitive pGhost9 plasmid (pCWT022). Although a 
single and double crossover event was observed and selected in the OG1RF WT strain 
which has previously been observed (Kristich et al., 2011), after several attempts, a ∆ireP 
strain was not observed in the single and double crossover events.  
  
 120 
 
Table 3.1: Summary of E. faecalis isogenic experimental strains and the associated genotype used in the 
study. 
 
OG1RF JH2-2 
Wild Type Wild Type 
∆ireK - 
Tn1549 (vanB) Tn1549 (vanB) 
Tn1549 ∆ireK (vanB) - 
 
3.3 Tn1549 is required for enhanced cephalosporin 
resistance and ireK is essential for both intrinsic and 
enhanced cephalosporin resistance in OG1RF strains 
 The effect of the presence of the Tn1549, VanB resistance genes was probed by 
measuring the MIC of these strains in the presence of a range of cephalosporin antibiotics 
Table 3.2). There was a significant difference in MIC when comparing OG1RF Wild-type 
(WT), ∆ireK and derivatives containing the Tn1549 resistance cassette. The MIC of 
vancomycin in OG1RF increases 16-fold, from 4 to 64 µg mL-1 in the presence of the 
Tn1549 cassette.  There was no change in MIC in the presence of teicoplanin which is to 
be expected as Tn1549 cassette conferring VanB type resistance is reported to be 
resistant to vancomycin but not teicoplanin (Garnier et al., 2000).  
 When challenged by cephalosporin antibiotics, the intrinsic resistance of the 
OG1RF strains containing the Tn1549 cassette increases significantly compared to WT 
OG1RF. Whilst vancomycin enhanced cephalosporin susceptibility has been seen in the 
past, this is the first time to our knowledge that the presence of the Tn1549 cassette upon 
enhanced cephalosporin resistance in E. faecalis has been observed in the absence of 
vancomycin (Kristich et al., 2007; Kristich et al., 2011). The addition of the Tn1549 
cassette causes a remarkable 128-fold increase in cefotaxime resistance in comparison 
to the OG1RF WT strain. 
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Table 3.2: Tn1549 causing VanB type resistance causes enhanced cephalosporin resistance: MIC OG1RF 
WT/Tn1549 with cephalosporin’s and vancomycin. E. faecalis ∆ireK strains in both WT and Tn1549 
strains removes intrinsic and enhanced cephalosporin resistance respectively. Experiments were in 
accordance to CSLI protocols and performed in duplicates. MIC reported in µg mL-1. *Note Teicoplanin is 
not an approved antibiotic in the USA, therefore there are no appropriate controls to compare the MIC 
ranges.  
 
 An ∆ireK mutation was introduced into strains of OG1RF WT and Tn1549. Of note, 
the MIC for vancomycin in the ∆ireK mutants is 4-fold lower than the wild type suggesting 
a direct interaction between IreK and some element of the Tn1549 resistance gene 
cassette (Table 3.2). Remarkably in the OG1RF ∆ireK strain, the overall level of resistance 
to all cephalosporin’s decreases to a level below that of the WT strain. Deletion of ireK 
results in a significant reduction of both intrinsic resistance as demonstrated previously 
(Kristich et al., 2007; Kristich et al., 2011) and enhanced cephalosporin resistance in E. 
faecalis. This effect is represented across all cephalosporin generations from 1st to 4th, 
but not in the case of ceftobiprole, a 5th generation cephalosporin drug recently approved 
to treat hospital-acquired pneumonia (Bogdanovich et al., 2005). These results suggest a 
direct causal linkage between IreK function and enhanced cephalosporin resistance, 
caused by an unknown component of the Tn1549 transposon responsible for vancomycin 
resistance, independent of vancomycin induction. To investigate the effect of ireK and 
Antibiotic Class Sub-Class 
MIC (µg mL-1) 
WT Tn1549 ΔireK Tn1549 
ΔireK 
Vancomycin Glycopeptide - 4 64 1 32 
Teicoplanin* Glycopeptide - 0.5 0.5 0.125 0.0625 
Cephalexin ß-lactam 
Cephalosporin (1st 
Generation) 
32 128 16 32 
Ceftriaxone ß -lactam 
Cephalosporin (3rd 
Generation) 
16 256 0.5 8 
Cefotaxime ß -lactam 
Cephalosporin (3rd 
Generation) 
2 256 0.0625 1 
Cefepime ß -lactam 
Cephalosporin (4th 
Generation) 
8 32 2 8 
Ceftobiprole ß -lactam 
Cephalosporin (5th 
Generation) 
0.03125 >0.00781 0.03125 0.03125 
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Tn1549 on antibiotic sensitivity on the OG1RF isogenic series, other drugs were tested 
including other cell wall antibiotics and other classes of antibiotics. Generally, the 
differences observed are not on the same scale to that of cephalosporin including small 
variations when ampicillin, meropenem, D-cycloserine, kanamycin, rifampicin and 
linezolid are used.  
 In all four isogenic strains, ampicillin sensitivity is observed which is consistent 
with the use of ampicillin as a clinical therapeutic in E. faecalis treatments (Beganovic et 
al., 2018). Although there is slight difference in MIC, the organisms still considered to be 
sensitive to ampicillin and that ireK strains in both the WT and Tn1549 as little effect. 
Little difference was also observed with meropenem, an antibiotic that is has been shown 
to be sensitive in a number of E. faecalis strains (Edwards et al., 1995).  
 
Table 3.3: MIC determination of the OG1RF isogenic series to determine the effect of the Tn1549 
cassette and ireK on other cell wall antibiotics. Experiments were in accordance to CSLI protocols and 
performed in duplicates. MIC reported in µg mL-1. 
  
 
 Of interest is the increase in fosfomycin from 16 to 128 µg mL-1 in a OG1RF WT 
and Tn1549 strain respectively. Fosfomycin targets MurA, a protein involved in the PG 
biosynthesis pathway. There are two homologs of MurA in E. faecalis denoted MurAA 
and MurAB. It has previously been determined that both proteins have distinct role in E. 
Antibiotic Class Sub-Class 
MIC (µg mL-1) 
WT Tn1549 ΔireK 
Tn1549 
ΔireK 
Ampicillin ß-lactam - 0.0313 0.0625 0.0156 0.0156 
Meropenem ß-lactam Carbapenem 1 2 0.5 2 
Fosfomycin 
MurA 
Inhibitor 
Intracellular Specific 
Target 
16 128 16 64 
D-Cyclo 
serine 
Ddl  
Intracellular Specific 
Target 
128 128 64 64 
Bacitracin Lipid II - 128 128 16 128 
Daptomycin Membrane - 64 32 8 16 
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faecalis physiology and that the MurAA homologue is involved in enhanced intrinsic 
cephalosporin resistance (Kristich et al., 2011). The enhanced fosfomycin resistance 
shown in Table 3.3 suggests that the Tn1549 cassette may have a role in the downstream 
PG biosynthesis pathway.  
 Although there was little difference in the MICs between bacitracin and 
daptomycin with the introduction of the Tn1549 cassette, in the OG1RF WT strain and 
OG1RF ∆ireK strain there was a decrease in MIC of both antibiotics with the deletion of 
ireK. Daptomycin interacts directly with the membrane and causes curvature, therefore 
as IreK is a membrane protein with a large extracellular domain, IreK in an OG1RF WT 
strain may be able to elicit a cellular response to overcome the effects of Daptomycin. 
OG1RF ∆ireK resulted in a 4-fold decrease in MIC in comparison to WT and 2-fold decrease 
when comparing a OG1RF Tn1549 and OG1RF::Tn1549 ∆ireK strain. Bacitracin targets C55-
isoprenyl pyrophosphate which is involved in PG biosynthesis and only in a ∆ireK strain is 
a difference in MIC observed in all strains. In comparison to OG1RF WT strain, there is a 
4-fold change in MIC.  
 Table 3.4 evaluates antibiotics that are not cell wall antibiotics. There is no 
difference in MIC between each strain and these antibiotics apart from a small shift in 
MIC in a ∆ireK strain against kanamycin. Kanamycin resistance is reported in many E. 
faecalis strains due to the presence of the aph(3’)-IIIa gene which confers high level 
resistance of kanamycin (Woegerbauer et al., 2014). As previously mentioned OG1RF and 
derivatives of the OG1X strains are resistance to rifampicin and fusidic acid to provide 
strain markers. All strains show resistance greater than 256 µg mL-1, therefore the 
variation between each strain cannot be evaluated due to higher concentration not being 
tested (Oliver et al., 1977). Each strain also showed sensitivity to linezolid and no 
difference in MIC. Linezolid is a protein synthesis inhibitor and like ampicillin, is also 
regularly used in the treatment of Enterococcal spp. infections (Beganovic et al., 2018). 
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 Table 3.4: MIC determination of the OG1RF isogenic series to determine the effect of the Tn1549 
cassette and ireK resistance to other classes of antibiotics. Experiments were in accordance to CSLI 
protocols and performed in duplicates. MIC reported in µg ml-1. 
  
 Although there are differences in the MIC of different antibiotics between the four 
strains of OG1RF E. faecalis with different antibiotics, the changes in MIC with the largest 
variations comes intrinsically from the cephalosporin’s with smaller differences in 
variation from other cell wall antibiotics including Bacitracin and Daptomycin. The effect 
of Tn1549 and ireK on enhanced cephalosporin resistance forms the main focus of the 
subsequent experiments to explore the phenotype further.  
3.4. Tn1549 is not required for enhanced cephalosporin 
resistance in JH2-2 strains 
 Although an isogenic series of JH2-2 with an ∆ireK mutation in both the WT and 
Tn1549 backgrounds could not be generated, the hypothesis of enhance cephalosporin 
resistance was tested by comparing the JH2-2 WT and Tn1549 strains (Table 3.5). There 
is a clear difference in MIC between the WT and Tn1549 strains (1 to 128 µg mL-1 
respectively) exhibiting a 128-fold difference in comparison to 16-fold difference when 
comparing the OG1RF WT and Tn1549 backgrounds. Unlike the OG1RF isogenic series, 
JH2-2 strains with the Tn1549 cassette does not exhibit enhanced cephalosporin 
resistance in comparison to WT. A factor that may contribute to this observation may 
include that JH2-2 is original clinical isolate that was derived from a patient undergoing 
antibiotic therapy. Although there is no acquired resistance mechanism in JH2-2, others 
virulent mechanism in the chromosomal genome may contribute to the high 
cephalosporin resistance independent of the Tn1549 cassette (Jacob and Hobbs, 1974). 
Another factor may include the location of conjugation of the Tn1549 cassette in both 
Antibiotic Class Sub-Class 
MIC (µg mL-1) 
WT Tn1549 ΔireK Tn1549 ΔireK 
Kanamycin Protein Synthesis Aminoglycoside 256 256 128 256 
Linezolid Protein Synthesis Inhibition Inhibitor 2 2 2 2 
Rifampicin RNA Synthesis RNA Polymerase <256 <256 <256 <256 
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strains and if such conjugation events disrupted essential genes involved in resistance to 
cell wall antibiotics resistance.  
Table 3.5: MIC of JH2-2 WT/Tn1549 with cephalosporin’s and vancomycin. Experiments were in 
accordance to CSLI protocols and performed in duplicates. MIC reported in µg mL-1. 
 
3.5. The linkage between cephalosporin resistance and the 
Tn1549 structural genes is not at the transcriptional level. 
 To investigate the possible linkage between enhanced cephalosporin resistance 
and the presence of the Tn1549 cassette at a transcriptional level, qPCR analysis of the 
expression of representative genes from the Tn1549 cassata was performed.  In this 
experiment, the transcriptional levels of vanY and vanB, whose expression is controlled 
by the same promoter were monitored when a E. faecalis OG1RF::Tn1549 cultures was 
challenged by either vancomycin (2 µg mL-1) or a representative cephalosporin antibiotic; 
cefotaxime (64 µg mL-1) (See Figure 3.3.A). Cefotaxime was chosen as its level of 
resistance is enhanced by over 8-fold (2 to 256 µg mL-1) compared of the OG1RF parental 
strain and thus provides a strong reporter system for comparison of both cephalosporin 
and vancomycin resistance. 
 The 16S ribosome gene was used as the control housekeeping gene and 
experiments were normalized to samples that were not induced with antibiotics (Figure 
3.3). Initial control experiments included comparison of the 16S ribosome gene under 
each experimental condition (uninduced, with vancomycin and with cephalosporin) for 
each strain (OG1RF WT, Tn1549 and Tn1549 ∆ireK). qPCR experiments to compare 
Antibiotic Class Sub-Class 
MIC (µg mL-1) 
WT Tn1549 
Vancomycin Glycopeptide - 1 128 
Ceftriaxone ß -lactam Cephalosporin (3rd Generation) 2048 2048 
Cefotaxime ß -lactam Cephalosporin (3rd Generation) 2048 2048 
Ceftazidime ß -lactam Cephalosporin (3rd Generation) <2048 <2048 
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contamination of cDNA and gDNA were also included in experiments without reverse 
transcriptase.  
A: 
 
 
B: 
 
Figure 3.2: 16S ribosome gene transcription profile via qPCR experiments in various OG1RF strains 
under different experimental conditions. A: Real time amplification plot of 16S ribosomal gene after 
generation of cDNA with reverse transcriptase (filled circles – positive control) and without reverse 
transcriptase (open circles – negative control). This shows that amplification of the 16S ribosome gene is 
from amplification of cDNA and not contaminating genomic DNA B: Comparison of cycle threshold (Ct) 
values for each strain and experimental condition in technical triplicate and experimental duplicate. Error 
bars show standard deviation between experimental replicates.  
 To compare the effect of the Tn1549 structural genes primers for vanY and vanB 
were designed and to also evaluate the effect of the TCS genes, primers for vanR were 
also designed (Figure 3.3). In cells challenged by a sub-inhibitory amount of vancomycin, 
a strong induction of expression of both vanY and vanB is observed as expected given the 
inducible nature of Tn1549 vancomycin resistance. Interestingly there is expression of 
VanR in both the uninduced and cefotaxime experiment but not to the same scale as 
vancomycin. When challenged with a sub-inhibitory concentration of cefotaxime, no 
apparent induction of the vanR, vanY or vanB in the OG1RF::Tn1549 strain was detected. 
There is no apparent transcriptional enhancement of the Tn1549 vancomycin resistance 
structural genes in the presence of cefotaxime. Interestingly, there is no noticeable 
difference in expression of the van genes when comparing the OG1RF::Tn1549 and 
OG1RF::Tn1549 ∆ireK strains. Figure 3.4 summarises the qPCR results demonstrating that 
the Tn1549 structural genes are not induced in the presence of cephalosporin’s.   
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A: 
 
B: 
   
 
Figure 3.3: Inducing transcriptional expression of the Tn1549 structural genes on OG1RF::Tn1549 and 
OG1RF::Tn1549 ∆ireK strains. (A) Representation of the Tn1549 cassette and genes associated with 
vancomycin resistance and regions for qPCR primers. (B) Normalised relative fold induction for each 
experimental condition and gene target in biological duplicate and technical triplicates. Error bars show 
standard deviation between biological replicates.  
A: B: 
  
Figure 3.4: Developing model for the role of Tn1549 in cephalosporin resistance. (A) In response to 
vancomycin, the VanSB HK phosphorylates the VanR RR which activates the transcription of the van genes 
to modify the cell wall to increase their resistance to vancomycin. (B) Cephalosporin stimulates 
expression of genes that likely modify peptidoglycan to increase resistance to cephalosporins. This 
enhanced resistance requires VanSB and IreK which phosphorylates VanSB but does not trigger the 
upregulation of the van genes.  
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3.6. Identifying possible substrates of VanSB  
 As previously demonstrated, IreK has been shown in vitro to interact and 
phosphorylate the T223 residue on VanSB. Likewise, it has been demonstrated that in 
OG1RF with the Tn1549 cassette, enhanced cephalosporin is exhibited, but this 
phenotype is not demonstrated in JH2-2. The enhanced cephalosporin resistance in 
OG1RF Tn1549 is lost in an OG1RF Tn1549 ΔireK strain. Cross talk between eSTKs and TCS 
has been shown previously and was discussed earlier. To identify potential targets of 
VanS T223 phosphorylation, the TCS of OG1RF and JH2-2 were compared. Of the 16 TCSs 
identified in OG1RF all but two were identified in JH2-2 draft genome sequence. These 
include TCS associated with RR10 and RR12 of the V538 and OG1RF genome. RR10 is 
involved in stress response and the upregulation of virulence factors (Hancock and 
Perego, 2002). RR12 is a homologue of the E. faecium RR DdcR which has been implicated 
in reprogramming of the cell wall by upregulating the protein DdcY, a homologue of VanY 
to generate a population of tetrapeptide lipid II substrates for Ldtfm for 3-3 PG crosslinking 
(D,D-transpeptidase) instead of 3-4 protein crosslinking (L,D-transpeptidase) (Sacco et al., 
2014). Although the counterpart DdcY is located in OG1RF, it is not present in the draft 
genome of JH2-2. To understand the potential effects of IreK phosphorylation of position 
T223 in the context of DdcY and its associated TCS, qPCR primers were designed to target 
ddcR and ddcY transcriptional upregulation in the conditions and strains described 
previously. Figure 3.5 highlights the difference between each strain and each 
experimental condition and were calculated using the ΔΔct value with respect to the 
uninduced sample and the 16S ribosome housekeeping gene.  
 In both the vancomycin and the cefotaxime experiments there is an upregulation 
in the transcription of ddcR and ddcY in the OG1RF::Tn1549 strain. In the OG1RF::Tn1549 
ΔireK strain there is no comparable expression of the ddcR and ddcY transcripts with 
regards to the OG1RF::Tn1549 strain but is comparable to the OG1RF WT strain where 
the Tn1549 cassette is not present. From these early experiments it can be suggested 
that the Tn1549 cassette, the ireK gene and the DdcSR TCS upregulating DdcY are 
important components of enhanced cephalosporin resistance in the OG1RF isogenic 
series (Figure 3.6). This also highlights a reason why the JH2-2 isogenic series did not 
exhibit enhanced cephalosporin resistance due to the lack of a full DdcSR TCS and DdcY.  
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Figure 3.5: The Tn1549 cassette, IreK and the DdcSR/DdcY TCS are essential for enhanced cephalosporin 
resistance. Relative fold expression determined by ΔΔct values against 16S ribosome housekeeping gene 
and uninduced sample. Experimental conditions include 2 µg mL-1 vancomycin and 128 µg mL-1 
cefotaxime at 37°C. Each experimental condition and gene target in biological duplicate and technical 
triplicates. Error bars show standard deviation between biological replicates.  
 
Figure 3.6: Schematic for possible TCS crosstalk leading to enhanced cephalosporin resistance. IreK 
phosphorylates VanSB on residue Thr 223 and cross phosphorylation could either phosphorylate the DdcS 
protein for subsequent DdcR phosphorylation (Route A) or VanSB directly phosphorylates DdcR for 
upregulation of DdcY which is a carboxypeptidase and alters the overall PG architecture. Sites for the 
DdcR promoter are yet to be identified, but like other TCS it is expected to be before the RR (ddcR) and 
substrate targets (ddcY). 
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3.7. Cephalosporin sensitivity in E. faecalis can be established 
by a chemical genetic approach 
 Having established that IreK is essential for high-level cephalosporin resistance in 
a vancomycin resistant strain, a chemical genetic approach was used to explore this 
phenotypic observation further. Many eukaryotic STKs are inhibited by staurosporine and 
that this effect may be extended to bacterial eSTKs as well (Pensinger et al., 2017). Many 
Gram-positive eSTK share strong sequence homology between eukaryotic STKs (Figure 
3.7) and has been previously explored in the context of IreK with in-vitro biochemical 
experiments and shown to inhibit IreK autophosphorylation activity (Goss, 2013; Figure 
1.16). Staurosporine is an indolocarbazole compound and is known to have a range of 
biological activities as a result of its ability to bind to the ATP site of protein kinases and 
has been tested as an anticancer drug.  
Figure 3.7: Amino acid alignment of the eSTK IreK from E. faecalis and CDK2 from Homo sapiens. 
Sequences were aligned using Cultural Omega. "*" amino acids are identical in all sequences in the 
alignment, ":" show where conserved amino acids substitutions have been observed and "." show where 
semi-conserved amino acids substitutions have been observed. 
3.7.1. Staurosporine and Cefotaxime work synergistally to restore 
cephalosporin sensitivity 
 To test the hypothesis that staurosporine might also affect IreK in E. faecalis, the 
MIC of Cefotaxime in the presence and absence of staurosporine was tested in a number 
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of strain backgrounds include ΔireK strains. In the WT OG1RF strain and its ΔireK variant 
that MIC for Cefotaxime was slightly reduced in the presence of staurosporine, however 
in the OG1RF::Tn1549 background there was a marked decrease of 256-fold in the 
presence of 50 µM staurosporine. This effect abolished the resistance to cefotaxime and 
returned it to essentially WT levels (Table 3.7). 
Table 3.3: Comparison of isogeneic strains of E. faecalis OG1RF and the effect of staurosporine. 
Experiments were in accordance to CSLI protocols and performed in duplicates. MIC reported are in 
comparison to cefotaxime (µg mL-1) 
Conc. 
Staurosporine 
MIC (µg mL-1) 
E. faecalis 
OG1RF WT 
E. faecalis 
OG1RF ΔireK 
E. faecalis 
OG1RF Tn1549 
E. faecalis OG1RF 
Tn1549 ΔireK 
0 µM 2 0.0625 256 1 
50 µM 0.125 0.03125 1 0.5 
 
3.7.2. Staurosporine and ΔireK confer similar phenotype 
 To further explore the effect of staurosporine, each OG1RF strain was incubated 
in a growth curve experiment with and without staurosporine (Figure 3.8). In each strain, 
the presence of staurosporine caused a decrease in the overall OD in comparison to WT 
strains but staurosporine did not prevent cell growth. When comparing OG1RF with 
staurosporine and OG1RF ΔireK strains it appears that staurosporine is targeting ireK as 
the growth profiles are similar between each experiment. Likewise, a similar trend can be 
observed between OG1RF::Tn1549 with staurosporine and OG1RF::Tn1549 ΔireK without 
but not to the same effect. This might be due to factors of the Tn1549 cassette that are 
not well described in the stationary phase.  
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A 
 
B 
 
C 
 
D 
 
Figure 3.8: Growth curves of OG1RF isogenic strains without (Blue) and with (Red) 50 µM staurosporine 
in MHII broth. (A) OG1RF WT, (B) OG1RF ΔireK (C) OG1RF::Tn1549 and (D) OG1RF::Tn1549 ΔireK. Samples 
were incubated at 37˚C and OD was recorded every 15 minutes with brief shaking before each read.  
Experiments were performed in duplicates with the mean represented by individual data points and 
standard deviation error bars.  
3.7.3. Enhanced cephalosporin resistant is observed in other VanB type 
genotypes and species and can be restored using staurosporine 
 This analysis was extended to a range of other vancomycin resistant E. faecalis 
and E. faecium strains. The two genotypes of greatest clinical importance are vanA 
(resistant to vancomycin and teicoplanin) and vanB (resistant to vancomycin only), with 
three alleles of the vanB ligase gene (vanB1, vanB2, and vanB3) (Ballard et al., 2005). Both 
the vanA and the vanB operons are associated with transposons, and the transfer of 
resistance among enterococci appears to be mediated via acquisition of these elements. 
Although the vanA operon is located on the transposon, Tn1546, three transposons have 
been described that contain the vanB operon: Tn1547, Tn5382, and Tn1549 (Ballard et 
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al., 2005). To demonstrate the effect that IreK has on enhanced cephalosporin across 
acquired vancomycin strains, the effect using cefotaxime resistance in the presence of 
staurosporine against VanA strains of E. faecium (Tn1546) and VanB strains of both E. 
faecalis and E. faecium including that of the vanB1 allele (Tn1547) and the vanB2 allele 
(Tn1549) was compared (Table 3.7).  In all strains tested, staurosporine restored the 
sensitivity of otherwise intrinsically and acquired resistant enterococcal strains to 
cefotaxime.  
 
Table 3.7: Comparison of multiple Enterococcus spp. strains with acquired Van resistance cassettes and 
the effect of staurosporine in each strain. Experiments were in accordance to CSLI protocols and 
performed in duplicates. MIC reported are in comparison to cefotaxime (µg mL-1). The vanA strain tested 
is highlighted in grey. 
Conc. 
Staurosporine 
MIC (µg mL-1) 
E. faecalis 
OG1RF Tn1549 
(vanB1) 
E. faecalis 
JH2-2 
Tn1549 
(vanB1) 
E. faecium 
BM4525 
Tn1549 
(vanB1) 
E. faecalis ATCC 
51299 Tn15482 
(vanB2) 
E. faecium ATCC 
700221 Tn1546 
(vanA) 
0 µM 256 1024 1024 1024 2048 
50 µM 1 1 4 0.125 2048 
 
3.7.4. Other potential eSTK kinase inhibitors  
 Although staurosporine has been demonstrated here and elsewhere as an 
inhibitor of eSTKs in most Gram-positive bacteria, it probably has little therapeutic 
potential due to its promiscuity to eukaryotic kinases. In a previous study looking at the 
eSTK in Listeria monocytes, a kinase screen has revealed a potential new inhibitor 
structurally different to staurosporine called AZD5438, (a CDK inhibitor) and showed to 
act synergistically with β-lactam antibiotics against L. monocytes (Pensinger et al., 2014) 
(Figure 3.9). In this study I observed that AZD5438 is an inhibitor of IreK in OG1RF Tn1549 
strains and works synergistically with the ß-lactam cephalosporin, cefotaxime (Table 3.8). 
Although staurosporine appears to have a stronger effect, AZD538 is a synthetic 
compound and not a natural product like staurosporine. 
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Table 3.8: Comparison of non-staurosporine kinase inhibitors in the presence of increasing 
concentrations of cefotaxime (µg mL-1). Tested on OG1RF Tn1549 with kinase inhibitors diluted in 5-fold 
dilutions from 50 µM. Experiments were in accordance to CSLI protocols and performed in duplicates. 
Concentration of Compound 
MIC (µg mL-1) OG1RF Tn1549 
AZD5438 UCN01 Staurosporine 
0 µM 256 256 256 
0.4 µM 256 256 256 
2 µM 256 256 124 
10 µM 16 256 8 
50 µM 2 256 1 
 
 As staurosporine has been a successful eukaryotic kinase inhibitor in vitro and has 
also gone through phase I and II clinical trials, many derivatives of staurosporine have 
been isolate or synthesised. For example, UCN-01, a staurosporine derivative was also 
tested. However, there was no difference in MIC against cefotaxime in the presence of 
UCN-01 at any concentration. The single difference between staurosporine and UCN-01 
is the presence of a single hydroxyl group suggesting a structure-activity relationship 
(SAR) between these compounds (Figure 3.9). Although not tested in this context UCN-
01 may target IreK but there might be pharmacokinetics problems targeting IreK in vivo.  
 Other inhibitors that were also explored included a GSK published kinase inhibitor 
set (Knapp et al., 2013; Bramson et al., 2001; Stevens et al., 2008; Tang et al., 2003).  This 
list includes 376 compounds in the hope to better identify new targets for these 
inhibitors. 30 of the 376 compounds were selected as they were strong inhibitors of CDK2 
which has already been demonstrated to have strong homology to IreK (Figure 3.7). The 
structures and identity of each compound are highlighted in (Chapter 8: Appendix 8.2). 
In an experiment similar to that demonstrated in Table 3.8, 0 µM, 0.4 µM and 4 µM was 
incubated with increasing concentrations of cefotaxime. No difference in MIC was 
observed with the two concentrations of each inhibitor. Like UCN-01, these inhibitors 
may target IreK but there might be pharmacokinetics problems targeting IreK in vivo. 
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Staurosporine UCN-01 AZD5438 
 
 
Figure 3.9: Structural comparison of eukaryotic kinase inhibitors that are potential prokaryotic eSTK inhibitors. Left: Staurosporine, Centre: UCN-01 and Right: AZD548.
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3.8. Exploring the contribution of each IreK domain on 
enhanced cefotaxime resistance   
 To understand the role of IreK in enhanced cephalosporin resistance, a series of 
complementation experiments with different mutations and truncations made in the IreK 
gene. Complementation experiments are advantageous over creating chromosomal 
mutants as creating chromosomal mutants is often time consuming and the creation of a 
mutant, truncation or chimera is not guaranteed.  
3.8.1. Background into the inducible complementation system  
 The complementation experiments used in this study were performed in the 
Plasmid TetH a kind gift from Stephane Mesnage. The plasmid is selective (Erm30) and can 
be readily transformed into electrocompetent E. faecalis cells. The plasmid enables 
tuneable expression of a gene of interest in a tetracycline inducible system (Figure 3.10). 
Tetracycline inducible systems offer advantages over other inducible systems such as 
metal ions as it is not confounded by secondary effects when anhydrotetracycline is used. 
Anhydrotetracycline binds the tetracycline repressor (TetR) 35-fold more strongly than 
tetracycline (Gossen and Bujard, 1993; Degenkolb et al., 1991). Anhydrotetracycline also 
binds poorly to the 30S ribosomal subunit compared to tetracycline so therefore shows 
very poor antibiotic activity (Rasmussen et al., 1991). 
 The TetH plasmid can be described as a Tetracycline “on” system where TetR 
induction is activated in the presence of anhydrotetracycline and binds to the tetracycline 
operator (tetO). In contrast, the tetracycline “off” system works when the presence of 
anhydrotetracycline causes reduced expression of the gene of interest by binding TetR. 
The Tet “on” functions by amino acid point mutations in the TetR that led to resilience in 
the presence of tetracycline for induction rather than repression (Gossen et al., 1995). 
The tetO is a 19-nucleotide promoter sequence upstream of the gene of interest and is 
recognised by TetR. Without the anhydrotetracycline, TetR is unable to bind to the tetO 
(Figure 3.11.A). Binding of anhydrotetracycline by TetR enables the protein to bind tetO 
and enable expression of the gene of interest (Figure 3.11.B). The system is inducible and 
enables tight regulation of the gene of interest.  
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Figure 3.10: TetH Plasmid map highlighting the key features of the plasmid. The gene of interest is 
cloned via Gibson assembly into the region highlighted in red. This plasmid was a kind gift from Dr. 
Stephane Mesnage, The University of Sheffield.  
A: 
 
B:  
 
Figure 3.11: A tetracycline inducible system for tuneable expression of a gene of interest. (A) No 
anhydrotetracycline present results no transcription of the gene of interest as TetR cannot bind the tetO. 
(B) In the presence of anhydrotetracycline transcription of the gene of interest is permitted as TetR is 
activate when bound to anhydrotetracycline and can bind to tetO (Gossen et al., 1995).  
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3.8.2. Increasing anhydrotetracycline can tune ireK expression  
 Iso-sensitest was used instead of Muller Hinton II as complementation was not 
achieved in Muller Hinton II. Iso-sensitest is another media used frequently in testing 
antibiotic susceptibility and is often employed to overcome issues in MHII (Koeth et al., 
2000).  
3.8.2.1. Testing complementation using E-test strips 
 To initially screen the enhanced cephalosporin phenotypes of the TetH-ireK 
plasmid in an OG1RF::Tn1549 ΔireK strains, the bacteria were plated onto Iso-sensitest 
agar plates following EUCAST protocols (Figure 3.12). The plates contained different 
concentrations of anhydrotetracycline and were tested using a ceftazidime E-test strip. 
The OG1RF::Tn1549 and OG1RF::Tn1549 ΔireK strains shows a clear phenotype which is 
comparable to previous observations (256 and 8 µg mL-1 ceftazidime respectively). 
Increasing concentrations of anhydrotetracycline shows an increase in ceftazidime 
resistance. These results using the E-test strips demonstrate that anhydrotetracycline can 
successfully induce the complementation of ireK to demonstrate enhanced 
cephalosporin resistance similar to a OG1RF::Tn1549 strain.  
 The limitations of this methods include the range of the ceftazidime E-test strip 
from 0.05 to 256 µg mL-1 which could be out of range of the MIC needed to be detected. 
Likewise, previous MIC determination have been undertaken in broth and are more 
directly comparable. Also, Macro colonies can be observed in some of the experiments 
with high concentrations of anhydrotetracycline and therefore makes interpretation of 
the true MIC difficult as reported by the manufacture of the E-test strips and the clinical 
standards agency (Oxoid and EUCAST respectively).  
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A:  
OG1RF::Tn1549  
(0 ng mL-1  
anhydrotetracycline) 
 
 
 
B: 
OG1RF::Tn1549 ΔireK 
(0 ng mL-1 
anhydrotetracycline) 
 
 
 
C: 
OG1RF::Tn1549 ΔireK TetH-
ireK(FL)  
(0 ng mL-1 
anhydrotetracycline) 
 
 
 
MIC: >256 µg mL-1 
 
MIC: 8 µg mL-1 
 
MIC: 8-16 µg mL-1 
D: 
OG1RF::Tn1549 ΔireK TetH-
ireK(FL)  
(10 ng mL-1 
anhydrotetracycline) 
 
 
 
MIC: 16 µg mL-1 
E:  
OG1RF::Tn1549 ΔireK TetH-
ireK(FL)  
(20 ng mL-1 
anhydrotetracycline) 
 
 
 
MIC: 32-64 µg mL-1 
F:  
OG1RF::Tn1549 ΔireK TetH-
ireK(FL)  
(50ng mL-1 
anhydrotetracycline) 
 
 
 
MIC: >256 µg mL-1 
   
Figure 3.12: Testing the effect of anhydrotetracycline complementation using E-test strips. MIC 
determination of OG1RF Tn1549, OG1RF::Tn1549 ΔireK in comparison to OG1RF::Tn1549 ΔireK TetH-
ireK(FL) with different concentration of anhydrotetracycline following EUCAST protocol for MIC 
determination using EUCAST with E-test strips. (A) OG1RF Tn1549, (B) OG1RF::Tn1549 ΔireK, (C) 
OG1RF::Tn1549 ΔireK-TetH-ireK(FL) (0 ng mL-1), (D) OG1RF::Tn1549 ΔireK-TetH-ireK(FL) (10 ng mL-1), (E) 
OG1RF::Tn1549 ΔireK-TetH-ireK(FL) (20 ng mL-1), (F) OG1RF::Tn1549 ΔireK-TetH-ireK(FL) (50 ng mL-1). 
Experiments were performed in duplicates with MIC ranges displayed under each figure.  
 
 To confirm the effect of the MIC phenotype from the E-test strips on Iso-sensitest 
agar and improve experimental conditions, different concentrations of 
anhydrotetracycline with either cefotaxime or ceftazidime was measured though 
microdilution series in Iso-sensitest broth. Initial experiments indicated that a much 
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lower concentration of anhydrotetracycline was required to complement ireK back to WT 
levels (Data not shown). The concentrations of anhydrotetracycline were adjusted 
accordingly and MIC using the TetH-ireK construct (CWT050) in OG1RF::Tn1549 ΔireK 
were compared to OG1RF isogenic strains in a Tn1549 background (Table 3.9). In 
presence of both antibiotics, in the absence of anhydrotetracycline an MIC is achieved 
that is higher when compared to the OG1RF::Tn1549 ΔireK and indicated leaky 
expression. In the presence of both antibiotics full complementation is achieved at a 
concentration of 20 ng mL-1 and in the case of cefotaxime, goes beyond WT MIC levels of 
cefotaxime. This initially shows that IreK has a tuneable effect on enhanced 
cephalosporin resistance. The results from these experiments allows other mutants of 
ireK to be measured at the assumed WT levels of IreK expression with 20 ng mL-1.  
 
Table 3.9: MIC determination of OG1RF Tn1549, OG1RF::Tn1549 ΔireK in comparison to OG1RF::Tn1549 
ΔireK TetH-ireK(FL) with different concentrations of anhydrotetracycline in Iso-sensitest broth. Samples 
were incubated at 37°C without shaking and without Erm30 present. Includes OG1RF Tn1549, 
OG1RF::Tn1549 and OG1RF::Tn1549 ΔireK-TetH-ireK(FL) at different concentrations anhydrotetracycline 
ranging from 0-25 ng mL-1. Experiments were performed in duplicates with MIC ranges reported for either 
cefotaxime or ceftazidime in µg mL-1 
  
3.8.3. Complementation experiments of various IreK constructs  
 To test the contribution of either the kinase or PASTA domains of IreK in E. 
faecalis, various mutants and constructs were designed and synthesised using the TetH-
 MIC Cefotaxime (µg mL-1) 
Concentration of 
anhydrotetracycline 0 ng mL
-1 5 ng mL-1 10 ng mL-1  20 ng mL-1 25 ng mL-1 
OG1RF Tn1549 512 512 512 512 512 
OG1RF::Tn1549 ΔireK 8 8 8 8 8 
OG1RF::Tn1549 ΔireK 
TetH-ireK (FL) 256 512 512 512 1024 
 MIC Ceftazidime (µg mL-1) 
Concentration of 
anhydrotetracycline 0 ng mL
-1 5 ng mL-1 10 ng mL-1  20 ng mL-1 25 ng mL-1 
OG1RF Tn1549 2048 2048 2048 2048 2048 
OG1RF::Tn1549 ΔireK 32 32 32 32 32 
OG1RF::Tn1549 ΔireK 
TetH-ireK(FL) 128 1024 1024 2048 2048 
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ireK(FL) plasmid (pCWT050) as the backbone vector. These constructs were 
electroporated into OG1RF::Tn1549 ΔireK strains and selected on Erm30 plates. To gain an 
understanding into the contribution of each domain, the enhanced cephalosporin 
resistance was phenotypically tested for each construct and compared to 
OG1RF::Tn1549, OG1RF::Tn1549 ΔireK and Tn1549 ΔireK TetH-ireK(FL) (Table 3.10). Each 
complementation strain was induced with 20 ng mL-1 anhydrotetracycline. Ceftazidime 
was used to test each of the different constructs as it had the strongest MIC that was in 
a detectable range and was thought to give the largest difference if any between each 
construct using the micro-dilution MIC method.  
Table 3.4: Complementation of different ireK constructs in the complementation plasmid under 20 ng 
mL-1 anhydrotetracycline in Iso-sensitest media. (Experiments performed in duplicates). Green – KD, Blue 
– TM, Red – E. faecalis PASTA, Yellow - Substituted PASTA. 
Schematic of Construct Construct Description (OG1RF) 
MIC Ceftazidime 
(µg mL-1) 
  
Tn1549 2048 
 Tn1549 ΔireK 32 
  
Tn1549 ΔireK TetH-ireK (FL) 2048 
        
Tn1549 ΔireK TetH-ireK (No Pasta) 128 
 
Tn1549 ΔireK TetH-ireK (K41R) 32 
        Tn1549 ΔireK TetH-ireK (No Kinase) 32 
        Tn1549 ΔireK TetH-ireK (PASTA 1-5 minus 
peptide) 
2048 
        
Tn1549 ΔireK TetH-ireK (PASTA 1-4) 2048 
        
Tn1549 ΔireK TetH-ireK (PASTA 1-3) 2048 
       
Tn1549 ΔireK TetH-ireK (PASTA 1-2) 1024 
       
Tn1549 ΔireK TetH-ireK (PASTA 1) 1024 
       
Tn1549 ΔireK TetH-ireK (PASTA 4-5) 2048 
       
Tn1549 ΔireK TetH-ireK (S. aureus PASTA) 1024 
       
Tn1549 ΔireK TetH-ireK (B. subtilis PASTA) 512 
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 When testing each of the TetH inducible constructs containing either a different 
mutant or truncation, the most significant differences were apparent when a whole 
domain was truncated (Kinase (KD) or PASTA). The truncation of the KD showed a large 
decrease in MIC that mirrored Tn1549 ΔireK levels at 32 µg mL-1. This illustrates the role 
of the kinase in phosphorylating other protein targets to cause enhanced cephalosporin 
resistance. Of particular note in Table 3.10 is the K41R mutation in the FL IreK construct. 
Initial characterisation of the eSTK in B. subtilis revealed that a mutation of residue K40 
to K40R removed the enzymatic activity of the protein (Madec et al., 2002). This residue 
was constructed following alignment of the B. subtilis study and the K40 reside was 
aligned and homologous to the IreK amino acid sequence (K41). This mutation was also 
constructed in the Tn1549 ΔireK TetH-ireK (FL) and demonstrated how critical this amino 
acid residue is on enzymatic activity as it caused the FL protein to become inactive in the 
enhanced cephalosporin phenotype experiment.  
 Removal of all the PASTA domains (Tn1549 ΔireK TetH-ireK (No Pasta)) resulted in 
a sharp decrease in MIC from 2048 to 128 µg mL-1 when compared directly with 
OG1RF::Tn1549 and Tn1549 ΔireK TetH-ireK (FL). Although the removal of all the PASTA 
domains does not result in a Tn1549 ΔireK MIC phenotype (32 µg mL-1 ceftazidime), this 
may be attributed to the ability of the kinase domain to self oligomerize independently 
of the PASTA domains and that the role of the PASTA domains is the concentrate the 
kinase domain of the protein in a particular location in the E. faecalis cell. In a study 
comparing the role of the IreK homologue in S. aureus PknB, two virulent strains were 
compared, including COL and USA300 (Tamber et al., 2010). Interestingly COL had a point 
mutation on the gene for PknB that resulted in a stop codon being introduced resulting 
in the truncation of the PASTA domains. When comparing the antibiotic resistance 
between both strains, it was suggested that the kinase alone was sufficient for antibiotic 
resistance. 
 Truncation of each individual PASTA domain resulted in a phenotype that was 
similar to OG1RF::Tn1549 MIC levels to ceftazidime (1024-2048 µg mL-1) and that a single 
PASTA domain (Tn1549 ΔireK TetH-ireK (PASTA 1)) was sufficient to complement to WT 
levels. Therefore, the number of PASTA domains present in E. faecalis is not directly 
linked to the enhanced cephalosporin resistance observed in this study and indicated that 
they may have a separate role. A recent paper has suggested that the PASTA domains 
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may act as a “molecular ruler” and monitor the thickness of the PG in growing cells. This 
was demonstrated in S. pneumoniae and the removal of each PASTA domain resulted in 
a decrease in PG thickness (Zucchini et al., 2018). It has also been recently demonstrated 
that in E. faecalis OG1 WT strains with various PASTA chromosomal truncations, that 
there is not much of a change in MIC against ceftriaxone with each truncation and is 
consistent with the phenotype observed here (Labbe and Kristich, 2017). In a previous 
study looking at the IreK homologue in E. faecium, a long C-terminal S/T terminal peptide 
is present and was suggested to interfere with PASTA oligomerisation (Desbonnet et al., 
2016). This motif is also present in E. faecalis but is much shorter. A truncation of this 
Ser/Thr terminal peptide was also constructed in IreK but showed no difference in MIC.  
 To explore the role of PASTA domains in the context of enhanced cephalosporin 
resistance further, the PASTA domains from E. faecalis were substituted with either the 
PASTA domains from S. aureus PrkC (containing 4 PASTA domains) or B. subtilis PrkC 
(containing 3 PASTA domains). Although the S. aureus PASTA domains did not show a 
large difference in MIC compared to E. faecalis IreK PASTA domains (1024 µg mL-1), there 
was a modest difference between the B. subtilis PASTA domains in IreK (512 µg mL-1). It 
has been suggested and shown in a different study that PASTA domains can bind PG 
directly and upregulate a cellular response when changes in the extracellular 
environment are detected (Shah et al., 2008). The major difference between E. faecalis 
and S. aureus is the PG cross linking stem (L-ala2 and G5 respectively) and the major 
difference between E. faecalis and B. subtilis is amidation in the second position, the 3rd 
position in the pentapeptide stem (Lys and Dap respectively) and therefore no 
crosslinking stem is present in B. subtilis.  
 There are also modifications of the glycan strands that can occur between each 
species including N-deacetylation (B. subtilis) and O-acetylation of the MurNAc residue 
(E. faecalis and S. aureus) (Vollmer, 2008). Therefore, the difference in MIC observed in 
this experiment with the PASTA domains substitutions might be due to the variation in 
the PG between each species. 
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3.9. Localisation of IreK in inducible complementation 
experiments 
 As discussed previously, the largest difference in enhanced cephalosporin 
resistance with regards to the PASTA domains comes from the removal of all PASTA 
domains in comparison to the full length IreK (MIC 2048 to 128 µg mL-1 ceftazidime 
respectively). A single PASTA domain was enough to almost follow a phenotype of a FL 
IreK construct. It has been established in M. tuberculosis and S. pneumonia that PASTA 
repeats are required for cellular division and localisation to the mid-cell (Mir et al., 2011; 
Giefing et al., 2010). As. E. faecalis has the most PASTA domains of any known eSTK in 
Gram-positive bacteria, the localisation of IreK was explored. To decipher the role of the 
PASTA repeats in localisation, the PASTA repeats were deleted, or substituted from other 
bacterial species. The role of the kinase in localisation was also explored. The TetH vector 
construct used previously was also used for testing localisation of IreK. 
3.9.1. Identification of valid fluorescent fusion constructs 
 To ensure that the addition of a fluorescent protein fusion did not impact on the 
overall function of IreK, the fluorescent protein had to have minimal oligomeric activity. 
Homologues of IreK are active oligomers and it was important that the activity was not 
contributed or impeded by the addition of the fluorescent protein (Barthe et al., 2010). 
A recent study quantitatively characterised the brightness, photo stability, pH stability 
and oligomeric properties of 40 fluorescent proteins (Cranfill et al., 2016). Enhanced GFP 
was the fluorescent protein of choice as it is frequently used in localisation studies and 
has been described as the gold standard of fluorescent proteins.  Most fluorescent 
proteins are oligomeric in their natural environment so to ensure that such interactions 
didn’t interfere with the results of the subsequent experiments, a A206K point mutation 
in the GFP domain was generated which has been shown to be mostly monomeric (98.1%) 
compared to WT GFP (76.5%) (Cranfill et al., 2016). In another experiment, codon 
optimised fluorescent mTFP and mCherry for microscopy experiments has been 
specifically designed in Enterococcus spp. and were also fusions that were fused to IreK 
(Vickerman et al., 2015).  
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3.9.2. Optimising concentration of conditions for localisation experiments  
 Although in localisation experiments, the effect of antibiotics was not tested, the 
effect of antibiotics was used to determine the right concentration of 
anhydrotetracycline to use as an inducer of ireK expression. As antibiotic susceptibility 
was not being tested in the context of localisation, BHI media was used instead of Iso-
sensitest media. As ceftazidime has a high MIC in the complementation experiments 
(2048 and 32 µg mL-1 respectively) and BHI is a rich media, cefotaxime was chosen as it 
still had a relatively large range in MIC between Tn1549 and Tn1549 ΔireK when tested 
in MHII (2 and 256 µg mL-1respectivley). Initial optimisation included testing the GFP 
fusion to full length ireK in TetH to map a phenotype that aligned with OG1RF::Tn1549. 
mEGFP, mCherry and mTFP all showed an antibiotic susceptibility phenotype that 
matched the phenotype of OG1RF::Tn1549 ΔireK (1 µg mL-1) with increasing 
concentrations of anhydrotetracycline. One concern was that the mEGFP construct used 
was not codon optimised. To overcome this issue, a codon optimised mEGFP gene was 
constructed using E. faecalis specific codon specificity.  
 Table 3.11. highlights all the constructs used to test the efficiency in the codon 
optimised mEGFP construct and at 20 ng mL-1 anhydrotetracycline can complement to 
OG1RF::Tn1549 levels (512 ng mL-1). Other key mutants and truncations show previously 
to have a large phenotype difference and shows a similar trend in MIC profile. Like the 
complementation experiments describes previously, 20 ng mL-1 anhydrotetracycline was 
sufficient to complement ireK to WT levels with the GFP fusion with a different media 
(BHI) and different antibiotic (Cefotaxime) and was used for all localisation experiments 
that are described.  
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Table 3.5: MIC determination of OG1RF Tn1549, OG1RF::Tn1549 ΔireK in comparison to OG1RF::Tn1549 
ΔireK TetH-gfp-ireK(FL) with different concentration of anhydrotetracycline in BHI broth. Samples were 
incubated at 37°C without shaking and without Erm30 present. Includes OG1RF Tn1549, OG1RF::Tn1549 
and OG1RF::Tn1549 ΔireK-TetH-ireK(FL) at different concentrations anhydrotetracycline ranging from 0-
25 ng mL-1. Experiments were performed in duplicate with MIC reported for either cefotaxime or 
cefotaxime in µg mL-1. 
 
 Before testing the localisation of each construct, the TetH-gfp-ireK FL construct in 
OG1RF::Tn1549 ΔireK was incubated with 20 ng mL-1 anhydrotetracycline in BHI, without 
Erm30 with shaking at 37°C until and OD600nm 0.6 was reached. Samples were harvested 
and whole cells were extracted, lysed and loaded onto an SDS-PAGE gel and western blot 
performed. Blots were incubated with anti-GFP antibody and screened to ensure no 
protein degradation had occurred with the addition of the mEGFP fusion which was 
confirmed (Figure 3.13).  
 MIC Cefotaxime (µg mL-1) 
Concentration of 
anhydrotetracycline 
0  
ng mL-1 
5  
ng mL-1 
10  
ng mL-1  
20  
ng mL-1 
25  
ng mL-1 
OG1RF Tn1549 
           
 
512 512 512 512 512 
OG1RF::Tn1549 ΔireK 
 
 
1 1 1 1 1 
OG1RF::Tn1549 ΔireK TetH-gfp 
   
 
1 1 1 1 1 
OG1RF::Tn1549 ΔireK TetH-gfp-
ireK(FL) 
 
1 2 64 512 512-1024 
OG1RF::Tn1549 ΔireK TetH-gfp-
ireK (No Pasta) 
 
1 1 2 128 256 
OG1RF::Tn1549 ΔireK TetH- gfp -
ireK (K40A)
 
1 1 1 1 1 
OG1RF::Tn1549 ΔireK TetH- gfp -
ireK (No Kinase) 
  
1 1 1 1 1 
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Figure 3.13: Expression of GFP fused IreK constructs. Expression of GFP-fused IreK via using 
complementation. Each construct was grown in BHI media with or without the presence of 20 ng µL-1 
anhydrotetracycline to OD600 0.6 before harvesting and lysing for processing. Ladders are represented in 
Lanes 2, 4, 6 and 8 with MW represented on the left-hand side. Lane 1: E. faecalis OG1RF WT cells. Lane 
3: OG1RF ΔireK cells. Lane 5: OG1RF ΔireK with pCWT080 complementation plasmid expressing GFP-IreK 
with no anhydrotetracycline. Lane 7: OG1RF ΔireK with pCWT080 complementation plasmid expressing 
GFP-IreK with 20 ng µL-1 anhydrotetracycline. Lane 9: OG1RF ΔireK with pCWT092 complementation 
plasmid expressing GFP only with 20 ng µL-1 anhydrotetracycline. Non-specific binding of antibodies is 
highlighted by *. Expected MW of IreK only is 77.4 kDa.  
3.9.3. Localisation of GFP-IreK(FL) in OG1RF strains 
 To establish experimental conditions that were to be replicated with each 
construct and strain, OG1RF delta ireK and OG1RF::Tn1549 ΔireK strains were both 
transformed with TetH-gfp-ireK (FL) and TetH-gfp optimised and tested for localisation. 
Homogeneity between each cell for localisation was achieved 100 mL BHI inoculated with 
a 1:100 overnight culture that had been selected in the presence of Erm30 but no longer 
contained the selective antibiotic in a 250 mL conical flask, with shaking at 37°C. Cells 
were incubated for 10 minutes with the FM 4-64 which stains the membrane of the cells. 
Figure 3.14 highlights the difference observed between each construct and each strain.  
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B:  
 
OG1RF ΔireK  
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C:  
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D:  
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TetH-gfp-ireK 
 
 
Figure 3.14: Localization of GFP and GFP-IreK constructs in OG1RF ΔireK. Images displayed are overlaid 
Phase contrast, GFP fluorescent signal (Green) and FM 4-64 dye (Red). Localisation of GFP constructs to 
the membrane (Yellow). Scale bar, 1 μm. 
 IreK localised to the septum of the dividing cells whereas GFP alone is distributed 
throughout the cytoplasm (Figure 3.14). GFP-IreK(FL) also localises to the division site in 
addition to membrane localisation. This observation has been observed in the 
homologous protein StkP in S. pneumoniae (Zucchini et al., 2018). As organisms like E. 
faecalis lack the protein MreB involved in peripheral growth and cell elongation in rod 
shaped bacteria, it is thought that PG synthesis occurs mainly at the septum. It has 
previously been determined in S. pneumoniae that the homologue of IreK, StkP is 
responsible for PG synthesis and controls septum progression and closure (Beilharz et al., 
2012). Therefore, localisation of IreK to the septum is in accordance of previously 
determined observations. As there was little difference in localisation observed between 
each strain of the FL GFP-IreK fusion, subsequent experiments were performed in OG1RF 
ΔireK strains. 
3.9.4. Localisation of GFP-IreK (Δkinase), GFP-IreK (ΔK41R) and GFP-IreK 
(ΔPASTA)  
 In the previous complementation study, the largest difference in phenotype with 
regards to MIC came from whole protein truncations from either the kinase to PASTA 
domains or a single amino acid substitution (K41R) in the kinase domain. The compare 
this phenotype with regards to localisation, these constructs were transformed into 
OG1RF ΔireK strains with a GFP fusion.  
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OG1RF ΔireK TetH-gfp-
ireK 
 
 
 
B:  
 
OG1RF ΔireK  
TetH-gfp-ireK(Δkinase) 
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OG1RF ΔireK  
TetH-gfp-ireK (K41R) 
 
 
 
D:  
 
OG1RF ΔireK 
 TetH-gfp-ireK 
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Figure 3.15: Localization of GFP-IreK constructs with domain mutations in the OG1RF ΔireK strains.  
Images displayed are overlaid Phase contrast, GFP fluorescent signal (Green) and FM 4-64 dye (Red). 
Localisation of GFP constructs to the membrane (Yellow). Scale bar, 1 μm. A is replicated from Figure 
3.14.B. for direct comparison.   
 When comparing each of the images in Figure 3.15, it is clear that the largest 
difference in localisation comes from the construct where no PASTA is present in which 
there is weak localisation and disruption of the GFP around the Periphery of the dividing 
cell but still maintains localised to the membrane. A similar localisation profile is observed 
in a recent study of StkP in S. pneumoniae with the removal of all the PASTA domains 
from the construct (Zucchin et al., 2018). In comparison, the construct where no kinase 
is present or the single K41R amino acid substitution, localisation is still observed even 
though these constructs are not functionally active.  
 These localisation experiments are in contrast to the complementation 
experiment where the largest observable difference was with the truncation of the kinase 
domains. This experiment highlights the key role of each domain of the protein. The 
kinase domains are essential in upregulating the cellular response to cephalosporin and 
enhanced cephalosporin resistance, and the PASTA domains are essential for protein 
localisation to the septum.  
3.9.5. Localisation of different PASTA truncations in IreK 
 When testing the effect of the removal of each PASTA domain in the 
complementation experiment, it was determined that the presence of at least one PASTA 
domain was sufficient to effectively upregulate cephalosporin resistance. To investigate 
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if the presence of an increasing number of PASTA domains is linked to stronger septal 
localisation, PASTA domains were truncated iteratively, and localisation measured. The 
final two PASTA domains (PASTA 4 and 5) were also individually tested. It is established 
that the absence of PASTA domains causes weak localisation and Figure 3.16 evaluates 
the contribution of each PASTA domain in the context of cellular localisation. 
 
 
Figure 3.16: Localization of GFP-IreK constructs in the OG1RF ΔireK strains with PASTA truncations. 
Images displayed are overlaid Phase contrast, GFP fluorescent signal (Green) and FM 4-64 dye (Red). 
Localisation of GFP constructs to the membrane (Yellow). Scale bar, 1 μm. A is replicated from Figure 
3.14.B. and B is replicated from Figure 3.15.D for direct comparison.  
 When comparing the contribution of each PASTA domains truncation with respect 
to localisation, it is clear that one PASTA domain is sufficient for protein localisation of 
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TetH-gfp-ireK 
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TetH-gfp-ireK 
(ΔPASTA_5) 
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TetH-gfp-ireK 
(ΔPASTA_345) 
 
 
G:  
 
TetH-gfp-ireK 
(ΔPASTA_2345) 
 
 
H:  
 
TetH-gfp-ireK 
(ΔPASTA_123) 
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IreK to the septum of growing and dividing E. faecalis. From a qualitative perspective, 
there is no difference in localisation between any of the PASTA domain truncations in 
comparison to the full removal PASTA domains (Figure 3.16.B) and appears to have a 
phenotype similar to that of the FL IreK protein (Figure 3.16.A). These results are 
comparable to the complementation experiment where there was little difference 
between the MIC of each PASTA truncation with respect to ceftazidime. Therefore, this 
further supports the hypothesis that the number of PASTA domains in an eSTK has a 
different role which has been suggested to act as a “molecular ruler” for measuring PG 
thickness in an organism, although in this study it is clear that at least one PASTA domains 
is required for both enhanced cephalosporin resistance and localisation to the septum 
(Zucchini et al., 2018).  
 
3.9.6. Localisation of different PASTA substitutions in IreK  
 In the previous complementation the main difference in MIC associated with the 
PASTA domains was with an IreK construct that contained the three PASTA domains 
derived from the B. subtilis eSTK (PrkC). The MIC to ceftazidime in the presence of the 
four PASTA domains from S. aureus PrkC had an MIC similar to that of E. faecalis. To test 
if there is a correlation between the MIC experiments and the localisation experiments, 
GFP fusion to IreK to the PASTA fusions from S. aureus and B. subtilis were constructed 
and tested and compared to FL IreK constructs and IreK-ΔPASTA constructs (Figure 3.17). 
 When comparing each of the substituted PASTA domains qualitatively, it is clear 
that the majority of the constructs localise strongly to the septum apart from the 
construct that contains the B. subtilis PASTA domains where localisation is still to the 
membrane and is evenly distributed around the cell.  
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TetH-gfp-ireK 
(ΔPASTA) 
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TetH-gfp-ireK (ΔS. 
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Figure 3.17: Localization of GFP-IreK constructs in the OG1RF ΔireK strains with PASTA subsitutions. 
Images displayed are overlaid Phase contrast, GFP fluorescent signal (Green) and FM 4-64 dye (Red). 
Localisation of GFP constructs to the membrane (Yellow). Scale bar, 1 μm. A is replicated from Figure 
3.14.B and B is replicated from Figure 3.15.D for direct comparison. 
    
3.10. Conclusions and future direction 
 There is a difference in phenotype between the OG1RF isogenic series and the 
Tn1549 isogenic strains where the OG1RF strains exhibit enhanced cephalosporin 
resistance with respect to the WT strain and the Tn1549 strains, JH2-2 strains do not. 
Staurosporine synergistic MIC experiments with cefotaxime managed to demonstrate 
that in both OG1RF and JH2-2 strains, cephalosporin sensitivity is restored with or without 
the addition of the Tn1549 cassette. One factor that might contribute to the JH2-2 strains 
not exhibiting enhanced cephalosporin resistance is due to the lack of a full DdcS/R TCS 
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and associated DdcY protein in JH2-2 strains that is present in OG1RF strains. qPCR 
experiments showed that ddcR and ddcY transcripts are upregulated in an 
OG1RF::Tn1549 background in the presence of both vancomycin and cefotaxime 
individually and the phenotype is removed when irek is deleted or in a WT strains. As 
described in the introduction, DdcY has been shown in E. faecium to be a major factor in 
reprogramming PG cell wall to bypass ß-lactam PBPs by generating tetrapeptide 
substrates for LDTfm (Sacco et al., 2014). This mechanism might also explain the 
contribution of enhance cephalosporin resistance in E. faecalis OG1RF::Tn1549.  
 To ensure the Tn1549 cassette has not inserted into an area in the genome which 
could contribute to the differences between the OG1RF and JH2-2 phenotype, 
sequencing of the strains OG1RF WT, OG1RF::Tn1549, JH2-2 WT and JH2-2::Tn1549 is 
required. When comparing the TCSs in OG1RF and JH2-2, the JH2-2 genome is only a draft 
sequence with the contigs not assembled. At the time of submission, the four strains were 
sent for sequencing at Microbe NG.  
 To complement the qPCR experiments which show transcriptional differences at 
a local level, RNA sequencing will give wide coverage of transcription at a global level. 
This will support the RT-PCR data and highlight other genes that might enhance 
cephalosporin resistance in a Tn1549. Recent studies have managed to successfully gain 
an insight into antibiotic resistance in different pathogenic bacteria. This includes a study 
where RNA sequencing was performed on 135 clinical P. aeruginosa isolates and 
identified a variety of transcription variations associated with resistance to different 
classes of antibiotics (Khaledi et al., 2016). The combination of RNA-sequencing and Tn-
sequencing also identified key fitness determinants in a vancomycin resistance E. faecium 
strain and concluded that 27.8% of the genes are differentially expressed in growth 
medium or human serum and most of the genes were associated with carbohydrate 
metabolism when grown in human serum (Zhang et al., 2017). RNA-sequencing could 
therefore provide a global evaluation of transcription variation in a Tn1549 E. faecalis 
strain to evaluate its overall effect on cephalosporin resistance.  
 The work from this study suggests that the DdcRS TCS and DdcY proteins are 
important in the observed enhanced cephalosporin resistance phenotype in the 
OG1RF::Tn1549 strain from the qPCR. The lack of enhanced cephalosporin resistance in 
JH2-2 strains due to the DdcRS TCS not being observed. Mutation experiments of the 
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DdcRS TCS can help identify if there is a direct link with DdcY with enhanced 
cephalosporin resistance. Previous experiments identified that IreK phosphorylates 
VanSB at position T223 in vitro. The same experiments could be transferred into a system 
to test whether IreK can directly phosphorylate DdcS or DdcR or whether the 
phosphorylation of VanSB is essential for the signal transduction cascade. As mentioned 
previously, DdcY has been determined to be a homologue of VanY which is a 
carboxypeptidase that forms tetrapeptide substrates for 3-3 crosslinking. To test if this is 
the case, uninduced cells or those that contain sub-inhibitory levels of vancomycin of 
cefotaxime can be grown harvested and the PG extracted and purified to look at the PG 
profile in the different experimental conditions. Recent advancement has been achieved 
to use automated systems to analyse PG structure through enzymatic digestion, followed 
by separation by reverse phase HPLC and collection of individual peaks for MALDI-TOF 
and tandem mass spectrometry where PG structural and chemical modifications can be 
automatically assigned (Bern et al., 2017). Therefore, mass spectrometry analysis of 
whole cell wall PG from E. faecalis strains under different antibiotic treatment could 
provide a suitable system for analysing the PG structure in these experimental conditions.  
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Chapter 4. Biophysical analysis of IreK Domains 
4.1. Introduction 
 The experiments summarised in Chapter 3 demonstrate that cephalosporin 
resistance in E. faecalis is enhanced by the presence of the Tn1549 cassette. In E. faecalis 
strains with intrinsic resistance to cephalosporin and enhanced cephalosporin resistance 
with the Tn1549 cassette, a deletion of the irek gene resulted in susceptible strains of E. 
faecalis. Likewise, the addition of staurosporine, a known ST kinase inhibitor, managed 
to result in inhibition of the KD of IreK and presents a comparable phenotype to an ireK 
deletion. Complementation and localisation studies provide insight into the role of IreK 
with an association to cephalosporin resistance and managed to identify that the PASTA 
domains are essential for localisation to the septum. This study showed that one PASTA 
domain is required and that the kinase is still partially functional but distributed around 
the growing cell and not the septum. 
 To support the results from Chapter 3, the protein domains from IreK have been 
recombinantly expressed and purified for a range of biophysical studies to gain further 
insight into the physical properties of IreK. Previous data on eSTKs in M. tuberculosis PknB 
suggested a model of ligand-dependent eSTK autophosphorylation. In this model, 
dimerization of the extracellular PASTA domains is in response to ligand binding and leads 
to activation via trans-phosphorylation of the cytoplasmic domain (Barthe et al., 2010). 
After initial protein domain characterisation including qualitative SDS-PAGE gels, mass 
spectrometry of samples to establish and compare experimental MW to theoretical MW, 
and CD analysis at a range of temperatures, the data in this Chapter aim to highlight the 
oligomeric states of the kinase and PASTA domains using size exclusion chromatography-
multiple angle light scattering (SEC-MALS) and analytical ultracentrifugation (AUC).  
 At present there is a lack of clarity on the nature and identity of ligands that 
associate with the PASTA domains between species, with a component of PG being the 
most likely associated ligand. I have screened the binding properties of PASTA domains 1 
to 5 against enzymatically cleaved E. faecalis native PG, highly purified and well 
characterised PG mimetic compounds and a range of different antibiotics. These 
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potential ligand candidates were then tested using microscale thermophoresis to remove 
any possibility of a false positive being detected from SPR through non-specific binding. 
4.2. Initial characterisation of each protein construct 
 The KD from E. faecalis and E. faecium IreK (pLG226 and pLG234 respectively) 
were previously cloned into pET Duet, and the constructs were used in this study. The 
PASTA domain constructs were cloned from the E. faecalis IreK plasmid (codon-
optimised) (pCWT001) into pProEX with an N-terminal histidine tag followed by a TEV 
cleavage site. PASTA constructs were cloned into the NcoI and HindIII sites and allowed 
only three residual amino acids not associated with the PASTA constructs to remain (G-
A-M) following TEV cleavage. All proteins were purified using IMAC purification on a 
nickel column and gel filtration on either a Superdex 75 or Superdex 200 column 
(depending on the size of the protein) as described in Chapter 2.4 of the Materials and 
Methods. Final constructs are illustrated in Figure 4.1.  
 
 
Figure 4.1: IreK domain constructs for recombinant protein expression. Schematic of protein constructs 
used in this study including the IreK PASTA domains in E. faecalis or the IreK KD domains from both E. 
faecalis and E. faecium. Size of constructs are represented post TEV cleavage (kDa). 
4.2.1. SDS-PAGE and SEC-MALS analysis 
 The overall purity and oligomeric states of the various domains of IreK were 
evaluated in the absence of ligands using SDS-PAGE and SEC-MALS analyses. These results 
are summarised in Figure 4.2 for KD constructs and Figure 4.3 for PASTA constructs. From 
inspection of the SDS-PAGE gels for each protein domain after IMAC and gel filtration, it 
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is clear that each protein domain has been produced at high purity (Figure 4.2 and Figure 
4.3). The pure proteins were also subjected to SEC-MALS analysis. SEC-MALS is an 
advantageous technique as it allows you to separate out protein species (oligomeric or 
protein containments from purification) using an analytical gel filtration column while 
gaining individual measurement properties of that species. MALS analysis of a sample 
allows multiple angles to be measured simultaneously where the scattering intensity can 
be directly related to the solution molecular mass of the sample (Philo, 2009; Some, 
2013).
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Kinase Domains 
A:  
 
A:  
 
B:  
 
A:  
 
Figure 4.2: Recombinantly expressed IreK Kinase domains analysed SDS-PAGE for purity and SEC-MALS for oligomerisation. Analysis of purified IreK kinase domains from 
E. faecalis (A) or E. faecium (B) by SDS-PAGE (Left) or oligomerisation by SEC-MALS (Right). Elution profiles of kinase domains were examined by SEC-MALS on a Superdex 
200 increase (10/300) at a flow rate of 0.75 ml min-1. Absorbance at A280 for each chromatogram was normalised. MALS data are presented in Red with predicted molecular 
weight above each peak.  
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Figure 4.3: Recombinantly expressed IreK PASTA domains analysed SDS-PAGE for purity and SEC-MALS for oligomerisation. Analysis of purified PASTA domains from E. 
faecalis including (A) PASTA 1-5, (B) PASTA 1-4), (C) PASTA 1-3 and (D) PASTA 1-2 by SDS-PAGE (Left) or SEC-MALS (Right). Elution profiles of PASTA domains were examined 
by SEC-MALS on a Superdex 75 increase (10/300) at a flow rate of 0.75 ml min-1. Absorbance at A280 for each chromatogram was normalised. MALS data are presented in 
Red with predicted molecular weight above each peak. 
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From the analysis of the SEC-MALS data of the kinase domains from E. faecalis 
and E. faecium, it is clear that the primary species is the monomeric form of the kinase 
from both species. In both experiments, another oligomeric species is present and is 
predicted to be a dimer for the E. faecalis kinase construct and a high molecular weight 
aggregate for the E. faecium kinase construct.  
For each of the PASTA domain constructs initially measured by SEC-MALS, each 
construct is predominately monomeric. A small molecular weight contaminant is present 
is the PASTA 1 to 5 construct and a small low MW shoulder  is present for the PASTA 1 to 
4 construct. There is a high molecular weight component present in the PASTA 1 to 3 
construct, but when compared to Figure 4.4 with an overlay each of the four PASTA 
constructs analysed, it appears that the high molecular weight contamination may have 
come from residual protein left in the sample loading loop from PASTA 1 to 4. The SEC-
MALS analysis for sample 1-2 shows a single species. The experimental molecular weight 
of each construct from SEC-MALS is compared later in this chapter with the theoretical 
molecular weight and other experimental molecular weights from other techniques. 
 
  
Figure 4.4: Overview of SEC-MALS data obtained for each PASTA construct. Chromatograms of each 
PASTA construct shown in PASTA 1-5 (Blue), PASTA 1-4 (Orange), PASTA 1-3 (Purple) and PASTA 1-2 
(Green). MALS data are presented in Red. 
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4.2.2. Determining the fold of each protein construct by CD 
 After analysis of each construct by SDS-PAGE and SEC-MALS, the secondary 
structure composition was measured using CD to gauge whether the proteins were well-
folded after being recombinantly expressed. CD is often used as a quality control check 
after recombinant protein production and gives early estimates of secondary structure 
and folding properties of the protein. Figure 4.5 highlights the structural features that 
can be identified using CD using when formed predominantly of that structural feature.  
 
 
Figure 4.5: Schematic showing a CD profile of a-helix, β-sheet and random coil spectra expected when 
predominately formed of that secondary structure feature. Most proteins will be a mixture of all three 
of these structural features but measuring 222 nm is often used to monitor changes in a-helix content in 
different buffers or temperatures.  
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  Although CD allows rapid quantification of protein structure on a global scale, it 
does not give residue specific information like other structural techniques including cryo-
EM, X-ray crystallography and NMR (Greenfield, 2006). Figure 4.6 and Figure 4.7 show 
processed CD data for either the KD or PASTA domains, respectively, and the associated 
predicted secondary structure composition as estimated from fitting of the data using 
DichroWeb (Figure 4.8) (Whitmore and Wallace, 2004). 
 
A:  
 
B:  
 
Figure 4.6: CD spectra of each KD of IreK. (A) KD from E. faecalis and (B) KD from E. faecium at 0.2 mg mL-
1 in 10 mM Sodium Phosphate, pH 7.4 buffer at 25°C. 
 Inspection of the CD spectra of KD from both E. faecalis and E. faecium IreK in 
Figure 4.6 suggests a significant amount of helical content due to the presence of 
negative maxima at 208 and 222 nm.  This is confirmed when using DichroWeb to 
estimate the secondary structure composition. Figure 4.8A shows that the domains are 
highly helical, with 70% and 75% a-helix for E. faecalis and E. faecium respectively. The 
β-sheet content is estimated as 12% and 11% for E. faecalis and E. faecium respectively. 
When comparing these estimations with structures obtained from homologous proteins 
including S. aureus (PDB: 4EQM, 34% and 17% α-helix and β-sheet respectively (Rakette 
et al., 2002)) and M. tuberculosis (PDB: 1O6Y, 35% and 19% α-helix and β-sheets 
respectively (Ortiz-Lombardia et al., 2013)), the percentage of α-helix is observed in the 
E. faecalis and E. faecium IreK KD is more than double, but still shows that the α-helix is 
the most dominant secondary structure in the protein. 
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Figure 4.7: CD spectra of each PASTA construct of IreK from E. faecalis. (A) PASTA 1 to 5, (B) PASTA 1 to 
4, (C) PASTA 1 to 3 and (D) PASTA 1 to 2 at 0.2 mg mL-1 in 10 mM Sodium Phosphate, pH 7.4 buffer at 
25°C. 
 The CD spectra of each of the PASTA domains (FL and truncations) from IreK E. 
faecalis are shown in Figure 4.7. The estimated secondary structure composition is 
highlighted in Figure 4.8.B for each construct and shows a decrease in secondary 
structure (and an increase in disorder) from PASTA 1 to 5 to PASTA 1 to 2. The estimated 
secondary structure composition of PASTA 1 to 5 (16% and 41 % α-helix and β-sheet, 
respectively) agrees well with the known structures of S. aureus PASTA domains (PDB: 
3M9G, 13% and 33% α-helix and β-sheet respectively (Paracuellos et al., 2010)) and M. 
tuberculosis PASTA domains (PDB: 2KUI, 16% and 30% α-helix and β-sheet respectively 
(Barthe et al., 2010), and it is apparent that PASTA domains are predominately β-sheet in 
secondary structure. 
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Figure 4.8: Secondary structure percentage distribution determined by CD. KD (A) and PASTA domains 
(B) according to DichroWeb determined by using the CDSSTR method with Reference set 3 (kinases) and 
Reference set 4 (PASTA) for data fitting. 
4.2.3. Determining the melting temperature (TM) of each protein construct by CD 
 The TM is determined by the midpoint of the unfolding transition from secondary 
structure components in proteins (Greenfield, 2006). As CD monitors secondary structure 
in a protein, heat can be applied at incremental temperatures to study how proteins lose 
these highly ordered structures. To assess the stability of each IreK construct and confirm 
that each domain is well-folded, melting temperatures (TM) were performed between 25-
100°C for kinase domains in 5°C increments or between 20-100°C for PASTA domains in 
1°C increments (Figure 4.9 and Figure 4.10 respectively).  
 The IreK kinase domains from E. faecalis and E. faecium have a high and similar 
melting temperature, confirming that the recombinantly expressed and purified protein 
is well-folded. When comparing the PASTA domains from E. faecalis and the incremental 
truncations, it is clear that the melting temperature decreases upon each truncation after 
PASTA 1 to 4. PASTA 1 to 5 and PASTA 1 to 4 have a high TM, but there is a decrease in TM 
associated with PASTA 1 to 3 and a very low TM observed for PASTA 1 to 2. To confirm 
that the PASTA domains were not unfolded after purification and after thawing from 
storage in -80°C, the TM was monitored across the whole CD spectrum (Figure 4.11).  
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Melting Temperatures (°C) of IreK KD from E. faecalis and 
E. faecium 
 
E. faecalis E. faecium 
73.5 70.6 
 
Figure 4.9: CD TM of IreK KD following 222 nm. Protein constructs at 0.2 mg mL-1 in 10 mM Sodium Phosphate, pH 7.4 buffer were incubated at incremental temperatures 
from 20 to 100°C with CD spectra collected at each temperature point. Including (A) overlay plot of kinase constructs, (B) IreK E. faecalis, (C) IreK E. faecium, with the 
Boltzman sigmoid fit (Solid Black line). Insert: table of TM of each construct as determined by the Boltzmann sigmoid equation 
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Figure 4.10: CD TM of IreK of PASTA constructs from E. faecalis following 222 nm. Protein constructs at 0.2 mg mL-1 in 10 mM Sodium Phosphate, pH 7.4 buffer were 
incubated at incremental temperatures from 20 to 100°C with CD spectra collected at each temperature point. Including (A) overlay plot of PASTA constructs, (B) PASTA 1 
to 5, (C) PASTA 1 to 4, (D) PASTA 1 to 3 and (E) PASTA 1 to 2 with the Boltzman sigmoid fit (Solid Black line). Insert: table of TM of each construct as determined by the 
Boltzmann sigmoid equation. 
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Figure 4.11: CD TM spectra of each PASTA construct of IreK. Protein constructs at 0.2 mg mL-1 in 10 mM Sodium Phosphate, pH 7.4 buffer were incubated at incremental 
temperatures from 20 to 100°C with CD spectra collected at each temperature point Includes (A) PASTA 1 to 5, (B) PASTA 1 to 4, (C) PASTA 1 to 3 and (D) PASTA 1 to 2 at 
0.2 mg mL-1 following a TM melt from 20 to 100°C. 
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4.3. Studying oligomerisation of IreK domains using AUC 
 Analytic ultracentrifugation (AUC) is a well-established technique and is readily 
used to study oligermisation of proteins (Uttinger et al., 2017). It has many advantages 
over other techniques such as SEC-MALS as biomolecules are free in solution, no 
immobilisation is acquired, and it can measure homo- and hetero-interactions and 
stoichiometry. It is known that sedimentation of macromolecules correlates with a 
concentration effect and the transport properties of macromolecules are related to their 
spatial distribution (Brown and Schuck, 2006). A major benefit of AUC is its ability to study 
weak interactions as even the weakest interaction can still cause a change in 
sedimentation and diffusion behaviour in concentrated systems (Solovyova et al., 2001).  
 To further explore the oligomerisation previously observed by SEC-MALS (Figure 
4.2 to 4.4) sedimentation velocity AUC experiments were used to study the kinase 
domains and PASTA domains (Table 4.1 and Table 4.2). The sedimentation coefficient 
distributions for the absorbance and interference data are shown in Appendix 8.4. In 
each table the characteristics in the MW calculated for a species in the c(s) 
(sedimentation coefficient) analysis which is dependent on the frictional ratio parameter 
(f/f0). The frictional ratio is fit globally during the analysis, thus when there is more than 
one species present the calculated f/f0 is an average value for all of the species present. 
MWs calculated using this average f/f0 will not give the true MW values for each 
individual species. Both the absorbance at 280 nm (A280nm) and interference data were 
used. The interference optics are more sensitive than the absorbance optics, which is 
good for low concentration samples, but has the drawback that they will also detect 
differences between the sample and reference buffers, which can affect the analysis. The 
greater sensitivity means they will also detect contaminants that are not visible in the 
absorbance data, meaning the presence of contaminants will have a greater effect on the 
accuracy of the interference data than on the absorbance data. 
 The kinase domain constructs do not exhibit any thermodynamic or 
hydrodynamic non-ideality, and there is clearly a self-association equilibrium (Table 4.1). 
When comparing the absorbance data, the predominant species is monomeric, but there 
is also a dimer and a possible trimer/tetramer. The interference data also reveals the 
presence of a low MW contaminant in both samples.  
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 To complement the AUC data, and clarify the oligomeric state of each species 
present in samples of the KD, a native-PAGE gel was run for the IreK kinase domains from 
E. faecalis and E. faecium (Figure 4.12). It is clear from the native-PAGE gel there are at 
least 4 oligomeric species present in the kinase domain. Although interpretation of which 
species type is difficult as a marker was not used, in comparison to the AUC data and the 
SEC-MALS data, it can be assumed that the bottom band is a monomer and the one 
following is a dimer with two higher order oligomers being visible. It is clear in these 
experiments that the KD can self-associate independent of the PASTA domains, and if 
dimerization is required for autophosphorylation, the PASTA domains might have 
different role from that of promoting oligomerization. 
 
Figure 4.12: Native-PAGE gel of Kinase domains from Enterococcus spp. 40 µg of either the KD of IreK 
from E. faecalis (Left) and E. faecium (Right) was loaded onto a 4-20% acrylamide gradient Native-PAGE 
gel for inspection of oligomerization.  
 When comparing the PASTA domain constructs (Table 4.2), no concentration 
dependence was noted for the sedimentation co-efficient of any of the PASTA constructs, 
suggesting no self-association or non-ideal behaviour, over this concentration range. The 
predominant species present in all of these samples appears to be a monomer (note the 
dependence of the MW on the best-fit f/f0). The interference data also reveals the 
presence of a low MW contaminant in PASTA 1- 3 and 1-4.  
 Although previous models have hypothesised that eSTKs oligomerize upon 
binding of a ligand to the PASTA domains (Barthe et al., 2010), the AUC and SEC-MALS 
data show no propensity for self-association of these domains, even at high 
concentrations. Therefore, a ligand must be essential to support the model, or a different 
mechanism of action is necessary for oligomerisation of eSTKs and activation of the kinase 
domains.
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Table 4.1: The estimated MW from each species as determined by AUC by the c(s) analysis of the KD. For each sample concentration the signal-weighted sedimentation 
co-efficient and the estimated MW of each species is shown, together with the best-fit frictional ratio for the distribution. * Average values of two unresolved species. 
Sedimentation coefficients are displayed in Appendix 8.4. 
Theoretical MW 
Monomer  
 (kDa) 
Detection 
method 
Concentration 
(mg mL-1) 
Identified Species  
Peak 1 Peak 2 Peak 3 Peak 4 
f/f0 MW 
(kDa) 
Sed. Co 
(S) 
MW 
(kDa) 
Sed. Co 
(S) 
MW 
(kDa) 
Sed. Co 
(S) 
MW 
(kDa) 
Sed. Co 
(S) 
Kinase (E. faecalis) 
40.1 
Absorbance 
1.0 - - 42.3 2.21 87.0 3.57 167* 5.51* 1.84 
0.5 - - 46.7 2.25 120* 4.24* - - 1.93 
0.25 - - 44.1 2.31 115* 4.38* - - 1.81 
Interference 
1.0 7.9 0.81 40.6 2.41 75.5 3.64 117.0 4.86 1.64 
0.5 8.1 0.88 37.0 2.42 70.1 3.70 115.0 5.17 1.54 
0.25 8.1 0.94 33.6 2.43 66.4 3.83 99.8* 5.03* 1.43 
Kinase (E. faecium) 
41.1 
Absorbance 
1.0 - - 43.2 2.20 91.9 3.65 162 5.32 1.87 
0.5 - - 42.1 2.25 127.0* 4.70* - - 1.81 
0.25 - - 45.9 2.29 136.0* 4.71* - - 1.88 
Interference 
1.0 6.5 0.73 39.3 2.41 77.1 3.78 128 5.29 1.61 
0.5 7.2 0.84 35.5 2.41 66.0 3.65 116 5.33 1.50 
0.25 8.7 0.94 36.6 2.45 78.4 4.08 140* 6.01* 1.51 
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Table 4.2: The estimated MW from each species as determined by AUC by the c(s) analysis of each PASTA domain truncation. Each sample concentration the signal-
weighted sedimentation co-efficient and the estimated MW of each species is shown, together with the best-fit frictional ratio for the distribution. Sedimentation 
coefficients are displayed in Appendix 8.4. 
Theoretical MW 
Monomer (kDa) 
Detection 
 method 
Concentration  
(mg mL-1) 
Identified Species 
f/f0 Peak 1 Peak 2 
MW (kDa) Sed. Co (S) MW (kDa) Sed. Co (S) 
PASTA 1-2 
15.4 
Absorbance 
1.0 17.1 1.58 - - 1.47 
0.5 16.8 1.59 - - 1.44 
0.25 16.5 1.59 - - 1.42 
Interference 
1.0 17.0 1.57 - - 1.48 
0.5 17.2 1.57 - - 1.49 
0.25 17.2 1.58 - - 1.48 
PASTA 1-3 
22.7 
Absorbance 
1.0 - - 25.8 1.66 1.86 
0.5 - - 31.9 1.68 2.11 
0.25 - - 31.3 1.65 2.13 
Interference 
1.0 9.3 0.93 25.9 1.84 1.68 
0.5 8.4 0.90 24.7 1.84 1.62 
0.25 - - 27.2 1.87 1.71 
PASTA 1-4 
30.3 
Absorbance 
1.0 - - 34.1 1.77 2.09 
0.5 - - 37.3 1.79 2.19 
0.25 - - 51.9 1.79 2.73 
Interference 
1.0 7.0 0.71 31.7 1.96 1.80 
0.5 8.4 0.84 30.5 1.98 1.73 
0.25 - - 31.4 1.99 1.76 
PASTA 1-5 
38.4 
Absorbance 
1.0 41.2 2.18 - - 1.96 
0.5 39.0 2.21 - - 1.87 
0.25 40.8 2.21 - - 1.93 
Interference 
1.0 42.0 2.14 - - 1.79 
0.5 44.4 2.14 - - 1.82 
0.25 40.4 2.17 - - 1.73 
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4.4. Confirming MW by determining experimental MW by mass 
spectrometry and summary of oligomerisation 
 As there was some ambiguity between oligomerisation states of the different 
constructs with different analytic techniques, mass spectrometry was used to validate 
the size of the protein constructs. Table 4.3 summarizes the MW obtained by mass 
spectrometry for each construct (spectra of each construct can be found in Appendix 
8.5), and well as the oligomeric states obtained from AUC and SEC-MALS. It is clear that 
the mass spectrometry results are in good accordance to the theoretical molecular 
weight. 
 Interestingly, the experimental KD MWs from both constructs are not comparable 
to the theoretical mass. Difference mass abundances are present and correspond to a 
mass difference that confers multiple phosphorylated residues (~80 Da) and indicated 
that the protein is autophosphorylated and that there is also non-specific 
phosphorylation. There also appears to be other post translational modifications present. 
Mass spec of the PASTA 1 to 5 with N-terminal His construct (non-TEV cleaved) (PASTA 1 
to 5 (His)) was also conducted as this construct was used in subsequent ligand binding 
experiments. Interestingly, the TEV cleaved PASTA 1 to 5 (PASTA 1 to 5 (TEV)) protein 
showed decreasing mass abundances that correspond to an approximate decreasing 
PASTA domain suggesting degradation over a long period of time. (See Appendix 8.5 - 
Figure 8.8).  
 The SEC-MALS data predict a single monomeric species for the PASTA domains, 
but two oligomeric species for the KD of E. faecalis and E. faecium (i.e. monomeric forms 
in both constructs and/or dimers or aggregates for the second oligomeric species). 
Generally, AUC data showed agreed with the theoretical MW when using the interference 
data to compare MW in both the kinase and PASTA domains. The absorbance data 
overestimates the MW of each construct and made it difficult to determine high order 
oligomeric states in the kinase domains. In conclusion, when comparing the oligomeric 
states of the kinase and PASTA domains, the PASTA domains only appear as a single 
monomeric state and the kinase domain can form multiple oligomeric states.
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Table 4.3: Summary of the MW of each construct and estimates their oligomeric states by a range of biophysical techniques including Mass Spectrometry, SEC-MALS 
and AUC (Absorbance and Interference). * Multiple posttranslational modifications are observed. 
Construct Theoretical (MW) Mass Spectrometry  SEC-MALS  
AUC 
Absorbance  
AUC 
Interference  
 kDa kDa Error  kDa Oligomeric State kDa 
Oligomeric 
State kDa 
Oligomeric 
State 
IreK KD 
E. faecalis  37726.78 38706.3008* 
38626.2500* 
38546.2148* 
38466.1289* 
38386.1992* 
0.0506 
0.0781 
0.1823 
0.0911 
0.5078 
37.30 
75.4 
Monomer 
Dimer 
44.37 
107.3 
167 
Monomer 
Aggregate 
Aggregate 
37.07 
70.67 
110.6 
Monomer 
Dimer 
Trimer 
E. faecium 38691.98 39008.3086 
38928.2266* 
38848.1836* 
38768.2734* 
0.1678 
0.1143 
0.2358 
0.3516 
39.00 
91.20 
Monomer 
Aggregate 
43.73 
118.3 
162 
Monomer 
Aggregate 
Aggregate 
37.13 
73.83 
128 
Monomer 
Dimer 
Trimer 
IreK PASTA domains from E. faecalis 
PASTA 1 to 5 38465.35 38464.8516 
 
0.0391 36.80 Monomer 40.33 Monomer 42.23 Monomer 
PASTA 1 to 5 (His) 41301.53 41301.6758 0.0318 ND ND ND ND ND ND 
PASTA 1 to 4 30294.67 30293.9219 0.0340 29.30 Monomer 41.1 Monomer 31.2 Monomer 
PASTA 1 to 3 22693.30 22692.8203 0.0434 22.20 Monomer 29.67 Monomer 25.93 Monomer 
PASTA 1 to 2 15403.22 15403.0957 0.0485 15.20 Monomer 16.8 Monomer 17.13 Monomer 
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4.5. Identification of Ligands that bind to IreK PASTA domains 
 PG is a highly complex matrix with wide structural variation. To initially test the 
binding of PASTA to PG, a chemi-enzymatic approach was adopted to obtain more 
chemically defined PG fragments. This approach has been initially used to assess the 
binding of S. aureus PG to LysM domains (Mesnage et al., 2014). This approach is one that 
can be transferred to initially study PG interactions with the PASTA domains form E. 
faecalis.  
 E. faecalis JH2-2 was grown until an OD600nm = 0.6 was reached. Cells were 
harvested, and the PG purified as described in Section 2.6 of the Material and Methods. 
Purified E. faecalis PG was then used as a substrate for various hydrolase enzymes to yield 
different PG profiles. Mutanolysin is a commercially available hydrolase (Sigma-M9901) 
and was used according to manufactures instructions. EnpA is a homologue of lysostaphin 
and is an endopeptidase. EnpA was recombinantly expressed and purified and its 
hydrolase activity has been tested previously (De Roca et al., 2010). Full activity from 
EnpA requires pre-digestion of the PG with mutanolysin first. Recombinantly expressed 
hydrolases including EnpA and AtlA were purified according to previous studies (Figure 
4.13.A and Figure 4.13.B respectively) (Figure 4.14) (De Rocca et al., 2010; Hayhurst et 
al., 2008). 
 
 
 
Figure 4.13: Schematic of hydrolases and location of cleavage for E. faecalis binding studies. Scissors 
highlights the location of the hydolases used in this study for ligand binding characterisation.  Includes the 
amidase AtlA, Endopeptidase EnpA and the 1-4 N-acetylmuramyl-N-acetylglucosamine mutanolysin.  
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A:  B:  
EnpA AtlA 
  
Figure 4.14: SDS-PAGE of recombinant hydrolases used in this study. Protiens purified by IMAC and GF 
including (A) Recombinantly expressed EnpA and (B) Recombinantly expressed AtlA.  
 The AtlA enzyme is isolated from S. aureus. Its hydrolase domains have been 
recombinantly purified and tested before using S. aureus PG (Mesnage et al., 2014). To 
initially test the activity of the AtlA amidase against PG from other species, the activity of 
the purified amidase enzyme AtlA, at different concentration of the amidase AtlA in 
buffer (25 mM Tris (pH 7.5), 50 mM NaCl, 0.1 mM CaCl2), the enzyme was mixed with 75 
µg PG that was labelled with [14C] GlcNAC in 15 µL (Roughly 50,000 cpm). Reactions were 
incubated at 37°C overnight then 400 µL H2O added where 200 µL was counted (Total 
scintillation count). Then 3.8 mL scintillation cocktail (Lablogic) was added to the 
remaining 200 µL digested PG and 225 µL was taken and centrifuged. The soluble fraction 
was harvested then counted to monitor PG hydrolysis (soluble scintillation count). Results 
of the amidase activity across three Gram-positive species are highlighted in Table 4.4.  
 From analysis of the radiolabelled PG hydrolysis from different Gram-positive 
species at different concentrations of enzyme, it appears that hydrolase activity is 
inhibited at high enzyme concentrations. For subsequent digestion of PG for the chemi-
enzymatic SPR study, 1 mg of PG was digested with 175 µg amidase in 300 µL overnight. 
To ensure full hydrolysis, samples were boiled for 10 minutes to denature and precipitate 
the protein. After centrifugation samples were hydrolysed further under the same 
amidase. Samples were stored in buffer at -20°C. 
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Table 4.4: Measurement of hydrolysis activity the hydrolase AtlA (amidase) from S. aureus against the 
PG from three different Gram-positive species. The AtlA enzyme was shipped and experiments 
performed by Dr. Stephane Mesnage on radio-labelled PG (University of Sheffield). Activity of the AtlA 
amidase was determined by measuring the percentage of hydrolysis. This was determined by measuring 
the total scintillation count (soluble and insoluble PG) and the soluble scintillation count (digested PG 
caused by amidase).  
Species Concentration of AtlA (µg) in 15 µL  
Total 
scintillation 
count 
Soluble 
scintillation 
count 
% of Hydrolysis 
E. faecalis JH2-2 
67.5 17303 13648 78.9 
22.5 16990 15535 91.4 
7.5 17577 16561 94.2 
2.5 17452 17555 95.5 
S. aureus COL 
67.5 7232 6531 90.3 
22.5 7585 6645 87.6 
7.5 7396 7517 101.6 
2.5 7546 7615 100.9 
B. subtilis 
67.5 12122 10305 78.9 
22.5 12226 12333 91.4 
7.5 12868 12534 94.2 
2.5 12101 11918 95.4 
4.6. Surface Plasmon Resonance 
4.6.1. Introduction to SPR 
 Surface plasmon resonance (SPR) is an optical biophysical technique used to 
measure molecular interactions. It is a label-free technique where radioisotope or 
fluorophore labelling is avoided, but the ligand is immobilised to the sensor surface. 
Interactions are measured from total internal reflection generated from an incident light 
source that passes and reflects back through a prism. The photons interact with a gold 
surface where some of the energy is converted to surface plasmons. The plasmons create 
an electrical field that extends wither side of the chip and produces an evanescent wave 
and can measure perturbations 300 nm from the gold surface. Changes in solution 
adsorption or viscosity can influence the refractive index and implicate the SPR angle. 
Therefore, binding of biomolecules to the sensor surface results in the change in 
refractive index and is measured as a change in resonance angle. (Figure 4.15.A) 
(Schasfoort, 2017).
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A:  B:  
 
 
Figure 4.15: Schematic view of SPR assay. The CM5 sensor chip and PASTA 1 to 5 (ligand) are included as examples. (A) Schematic view of SPR Detector. The incident 
polarised light is coupled by a glass prism on the CM5 chip coated with a thin gold layer that is integrated with the flow cell channel for continuous buffer flow. (B) 
Schematic of reflective light comparing unbound and bound ligands with analytes to produce a typical SPR sensorgram (Adapted from Skankaran and Miura (2007)).  
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 In a typical SPR experiment, the ligand is immobilised onto the sensor surface. Its 
binding partner (the analyte) is injected in aqueous buffer solution through the flow cell 
under continuous flow. Interactions between biomolecules leads to an increase in the 
mass at the SPR interface, changing the observable SPR angle in real time yielding a 
binding curve (sensorgram) (Figure 4.15.B). Sensorgrams are presented in response units 
(RUs). Analytes are also subjected to a blank channel to ensure any contributions with 
the analyte and the sensor surface chip are subtracted from the experimental data.   
 The immobilization of either one of the binding partners onto the chip surface as 
ligand can be achieved by a number of different immobilisation methods using a BIACORE 
system. There are three main ways to attach biomolecules to a surface including 
covalently, affinity-tag or capture partner immobilization. Generally covalent 
immobilisation involves the biomolecule covalently immobilising to the dextran matrix 
on the sensor surface and often provides a very stable attachment of the ligand to the 
sensor surface. Amide coupling covalently links the ligand to the surface through primary 
amine surface residues or nucleophilic groups forming an amide bond. Thiol coupling 
exploits thiol-disulphide exchange between thiol groups and active disulphides that have 
been introduced to either the ligand or matrix surface. Aldehyde coupling uses the 
reaction between hydrazine or carbohydrazine groups introduced on the surface or 
aldehyde groups obtained by oxidation in the ligand.  
 Biotin capture requires the ligand to have a biotinylated linker group to bind to a 
streptavidin-coated surface where the biotin-streptavidin interaction is one of the 
strongest non-covalent interactions (Green, 1975) lending itself well to SPR 
immobilization. His-capture works for proteins with a poly-Histidine tag to co-ordinate 
with a Ni2+ cation. Antibody capture relies on firstly capturing an antibody protein onto 
the surface via any of the previous techniques and then subsequently capturing the ligand 
containing the complimentary antibody epitope.  
 The chip surface containing the immobilised ligand requires regeneration to 
ensure multiple analytes at different concentrations can be screened. Regeneration is the 
involves removing the bound analyte from the surface after the analysis cycle without 
damaging the ligand in preparation for a new cycle. The regeneration solution should not 
also degrade the sensor surface so as to cause the immobilized ligand to detach.  
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 To test the binding of a sub set of ligands to the extracellular PASTA domains, a 
CM5 chip was used to which the protein was immobilised by amide coupling as it is often 
recommended as a starting chip for testing initial immobilisation. Its general properties 
include, high capacity capture and support of a wide range of immobilisation levels which 
is advantageous when studying small molecules.  
4.6.2. pH Scouting and immobilisation of the extracellular PASTA domain 
 Amine coupling is based on amide bond formation between a carboxylic acid 
group on the chip and a primary amine on the ligand surface. In order to drive the 
formation of an amide bond, the OH of the carboxylic acid group must be activated into 
a better leaving group. This is achieved by conversion of the OH into a reactive 
succinimide ester group via EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) and 
then NHS (N-hydroxysuccinimide) additions to yield a stabilized but highly reactive NHS 
ester. Once activated, a ligand in favourable buffer conditions will be conjugated to the 
carboxylic acid group and immobilized. Any remaining activated esters are reacted with 
ethanolamine. Amide coupling can result random orientation of the ligand to the dextran 
surface and may block potential binding sites.  
 When immobilising the ligand using amide coupling, the surface chemistry needs 
to be considered. Above pH 3.5, the dextran matrix is negatively charged and will 
concentrate positively charged ligands through electrostatic attractive forces. This 
process requires the pH of the buffer to be between 3.5 and the isoelectric point (pI) of 
the ligand to maintain a cationic protein surface on the latter. In order to maximize ligand 
capture, a “pH scouting” protocol is used to identify the pH for maximum ligand attraction 
prior to activating the surface for covalent ligand capture where 10 mM sodium acetate 
buffers in 0.5 pH unit increments is used (i.e. pH 4, 4.5, 5 and 5.5). 
 Binding of PASTA domains to various ligands was studied using SPR. Recombinant 
PASTA proteins made of the full extracellular modules (PASTA 1 to 5) that were 
immobilized on a sensor chip with the poly-his(x6) tag with TEV cleavage site (PASTA 1 to 
5 (His)), or with TEV Cleaved protein (PASTA 1 to 5 (TEV)). Before immobilisation of the 
PASTA constructs onto the sensor surface chip, pH scouting was performed (Figure 4.16). 
Conditions for pH scouting included 180 seconds contact time and a flow rate of 5 µL min-
1. Only the constructs that were diluted in pH 5 and 5.5 showed association with the 
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sensor surface with the TEV cleaved PASTA, whereas all diluted PASTA constructs without 
TEV cleavage showed association to the surface chip and also showed weak dissociation 
and required a regeneration step to clean the surface. A pH of 5.5 did not show the 
highest response unit in comparison to the other adjusted pH, but it did reach saturation 
and also had the highest response after injection of the protein stopped. Although pre-
concentration is more efficient at high pH values, the amine coupling chemistry requires 
uncharged amino groups, immobilisation it is more efficient at a higher pH. Therefore, 
for both constructs, immobilisation was performed in pH 5.5 sodium acetate. 
 
A:  
 
B:  
 
Figure 4.16: Pre-concentration pH scouting. Each PASTA 1 to 5 construct was diluted to a final 
concentration of 0.02 mg mL-1 in 10 mM sodium acetate at either pH 4, 4.5, 5 or 5.5. The affinity for the 
CM5 sensor surface for each construct was assessed (A) PASTA 1 to 5 (HIS) and (B) PASTA 1 to 5 (TEV) in 
each of the buffer conditions at a flow rate of 5 µL min-1 on a BIACORE T200.  
 After pH scouting, the two PASTA 1 to 5 constructs were immobilised onto the 
CM5 surface chip using amide coupling with the ligand diluted in 0.02 mg mL-1 and pH 5.5 
for the constructs PASTA 1 to 5 (His) and PASTA 1 to 5 (TEV). Conditions included 420 secs 
contact time and a flow rate of 10 µL min-1. Figure 4.17 highlights the immobilisation 
profile for PASTA 1 to 5 (TEV) giving a final response of 725 RU and Figure 4.18 highlights 
the immobilisation of the PASTA 1 to 5 (His) giving a final response of 6347 RU. 
Immobilisation in other experiments in these conditions were performed on the PASTA 1 
to 5 construct (His) (7750 RU and 4536 RU).  
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A:  
 
B:  
 
Figure 4.17: Immobilisation of PASTA 1 to 5 (TEV). PASTA 1 to 5 (TEV) was diluted to a final concentration 
of 0.02 mg mL-1 in 10 mM sodium acetate, pH 5.5 and immobilised on a CM5 sensor surface chip on a 
BIACORE T200 at a flow rate of 10 µL min-1. Sensogram demonstrate immobilisation by amide coupling of 
(A) blank flow cell and (B) PASTA 1 to 5 (TEV). 
A:  
 
B:  
 
Figure 4.18: Immobilisation of PASTA 1 to 5 (His). PASTA 1 to 5 (HIS) was diluted to a final concentration 
of 0.02 mg mL-1 in 10 mM sodium acetate, pH 5.5 and immobilised on a CM5 sensor surface chip on a 
BIACORE T200 at a flow rate of 10 µL min-1. Sensogram demonstrate immobilisation by amide coupling of 
(A) blank flow cell and (B) PASTA 1 to 5 (HIS). 
4.6.3. Identification of a suitable regeneration solution 
 Prior to full titration experiments, a suitable regeneration solution was required 
for subsequent high-throughput analysis. Binding was analysed using analyte mixtures 
prepared from PG sacculi hydrolysed by enzymes displaying distinct cleavage specificities. 
Initial binding was observed by the amidase treated E. faecalis PG construct and provided 
a suitable control to look into suitable regeneration solutions. Although binding was not 
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observed for the TEV cleaved construct, binding was observed for the non-TEV cleaved 
construct. Ligand regeneration using 10 mM NaOH caused a decrease in RU of the 
immobilised protein (Figure 4.19.A) and regeneration using 5 M NaCl did not allow the 
regeneration step to reach base line (Figure 4.19.B). In a previous study where the 
extracellular domains of LysM from the E. faecalis protein AtlA were studied, 6M 
guanidine hydrochloride was efficient to regenerate the immobilised construct on the 
sensor surface chip (Mesnage et al., 2014). Figure 4.19.C shows that guanidine 
hydrochloride is efficient in removing the analyte from the immobilised ligand and that 
the baseline is restored after regeneration. All subsequent binding experiments were 
performed in triplicates to ensure there was no irreversible damage to the immobilised 
ligand.  
4.6.4. Issues with the TEV-cleaved PASTA 1 to 5 construct 
  After initial scouting for a suitable regeneration solution using PASTA 1 to 5 (His), 
the immobilised TEV cleaved PASTA construct was screened against the analytes used to 
study PASTA 1 to 5 (TEV). Unfortunately, no binding was observed. Initial observation of 
the immobilisation of PASTA 1 to 5 (TEV) shows very weak immobilisation to the sensor 
surface chip (Figure 4.17). The pIs of the cleaved and non-cleaved PASTA 1 to 5 domains 
are close to one another (4.78 and 4.89, respectively). Although there is no conclusive 
explanation for the difference in immobilisation between the two constructs, it is possible 
that the addition of the His-tag and TEV cleavage site gives the protein slightly more 
charge and more propensity to interact with the sensor surface chip. For all subsequent 
studies, the non-TEV cleaved PASTA constructs were used to study interactions with 
potential analytes. 
 
 
 183 
 
Figure 4.19: Sensogram profile of candidate regeneration solutions using PASTA 1 to 5 (HIS) constructs. Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip 
was subjected to regeneration scouting to optimise conditions for testing multiple analytes and concentrations on the same ligand on the same sensor surface. Running 
conditions included 10 µL min-1 and initial runs were tested with just SPR running buffer to ensure a steady baseline. (A) The first regeneration step using 10 mM NaOH 
caused a sharp decrease and removed immobilised protein from the sensor surface. Data not normalised to baseline. (B) After 1 injection of 10 µg mL E. faecalis digested 
PG with amidase, regeneration with NaCl did not restore the sensogram to baseline and indicates NaCl was inefficient at removing the analyte from the ligand. (C) After 1 
injection of 10 µg mL E. faecalis digested PG with amidase, regeneration with 6M guanidine hydrochloride did restore the sensogram to baseline and indicates 6M 
guanidine hydrochloride was efficient in removing the analyte from the ligand. 
A:  B:  C:  
10 mM NaOH 5 M NaCl 6 M Guanidine Hydrochloride 
   
 184 
4.6.5. Screening potential analytes against E. faecalis PASTA domains 1 to 5 
 It was previously determined in Chapter 3 that the PASTA domains in IreK localise 
the protein to the septum of growing cells where PG polymerisation and cell division 
occur. As this is the site of high PG activity, including transpeptidation and 
transglycosylation, it is also the location of antibiotic targets that target PBPs. The 
subsequent experiments aimed to characterise potential interactions between PASTA 
domains and PG derivatives and antibiotics. 
4.6.5.1. Binding of Heterogeneous PG derivatives to E. faecalis PASTA domains 1 
to 5 
 To determine the impact of PG motifs on binding to PASTA, hydrolysed PG 
fragments were generated and have been shown to bind using this method to the E. 
faecalis LysB domains using SPR (Mesnage et al., 2014). Dose-dependent binding was 
observed with soluble PG hydrolysed fragments from E. faecalis using amidase, 
muramidase or endopeptidase digestion. Fragments treated with amidase showed an 
apparent higher binding affinity compared to those treated with muramidase or 
muramidase and endopeptidase, but binding was still observed in the presence of other 
PG hydrolases (Figure 4.20). 
 Interestingly, there was little difference in binding when comparing the 
muramidase treated PG products and the muramidase and endopeptidase treated 
products (Figure 4.20.B and Figure 4.20.D respectively).The greatest difference in binding 
was in comparison to the amidase treated PG with heterogeneous  populations of glycan 
strands and peptide stems and that endopeptidase treatment followed my muramidase 
treatment giving heterogeneous populations of peptide stems and shorter glycan strands 
(Figure 4.20.A and Figure 4.20.C respectively). This indicates that longer glycan strands 
provide a more favourable ligand for binding of PASTA domains than shorted glycan 
strands.  
 To complement the experiments studying the hydrolysis of PG from E. faecalis, 
Figure 4.21 illustrates the dose dependency of S. aureus PG against E. faecalis 
extracellular PASTA domains. Interestingly, the only experiment to demonstrate ligand 
binding is that of S. aureus PG that has been digested with amidase to give a 
heterogeneous population of long glycan strands and peptide stems. The other 
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experiments showing endopeptidase treatment of muramidase treatment did not show 
any dose dependent response. This indicates that the oligomeric glycan strand is the main 
ligand for the PASTA domains of E. faecalis from both E. faecalis and S. aureus amidase 
treated PG and that the pentapeptide bridge in E. faecalis (Ala-Ala) is also important since 
binding is also observed when the glycan strands are hydrolysed with mutanolysin. 
Binding is not observed in S. aureus PG treated with mutanolysin and indicates that the 
S. aureus PG bridge (Gly5) is not important for PASTA interactions.  
 To study the effect of glycan motifs binding to PASTA domains form E. faecalis, 
whole cell PG and natural polymeric derivatives with different sugar chains were tested 
in an SPR experiment. Insoluble PG was used with a GlcNAC-MurNAc glycan backbone, 
chitin presented a comparable poly-GlcNAc ligand, cellulose as an alternative linear 
polysaccharide containing multiple glucose motifs and xylan containing xylose as it 
polysaccharide sub-unit (Figure 4.22). The E. faecalis PG showed the highest binding 
activity and also showed a dose dependent response with a two-fold serial dilution of the 
ligands. The other polysaccharide substrates showed either weak (chitin and xylan) or no 
binding of cellulose. These experiments indicate that at least the GlcNAc and MurNAc 
motifs are required for biding to the PASTA domains. 
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A:  B: 
Amidase treated E. faecalis PG (AtlA) Muramidase treated E. faecalis PG 
(Mutanolysin) 
 
 
  
C: D: 
Amidase and Muramidase treated E. faecalis PG 
(AtlA and Mutanolysin) 
Muramidase and Endopeptidase treated E. 
faecalis PG (Mutanolysin and EnpA) 
  
  
Figure 4.20: Identification of PG motifs recognised by the PASTA domains using E. faecalis PG. 
Experiments performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate 
of 10 µL min-1. This chemi-enzymatic approach provides a heterogeneous population of E. faecalis PG that 
have been specifically cleaved by certain cell wall hydrolases. These include (A) The AtlA amidase, (B), The 
mutanolysin muramidase, (C), Amidase and Muramidase treatment with AtlA and Mutaolysin respectively 
and (D) Muramidase and Endopeptidase treatment with Mutanolysin and EnpA respectively. All were 
performed in a titration series including 100, 50, 25, 12.5 and 6.25 µg mL-1 of each hydrolysed PG product. 
Schematics of a typical digestion profile is also highlighted above each respective sensogram. Each 
concentration was performed in triplicates. 
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A: B: C: 
Amidase treated S. aureus PG (AtlA) Endopeptidase treated S. aureus PG (Lysostaphin) Muramidase treated S. aureus PG (Mutanolysin) 
 
 
 
   
Figure 4.21: Identification of PG motifs recognised by the PASTA domains using S. aureus PG (Kind gift from Stephane Mesnage, The University of Sheffield). Experiments 
performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate of 10 µL min-1. This chemi-enzymatic approach provides a heterogeneous 
population of S. aureus PG that have been specifically cleaved by certain cell wall hydrolases. These include (A) The AtlA amidase, (B), The mutanolysin muramidase and (C) 
Endopeptidase treatment lysostaphin. All were performed in a titration series including 100, 50, 25, 12.5 and 6.25 µg mL-1 of each hydrolysed PG product. Schematics of a 
typical digestion profile is also highlighted above each respective sensogram. Each concentration was performed in triplicates.  
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A:  
Peptidoglycan 
B-1,4−GlcNAc-MurNAc-peptide polymer 
B:  
Chitin 
B-1,4−GlcNAc polymer 
 
 
  
C:  
Cellulose 
B-1,4−Glucose polymer 
D:  
Xylan 
B-1,4-xylose polymer 
  
  
Figure 4.22: Binding activity of PASTA domains 1 to 5 with sugar polysaccharides. Experiments 
performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate of 10 µL min-
1. Includes (A) whole cell PG with an increasing titration (10, 50, 100, 500, 1000 µg mL-1, (B) Chitin at 1000 
µg mL-1, (C) Cellulose at 1000 µg mL-1, and (D) Xylan at 1000 µg mL-1 including schematics of structures of 
each polysaccharide used where differences are highlighted in Red. Each binding experiment of 
polysaccharide was performed in triplicate. 
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5.3.6.2 Binding of PASTA 1 to 5 to pure PG motifs 
 In a previous in vivo model studying the effect of the eSTK in PrkC in B. subtilus, it 
was shown that B. subtilus spores could germinate in the presence of DAP-type but not 
Lys-type cell wall muropeptides (Shah et al., 2008). The extracellular PASTA domains of 
PrkC were further explored in a ligand binding study using STD NMR and had showed that 
the PASTA domains for PrkC in B. subtilus interacted directly with the DAP moiety of a 
muropeptide and interact directly with an arginine residue in the C-terminal PASTA 
domain. Mutation of this residue completely suppressed muropeptide binding and gave 
the first indication into the sensing mechanism of the PASTA domains in PrkC (Squeglia 
et al., 2011). Although in these experiments the binding of muropeptides was not tested, 
they were tested in MST experiments described later. It was clear from earlier 
experiments that the glycan chains may be implicated in the binding of PASTA 1 to 5 of 
IreK in E. faecalis unlike muropeptides shown previously. In. Figure 4.23, the monomeric 
units of the glycan chain of PG were tested individually at a high concentration (2 mM) in 
triplicates. From the preliminary analysis of these two ligands, it appears that MurNAc 
binds slightly higher than GlcNAc but the initial binding activity of either is not high even 
at 2 mM concentration. 
A:  B:  
GlcNaC MurNAc 
  
  
Figure 4.23: Binding of PG glycan monomers extracellular PASTA domains of E. faecalis IreK. 
Experiments performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate 
of 10 µL min-1.  Includes (A) GlcNAc and (B) MurNAc at 2 mM in triplicates.  
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5.3.6.3. Binding of PASTA 1 to 5 to b-lactam antibiotics 
 PASTA domains are not only found on eSTKs but can also be found on some PBPs 
such as PBP2x in S. pneumoniae. Previous experiments have demonstrated that Bocillin 
FL (a fluorescent penicillin) was essential in the binding to the PASTA domains, and that 
the binding also provided stability to PBP2x (Schweizer et al., 2014). Consistent with the 
role of PASTA domains in PBPs binding β-lactams, the X-ray structure of an acylated PBP2x 
crystallised was solved in the presence of a high concentration (14 mg mL-1) of cefuroxime 
with two molecules bound. One was covalently bound to the active site serine and the 
second was non-covalently positioned between the TP and the first PASTA domain 
(Gordon et al., 2000). 
 Figure 4.24 shows an SPR experiment studying the interactions between two b-
lactams of the cephalosporin class ceftriaxone and cefoxitin. In Chapter 3, it was 
highlighted that IreK was essential in intrinsic and enhanced cephalosporin resistance in 
E. faecalis. The SPR experiment where 2 mM of each antibiotic was tested against PASTA 
1 to 5 found that there is no interaction.  
A:  B:  
Ceftriaxone Cefoxitin 
  
  
Figure 4.24: Binding of cephalosporin antibiotic to the extracellular PASTA domains of E. faecalis IreK. 
Experiments performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate 
of 10 µL min-1. Includes structures of each cephalosporin and SPR sensorgrams showing a dose 
dependence response. Antibiotics were 2-fold serially diluted from 2 mM. 
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5.3.6.4. Binding of PASTA 1 to 5 to aminoglycoside antibiotics 
 Previous research has highlighted that aminoglycosides have little effect on IreK 
homologues in other species including PknB in S. aureus (Tamber et al., 2010). In this 
study in Chapter 3, it is also highlighted that there is little difference in the MIC when 
comparing gene deletions of ireK. A small subset of aminoglycosides was tested against 
the PASTA domain 1 to 5 from E. faecalis IreK including kanamycin, neomycin, 
spectinomycin and streptomycin (Figure 4.25). 
 Interestingly, although there is little difference in the MICs that have been 
observed when studying eSTKs in Gram-positives and aminoglycosides, there appears to 
be a dose dependent response with increasing concentrations of each aminoglycoside. It 
was previously described in this chapter that the PASTA domains may potentially have an 
interaction with the glycan chains of the heterogeneous PG samples. In comparison to 
the glycan backbone of PG, an important feature of aminoglycosides is the presence of 
an amino-modified glycoside. This chemical property might suggest why there is an 
interaction between the aminoglycosides and the PASTA domains from IreK. 
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A: B: 
Kanamycin Neomycin 
  
  
C: D: 
Spectinomycin Streptomycin 
  
  
Figure 4.25: Binding of aminoglycoside antibiotic to the extracellular PASTA domains of E. faecalis IreK. 
Experiments performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate 
of 10 µL min-1. Includes structures of each aminoglycoside and SPR sensorgrams showing a dose 
dependence response. Antibiotics were 2-fold serially diluted from 2 mM.   
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5.3.6.5. Binding of PASTA 1 to 5 to glycopeptide antibiotics 
 In Chapter 3 it has highlighted that although the Tn1549 resistance cassette 
conferring vanB type resistance and its interaction with IreK was essential for enhanced 
cephalosporin resistance, it appeared that IreK was only important to vancomycin 
tolerance (not resistance) as there was only a small difference in MIC. Like the 
aminoglycosides, glycopeptides such as vancomycin have not been shown to have a 
direct impact on strains when comparing WT and mutation strains of eSTKs including S. 
aureus and L. monocytes indicating that any interaction with eSTKS is not associated with 
resistant mechanisms (Tamber et al., 2010; Pensinger et al., 2014).  
 Similar to the aminoglycoside sensorgrams in Figure 4.25, the glycopeptides 
vancomycin and teicoplanin also appear to be ligands for the PASTA domains of IreK from 
E. faecalis as shown in Figure 4.26, it is clear that vancomycin and teicoplanin bind to the 
PASTA domains in a dose dependent manner as determined by the SPR sensorgrams, and 
unlike the aminoglycosides, binding reached saturation for both antibiotics. Therefore, 
the steady state binding kinetics were determined for both antibiotics. This included 
vancomycin KD at 929 µM ± 41 µM and teicoplanin KD at 238 µM ± 8.6 µM. Although these 
ligands show a low binding affinity to the IreK PASTA domains, they do provide a 
reference point for future experiments using other techniques. Along with the 
aminoglycosides, the glycopeptides may not be the true ligands for the PASTA domains, 
but may provide further evidence that the PASTA domains are detecting sugar like 
molecules such as the glycan chain of PG. It is clear when determining the KD using SPR 
of these two analytes, that teicoplanin binds more readily to the PASTA domains that 
vancomycin. 
 Although SPR has many advantages over other binding techniques due to its 
ability to calculate not only the dissociation equilibrium constant (KD), but also the 
association rate constant (ka) and dissociation rate constant (kd). As most ligands that 
have bound efficiently have been heterogeneous in the study, only a dose dependent 
response can be reported. When studying the glycopeptides, a KD could be determined 
from the steady state binding kinetics, but the binding constants ka and kd were difficult 
to determine as they were approaching the limits of the instrument.  
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A:  B:  
Vancomycin Teicoplanin 
  
  
  
Figure 4.26: Binding of glycopeptide antibiotics to the extracellular PASTA domains of E. faecalis IreK. 
Experiments performed on Immobilised PASTA 1 to 5 (HIS) construct on a CM5 surface chip at a flow rate 
of 10 µL min-1. Includes structures of each glycopeptide and SPR sensorgrams showing a dose 
dependence response. Binding curves of steady state saturation are also included and performed in 
triplicate. Antibiotics were 2-fold serially diluted from 8 mM for vancomycin or 4 mM for teicoplanin. 
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4.7. Microscale Thermophoresis (MST) 
 MST is a relatively new technology for studying the interaction between 
biomolecules. It measures the diffusion of molecules in a temperature gradient produced 
by IR irradiation. There are currently two methods, the first is a label free method that 
uses the inherent fluorescence of tryptophan residues in proteins, and the second 
requires the use of fluorescent labels that are covalently linked to the protein via lysine, 
cysteine or polyhistidine. Due to the PASTA domains in E. faecalis containing few aromatic 
amino acids and no tryptophan’s, fluorescent labelling techniques were used. 
 To ensure that the fluorescent label would not interfere with the binding of 
different ligands to the PASTA domains, the His-label kit was used. In both the label free 
and labelling methods, an infrared (IR) laser was used to induce the temperature gradient 
and a detector that can measure and quantify the movement of the fluorescent 
molecules. MST has offered many advantages over SPR and NMR as it only requires a 
relatively small volume of ligand and receptors in a final volume of 10 µL in each capillary. 
Another major advantage includes that proteins and ligands are free in solution when 
using MST and not immobilised to a surface. As some of the ligands used in this study are 
very expensive and available in only small quantities, MST proved an excellent technique 
not only to validate ligands from other experiments, but to establish binding affinities for 
expensive ligands. These ligands included pure PG peptides that are synthesised and a 
polymeric PG glycan.  
 Labelling of the PASTA 1 to 5 domains was achieved with the florescent labels that 
targets the 6x poly His-tag. To ensure samples were not aggregating with the addition of 
the tag, initial experiments included that there was homogeneity between different 
capillaries of the same labelled protein and that there was no difference in the diffusion 
of the samples when a temperature gradient was applied (See Appendix 8.6). It can be 
concluded that homogeneity was best achieved with the labelled PASTA 1 to 5 protein 
when the protein was diluted to a final concentration of 50 nM in PBS-Tween.  
 Initial experiments using MST determined the binding affinities of vancomycin 
and teicoplanin. This initial experiment would not only set up initial parameters for 
identifying ligands with higher KD than vancomycin and teicoplanin and their KD were in 
the mM and high µM range respectively, it would also validate they are true ligands and 
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not false positives. Table 4.5 highlights all the ligands screened against PASTA 1 to 5 using 
MST including vancomycin and teicoplanin. Although the KD between each technique is 
different using either SPR and MST for vancomycin and teicoplanin, (Vancomycin: SPR (KD 
= 929 µM) and MST (KD = 2.1 mM) and Teicoplanin: SPR (KD = 238 µM) and MST (KD = 930 
µM)), both techniques estimate the KD of vancomycin to be higher than that of 
teicoplanin. The binding curves for both vancomycin and teicoplanin are highlighted in 
Figure 4.27.A and Figure 4.27.B respectively.  
 After confirming that teicoplanin and vancomycin are ligands for the PASTA 
domains by MST and SPR, a series of PG derivatives were screened that could not be 
screened using SPR because of the availability including derivatives of the glycan strand 
and the peptide stem. Before a binding profile was determined for each ligand, an 
experiment was set up to compare the differences of the highest concentration of ligand 
with a sample that had no ligand. If the response altitude is large enough, experiments 
can then proceed to characterise the binding affinities between the two biomolecules. 
Unfortunately, all the experiments where derivatives of the peptide stem were tested, 
the response altitude was not large enough to conclude binding (Table 4.5; See Appendix 
8.6). Although binding has been observed in M. tuberculosis and B. subtilus of the peptide 
stems to their respective PASTA domains, these organisms do not contain a crosslinking 
bridge in the 3rd position of the peptide stem like E. faecalis (Ala-Ala) (Squeglia et al., 
2011; Mir et al., 2011). Unfortunately, a suitable ligand was not available to test in these 
circumstances that looked at the pentapeptide stem with a Ala-Ala-bridge and may be a 
suitable ligand candidate for the PASTA domains.  
 In the SPR study, amidase treated PG from E. faecalis showed strong interactions 
with the PASTA 1 to 5 domains of E. faecalis. Dr. Stephane Mesnage (University of 
Sheffield) provided pure (GlcNAc-MurNAc)4 to test binding of the PASTA domains using 
MST (Figure 4.27.C and Table 4.5). The KD is 199.7 ± 5.7 µM and shows the strongest 
binding out of the three ligands where a KD was determined. In a comparison study, 
chitoctose (GlcNAc)8 was screened and although binding was observed, saturation could 
not be reached to determine a KD Table 4.5.  
 A recent study studying the interactions of PknB in M. tuberculosis with synthetic 
PG fragments identified that muropeptides containing a 1,6-anhydro-MurNAc and longer 
glycan chains exhibit high binding affinity and identified that the binding stoichiometry of 
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PASTA to ligand was 1:1 (Wang et al., 2017). This data supports the results in this study 
includes the heterogeneous PG samples from S. aureus and E. faecalis that had been 
treated amidase to give long glycan chains and also the pure synthetic (GlcNAc-MurNAc)4 
substrate used in the MST study, although a 1,6-anhydro-MurNAc was not tested.  
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Table 4.5: Summary of ligands tested using MST against PASTA 1 to 5. KD values of the IreK PASTA domains 1 to 5 with PG substrates and cell wall antibiotics obtained 
from fitting the data from at least 3 independent MST experiments in a 1:2 dilution series. Ligands with a small response amplitude with the highest ligand concentration 
are reported, but KD values not determined. Experiments were obtained at room temperature. The response amplitude is the fluorescence intensity shift between bound 
and unbound state. Replicates increased to 4 for ligands with a low response amplitude.   
Analyte Ligand KD [μM] 
Response 
Amplitude [counts] 
# of 
Replicates 
SE of 
Regression 
Reduced 
χ² 
Signal to 
Noise 
IreK: PASTA Domains 1 to 5 
Vancomycin 2102 ± 159.8 24.11 3 0.88 2.23 36.15 
Teicoplanin 930 ± 41.75 63 3 0.98 3.2 20.6 
(GlcNAc-MurNAc)4 199 ± 5.7 30.93 3 0.76 1.71 49.88 
(GlcNAc)2 ND 0.40 4 ND ND 2.20 
(GlcNAc)8 ND ND 4 ND ND ND 
MurNAc ND 0.20 4 ND ND 1.20 
MurNAc-L-Ala-D-isoGlu ND 0.40 4 ND ND 0.90 
MurNAc-L-Ala-L-isoGlu ND 0.30 4 ND ND 0.90 
D-isoGlu-DAP ND 0.90 4 ND ND 1.30 
D-isoGlu-Lys ND 2.20 4 ND ND 20.20 
MurNAc-L-Ala-D-isoGlu-mDAP ND 0.7 4 ND ND 1.8 
MurNAc-L-Ala-D-isoGlu-Lys ND 0.5 4 ND ND 1.8 
L-Ala-D-isoGlu-mDAP ND 0.7 4 ND ND 1 
L-Ala-D-isoGlu-Lys ND 1.1 4 ND ND 6.2 
L-Ala-D-isoGlu-Lys-D-Ala-D-Ala ND 0.2 4 ND ND 0.9 
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A: B: C: 
Vancomycin Teicoplanin (GlcNAc-MurNac)4 
   
Figure 4.27: Dose-response curves of MST analysis. Experiments performed on PASTA 1 to 5 labelled with the Monolith His-Tag Labeling Kit RED-tris-NTA following 
manufacturers protocol and conducted on a Monolith NT.115. Includes IreK PASTA domains 1 to 5 with (A) Vancomycin KD == 2.102 mM ± 0.160 mM, (B) Teicoplanin KD == 
930.2 µM ± 41.75 µM and (C) (GlcNAc-MurNAc)4 KD == 199 µM ± 5.7 µM (% bound, 3 repeats). 
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4.8 Conclusions and Future Directions 
 The previous model for oligomerisation of the eSTKs kinase domains is based on 
ligand-induced dimerization in analogous eukaryotic systems. The evidence for this 
situation in bacterial S/T kinases is not well established however (Manuse et al., 2016). 
Greenstein et al., 2007, described an in-vitro experiment demonstrating the dimerization 
of M. tuberculosis PknD KD dimerization was required for PknD autophosphorylation. 
Thus, based upon a model of eukaryotic S/T kinase dimerization and in-vitro observation 
of PknD dimerization in M. tuberculosis, one might expect to see evidence for dimer 
activation of IreK and by extension homologs in other species.  
 When the structure of the PASTA domains form M. tuberculosis was determined, 
a model for ligand induced dimerization via the PASTA domains was proposed (Barthe et 
al., 2010) (Figure 4.28.A). This study has tried to use a range of in vivo microbiology and 
in vitro biophysical techniques to explore the role of eSTKs in Gram-positive bacteria using 
E. faecalis IreK as a model protein. From the experiments in Chapter 3, it can be 
concluded via the complementation experiments that the kinase domain could function 
independently from the PASTA domains as the MIC of cefotaxime did not reach ΔireK 
levels. Therefore, the kinase domains could dimerise and autophosphorylate by 
themselves. The fluorescent microscopy experiments indicated that the PASTA domains 
are essential in localisation to the septum of growing E. faecalis cells. The in vitro 
biophysical experiments described in this Chapter demonstrate that the polymeric glycan 
backbone of PG is an important potential ligand for the PASTA domains of E. faecalis. As 
PG is polymerised at the site of cell division at the septum, a possible alternative model 
might include the PASTA domains not dimerising in the presence of a ligand but 
interacting with the PG at the septum in a symmetrical manner such that IreK is 
concentrated at the septum and kinase autophosphorylation can readily happen. The 
location of IreK at the site of PG polymerisation also enables the PASTA domains to detect 
the local effects of certain antibiotics (e.g. cephalosporins) indirectly, since a lack of 
transpeptidase crosslinking leads to an increase in the amount of uncrosslinked MurNac-
GlcNAc glycan strands. Thus, the PASTA domains are able to detect disruptions in the 
surrounding PG. This in turn upregulates a cellular response through the IreK signal 
transduction mechanism (Figure 4.28.A).  
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A: B: 
Model of ligand dependent dimerization 
(Barthe et al., 2010) 
Localisation at the site of cell division 
(This Study) 
  
Figure 4.28: Possible models for IreK oligomerisation. Comparison of the models proposed for the 
function of eSTKs in bacteria using E. faecalis IreK as an example. A: highlights the model for 
oligomerisation of eSTKs in Gram-positive bacteria via a ligand. B: highlights an alternative model in which 
the PAST domains interact with the glycan backbone of PG as demonstrate in this chapter (Chapter 5). 
Chapter 4 also highlighted that IreK from E. faecalis localises at the site of cell division, a region where 
newly synthesised PG is actively being incorporated into existing PG. Arrows point to sites of 
oligomerisation determined by each model.  
 In B. subtilus it has been shown that spores will exit dormancy in the presence of 
DAP containing muropeptides and removal of the PASTA domains from PrkC prevented 
germination (Shah et al., 2008). Likewise, with PknB in M. tuberculosis, the KD of several 
muropeptides have been determined using SPR (Mir et al., 2011). In experiments in this 
study where muropeptides were tested against PASTA 1 to 5 in E. faecalis using MST, the 
signal was not strong enough for determining the KD.  
 The model for ligand-dependent dimerization is also a possibility in particular in 
the organisms such as PknB from M. tuberculosis and PrkC from B. subtilis. Although 
dimerization through the PASTA domains was not observed with E. faecalis IreK under 
the range of biophysical techniques used, these experiments were conducted without 
the presence of a potential ligand.  
 When comparing E. faecalis with M. tuberculosis and B. subtilus, these organisms 
are distantly related and have many features that may contribute to a different model for 
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eSTK kinase dimerization. M. tuberculosis is a part of the Actinobacteria phylum and has 
a bacterial cell wall much different to that of Gram-positive bacteria, and B. subtilus is a 
part of the Bacilli class in the Firmicutes phylum and Bacillales order and has DAP in the 
3rd position of the pentapeptide stem. Other Gram-positive such as E. faecalis are in the 
Firmicutes phylum and Baccili class but are in the Lactobacillales order, and most have 
Lys in the 3rd position of the pentapeptide stem and also have a crosslinking bridge that 
both M. tuberculosis and B. subtilus do not have. Therefore, the PASTA domains of these 
organisms might have evolved accordingly to enable them to detect the changes in their 
PG environment. 
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Chapter 5. Towards structural studies of IreK 
PASTA domains 
5.1. Introduction 
 In this chapter, small-angle X-Ray scattering (SAXS) and nuclear magnetic 
resonance (NMR) techniques have been used to study the structure and interactions of 
the PASTA domains. The major advantage of NMR and SAXS over other structural 
techniques such as X-Ray crystallography and cryo-electron microscopy is that 
experiments are carried out in aqueous solution and can allow different conditions to be 
studied readily, including buffer type and pH which are factors that are important when 
considering structure-function relationships (Montelione et al., 2000). Although 
significant progress has been made to study large proteins, the main limitation of solution 
NMR is that structural assignment is not possible above 30 kDa.  
5.2. Small angle X-ray scattering 
5.2.1. Introduction  
 Small angle X-ray scattering is considered to be an additional and complimentary 
structural and biophysical technique used to measure proteins in solution and does not 
have the size limitations of NMR nor the conformational restriction of X-ray 
crystallography. Although SAXS models do not have the same resolution achieved by X-
ray crystallography or NMR, SAXS data analysis allows the ternary and quatarery 
structures from overall size and shape to be identified. X-rays irradiate the sample, then 
every atom inside the sample scatters the incident radiation into all directions and gives 
background radiation that is almost constant at small angles. Clusters of atoms inside the 
sample will produce additional scattering as the atoms have a different density and are 
in the size range of the X-ray wavelength. Measuring the angle dependent distribution of 
the scattered radiation allows the average particle size to be determined (Kikhney and 
Svergun, 2015). 
 As the PASTA domains from E. faecalis IreK are multi-modular, it is likely that these 
structures will exhibit inter-domain flexibility and will complicate or prevent 
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crystallisation for X-ray crystallography. Flexibility of proteins is also important for 
function, therefore characterisation of these PASTA domains by crystallography may be 
unsuitable as it requires the sample to be in a single dominant state (Wen et al., 2014). 
To confirm the flexibility of PASTA domains, small angle X-ray scattering (SAXS) was used. 
5.2.2. Initial characterisation of PASTA constructs   
 Proteins were analysed at the ESRF (Grenoble) and processed and analysed using 
SCATTER as described in the Material and Methods. Figure 5.1 highlights the scattering 
data collected including the scattering intensity (Figure 5.1.A) and dimensionless Kratky 
plot (Figure 5.1.B) of the IreK PASTA domain truncations. The scattering intensity is 
proportional to the concentration and confirms that all proteins analysed were roughly 
the same concentration. The Kratky plot allows disordered states in proteins to be 
identified and to distinguish them from globular proteins. The profile allows the 
visualisation of particular features of the scattering profile to be represented and allows 
identification of the folding state and flexibility (Uversky and Dunker, 2010).  
 
A:  B:  
  
Figure 5.1: SEC-SAXS analysis of PASTA domains from E. faecalis IreK. (A) Log10 Intensity plot and (B) 
dimensionless Kratky plot. 1 mg ml-1 of purified protein was used in the SEC-SAXS experiment including 
PASTA 1 to 2 (Red), PASTA 1 to 3 (Blue), PASTA 1 to 4 (Green) and PASTA 1 to 5 (Pink). Data was 
processed including subtraction from the buffer blank and analysed using SCATTER (Bioisis).  
 The dimensionless Kratky plot for a folded globular protein will show a compact 
bell-shaped curve, and deviations from this suggests protein flexibility or unfolding 
(Receveur-Brechot and Durand, 2012; Durand et al., 2010). Unfolded proteins will often 
present a hyperbolic plateau (Figure 5.2). In Figure 5.1.B, each of the PASTA constructs 
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show a bell-shaped curve with PASTA 1 to 2 (Red) being the most compact and the 
addition of each PASTA domain amplifying the flexibility. Therefore, structural 
characterisation of the full-length PASTA domains using X-ray crystallography is likely to 
be unsuitable.   
 
Figure 5.2: Schematic demonstrating the different protein characteristics from processed SAXS data 
using the dimensionless Kratky plot. Figures are based on experimental data obtained from Burger et al., 
(2016). Red: folded protein in a compact curve, Blue: Partially unfolded or flexible and Magenta: Unfolded 
or intrinsically disordered.  
 Several characteristic parameters can also be obtained directly from experimental 
scattering patterns including molecular weight and radius of gyration (Rg). These 
parameters are useful for quantitatively characterising the flexibility of proteins. Rg 
provides a measure of the overall size of the macromolecule. The Rg is the root-mean-
squared distance to the centre of density in the molecule weighted by the scattering 
density length. The Rg is smaller for proteins with a compact shape compared to extended 
proteins. A Guinier fit is used to provide a linear fit to determine the Rg and the intercept 
gives the forward scattering I(0) which is proportional to the molecular weight and the 
concentration of the protein. The predicted MW is determined for each protein but is 
lower that than of the theoretical MW and the experimental MW previously determined 
(Kikheney and Svergun, 2015). Table 5.1 highlights some of the parameters determined, 
and the Rg increases as the number of PASTA domains increase also providing evidence 
of protein flexibility. 
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Table 5.1: Parameters from analysed SAXS data using SCATTER (Bioisis) of each PASTA truncation. The 
parameters determined including Rg (radius of gyration) show that the addition of each PASTA construct 
increases the overall protein flexibility.  
 I(0) Rg Volume Predicted MW 
(kDa) 
Expected MW 
(kDa) 
PASTA 1 to 5 6.3 +-0.16 53.67+- 1.26 52 35 38.2 
PASTA 1 to 4 4.5+-0.14 41.24+- 0.34 40 26 30.3 
PASTA 1 to 3 4.3 +-0.08 31.31+- 0.35 31.7 18.2 22.7 
PASTA 1 to 2 3.6 +-0.05 22.82+- 0.17 22.7 13.4 15.4 
 
 As mentioned previously, NMR is a useful structural technique for studying 
dynamic proteins but is often limited by the size. Therefore, a smaller PASTA construct 
would be required. Hybrid approaches in structural biology by combining different 
structural techniques can provide great structural insight than can a single individual 
technique. The combination of high-resolution structural methods such as NMR, 
providing atomic scale structural and dynamics information, with lower resolution 
methods such as SAXS that yield nanometer scale structure, is a powerful approach for 
the study of biomacromolecules in near native environments. In particular, NMR and 
SAXS are considered the most appropriate tools for the study of highly dynamic and 
flexible systems, which for both modern electron microscopy (EM) and X-ray 
crystallography remain problematic (Mertens and Svergun, 2017). High resolution 
structural information from the PASTA domain truncations using NMR and global 
characterisation of the full PASTA set from IreK may allow a system to be developed to 
study the dynamics of these flexible domains. 
 
5.3. Identifying a suitable PASTA construct for NMR studies 
 NMR is particularly valuable for analysing protein structures outside the scope of 
X-Ray crystallography, unfortunately, the full length extracellular PASTA domains from 
IreK are outside the size limitations for standard NMR studies. Suitable truncations of the 
PASTA domains are therefore required to perform subsequent NMR studies. When 
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comparing the alignment of the individual PASTA domains in Figure 5.3., it is clear that 
PASTA 5 has the most unique sequence as well as a C-terminal extension. 
 
 
Figure 5.3: Sequence alignment of the individual PASTA domains from E. faecalis Irek OG1RF. Domains 
are organised by phylogenetic disruption aligned using Clustal Omega. "*" amino acids are identical in all 
sequences in the alignment, ":" show where conserved amino acids substitutions have been observed 
and "." show where semi-conserved amino acids substitutions have been observed. 
5.3.1. Initial characterisation of PASTA domains 4 to 5  
 To understand the dynamics between PASTA domains, a recombinant protein 
with at least two PASTA domains is required. From initial CD experiments highlighted in 
Chapter 3, PASTA 1 to 2 may be unsuitable for NMR studies as it has a low TM which 
suggests that it is the least stable of all constructs investigated and thus unsuitable for 
long experimental times during NMR acquisition. Instead of the initial two PASTA 
domains, (PASTA 1 to 2), the terminal two PASTA domains were recombinantly expressed 
and purified with and without the 10 AA C-terminal extension (PASTA 4 to 5). Figure 5.4 
highlights the purity of both constructs by SDS-PAGE analysis and the oligomeric state by 
SEC-MALS. The C-terminal extension has been hypothesised in E. faecium to be involved 
in oligomerisation dynamics in IreK in E. faecium (Sacco et al., 2014). Initial SEC-MALS 
analysis shows that both constructs appear to be monomeric although construct PASTA 
4 to 5 appears to have a tailing shoulder. 
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A:  
 
A:  
 
B:  
  
Figure 5.4: SDS and SEC-MALS analysis of purified Terminal PASTA domains from E. faecalis IreK. 
Includes (A) PASTA 4 to 5 with C-terminal truncation or (B) PASTA 4 to 5 without C-terminal truncation by 
SDS-PAGE (Left) or SEC-MALS (Right). Elusion profiles of the PASTA domains were examined by SEC-MALS 
on a Superdex 75 increase (10/300). Absorbance at A280 for each chromatogram was normalised. MALS 
data are presented in Red with predicted molecular weight above each peak. 
5.3.2. AUC characterisation of the terminal PASTA domains 
 To confirm these observations, AUC was also performed on both constructs and 
confirmed that the C-Terminal extension is not involved in oligomerisation and that they 
are both monomeric, as a single oligomeric species was observed around the MW of the 
protein (Table 5.2).  
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Table 5.2: Species estimated molecular weights from the c(s) analysis of each PASTA domain 
truncation. For each sample concentration the signal-weighted sedimentation co-efficient and the 
estimated molecular weight of each species is shown, together with the best-fit frictional ratio for the 
distribution. 
 
5.3.3. CD characterisation of PASTA domains 4 to 5 
 As the C-terminal extension does not appear to have an effect on oligomerisation, 
the full-length PASTA 4 to 5 was tested for overall stability using a TM by CD. As mentioned 
previously, the TM for PASTA 1 to 2 was very low, and it is important for NMR studies that 
the protein is sable and can withstand long incubations at temperatures great than 
storage conditions. Figure 5.5 highlights TM of PASTA 4-5 and compares it to the TM of 
PASTA 1 to 5 (Figure 4.10). Interestingly, unlike PASTA 1 to 2 where the TM was lower than 
that of PASTA 1 to 5, PASTA 4 to 5 is actually higher than that of PASTA 1 to 5 (12.5°C 
difference) and is therefore a stable candidate protein for isotopic labelling and NMR 
studies. The increased stability of ther terminal PASTA domains as determined by the CD 
TM might indicate that the role of the terminal PASTA proteins is different to that of the 
PASTA domains closer to the cell membrane and be related to the overall function of the 
protein.  
 
 
Monomer MW 
(kDa) Detection method 
Concentration 
 (mg mL-1) 
Peak   
f/f0 MW (kDa) Sed. Co (S) 
PASTA 4-5 (Full Length)  
16.0 
Absorbance 
0.75 19.4 1.33 2.01 
0.5 20.2 1.37 2.02 
0.25 18.1 1.37 1.87 
Interference 
0.75 16.1 1.50 1.58 
0.5 18.3 1.55 1.66 
0.25 15.1 1.51 1.50 
PASTA 4-5 (C-Terminal Truncation (10 aa))  
14.6 
Absorbance 
0.75 18.0 1.33 1.88 
0.5 17.9 1.36 1.84 
0.25 18.6 1.40 1.82 
Interference 
0.75 15.9 1.49 1.55 
0.5 15.5 1.49 1.52 
0.25 15.6 1.53 1.51 
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A  
 
B 
 
C 
 
 
 
 
 
Melting Temperatures (°C) full length domain 1-
5 and truncation 4-5 of the PASTA domains from 
E. faecalis 
 
PASTA 1 to 5 PASTA 4 to 5 
62.3 75.2 
 
Figure 5.5: Temperature melts of IreK terminal PASTA domains following CD at 222 nm. Protein 
constructs at 0.2 mg mL-1 in 10 mM Sodium Phosphate, pH 7.4 buffer were incubated at incremental 
temperatures from 20 to 100°C with CD spectra collected at each temperature point. Includes (A) overlay 
plot of PASTA constructs, (B) PASTA 1 to 5 and (C) PASTA 4 to 5 without C-terminal truncations, with the 
Boltzman sigmoid fit (Solid Black line). Insert table displays TM of each construct as determined by the 
Boltzmann sigmoid equation. 
 
5.3.4. SAXS characterisation of the terminal PASTA domains 4 to 5 
 To determine the flexibility of the PASTA 4 to 5 construct, SAXS was also 
performed on these constructs to obtain data that can later be used to produce an Ab 
initio model of the constructs. Figure 5.6 shows the analysed SAXS data from the PASTA 
4 to 5 constructs. Generally, the two constructs overlay each other, in particular when 
comparing them in the normalised Kratky plot (Figure 5.6.B), but there is an increase in 
protein flexibility in the PASTA 4 to 5 construct containing the 10 aa C-terminal extension. 
The C-terminal peptide is likely to generate disorder at the terminus of the protein. 
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A:  B:  
  
Figure 5.6: SAXS analysis of ther terminal PASTA domains from E. faecalis IreK. (A) Log10 Intensity plot 
and (B) dimensionless Kratky plot including PASTA 4 to 5 (Purple) and PASTA 4 to 5 with 10 aa truncation 
(Red). Data was processed including subtraction from the buffer blank and analysed using SCATTER 
(Bioisis). 
 Table 5.3. highlights the parameters obtained from the processed SAXS data from 
the PASTA 4 to 5 constructs. The Rg also confirms that the presence of the C-terminal 
peptide causes a degree of protein flexibility or disorder in this region of the protein. 
Although the MW is not predicted to be correct, the predicted MW decreased with the 
truncation of the 10 aa C-terminal peptide, as expected.  
 
Table 5.3: Parameters from analysed SAXS data using SCATTER of each terminal PASTA truncation. The 
parameters determined including Rg (radius of gyration). The presence of the 10 aa on the C-terminus of 
the PASTA domains does increase the overall flexibility of the protein.  
 I(0) Rg Volume Predicted MW 
(kDa) 
Expected MW 
(kDa) 
PASTA 4 to 5  2.8 25.11 22 15 16 
PASTA 4 to 5 (10 aa 
truncation) 
3.2 23.41 20 13 15 
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5.3. Nuclear magnetic resonance  
5.3.1. Introduction 
 PASTA 4 to 5 was identified as suitable for studying the overall effects of the 
PASTA domains by NMR due to its biophysical properties. For ligand binding studies, 
PASTA 4 to 5 was a suitable candidate as PASTA 4 shared similar sequence homology to 
that of PASTA domains 1 to 3. This also enabled characterisation of PASTA domains that 
has lowered sequence homology to the other PASTA domains (Figure 5.3). This construct 
was stable over a long period of time as determined by CD and presented inter-domain 
flexibility as determined by SAXS. PASTA 4 to 5 also behaves like the other PASTA domains 
in terms of its oligomerisation (primarily monomeric) and bioinformatics comparison 
between individual PASTA domains from E. faecalis IreK. The PASTA 4 to 5 construct was 
isotopically labelled for initial ligand binding experiments and structural characterisation. 
5.3.2. The Heteronuclear Single Quantum Coherence (HSQC) experiment 
 The HSQC is one of the most important and frequently used experiments in 
biomolecular NMR and is usually a prerequisite experiment used to assess the 
characteristics of the protein before further NMR experiments are performed. The HSQC 
provides a ‘fingerprint’ of the labelled protein due to the NH functional groups of amino 
acids (except prolines) in the protein backbone.  
 The HSQC involves the transfer of the magnetisation on the proton to the 15N 
through an INEPT (Insensitive nuclei enhanced by polarisation transfer) step, which uses 
J-coupling for the polarisation transfer. After a time delay (t1) the magnetization is 
transferred back to the proton for detection (Figure 5.7). In a 2D HSQC experiment, a 
series of experiments with an increasing incremental t1 time delay are acquired. The 
proton signal is directly measured in each experiment and the chemical shift of the 15N is 
recorded in the indirect dimension. The HSQC was used to test standard conditions 
including optimisation of pH and temperature of the protein sample. All experiments 
were conducted on a 700 MHz spectrometer as detailed in Chapter 2: Material and 
Methods.  
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Figure 5.7: Schematic showing correlations for 1H-15N HSQC experiments. Magnetisation is transferred 
through J-coupling from the hydrogen attached to the 15N nuclei and the chemical shift is evolved on the 
15N and the magnetisation is transferred back to the hydrogen for detection.  
 Before the initial HSQC experiments were performed, short 1D proton 
experiments of the PASTA 4-5 terminal domains were acquired. 1D 1H data allows the 
different chemical structures present in the sample to be distinguished though chemical 
shifts of each nucleus in the sample precessing at a different frequency resulting in 
separation of the signals in the NMR spectrum. Evaluation of the chemical shifts of a 
protein sample in a 1D-1H spectrum is useful as it can also give information on the extent 
of protein folding in the sample due to the dispersion of the chemical shift peaks. A well 
dispersed spectrum indicated that the nuclei are in many different environments, 
suggesting the presence of elements of secondary structure and tertiary folding. Figure 
5.8 demonstrates that, although the protein shows evidence of folding by excellent 
chemical shift dispersion, there are many overlapping peaks due to the size of the protein 
and, as expected, the protein is too large to interpret the 1D data. For this reason, 2D and 
3D heteronuclear (15N and 13C) experiments were utilised. 
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Figure 5.8: 1D NMR of 1.2 mM PASTA 4 to 5 constructs. Experiments were performed in a Bruker 700 
MHz NMR spectrometer. Indicates protein folding due to the presence of sharp and narrow peaks with 
good chemical shift dispersion in 10 mM Sodium Acetate, pH 4.6 at 25°C. 
5.2.2.1 Optimisation of protein samples for NMR experiments 
 Acquisition of data for the PASTA domains from M tuberculosis PknB was 
previously performed in sodium acetate at a low pH (4.6). Initial experiments for IreK 
PASTA 4 to 5 were also performed in sodium acetate pH 4.6, and the 1H-15N HSQC 
spectrum of PASTA 4 to 5 shows well dispersed resonances between 6 to 10 ppm in the 
1H dimension (Figure 5.9.A) at 25°C. Certain amino acid resonances are readily identified, 
including Gly in the top region (<115 ppm 15N ) of the spectrum and side chain peaks from 
Asn and Gln where two parallel peaks are present in the same 15N dimension but different 
1H dimension. There are areas of peak overlap in the center of the spectrum that may 
prove difficult for assignment. From this spectrum 176 peaks were observed, whereas 
the theoretical number of HSCQ peaks calculated from the IreK PASTA 4 to 5 sequence is 
148. This number is calculated by taking the total number of residues and subtracting the 
number of Pro residues in the sequence, then adding on any NH-bearing side chains. 
There is a total of 6 Pro residues in the peptide sequence and 7 Asn and 4 Gln residues 
bearing NH-side chains. There is a total of 155 aa in the sequence for PASTA 4 to 5.  
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 To investigate the impact of solution pH on the quality of the NMR spectrum, the 
sample was buffer exchanged into sodium phosphate pH 6.5 and the resulting HSQC is 
shown in Figure 5.9.B. Although there is good dispersion of resonances over the 6 to 10 
ppm region in the 1H dimension, there are slight differences when comparing the samples 
in sodium acetate, pH 4.6 (Figure 5.9.A) and sodium phosphate (Figure 5.9.B) highlighted 
by boxes. Box 1 highlights a region of overlap in both buffer systems but is more resolved 
in the presence of sodium acetate, pH 4.6. There is a loss of a peak in box 2 in the presence 
of sodium phosphate pH 6.5, and in box 3 there is a loss of 4 peaks in the sodium 
phosphate sample in the 140 to 130 ppm region of 15N chemical shift. It is known that 
protein samples in the low pH region can give good quality spectra due to slow NH 
exchanges which is evident when comparing PASTA 4 to 5 in the presence of sodium 
acetate pH 4.6 and sodium phosphate pH 6.5. Further experiments were performed in 
sodium acetate pH 4.6 unless otherwise stated.  
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A: 
Sodium Acetate (pH 4.6) – 25°C 
 
B: 
Sodium Phosphate (pH 6.5) - 25°C 
 
Figure 5.9: Buffer optimisation for NMR studies of PASTA 4 to 5. Experiments were performed in a 
Bruker 700 MHz NMR spectrometer. A 1H–15N HSQC spectrum of uniformly labelled 1 mM 15N-PASTA 4 to 
5 in (A) 10 mM sodium acetate pH 4.6 and (B) 10 mM sodium phosphate pH 6.5 on a Bruker 700 MHz 
spectrometer at 25°C. Major regions of broadness and differences between the spectra are highlighted in 
a black box. 
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 To continue the optimisation of the PASTA 4 to 5 IreK construct, HSQC 
experiments were performed over a range of different temperatures including 10°C, 25°C 
(RT) and 37°C. Previous characterisation of PASTA domains from M. tuberculosis PknB 
was performed at 10°C (Barthe et al., 2010). Using the same box regions described 
previously, when comparing PASTA 4 to 5 at 25°C (Figure 5.9.A) and PASTA 4 to 5 at 10°C 
(Figure 5.10.A) it is clear that there is a loss in resolution of the resonances in these 
regions and overall in the spectrum at a lower temperature. Globally, there are variable 
peak intensities at 10°C  
 When comparing PASTA 4 to 5 at 25°C (Figure 5.9.A) and PASTA 4 to 5 at 37°C 
(Figure 5.10.A) there is little difference when comparing the overall resolution for the 
whole spectrum, but there is some peak overlap in Box 1 and Box 2 and loss of 2 peaks in 
Box 3 at 37°C compared to 25°C.  
 As previous ligand binding experiments were performed at 25°C using other 
methods, and good resolution was achieved at 25°C in these NMR optimisation 
experiments, future NMR experiments including chemical shift perturbation experiments 
for ligand binding studies and 3D experiments for structure characterisation were carried 
out at 25°C. 
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A: 
Sodium Acetate (pH 4.6) - 10°C 
 
B: 
Sodium Acetate (pH 4.6) - 37°C 
 
Figure 5.10: Temperature optimisation for NMR studies of PASTA 4 to 5. Experiments were performed in 
a Bruker 700 MHz NMR spectrometer. A 1H–15N HSQC spectrum of uniformly labelled 15N-PASTA 4 to 5 in 
10 mM sodium acetate pH 4.6 at (A) 10°C and (B) 37°C on a Bruker 700 MHz spectrometer. Major regions 
of broadness and differences in comparison of each spectra are highlighted in a black box. 
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5.3. Ligand binding studies using NMR  
 Chemical shift perturbation experiments were used to determine the binding 
affinity of the PASTA 4 to 5 protein from E. faecalis to vancomycin. Chemical shift 
perturbations in NMR studies provide a powerful and useful technique by not only 
determining the ligand binding affinity, but also following changes in the chemical 
environments of residues within the protein to determine the exact location of the 
binding site. The chemical shifts are very sensitive to structural changes that can occur 
and can be measured very accurately. Therefore, all of the genuine binding interactions 
will produce chemical shift perturbations. To determine the location of a bound ligand in 
the protein, 15N HSQC spectra of PASTA 4 to 5 were acquired with increasing ligand 
concentration. This enables the changes in chemical shift of all peaks to be determined 
and enables the specific amino acids in the protein that directly interact with the ligand 
to be determined (Williamson., 2013). 
 The aim here was to use the chemical shift perturbations to provide important 
validation that the ligands that bound to PASTA 4 to 5 according to both the SPR and MST 
experiments were not false positives. Vancomycin was used as a control molecule as it 
yielded a dose dependent response and measurable binding affinity using both SPR and 
MST experiments, and it is relatively inexpensive. Therefore, chemical shift perturbation 
NMR experiments can remove the premise of false positives from other biophysical 
experiments. 
 Figure 5.11 highlights the chemical shift perturbations observed in a sample of 1 
mM 1H-15N labelled PASTA 4 to 5 in the absence and presence of 8 mM vancomycin. 
Although there is not a global change in chemical shifts when comparing the overall 
resonances in the spectrum, there are local chemical shift changes observed which 
suggest direct binding to a region in the PASTA 4 to 5 construct. Boxes in Figure 5.11 
highlight regions where chemical shift perturbations are observed and include a region 
where 2 amino acid side chain resonances (Box 3) also display chemical shift 
perturbations, indicating that 2 Gln or Asn residues are affected by the binding of 
vancomycin. 
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Figure 5.11: PASTA domains 4 and 5 bind to vancomycin. Experiments were performed in a Bruker 
700 MHz NMR spectrometer. Overlaid 1H–15N HSQC spectra of 1 mM PASTA 4 to 5 (Black) and 1 mM 
PASTA 4 to 5 with 8 mM vancomycin (Orange) in 10 mM sodium acetate pH 4.6. Chemical shift 
perturbations are observed only for some peak and key peaks are highlighted by boxes. Dashed lines 
represent side chain peaks from either Asn or Gln residues. Six other resonances display chemical shift 
perturbations. 
 Figure 5.11 highlights each of the individual boxed regions shown in Figure 5.10, 
where experiments were performed with increasing concentrations of vancomycin. 
Where chemical shift perturbations were observed in Figure 5.10, Figure 5.11 
demonstrates that each of the resonances in these regions are affected by an increasing 
concentration of vancomycin. Experiments were performed with 0.25 – 8 mM 
vancomycin, with spectra acquired upon a 2-fold increase in concentration in the titration 
series. The pH was monitored at each titration point to ensure any chemical shift changes 
are not simply a result of changes in pH. 
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A: B: C: 
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D: E: F: 
   
 
Figure 5.12: Local overview of PASTA domains 4 and 5 binding to vancomycin. Experiments were performed in a Bruker 700 MHz NMR spectrometer. Overlaid spectra of 
1 mM PASTA 4 to 5 (Black) with 0 mM vancomycin and increasing concentrations of vancomycin 0.25 mM (Grey), 0.5 mM (Purple) 1 mM (Blue), 2 mM (Green), 4 mM (Pink) 
and 8 mM vancomycin (Orange) in 10 mM sodium acetate pH 4.6. Chemical shift perturbations are initially assigned by the boxed regions described in Figure 5.11.  
 
 
 
 223 
 Although chemical shift perturbations were observed in the titration experiments 
highlighted in Figure 5.12, saturation of vancomycin binding to PASTA domains 4 and 5 
was not achieved. Figure 5.13 highlights that, at high vancomycin concentrations of up to 
16 mM, spectral lines were significantly broadened across the spectrum. After acquisition 
and removal of the sample from the spectrometer, protein aggregation was visible. This 
broadening and precipitation suggest aggregation of the PASTA 4 to 5 protein at high 
vancomycin concentration, preventing saturation of binding and calculation binding 
kinetics (and a value for KD) using NMR. 
 
 
Figure 5.13: 16 mM vancomycin causes PASTA 4 to 5 to aggregate in these experimental conditions. 
Experiments were performed in a Bruker 700 MHz NMR spectrometer. 1 mM PASTA 4 to 5 (Black) with 16 
mM vancomycin in 10 mM sodium acetate pH 4.6. Peak broadness is observed across each of the 
resonances in the presence of 16 mM vancomycin. Visual inspection after acquisition indicated protein 
precipitation.  
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 To ensure that the binding of vancomycin in low pH buffer was not adversely 
impacting binding (SPR and MST experiments were performed at pH 7.5), a chemical shift 
perturbation experiment was performed in sodium phosphate pH 6.5 with 1 mM PASTA 
4 to 5 in the absence and presence of 8 mM vancomycin (Figure 5.14). 
 
 
Figure 5.14: PASTA domains 4 and 5 also bind to vancomycin in pH 6.5 sodium phosphate. Experiments 
were performed in a Bruker 700 MHz NMR spectrometer. Overlaid spectra of 1 mM PASTA 4 to 5 (Black) 
and 1 mM PASTA 4 to 5 with 8 mM vancomycin (Pink) in 10 mM sodium phosphate pH 6.5. Chemical shift 
perturbations are observed only for some peaks and key peaks are highlighted by boxes. Dashed lines 
represent side chain peaks from either Asn or Gln residues.  
 Generally, the same chemical shift perturbations are observed at pH 4.5 (Figure 
5.11 and Figure 5.12), but two new regions demonstrate additional chemical shift 
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changes after addition of 8 mM vancomycin (Box 1 and Box 2, Figure 5.14). Box 1 
resembles the addition of side chain peaks from either a Gln or Aln residue. Box 2 contains 
a unique peak that is only present in the 8 mM vancomycin sample. When using NMR 
chemical shift perturbations to determine the protein ligand interactions, two different 
exchange rates can occur. When the exchange rate is fast on the NMR chemical shift 
timescale (Koff is significantly greater than the difference in ppm of chemical shifts 
between free and bound protein), they move smoothly though the spectrum. The 
frequency in the signal of any titration point is the weighted average of free and bound 
shifts (Figure 5.15, left). When the exchange rate is slow on the chemical shift timescale 
(Koff is significantly slower than the difference in ppm of chemical shifts between free and 
bound protein), a free signal will disappear and appear somewhere else in the spectrum 
(Figure 5.15, right) (Wiliamson, 2013). 
 
 
Figure 5.15: The effect of exchange rate on NMR peak shapes. (Left) Fast exchange: a gradual transition 
from unbound to bound. Slow exchange: the peak representing the unbound state reduces in intensity as 
the peak from bound state increases in intensity. Figure adapted from Williamson (2013). 
 Box 3 and 4 in Figure 5.14 show increased signal intensity of peaks that may be 
explained by the slow exchange rate. It is unclear if Box 2, which contains the additional 
resonance, is described by fast or slow exchange chemical shifts as there is not another 
resonance on the HSQC spectrum that is missing an overlapping resonance. 
5.4. Backbone assignment  
 Previous experiments have shown that certain resonances exhibit chemical shift 
changes in the presence of vancomycin. Although vancomycin at the highest 
concentration measurable in these experiments did not yield a Kd, the resonances that 
 226 
displayed a chemical shift change prompts further examination of what amino acids these 
resonances represent. As teicoplanin or (GlcNAc-MurNAc)4 could not be used in this NMR 
study because of the expense of the ligand, by identifying the amino acids in the HSQC 
that exhibit a chemical shift perturbation in the presence of vancomycin, constructs could 
be generated that contain a point mutation for further experiments using other 
techniques like MST that require a significantly smaller ligand concentration. The Kd can 
then be compared across the different mutants to the WT protein to determine if 
vancomycin, teicoplanin and GlcNAc-MurNAc)4 are binding to the same residues.  
5.4.1. 3D HSQC TOCSY Experiments 
 HSQC-TOCSY (Total correlation spectroscopy) is a useful experiment that can help 
aid assignment of amino acid types from an HSQC spectrum. An isotropic mixing step 
transfers the magnetisation between 1H spins and then is transferred back to the 
neighbouring 15N and back to 1H for detection. In a spectrum, a strip can be identified 
where the side chain hydrogen residues of that amino acid can be identified. 
 Figure 5.16 illustrates strips in the HSQC-NOESY experiment that correspond to 
the resonances that exhibited chemical shift perturbations in Figures 5.11 and 5.12 (CSP 
1.1, 1.2, 2.1, 4.1, 4.2, 5.1 and 6.1). Amino acid types were determined by comparing a 
particular amino acid’s 1H chemical shifts to published values for each amino acid in a 
disordered peptide sequence (GGXA) (Richarz and Wuthich, 1978). Two amino acid types 
have been estimated using HSQC TOCSY including Gly (CSP: 1.1) and Ser (CSP5.1). One 
residue has been estimated to be either a Gln or Glu residue, but the proton chemical 
shifts are similar (CSP: 2.2 and CSP: 6.1). The two other peaks display proton chemical 
shifts that are similar to several other amino acid types and could not be determined. 
 To further characterise the other amino acid types, further 3D experiments with 
13C,15N labelled protein was required for 3D experiments that help identify these amino 
acid types and also identify where in the protein sequence they occur. The HSQC TOCSY 
experiments will be used with further 3D experiments to confirm amino acid types 
being identified in the backbone assignment. 
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A: B: C: 
CSP: 1.1 CSP: 2.1 CSP: 4.1 
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D: E: F: 
CSP: 4.2 CSP: 5.1 CSP: 6.1 
   
Figure 5.16: HSQC- TOCSY strips corresponding to the residues that observed chemicals shifts in the presence of 8 mM vancomycin. Experiments were performed in a 
Bruker 700 MHz NMR spectrometer. Corresponding residues are boxed and when determined protons assigned.  
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5.4.2 Backbone assignment using triple resonance (CHN) 3D NMR 
 To assign each peak in the HSQC spectrum, in order to determine the amino acid 
information for future chemical shift perturbation experiments, triple resonance 3D 
experiments were used to sequentially assign the protein backbone. Higher dimensional 
experiments have lower sensitivity, and some 3D experiments are less sensitive than 
others, so it is essential to ensure the initial acquisition parameters are optimised. 3D 
experiments for backbone assignment utilise the same proton and nitrogen dimensions 
as observed in the HSQC, with an additional dimension of carbon chemical shift. By 
correlating each dimension, the CA (alpha carbon), CB (beta carbon), and CO (carbonyl 
carbon) can be identified within the same residue (i) and the preceding residue (i-1) of a 
protein sequence. The known protein sequence can then be used to follow the 
connectivity between 3D experiments to assign the HSQC spectrum. Certain amino acid 
types can also be determined using these triple labelled proteins in 3D experiments such 
as Gly residues, that do not contain a CB atom, and help validate an assignment. The 3D 
experiments will be described to highlight how they are used in the backbone 
assignment. 
5.4.2.1. CBCACONH and CBCANH 
 The CBCACONH and CBCANH 3D experiments form a complementary pair, and 
the data in both correlate the chemical shifts of the backbone N, the NH, and the CA and 
CB atoms. In the CBCACONH experiment, magnetisation is transferred from the CBi-1 and 
CAi-1 respectively and transferred to the COi-1 and then the NHi. This experiment will 
usually produce two 13C peaks at each N-H correlation, corresponding to the CA and CB 
from the preceding residue (i-1). It can confirm if the residue follows a Gly residue as a 
CBi-1 resonance would not be present (Figure 5.17.A Top).  
 In the CBCANH experiment, magnetisation is transferred from the NHi to the CA 
and CB of both residues i and i-1, resulting in four assignable resonances. The CAi and CBi 
will exhibit greater resonance intensity over the CAi-1 and CBi-1. Differentiating between 
CA and CB residues is easy due to CA resonances being positive and CB resonances being 
negative (Figure 5.17.A Bottom). The CBCACONH and CBCANH experiments can be used 
in conjunction for the identification of CA and CB I and i-1 resonances.  
 230 
5.4.2.2. HNCA and HNCOCA 
 The HNCA and HNCOCA experiment pair correlate the chemical shifts of the 
backbone N, the NH, and the CA atoms for sequential backbone assignment. In the HNCA 
experiment, magnetisation is transferred from the NH to the CA and CAi-1 atoms and 
produces two CA resonances at each N-H correlation. The CAi resonances are more 
intense then the CAi-1 due to the coupling between the Ni-CAi being greater than the CA 
Ni-CAi-1 (Figure 5.17.B Top).  
 In the HNCOCA experiment, magnetisation is transferred through the COi-1 and 
produces only a single resonance belonging to the CA i-1 atom. The resonance correlates 
to the backbone NHi and allows assignment of the CA atom (Figure 5.17.B Bottom). In 
conjunction with the HNCA experiment, the CA peaks that overlap in both experiments 
correspond to the CAi-1 and the single resonance in the HNCA corresponds to the CAi. 
5.4.2.3. HNCO and HNCACO 
 The HNCO and HNCOA experiment pairs displays resonances of the CO groups in 
the protein. In the HNCO experiment, magnetisation is transferred through the NHi to the 
preceding COi-1 via J-coupling. J-coupling occurs where there is an indirect interaction 
between two nuclear spins. The interactions are mediated via electrons participating in 
the bonds connecting the nuclei. This residue therefore produces a single resonance 
correspond to the COi-1 atom (Figure 5.17.C Top). This experiment is the most sensitive 
of the 3D experiments and is used to validate backbone assignment of the HSQC 
spectrum.  
 In the HNCACO experiment, the magnetisation is transferred through the CA i and 
CA i-1 to both the CO i and CO i-1. As there is stronger coupling between the Ni and CAi 
compared to the Ni-1 and CAi-1 atoms, the COi residue is generally more intense (Figure 
5.17.C Bottom). In conjunction with the HNCO experiment, the COi and COi-1 resonances 
can be identified for validation of the backbone assignment.  
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A: B: C: 
   CBCACONH 
CBCANH 
HNCA 
HNCOCA 
HNCO 
HNCACO 
Figure 5.17: Correlation for triple resonance experiments. (A) CBCACONH and CBCANH: During CBCACONH, the residue (i) is correlated with Cα and Cβ of the preceding 
residue (i−1) whereas in CBCANH the residue (i) is correlated with Cα	and Cβ of the same residue as well as the previous residue. (B) HNCA and HNCOCA: HNCA correlates 
the residue (i) with the Cα of the same residue as well as the previous residue (i−1) whereas HNCOCA correlates the residue (i) with Cα of the previous residue (i−1). 
(C)HNCO and HNCACO: HNCO correlates residue (i) with the CO of the preceding residue whereas HNCACO provides the same correlation in addition correlating it the CO 
of the current residue. 
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5.4.3. Examples of Backbone assignment of PASTA 4 to 5 
 CBCACONH and CBCANH, HNCA and HNCOCA and the HNCO and HNCACO pairs 
were used to assign the back-bone of the PASTA 4 to 5 domains form E. faecalis IreK. An 
example of each experiments in the assignment of PASTA 4 to 5 domain is illustrated 
below (Figure 5.18, Figure 5.19 and Figure 5.20).  
 
Figure 5.18: CBCACONH and CBCANH experimental example of the backbone assignment of 1 mM 
PASTA 4 to 5 IreK from E. faecalis. Includes the CBCACONH (Black) and CBCANH pair (Red: CA positive; 
Pink: CB negative). 
 The CBCACONH and CBCANH experiment illustrates the assignment of the CA and 
CB atoms. It also highlights the easy identification of Ser and Thr residues where the CB 
atom appears below the CA atom in the spectrum (Figure 5.18).  
 The HNCA and HNCOCA experiment illustrates the backbone assignment of the 
CA atoms and confirms and validates assignments made in the CBCACONH and CBCANH 
(Figure 5.19). The HNCO and HNCOCA experiment pairs illustrates the backbone 
assignment of the CO atoms (Figure 5.20). The acquisition and processing of the data 
form the HNCO experiment generally result in well resolved resonances, the HNCOCA 
experiment resulted in distorted resonances that can be seen in Figure 5.20 (Red peaks). 
This made the initial assignment of the protein backbone difficult.  
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Figure 5.19: HNCA and HNCOCA experimental example of the backbone assignment of PASTA 4 to 5 
IreK from E. faecalis. Includes the HNCA (Pink) and HNCOCA (Brown) pair. 
 
Figure 5.20: HNCO and HNCACO experimental example of the backbone assignment of PASTA 4 to 5 
IreK from E. faecalis. Includes the HNCO (Blue) and HNCACO (Red) pair. 
 Figure 5.21 illustrates the sequence of PASTA 4 to 5 from IreK E. faecalis and 
highlights the residues that have been assigned during the backbone assignment. In the 
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3D experiments, many of the residues were overlapped which made interpretation of the 
preceding or proceeding residue in the sequence chain difficult. There is also a large 
number of possible serine or threonine residues that contributed to the ambiguity in the 
backbone assignment. 
 
 
Figure 5.21: Amino acid sequence of PASTA domains 4 to 5 from IreK E. faecalis and progress of 
backbone assignment. Black letters and underline indicates the residual amino acids from post-TEV 
cleavage not associated to the native PASTA domains. Proline residues are highlighted in black bold. The 
backbone assignment of PASTA residues is highlighted in green. The backbone assignment of the two 
amino acids that display a chemical shift perturbation in the presence of vancomycin is highlighted in 
green and underlined. 
  From the backbone assignment two of the peaks involved in the chemical shift 
perturbation against vancomycin were identified including CSP2.1 (Gly) and CSP4.2 (Leu) 
from Figures 5.11, 12 and 16. Figure 5.22 highlights the location of these residues (bold 
and underlined) and compares them to the PASTA sequences of M. tuberculosis and S. 
aureus. These homologous residues were then mapped onto the corresponding 
structures of the PASTA domains that had been determined for these species and shows 
an unordered region flanked between an alpha helix and beta sheet and in M. 
tuberculosis maps onto the end of an alpha helix. The unordered loop is larger in the S. 
aureus PASTA domain compared to the M. tuberculosis structures and might explain the 
binding properties of these PASTA domains from different species binding to different 
ligands. It is worth considering that the PASTA domains from M. tuberculosis was 
determined using NMR and offer more of a dynamic representation of the PASTA 
structure. Full backbone assignment will confirm the other resides that showed chemical 
shift perturbations and confirm if these residues also reside in the same site as the Leu 
and Gly residue highlighted in Figure 5.22.C.  
 
 
 235 
A: B: 
  
PrkC PASTA S. aureus  
X-ray crystallography (PDB:3M9G) 
PknB PASTA M. tuberculosis  
NMR (2KUF) 
C: 
 
Figure 5.22: Regions of possible site of ligand interaction. (A) PASTA domains S. aureus (PDB: 3M9G) and 
(B) M. tuberculosis (PDB: 2KUF) identify possible regions of ligand interaction. Highlighted in Red is the 
region of possible ligand binding. (C) Sequence homology of PASTA 3 from M. tuberculosis, PASTA 4 from 
E. faecalis and PASTA 2 from S. aureus with possible binding site highlighted in Bold.  
 
5.5. Ab initio modelling  
 Using the SAXS data generated for PASTA domains 4 to 5 from E. faecalis IreK, a 
dummy atom model was generated to understand the shape of the protein to aid 
structural studies and dynamics in future NMR experiments (Figure 5.23). To obtain the 
model, dmax (the maximum vector) was determined P(r) (distance distribution function) 
of ~83.5 Å. dmax calculates the protein radius where it is large enough to contain an entire 
molecule but small enough to exclude neighbouring molecules. These parameters were 
used with the experimental SAXS data to generate dummy atom models.   
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 Figure 5.23 highlights the programmes used to generate the dummy atom models 
for PASTA domains 4 to 5. DAMMIF was used to generate dummy atom models to look 
at the overall shape determination of PASTA domains 4 to 5 from E. faecalis. In dummy 
atom modelling, a particle is represented as a collection of a large number of densely 
packed beads inside a search volume. Each bead belongs either to the particle or to the 
solvent. DAMMIF constructs a compact interconnected model yielding a scattering 
pattern that fits the experimental data (Franke and Svergun, 2009). 17 Ab initio models 
were generated using the DAMMIF programme. Each model was processed to find those 
that are the most similar and superimpose and average the selections. DAMSEL was used 
to select models and identify and remove outliers. A normalised spatial discrepancy (NSD) 
value where NSD is > 1 implies that models are similar. From the 17 models, only 1 was 
discarded and an NSD value 0.889 ± 0.083. DAMSUP (Dummy atom model superposition) 
is used to align the set of models to a reference model. The models are then averaged 
using two methods. The first is DAMAVER which created a bead density probability within 
the search volume and DAMFILT that generates the averaged model created from a 
DAMAVER model where low occupancy and loosely connected dummy atoms are 
present.  
 
 
Figure 5.23: Schematic demonstrating the process of obtaining a dummy atom model of the PASTA 4 to 
5 domains from E. faecalis IreK. Data was analysed SEC-SAXS data acquired on PASTA 4 to 5 and 
processes using SCATTER (Bioisis) with the built in ATSAS programme (EMBL) .  
 
 Visualisation of the DAMAVER and DAMFILT output (Figure 5.24.A and Figure 
5.24.B, respectively). Representation for the PASTA 4 to 5 PASTA domains suggests that 
the PASTA domains from E. faecalis IreK in solution are elongated, which is similar to 
observations made of M. tuberculosis PknB PASTA domains NMR and SAXS experiments 
(Barthe et al., 2010).  
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A: B: C: 
 
 
 
DAMAVER DAMFILT  Overlay 
Figure 5.24: Dummy atom model of PASTA domains 4 to 5 from IreK E. faecalis. Dummy atom models 
were determined using DAMAVER (A) based on the bead density probability of the search volume and 
DAMFILT which generates the averaged model created from a DAMAVER model where low occupancy 
and loosely connected dummy atoms are present. The overlay of both models is represented by (C).  
5.6. Conclusions and future directions  
 In this Chapter, confirmation of direct ligand binding using vancomycin as an 
example ligand was observed in chemical shift perturbation experiments in NMR. A 
platform has been established where the terminal PASTA domains 4 to 5 from IreK E. 
faecalis can be used to understand dynamics between neighbouring PASTA domains in 
future structural studies.  
 Although a full backbone assignment was not achieved in the time frame of this 
study due to difficulties differentiating between resonances in the 3D experiments, 
partial assignment was achievable. Future NMR experiments may include longer 
acquisition time of the HNCACO experiment and also an HSQC of the terminal PASTA 
domains without the C-terminal peptide sequence. This region is Ser and Thr rich and the 
protein already has a large number of Ser and Thr residue in the protein sequence (28 
residues (18.1%) and 11 residues (7.1%) respectively). An HSQC experiment without the 
C-terminal peptide will help aid in the identification and differentiation of other Ser and 
Thr residues in the protein back bone assignment. On completion of the backbone 
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assignment, further experiments are required including H(CCO)NH, (H)C(CO)NH and 
HCCH TOCSY NOSEY experiments to assign the protein side chains.  
 From the partial backbone assignment, some of the chemical shift perturbation 
residues were identified. They were associated in a region that has not secondary 
structure elements. In a previous experiment looking at ligands interaction with PrkC 
from B. subtilis using STD NMR, it was established that R500 in the protein was essential 
for binding to the DAP moiety of the PG tripeptide mimetic. Figure 5.25 demonstrates 
that this conserved Arg residue is not present in any of the E. faecalis PASTA domains and 
instead either has a Pro residue (PASTA 1, 5 or 3) which would not be detected in a 
chemical shift perturbation experiment or Ala (PASTA 2) or Ser (PASTA 4). The observed 
site for vancomycin binding appears to be in a different location to that proposed of B. 
subtilis PrkC. Only the terminal PASTA domains 4 to 5 were examined in NMR 
experiments and it was not determined with there was a direct interaction between any 
of the other PASTA domains. A possibility to why saturation was not achieved in the 
chemical shift perturbation experiments is that there may be a number of sites 
vancomycin binds too between the PASTA domains that was measured in MST and SPR 
experiments where the full-length PASTA 1 to 5 domains was used.  
 
Figure 5.25: Comparison of ligand binding locations on PASTA domains. Sequence alignment of the 
individual PASTA domains from E. faecalis and the terminal PASTA domain from B. subtilis (PASTA domain 
3) with the key R500 residue associated with ligand binding highlighted in red. "*" amino acids are 
identical in all sequences in the alignment, ":" show where conserved amino acids substitutions have 
been observed and "." show where semi-conserved amino acids substitutions have been observed. 
 Of the three ligands where a KD was determined in Chapter 4 (vancomycin, 
teicoplanin and (GlcNAc-MurNAc)4), vancomycin which had the highest KD of the three 
ligands was used in this NMR study due to the expense of the other two ligands. As 
chemical shift perturbations were observed in a region of the PASTA domains and the 
amino acids identified form the partial backbone assignment, further mutagenesis 
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experiments of these residue may be used to help validate the contribution of this 
residues involved in ligand binding. These mutant constructs can then be sued in an MST 
experiment against the other ligands where a KD was determined in the full-length PASTA 
1 to 5 constructs and compared to the WT construct. This would also confirm that all 
three ligands are binding to the same site or if they target different regions in the protein.  
 One of the main goals of this study was to establish the global dynamics that can 
occur between PASTA domains. SAXS experiments demonstrated that the addition of the 
PASTA domains resulted in increased flexibility of the protein and that the PASTA domains 
generally represent and elongated shape. Although an NMR structure of PASTA domains 
4 to 5 was not obtained in the time frame of this study, future experiment would include 
the combination of the NMR structure with the SAXS data obtained to be used in hybrid 
modelling (Figure 5.26). This would give valuable data that could help gain further insight 
into the dynamic properties of these proteins that techniques such as X-ray 
crystallography cannot elucidate.  
 
Figure 5.26: Towards dynamic hybrid modelling. Schematic adapted from Mertens and Svergun (2017) 
illustrating hybrid methods for determining dynamics of NMR structure of PASTA 4 to 5 and SAXS models 
of multiple PASTA constructs that can be mapped to the NMR data. Tick and crosses highlights completed 
experiments and areas where further experiments are required respectively. 
 Other experiments may include saturation transfer diffusion(STD) NMR where the 
chemical shift of the ligand is assigned (eg. vancomycin) and increasing concentration of 
the protein is added to saturate the chemical shift signals from the ligand in a 1D 
spectrum. It is an alternative technique that is useful for monitoring weak ligand binding 
(mM - µM) (Venkitakrishnan et al., 2012). Regions where the protein is interacting with 
the ligand can be identified for epitope mapping.   
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Chapter 6. General Discussions and Conclusions 
6.1. Impact of Tn1549 acquisition and enhanced cephalosporin 
resistance 
 It is well established that Enterococcus species are intrinsically resistant to 
cephalosporin antibiotics (Kristich et al., 2007). Although the Tn1549 cassette was 
originally thought solely associated with acquired vancomycin resistance (Healy et al 
2000), in a novel and unexpected finding, I demonstrate in this study that E. faecalis has 
a phenotype of enhanced resistance to cephalosporins in the presence of the Tn1549 
cassette and that the two are linked via the serine-threonine kinase, IreK and the two-
component system, VanS.  
 One consequence of this finding is the impact this linkage may have upon the 
widespread usage of cephalosporins in clinical practice. Cephalosporin’s are used to treat 
a variety of infections including skin, UTI and respiratory tract infections commonly 
caused by Gram-positive and Gram-negative bacteria (Barry and Klasner, 2009). Both E. 
faecalis and E. faecium can cause a number of infections as highlighted in Chapter 1 
including UTIs, bacteraemia and infective endocarditis. In patients under cephalosporin 
therapy therefore, a cause of concern would be a clinical treatment environment where 
cephalosporin treatment is used to eradicate systemic bacterial species but as a 
consequence, VRE can proliferate and cause further infection as a consequence of their 
enhanced cephalosporin resistance. It has already been noted in the literature that there 
are a number of risk factors for VRE infection which include this scenario: 
 
“In addition to prior exposure to vancomycin, treatment with cephalosporins or 
antimicrobial drugs with significant activity against anaerobic bacteria (e.g. 
metronidazole, clindamycin, imipenem) is associated with increased risk for colonization 
or infection with VRE”  
(Shepard and Gilmore 2002) 
 
 
 A study of the acquisition of VRE in patients, found a correlation between higher 
rates of VRE infection and the use of 3rd generation cephalosporin’s and vancomycin 
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(Fridkin et al., 2001). The reduction in the use of vancomycin alone had previously failed 
to reduce the rate of VRE in patients and it had been suggested that the reduction of the 
use of cephalosporins was more important in reducing rates of VRE colonisation (Morris 
et al., 1995; Quale et al., 1996). The selection pressure for VRE infection was from the use 
of cephalosporin, not the use of vancomycin and we now have a molecular level 
explanation for this observation.  
 In this study, I demonstrated that IreK; an eSTK in E. faecalis, is involved in intrinsic 
cephalosporin resistance and also involved in the enhance acquired resistance 
mechanism of cephalosporin resistance as a consequence of the presence of the Tn1549 
vancomycin resistance transposon. Deletion of ireK in a Tn1549 strain, restores 
susceptibility to cephalosporin’s. This study went further to characterise potential 
inhibitors of the IreK kinase domain and has identified that the eukaryotic kinase inhibitor 
staurosporine was effective in also causing cephalosporin sensitivity thus establishing the 
role of IreK at a genetic and chemical level. This experiment was extended into a variety 
of different vanB phenotypic resistant strains and that cefotaxime sensitivity was 
obtained in those strains by staurosporine treatment. This sensitivity was not found in 
VanA phenotypic resistant strains. Further characterisation will require understanding 
further analysis of the VanA resistance strains but is likely to be due to the lack of IreK 
phosphorylation of VanS in these strains. 
6.2. Characterisation of phosphorylation targets 
 This thesis was an extension from work carried out by the Dworkin group at the 
Columbia University, New York where the auto phosphorylation of IreK and transfer of 
the phosphate to residue T223 on the Kinase domain of VanSB was observed in vitro. 
However, the trans-phosphorylation from phosphorylated VanSB to VanRB was not 
observed. In this study, experiments in vivo suggest that the Tn1549 cassette and IreK are 
interacting at a genetic level, and qPCR experiments indicate that the Tn1549 structural 
genes (vanY and vanB) were not upregulated in the presence of cefotaxime but were in 
the presence of vancomycin as perilously known (Healy et al., 2000, Walsh et al., 1996).  
 It has been highlighted in the Introduction (Chapter 1), that TCS cross talk can 
occur and that HK and RR derived from paralogue gene families that share significant 
sequence structural features can cross-talk in the same organism (Fisher et al., 1995; 
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Fisher et al., 1996). In S. pneumoniae, it had been shown that WalK from the WalKR TCS 
has an aa sequence similar to that of five other HKs and that low-level crosstalk was 
observed between three other HKs to Walk (Wayne et al., 2012). 
 In this study I used qPCR to demonstrate that the DdcSR TCS was unregulated in 
the presence of vancomycin and cefotaxime, (independent of each other) only in strains 
that contained the Tn1549 cassette. This strongly implicates that the Tn1549 cassette is 
essential in the upregulation of the DdcSR TCS in the presence of these antibiotics. A 
possible mechanism of action for enhanced cephalosporin resistance is via the DdcSR TCS 
that can lead to an altered PG profile. A direct connection between Tn1549 and DdcSR 
could be provided by trans-phosphorylation (cross talk) of VanSB to either DdcS or DdcR 
and this could be tested in future work. 
 
6.3. Further characterisation of IreK domains  
 After the identification of an enhanced cephalosporin resistance phenotype 
associated with IreK in E. faecalis, Chapters 4 and 5 focused on the contribution of each 
domain from IreK and their function in signal transduction with focus on oligomerisation. 
Oligomerisation of the intracellular kinase domains was characterised and further work 
is required that could include the identification of new inhibitors in addition to 
staurosporine and AZ5438 described here in both an in vivo and in vitro context. It was 
demonstrated in Chapter 3 that staurosporine and the AZ5438 inhibitors could be used 
in conjunction of cefotaxime to restore cephalosporin sensitivity. I have demonstrated 
that an in-vivo screen could be used in this context to screen for new inhibitors in the 
presence of cefotaxime. Due to the pharmaceutical interest in kinase inhibitor discovery, 
generally for cancer therapy, there is potential that a number of existing kinase inhibitors 
for eukaryotic targets may be “repurposed” as an antibiotic potentiator for Enterococcal 
infection. Upon selection and identification of other inhibitors, further characterisation 
may include in vitro experiments where the binding affinities of these inhibitors are 
characterised using techniques such as SPR and MST.  
 A number of Eukaryotic kinase inhibitors have been developed but have been 
unsuccessful in laboratory experiments and clinical trials to treat cancer. Many of these 
inhibitors are synthetic analogues of staurosporine and include such drugs as Becatecarin 
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which has passed Phase II clinical trials (Gani and Engh, 2010). Therefore, a number of 
these inhibitors may be suitable as bacterial kinase targets and repurposed for treatment 
of infections particularly as they would need to be administered in combination with 
antibiotics for a relatively short period (days or weeks compared to longer term 
chemotherapy). A recent review at the time of this study has also highlighted the 
potential for these inhibitors to be used in treatment of bacterial infections (Pensinger et 
al., 2017).  
6.4. Structural and Functional Properties of PASTA domains  
 Chapter 4 characterised the oligomerisation events of each soluble domain of IreK 
from E. faecalis and the KD from E. faecium. It concluded that the kinase domains were 
able to self oligomerize, but the PASTA domains remained monomeric. Ligand binding 
studies using MST and SPR identified 3 ligands that interacted with PASTA domains 1 to 
5 where a Kd was determined. These included for (GlcNAc-MurNAc)4 which was used as 
a pure PG glycan derivative.  Binding of this ligand supports the model of localised 
concentration of eSTKs (Figure 4.28.B). This model is also strongly supported by 
fluorescence microscopy experiments in Chapter 3, demonstrating that  removal of the 
PASTA domains results in delocalisation from the cell septum where PG synthesis occurs. 
Possible mode of action for cephalosporin resistance in Enterococcus via IreK includes 
changes in PG structure and crosslinking. These changes occur due to cephalosporin’s 
targeting PBPs, causing changes in the local PG environment and structure which are 
detected by the IreK PASTA domains resulting in signal transduction.  
 The classical mechanism for upregulation of eSTks in Gram-positive bacteria is via 
ligand induced dimerization Figure 4.28.A. In this study, I have shown that the PASTA 
domains in isolation do not oligomerize in the absence of ligands.  However, it is possible 
that ligands such as vancomycin may cause dimerization and this is a potential area for 
further work. By contrast, I have shown that vancomycin can also upregulate ddcY 
independent of cefotaxime and removal or the ireK gene prevents the upregulation. 
Therefore, both models may have a role in the function of eSTKs in Gram-positive 
bacteria.  
 Previous studies have determined the structures from eSTKs in Gram positive 
bacteria including the PASTA domains from S. aureus (X-ray crystallography (Paracuellos 
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et al., 2010)), the single terminal PASTA domain from S. pneumoniae (X-ray 
crystallography (Zucchini et al., 2018) and the PASTA domains from M tuberculosis (NMR 
(Barthe et al., 2010) and X-ray crystallography (Prigozihn et al., 2016)).  
 The aim of this study in Chapter 5 was to characterise one of the ligand 
interactions using vancomycin with PASTA domains 4 to 5 from IreK E. faecalis. Although 
the previous structural studies used a range of techniques including NMR, SAXS and X-ray 
crystallography, none of them showed any interaction with potential ligands. Ligand 
binding experiments were characterised in the B. subtilis PASTA domains using STD NMR, 
but no structural information gained as STD NMR measures peak intensity changes of the 
ligand (Squeglia et al., 2011).  
 Although high resolution structural information was not obtained using the PASTA 
domains from IreK from E. faecalis, SAXS experiments managed to demonstrate that 
these domains are flexible and increase in flexibility in the presence of PASTA domains. 
These features make crystallisation of types of proteins difficult and the dynamics and 
flexibility of the PASTA proteins may play and important role of its mechanism of action. 
The terminal PASTA domains (PASTA 4 to 5) were studied using NMR gain structural 
information. Full backbone assignment was not achieved in the time frame of this study 
due to difficulties in the resolution of overlapping resonances in the 3D experiments. 
Further experiments may include longer acquisition windows to enhance signal 
resonances.  
 However, in a chemical shift perturbation experiment, direct interaction of 
vancomycin with PASTA 4 to 5 was observed with chemical shift perturbations observed 
on select amino acid resonances. Backbone assignment of some of the chemical shift 
perturbation resonances were assigned and binding appears to be in a region of no 
secondary structure within the PASTA 4 to 5 domain. This region is distinctly different to 
that observed previously with PrkC from B. subtilus and the Tri-DAP peptide ligand at 
R500. The interaction of R500 in PrkC was with the peptide step of PG and observation 
here may suggest that GlcNAc and MurNAc residues may also bind in the region observed 
in the chemical shift perturbation experiments, but further mutagenesis experiments of 
residues in this region are required and experiment performed using MST to confirm the 
binding site.  
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6.5. Final Conclusion  
 This study has highlighted that cephalosporin therapy in a clinical environment 
may select for vancomycin resistance cassettes such as Tn1549 conferring vanB type 
resistance. It has been demonstrated here that the Tn1549 transposon can enhance 
cephalosporin resistance in E. faecalis and that phosphorylation from IreK to VanSB and 
transphosphorylation to other TCS like DdcS/R may cause the enhanced cephalosporin 
phenotype through TCS cross-talk. Staurosporine was shown to reverse the effect of the 
enhanced and intrinsic cephalosporin resistance and is thought to bind directly to IreK 
This highlights the possibility of the development of using eSTKs in Gram-positive bacteria 
as an antibiotic target in conjunction with other antibiotic therapies like cephalosporins. 
Further work is now possible in identifying other inhibitors that targets eSTKs like IreK in 
developing novel antibiotic therapies.  
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Chapter 8. Appendix 
8.1. DNA gBlock Sequences 
Table 8.1: gBlock sequences. gBlock identifiers and associated sequences as described in Table 2.12. 
gBlocks were ordered from IDT. 
gCWT001 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTA
AACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGT
TCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGT
GCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCC
AGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGA
CACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGA
ACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCC
CAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAA 
gCWT002 
ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGG
AGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCC
AGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTC
ATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAG
GGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCC
TGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATG
CAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGC
GAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAG
GCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGA
GGACTACACCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTG
TACAAGTAA 
gCWT003 
ATGGTGAGCAAGGGCGAGGAGACCACAATGGGCGTAATCAAGCCCGACATGAAGATCAAGCTGAAGATG
GAGGGCAACGTGAATGGCCACGCCTTCGTGATCGAGGGCGAGGGCGAGGGCAAGCCCTACGACGGCACC
AACACCATCAACCTGGAGGTGAAGGAGGGAGCCCCCCTGCCCTTCTCCTACGACATTCTGACCACCGCGTTC
GCCTACGGCAACAGGGCCTTCACCAAGTACCCCGACGACATCCCCAACTACTTCAAGCAGTCCTTCCCCGAG
GGCTACTCTTGGGAGCGCACCATGACCTTCGAGGACAAGGGCATCGTGAAGGTGAAGTCCGACATCTCCAT
GGAGGAGGACTCCTTCATCTACGAGATACACCTCAAGGGCGAGAACTTCCCCCCCAACGGCCCCGTGATGC
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AGAAGAAGACCACCGGCTGGGACGCCTCCACCGAGAGGATGTACGTGCGCGACGGCGTGCTGAAGGGCG
ACGTCAAGCACAAGCTGCTGCTGGAGGGCGGCGGCCACCACCGCGTTGACTTCAAGACCATCTACAGGGC
CAAGAAGGCGGTGAAGCTGCCCGACTATCACTTTGTGGACCACCGCATCGAGATCCTGAACCACGACAAGG
ACTACAACAAGGTGACCGTTTACGAGAGCGCCGTGGCCCGCAACTCCACCGACGGCATGGACGAGC 
TGTACAAGTAA 
gCWT004 
ATGGTTTCTAAAGGAGAAGAATTGTTTACTGGGGTCGTCCCTATTCTTGTGGAACTTGACGGCGATGTAAAC
GGGCATAAATTCTCTGTATCTGGGGAAGGTGAGGGAGATGCGACGTATGGAAAGCTTACCCTTAAATTCAT
CTGCACGACCGGCAAATTGCCTGTACCGTGGCCGACTTTGGTCACGACGTTAACATATGGAGTACAGTGTTT
CTCTAGATACCCAGACCACATGAAACAACATGACTTTTTCAAAAGTGCAATGCCTGAGGGGTATGTCCAAGA
GCGAACCATCTTCTTTAAAGATGACGGAAACTACAAGACTAGAGCGGAAGTTAAGTTTGAGGGCGACACAT
TGGTCAACCGCATTGAACTAAAGGGGATTGACTTTAAAGAAGACGGCAACATTCTAGGGCACAAGTTAGAG
TATAACTACAACAGTCATAATGTGTATATCATGGCGGATAAGCAAAAGAACGGCATTAAGGTCAATTTCAA
GATCCGCCATAACATAGAAGATGGAAGTGTGCAATTAGCAGATCATTATCAGCAAAATACCCCGATAGGGG
ATGGTCCAGTGCTACTTCCGGATAATCACTACTTGAGCACTCAGTCTAAGTTGAGCAAAGATCCTAACGAAA
AGCGCGACCACATGGTTTTGTTGGAATTTGTCACTGCCGCTGGAATAACCCTTGGCATGGACGAGCTTTACA
AG 
gCWT005 
GGTAATAAATACGAAGAGACACCTGATGTAATCGGGAAAACTGTAAAAGAAGCAGAGCAAATATTCAATA
AAAATAACCTGAAATTGGGTAAAATTTCTAGAAGTTATAGTGATAAATATCCTGAAAATGAAATTATTAAGA
CAACTCCTAATACAGGTGAACGTGTTGAACGTGGTGACAGCGTTGATGTTGTTATATCAAAAGGCCCTGAA
AAGGTTAAAATGCCAAATGTCATTGGTTTACCTAAGGAGGAAGCCTTGCAGAAATTAAAATCGTTAGGTCTT
AAAGATGTTACGATTGAAAAAGTATATAATAATCAAGCACCAAAAGGATACATTGCAAATCAAAGTGTAAC
CGCAAATACTGAAATCGCTATTCATGATTCTAATATTAAACTATATGAATCTTTAGGCATTAAGCAAGTTTAT
GTAGAAGACTTTGAACATAAATCCTTTAGCAAAGCTAAAAAAGCCTTAGAAGAAAAAGGATTTAAAGTTGA
AAGTAAAGAAGAGTATAGTGACGATATTGATGAGGGTGATGTAATTTCTCAATCTCCTAAAGGGAAATCAG
TAGATGAGGGGTCAACGATTTCATTTGTTGTTTCTAAAGGTAAAAAAAGCGACTCATCAGATGTCAAAACG
ACAACTGAATCGGTAGATGTACCATACACTGGTAAAAATGATAAGTCACAAAAAGTTAAAGTTTATATTAAA
GATAAAGATAATGACGGTTCAACTGAAAAAGGTAGTTTCGACATTACTAGTGATCAACGTATAGACATTCCT
TTAAGAATTGAAAAAGGAAAAACAGCAAGTTATATTGTTAAAGTTGACGGTAAAACTGTAGCTGAAAAAGA
AGTCAGTTATGATGATATTTAA 
gCWT006 
ATGCCTAAGGATGTCAAAATACCTGATGTCTCCGGAATGGAATACGAAAAAGCCGCAGGGCTCTTGGAAAA
AGAAGGTTTACAGGTTGATTCCGAGGTGTTGGAAATCTCAGATGAAAAAATTGAAGAGGGCCTGATGGTA
AAAACGGATCCTAAAGCGGATACCACAGTCAAAGAAGGCGCCACGGTCACCCTTTATAAGAGCACCGGAA
AAGCAAAAACGGAGATCGGTGATGTGACAGGCCAAACGGTCGACCAAGCAAAAAAAGCGTTGAAGGACC
AAGGGTTTAATCATGTAACAGTAAATGAAGTGAATGACGAGAAAAATGCGGGCACTGTCATTGACCAAAAT
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CCTTCAGCAGGGACTGAGCTGGTCCCGAGTGAAGATCAAGTCAAACTTACAGTCAGTATCGGACCCGAAGA
CATTACGCTTAGAGACTTGAAAACCTACAGTAAAGAAGCAGCGTCTGGATATCTGGAAGACAACGGATTGA
AGCTTGTAGAAAAAGAAGCATACTCAGATGATGTTCCAGAAGGACAGGTTGTCAAACAAAAACCAGCAGC
AGGTACGGCAGTAAAGCCGGGAAACGAAGTTGAAGTGACATTCTCTCTCGGACCAGAGAAAAAACCTGCG
AAAACAGTGAAAGAAAAGGTCAAGATCCCCTACGAACCAGAAAATGAAGGGGACGAGCTTCAAGTGCAAA
TCGCGGTTGACGATGCGGATCACAGCATCTCTGACACTTACGAAGAATTTAAGATAAAAGAGCCGACTGAA
CGAACGATCGAACTAAAGATTGAACCAGGCCAAAAAGGGTACTATCAAGTAATGGTAAACAATAAAGTTGT
CAGCTACAAAACCATTGAGTATCCGAAAGATGAA 
gCWT007 
AAGCCAACATCAGTCAAGGTTCCTAACGTCGCGGGTACGAGCCTTAAGGTTGCCAAACAGGAGCTATACGA
CGTTGGGCTAAAGGTAGGCAAAATACGACAGATAGAAAGTGACACAGTTGCGGAGGGTAACGTGGTCCGT
ACTGATCCGAAGGCAGGTACTGCAAAGCGCCAGGGGAGCTCTATTACTCTTTATGTTAGTATCGGTAATAA
GGGGTTCGACATGGAGAACTACAAGGGACTTGATTACCAGGAAGCGATGAACTCTCTAATAGAGACGTAT
GGTGTCCCTAAAAGTAAGATCAAGATCGAGCGTATTGTGACTAATGAGTATCCTGAGAATACTGTCATCTCA
CAAAGTCCTAGCGCAGGAGACAAGTTCAATCCGAATGGGAAATCAAAGATAACACTAAGTGTAGCTGTTAG
TGATACCATCACAATGCCGATGGTAACTGAGTATAGCTATGCCGATGCTGTGAATACTTTAACCGCTTTGGG
CATAGACGCATCTCGAATTAAAGCATATGTGCCGTCATCATCATCAGCTACCGGATTTGTGCCAATACATAG
TCCGAGCAGTAAAGCCATAGTGAGCGGGCAGAGTCCATATTACGGGACAAGTCTTAGCCTTAGCGACAAA
GGAGAGATCAGCTTGTATTTGTACCCAGAAGAAACTCACTCATCTAGCAGTTCTAGCTCTAGCACTAGTTCA
AGCAACAGCAGTTCAACGAACGATTCTACTGCTCCAGGTAGCAACACCGAATTGTCTCCGTCTGAAACCACC
GCTCAGACTCCT 
gCWT008 
TCACCAGATGAGGTAGCTGTTCCAGACGTATCAGGGAAGACGGAGGACCAAGCAGTTGCGCTATTGCAAA
AGGAGGGGTTCGTAATTGGCAAGACGGCGGAAAAGAACTCTGATGAAGTGGACGAAGGCAAAGTCATAA
ATACTGATCCGGAAGCGGGTGAGATGAAGGAGAAAGGGACGAAAATAAACCTTTTCGTCTCAATAGGTTC
AAAGAAGATAACAATGGACGATTACACAGGTCGTAGTTATACTGACACCAAGGCATTGTTGGAGGAGCAG
GGATTCAAGAATATTTCAAGCGAAGAGGCATATTCTAGTGAGATAGAAAAGGGATTGATTATCAGCCAGAC
TCCTACGCAAGGCACTGAGGTGGTCGCTAAATCAACTGACGTGAAGTTTGTAGTGAGTAAGGGCGCTGAAC
CGATAACATTGAAGGACTTACGAGGGTATACCAAAACTGCCGTGGAGGATTACGCGAGCCCATTAGGACTT
AAAGTATCATCTAAGGAGGAGAATAGTAGTACAGTGGAAAAAGGTCAGGTGATTTCTCAATCTCCTTCAGC
CGGAACTGCTATGAATAGTGGAGACACTATTGAAATCGTAATTAGTGCTGGGCCAAAGGAAAAACAGGTA
AAGGAGGTTACGAAGACATTTAACATACCGTACACCCCTAGTGATGAAGAAAACCCTCAGCCACAAAAGAT
CCAGATATATATCCAGGATAAAGATCACAGCATGACGAGCGCATACAGAGAAATGAGTATCACTCAGAACA
CCTCTGTGGAGATTACGTTTCAAATCGAAGAGGGAAGCTCTGCCGGCTATAAAATCATTAGTGACGACAAA
GTGATTGATGAAGGAACGGTGCCATATCCGAAT 
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gCWT009 
GGAAATGACAAGGTCCCTGTCCCAGCCTTCATTGGATTATCTAAGGCAGACGCCCAACAACAAGCGGATAA
TATCGACTTGGTCTTGACGTTCAAGCAGCAAGAATGCGAAGATCAGCCTAAGGGCAATATATGCGCACAGG
ATCCAAAACAGGGTACTGACGTAGACAAAGAGTCTACAGTAAACCTAGTCGTGTCTACCGGTGCCCCGAAA
GTCGCGGTCCCAAATGTAATTGACAAAAATATAGACGAGGCTAAGAAGCAGCTTGAGGACAAAGGCTTCG
AGGTTGAAACGAAGCAAACCGAATCATCTCAGGATGAAGGGACCATTTTAAGCCAGAATCCGGACCCAGG
CAAAGAATTAGAGAAAGGCTCTACGGTGACACTTGAAGTTGCAAAAGCTGAGGAGAAAGCCACGGTGCCA
GATGTTGTAGGACGTACCTGCGACGAAGCTAAAGCACAGGTTGAGAGCGGGGGTGATCTTACTGCGGTCT
GCACGGACCAGCCTACTAATGACCCGAACCAGGTAGGCAAAGTAATTTCTACGACACCTCAATCTAGCACCC
AAGTGGACCCGGGAAGCAAAGTTACTATCGTAGTCGGAAAGGCAGTCGAAAAAACAAAGGTGCCGGAGG
TGCGTGGTAAGACCTTGGCAGAGGCGCGACAAATCCTTCAGCAGTCTGGTTTTACGAACGTACAGGTGGCC
CAAGGGTCACCAGGGGACGATAACGCAAAAGTGTTCGCAAGCAACCCGCAGCCGGGGAGCGAAGTAGAC
GATCCTGCTGCTACTCCGATAACTTTAATGACCGTCCCGGGGGATGGTGGTAACGGTAATGGAGGGAATGG
CAATGGGGGCGCTATCGCTGGCTTGCCGGGCTTCGGCGAT 
gCWT010 
ATCACCCGAGATGTACAAGTCCCTGACGTCCGCGGCCAAAGCTCTGCCGATGCCATCGCAACACTTCAAAAT
CGTGGGTTTAAGATACGAACTTTACAGAAGCCAGATAGTACAATTCCGCCGGATCACGTAATTGGAACGGA
CCCTGCGGCGAATACTAGTGTGAGCGCAGGAGATGAGATTACGGTCAATGTAAGTACTGGGCCGGAGCAA
CGAGAAATCCCTGACGTGAGCACACTTACCTATGCTGAGGCGGTTAAAAAACTTACTGCGGCTGGCTTTGG
GCTATTCAAGCAGGCTAATAGTCCGTCAACCCCAGAACTAGTCGGAAAAGTCATTGGGACTAACCCGCCTG
CTAATCAAACAAGCGCAATTACAAACGTGGTGATAATAATTGTGGGTAGTGGTCCTGCCACTAAGGACATT
CCTGATGTAGCAGGCCAAACAGTGGATGTTGCCCAGAAGAATCTTAACGTATATGGTTTTACGAAGTTTAG
CCAGGCTAGTGTTGATTCTCCTAGACCTGCTGGAGAAGTTACGGGAACCAACCCGCCTGCCGGAACTACTG
TACCTGTGGATAGCGTCATAGAACTTCAAGTATCAAAGGGTAACCAGTTTGTGATGCCAGACCTTAGTGGA
ATGTTTTGGGTAGATGCCGAGCCTAGACTTCGAGCCTTAGGCTGGACCGGGATGCTAGATAAGGGTGCAG
ACGTTGATGCAGGCGGTAGCCAGCACAATCGCGTCGTCTATCAGAATCCACCAGCGGGTACAGGTGTAAAT
AGAGATGGGATAATTACCCTACGCTTTGGGCAG 
gCWT011 
AGTCCTAAAAAGATAGCTGTTCCAGATGTCGCGAACATGACCGTTGAAGAAGCAAAGAAGGAATTGGAAA
AGCAGGGATTCATAGTCGGCGAACAACAGAAGCGTCATTCTGAGGACATCGAAAAGGATAAAGTGATTGA
GACAGATCCAGCTGAGGGCACGTTACGTGTGAAGGACACCGAAGTAGACCTTATTGTAAGTCTTGGGGTG
GAAAAGTCACCTATGGACAACTATATAGGGCAGAAAATCGACCAGGTCCAAAGCGTTCTAAAAGACAAGTT
CATGGGCGATGTCCGTGTAAACTACGTCCATAGCAGTGAGGAGGCAGGCTCTATAATAGATCAGGACCCG
GCTCCGAATACAGAGATCGTGCCGAAGGAAACCAATGTCGTATTTACAGTCTCACAGGGCAAGAAGCCAAT
ATCAGTAAGAAACGTAGTGGGGTATAGCAAGACAGACCTTGATAATTATGTCAACTCTGAAGGTTTGAAGT
GGCGAGTCGAAAGAGAAGATTACAGTCCTACCATCGCTAAAGGATTGGTGATCTCACAGAAGCCAGCGGC
AGGAACTAATTTGGTTGAGGGCGACACCATAGCGGTGGTGCTTTCTAAGGGCCCAGAGGAAAAACCGGTA
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AAAACTTTCGTTAAGACTATGTTGATTCCGTATGAGCCAACGGAGGAGGGCATGGAGCAGTTAATTCGCAT
TGAAATCCAGGACAAGAATCACAGTATGGCGAAGCCGCTTGAAGAATTTTTTATCAACAGCGACCGAGAAT
ACAAAATCCAGCTTGTTATTGAAGAAGGCGAAGAAGCCGCCTACAAGATATTACGCGATTCTGCTATTATAG
CAGAGGAGAAGTTCAGTTACGATGATGTAAAC 
gCWT012 
TTAGGAATGGGGACAACCGTGGTTGGTGCCATCCTTTTACCAGATTCATTTGTCTTAGCAAATGTGGGGGAC
AGTCGTGCTTATTTAGTTCGTGACCAACACATGTTACAATTAACAGAAGATCATTCTTTAGTGAATGAACTA
GTAAAATCAGGGGAGATTACTCGTGAGATGGCTGCAAATCATCCACGAAAAAATGTCCTAACACGTTCTTT
GGGAATGCCTGGCACTGTCGAAGTCGATGTAACCAATCATGAATGGCTGCCTAATGACTATTTACTGTTATG
TTCGGACGGTTTAACCAATATGGTTCCTGAGACAAAAATTTTAGAAATTTTAGAGACGTCAGATCCCTTAGA
ATCCAAATTAAGCCAACTCGTTGCCCAAGCAAATGAAGCGGGTGGTTTAGATAACATTACCGTGTTAGTGAT
ACACTTTGACGAACAGAAGGAGGAAAACCAATGATAGAAATCGGCAAGAAGCTGAATGGTCGATATCACG
AAAGTAGTACGAGTAATTAAGACAAGAGGTTGGGACAGGAGTGTTTAGCTTCAAGAACCAAGTAGGTACT
GTTTAACATCTATTTGCTTTTCAAATAGTGTTTCTCAGCAATAAGAAGAAGCTGCTCCTGTCCCGCCGTTTAT
CTTAAGGTTTAAGTCTAGGAAGGTAAGTCATTTCGACTTATGTCCTAGGCTCTTTTTAATTAATAGAATCGAG
AGGCTCCCTTGATTTCTCTGCCACTATCCTGTATATTCGAAAGTAGTTAGGAGTGGTTTATCTGAAAGGTCAA
ATCAGAAAAGCGTTAAGCGGTTTTTATTATGTATACGCAGATGGAGAAACATATCAAACAAGAGCGCGAGG
GAATTTTCGTAATCGAAAAATTACGCCACTCGTGGGAGATGAAGTACTTTTTGAAAGCGATAATTTAACAGA
TGGTTATGTGTTGGAAATTTTACCAAGACGAAATGAATTAGTGCGCCCGCCTGTTGCAAATGTGGAT 
gCWT013 
AGTTGATGCGCCATGTTCAGGCTTAGGGCTAATGCGCCGTAAACCAGACATTAAATACCATAAAACGGCCA
ATGATTTTCAAAATTTACCTAAAATTCAGTTAGAAATCTTAGAAAGTGTTGCCCCAACACTAAAACAATGGG
GTATAATGGTCTATAGCACTTGTACTATTACGCCAGAAGAAAATCAGGAAGTGGTGGCAGCCTTTTTAGCCA
AACACCCTGAATTTGAAAAAATTGAAATTGTTGCAAATGAAAACGTCCAAGCAGTAGTAAAAGAGCAAGAA
CTGGTTCTGTATCCCCATCAATACATGACAGATGGCTTCTTTATTTGCTGTATGCGGAAAGTTAGTTCAAATG
AGGTGAAATAATTTGGAAATCAACGTTCAATCAGATGTCGGTCGCAAAAGAAATACGAACCAAGATTATGC
CAACGTTTTTGAGAACCAACAACACATAACCTTTGCTGTTTTAGCAGATGGCATGGGTGGTCACCAAGCACA
GAAGGAGGAAAACCAATGATAGAAATCGGCAAGAAGCTGAATGGTCGATATCACATTATTGGCAGCATCG
GAAGCGGCGGCATGGCCAACGTTTATTTAGCACACGATTTAATTTTAGACCGAGACGTTGCAGTAAAAGTC
TTGCGCTTTGACTTCCAAAACGATCAAGCCGCCATCCGACGTTTTCAGCGTGAAGCACTAGCCGCAACTGAG
CTGGTTCACCCGAATATCGTCAGTGTGTACGATGTAGGCGAAGAAGATGGACTACAATATTTAGTCATGGA
ATATGTGAAAGGAATGGACTTAAAACGTTACATCCAAACGCATTTCCCAATTCCTTATTCCACAGTTGTGGA
CATTACGCAACAAATTTTATCTGCTGTCGCAATGGCACATGAACATAGAATTATTCACCGGGATTTAAAACC
GCAAAACATTCTGATTGACGAACACGGCACAGTCAAAATTACTGACTTTGGGATTGCGATTGCCTTGTCA 
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8.2. MIC of Enterococcal isogenic series and CSLI controls for each antibiotic 
Table 8.2: MIC of OG1RF isogenic series with CSLI control strains. Experiments were in accordance to CSLI protocols and performed in duplicates. MIC reported in µg mL-1. 
Antibiotic E. faecalis OG1RF WT 
E. faecalis OG1RF 
ΔireK 
E. faecalis OG1RF 
Tn1549 
E. faecalis OG1RF 
Tn1549 ΔireK 
S. aureus ATCC 
29213 E. coli ATCC 25922 
K. pneumoniae 
ATCC 700603 
Ampicillin 0.03125 0.015625 0.0625 0.015625 0.0625 0.25 256 
Cefazolin 32 8 32 32 0.5 1 256 
Cephalothin 16 4 64 64 0.0625 8 <256 
Cephalexin 32 16 128 32 2 8 64 
Cefoxtin <256 128 <256 <256 2 4 128 
Ceftriaxone 16 0.5 256 8 4 0.0625 8 
Cefotaxime 2 0.0625 256 1 1 0.0625 8 
Ceftazidime 128 8 <256 64 8 0.25 64 
Cefepime 8 2 32 8 2 0.01563 2 
Ceftabiprole 0.03125 >0.00781 0.03125 0.03125 0.125 <256 8 
Meropenam 1 0.5 2 2 0.0625 >0.00781 >0.00781 
Vancomycin 4 1 64 32 0.5 <256 <256 
Fosfomycin 16 16 128 64 16 <256 <256 
Bacitracin 128 16 128 128 128 <256 <256 
D-Cyclo serine 128 64 128 64 32 32 64 
Daptomycin 64 8 32 16 4 <256 <256 
Kanamycin 256 256 256 128 1 0.5 16 
Linezolid 2 2 2 2 0.0625 <256 <256 
Rifampcin <256 <256 <256 <256 <256 4 8 
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Table 8.3: GSK protein kinase inhibitor set 1. Includes inhibitors from Tang et al., (2003) tested in MIC 
experiment against E. faecalis OG1RF Tn1549 
GW824645A GW831090X GW831091X 
   
 
 
Table 8.4: GSK protein kinase inhibitor set 2. Includes inhibitors from Stevens et al., (2008) tested in MIC 
experiment against E. faecalis OG1RF Tn1549 
GW805758X GW781673X GW780056X 
   
GW779439X GW778894X GW708336X 
   
GW683768X GW683109X GW683003X 
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Table 8.5: GSK protein kinase inhibitor set 3. Includes inhibitors from Bramson et al., (2001) tested in 
MIC experiment against E. faecalis OG1RF Tn1549 
GW589933X GW416981X GW416469X 
   
GW396574X GW352430A GW335962X 
   
GW305178X GW301784X GW300660X 
   
GW300657X GW300653X GW297361X 
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GW290597X GW282536X GW280670X 
   
GW279320X GW276655X GW275944X 
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8.4. Extended AUC data 
A: B: 
E. faecalis IreK KD domain 
  
E. faecium IreK KD domain 
  
E. faecalis IreK cognate phosphatase IreP  
  
Tn1549 VanSB KD 
  
Figure 8.1: Sedimentation coefficient distributions of Kinase and Phosphatase domains used in this 
study. (A) Absorbance data and (B) Interference data.
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Table 8.6: Species estimated molecular weights from the c(s) analysis of IreP. For each sample concentration he signal-weighted sedimentation coefficient and he 
estimated MW of each species is shown together with the best-fit frictional ratio (f/f0) for the distribution. IreP Phosphatase domain all appear as predominantly one 
species with a best-fit molecular weight consistent with that of a monomer. 
Monomer MW 
(kDa) 
Detection method 
Concentration 
(mg mL-1) 
Peak 1 Peak 2 
f/f0 MW 
(kDa) 
Sed. Co (S) MW (kDa) Sed. Co (S) 
IreP Phosphatase 
28.3 
Absorbance 
1.0 - - 28.9 2.37 1.35 
0.5 - - 28.6 2.37 1.34 
0.25 - - 28.7 2.40 1.33 
Interference 
1.0# 7.4 0.93 28.9 2.31 1.39 
0.5# 8.7 1.16 24.8 2.34 1.24 
0.25# 8.5 1.08 26.9 2.33 1.31 
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Table 8.7: Species estimated molecular weights from the c(s) analysis of VansB. For each sample concentration he signal-weighted sedimentation coefficient and he 
estimated MW of each species is shown together with the best-fit frictional ratio (f/f0) for the distribution. The VanSB constructs all appear to be in an equilibrium between 
two different species. This is most likely a monomer/dimer equilibrium, but it is difficult to be certain from these calculated molecular weights as the f/f0 varies. 
(Determining the KD of the self-association would require a broader concentration range).  
 
Monomer 
MW 
(kDa) 
Detection method 
Concentration 
(mg mL-1) 
Peak 1 Peak 2 Peak 3 
f/f0 MW 
(kDa) 
Sed. Co (S) MW (kDa) Sed. Co (S) MW (kDa) 
  IreP Phosphatase 
32.4 
Absorbance 
1.0 - - - - 65.0* 3.80* 1.36 
0.5 - - - - 53.1* 3.67* 1.24 
0.25 - - - - 56.6* 3.56* 1.33 
Interference 
1.0# 8.8 0.88 27.6 1.88 81.4* 3.85* 1.56 
0.5# 10.9 1.14 - - 60.4* 3.56* 1.39 
0.25# 10.2 1.33 22.8 2.26 44.4* 3.53* 1.14 
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A: B: 
PASTA 1-2 
  
PASTA 1 to 3 
  
PASTA 1 to 4 
  
PASTA 1 to 5 
  
Figure 8.2: Sedimentation coefficient distributions of PASTA domains from E. faecalis IreK used in this 
study. (A) Absorbance data and (B) Interference data. 
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A: B: 
PASTA 4 to 5 
  
PASTA 4 to 5 C-terminal truncation 
  
Figure 8.3: Sedimentation coefficient distributions of the terminal PASTA domains from E. faecalis IreK 
used in this study. (A) Absorbance data and (B) Interference data. 
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8.5. Mass Spectrometry 
A:  C:  
 
 
B:  
 
Figure 8.4: ESI-MS of E. faecalis KD. (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) mock mass 
spectrum from maximum entropy algorithm.  
 308 
A:  C:  
 
 
B:  
 
Figure 8.5: Highlighted ESI-MS of E. faecalis KD to show post translational modifications. (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data 
from maximum entropy algorithm (C) mock mass spectrum from maximum entropy algorithm. 
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A:  C:  
 
 
B:  
 
Figure 8.6: Highlighted ESI-MS of E. faecium. (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) mock 
mass spectrum from maximum entropy algorithm. 
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A:  C:  
 
 
B:  
 
Figure 8.7: Highlighted ESI-MS of PASTA 1 to 5 (His). (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) 
mock mass spectrum from maximum entropy algorithm. 
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A:  C:  
 
 
B:  
 
Figure 8.8: Highlighted ESI-MS of PASTA 1 to 5 (TEV). (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) 
mock mass spectrum from maximum entropy algorithm. 
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A:  C:  
 
 
B:  
 
Figure 8.9: Highlighted ESI-MS of PASTA 1 to 4 (TEV). (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) 
mock mass spectrum from maximum entropy algorithm. 
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A:  C:  
 
 
B:  
 
Figure 8.10: Highlighted ESI-MS of PASTA 1 to 3 (TEV). (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) 
mock mass spectrum from maximum entropy algorithm. 
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A:  C:  
 
 
B:  
 
Figure 8.11: Highlighted ESI-MS of PASTA 1 to 2 (TEV). (A) Raw Mass Spectrum, (B) Superimposition of Raw data and mock mass data from maximum entropy algorithm (C) 
mock mass spectrum from maximum entropy algorithm. 
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8.6. Nanotemper MST controls 
 
 
A: B: 
Vancomycin 
  
Teicoplanin 
 
 
(GlcNAc-MurNAc)4 
  
Figure 8.12: Nanotemper experiment controls with ligand that produced a KD. 
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 A: B: C: 
MurNAc 
   
GlcNAc 
   
Figure 8.13: Nanotemper experiment controls with PG glycan monomers. 
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A: B: C: 
Lys-Pentapeptide 
   
Figure 8.14: Nanotemper experiments with PG pentapeptide stem.  
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A: B: C: 
Chitobioise 
   
Chitoctose 
   
Figure 8.15: Nanotemper experiment controls with GlcNAc polymers 
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A: B: C: 
MDP Control 
   
MDP  
   
Figure 8.16: Nanotemper experiment controls with PG peptide stem (Dipeptide) 
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A: B: C: 
Lys Tri Peptide 
   
Dap Tri Peptide  
   
Figure 8.17: Nanotemper experiment controls with PG peptide stem (Unamidated Tripeptide). 
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A: B: C: 
MurNAc Lys Tri Peptide 
   
MurNAC Dap Tri Peptide  
   
Figure 8.18: Nanotemper experiment controls with PG peptide stem (Unamidated MurNAc Tripeptide). 
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A: B: C: 
Amidated Lys Tri Peptide 
   
MurNAC Dap Tri Peptide  
   
Figure 8.19: Nanotemper experiment controls with PG peptide stem (Amidated Tripeptide) 
